[
    {
        "Patient Information": {
            "Name": "Liam Chen",
            "Age": "33",
            "Gender": "Male",
            "Medical History": "Recent episodes of fatigue, anemia, and frequent infections; history of lymphadenopathy and splenomegaly"
        },
        "Disease Information": {
            "Disease": "Acute Myeloid Leukemia",
            "Severity Level": "Major Severity",
            "Symptoms": "Fever, anemia, frequent infections, lymph node enlargement, fatigue, bone pain, oral bleeding",
            "Duration": "Symptoms have intensified over the past few weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "48 IU /L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.7 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "95 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "2.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "28% (35 − 50)",
                "Hemoglobin (Hb)": "85 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "70 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "45% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "30% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "4.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "20% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.05 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "1% (0 − 1)",
                "Mean Platelet Volume (MPV)": "12 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "750 ng/mL (20 − 500 for males)",
                "CRP": "20 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.8 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "AB",
                "Specific Antigen": "None",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Bone Marrow Aspiration": "Presence of myeloblasts and abnormal proliferation of immature myeloid cells",
            "Cytogenetic Analysis": "Positive for complex karyotype abnormalities",
            "Immunophenotyping": "Presence of CD13, CD33 antigens",
            "Chest X-ray": "Normal",
            "Respiratory Function Test": "Normal",
            "Serum Antibody Test": "Negative for associated viral infections",
            "Nucleic Acid Amplification Test": "Negative",
            "CT Scan": "No infiltration observed",
            "Ultrasound of Abdomen": "Splenomegaly observed",
            "Oral Pharyngeal Examination": "Swelling and bleeding of gums",
            "Allergen Test": "Normal"
        },
        "Treatment Plan": "Liam Chen has been diagnosed with acute myeloid leukemia, necessitating immediate and intensive treatment to address rapid disease progression. He will undergo induction chemotherapy, aiming for a swift reduction of the leukemia cell burden and achieving hematologic remission. Chemotherapy will consist of an anthracycline such as Daunorubicin combined with Cytarabine (Ara-C), monitored closely for adverse effects. Supportive care is essential, including blood transfusions for anemia and platelet transfusions to manage bleeding risks. Monitoring for signs of secondary infection is crucial, with prophylactic antibiotics if needed. Nutritional support will be prioritized to maintain overall health and recovery potential, including high-protein meals and possible intravenous nutrition. Given the severity of his condition, hematopoietic stem cell transplantation is considered post-remission, provided a suitable donor can be found. Continuous monitoring through blood tests and bone marrow biopsies will be conducted to assess treatment response, and cytogenetic analysis will guide therapeutic adjustments. Family support and education are vital to ensure adherence to the treatment plan. Post-recovery, regular health check-ups will be scheduled to monitor for minimal residual disease and early signs of relapse."
    },
    {
        "Patient Information": {
            "Name": "Jessica Wu",
            "Age": "28",
            "Gender": "Female",
            "Medical History": "Previously healthy, occasional upper respiratory infections"
        },
        "Disease Information": {
            "Disease": "Acute Myeloid Leukemia (AML)",
            "Severity Level": "Major Severity",
            "Symptoms": "Fatigue, fever, anemia, bleeding such as nosebleeds and gum bleeding, bone pain, lymphadenopathy, splenomegaly",
            "Duration": "Symptoms have been present for several weeks, gradually worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "33 IU /L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "120 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "32% (35 − 50)",
                "Hemoglobin (Hb)": "90 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "70 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "18% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "75% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "90 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "1.0 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "12 f l (9 − 13)",
                "Lactate Dehydrogenase": "400 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "160 U/L (22 − 198 for females)",
                "Myoglobin": "85 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for females)",
                "CRP": "20 mg/L (< 3 mg/L)",
                "ESR": "45 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "1.2 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Positive for abnormal myeloid antigen",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Bone Marrow Biopsy": "Significant infiltration of leukemic blast cells",
            "Cytogenetic Analysis": "Complex karyotype with multiple chromosomal aberrations",
            "Flow Cytometry": "Presence of specific leukemia-associated antigens",
            "Molecular Testing": "Dominance of specific mutations linked to AML",
            "Blood Chemistry": "Elevated lactate dehydrogenase and uric acid levels",
            "Serum Antibody Test": "Negative for infectious causes",
            "Coagulation Profile": "Abnormal platelet function",
            "Imaging Studies": "Enlargement of spleen and lymph nodes observed in ultrasound"
        },
        "Treatment Plan": "Jessica Wu has been diagnosed with acute myeloid leukemia, exhibiting symptoms such as fatigue, anemia, bleeding, and significant leukocytosis, demanding immediate and aggressive treatment. She will undergo induction chemotherapy aimed at achieving hematologic remission and eliminating the leukemic cells, starting with a combination of anthracycline drugs like Daunorubicin and Cytarabine, following monitoring and adjustment based on her cytogenetic profile. Due to her younger age, hematopoietic stem cell transplantation will be considered after achieving remission, which offers potential curative prospects, with matches being actively sought within her family or national registry. Supportive care involving transfusions for anemia and thrombocytopenia, hydration, and management of uric acid levels to prevent nephropathy during treatment are critical to minimize complications. Molecular targeted therapy with tyrosine kinase inhibitors may be introduced depending on the presence of specific mutations, particularly if her initial response to chemotherapy is unsatisfactory. Regular monitoring will include complete blood counts, bone marrow assessments, and coagulation studies to evaluate her progress and prevent relapse, with further adjustments made to her treatment protocol based on her clinical response. Nutritional support, including high-protein intake and potential intravenous supplementation during treatment phases, will be provided to maintain strength and wellbeing. Counseling regarding her condition, potential side effects of treatment, and adherence to follow-up care with weekly assessments will be ensured, focusing on comprehensive care and support for recovery."
    },
    {
        "Patient Information": {
            "Name": "Emma Li",
            "Age": "34",
            "Gender": "Female",
            "Medical History": "Family history of leukemia, frequent infections, anemia in the past year"
        },
        "Disease Information": {
            "Disease": "Acute Myeloid Leukemia",
            "Severity Level": "Major Severity",
            "Symptoms": "High fever, severe anemia, frequent infections, bone pain, splenomegaly, gum bleeding",
            "Duration": "Symptoms have been progressively worsening over the past three weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "75 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "60 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "28% (35 − 50)",
                "Hemoglobin (Hb)": "85 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "90 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "12 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "42 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.15 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.8% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "750 ng/mL (20 − 300 for females)",
                "CRP": "45 mg/L (< 3 mg/L)",
                "ESR": "50 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "1.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Bone Marrow Aspiration": "Presence of numerous immature myeloid cells indicating acute myeloid leukemia",
            "Cytochemical Staining": "Positive for myeloperoxidase staining",
            "Immunophenotyping": "Positive for CD13, CD33, and CD34 antigens",
            "Chromosome Karyotype": "Presence of 8;21 translocation mutation",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Pulmonary Function Test": "Reduced gas exchange efficiency",
            "Chest X-ray Exam": "Normal",
            "Liver Function Test": "Normal",
            "Kidney Function Test": "Normal",
            "Blood Chemistry": "Elevated lactate dehydrogenase and uric acid levels",
            "Bone and Joint Imaging": "No abnormalities detected"
        },
        "Treatment Plan": "Emma Li has been diagnosed with acute myeloid leukemia and requires immediate comprehensive treatment to address her severe symptoms, such as high fever and pronounced anemia. Given the major severity of her condition, induction chemotherapy with a combination of cytarabine and daunorubicin will be initiated to achieve hematologic complete remission, followed by consolidation therapy to prevent relapse. In consideration of her elevated uric acid levels, increased hydration and allopurinol will be administered to prevent hyperuricemia-associated nephropathy. Blood transfusions will be given to manage her anemia and maintain hemoglobin levels above 80g/L, alongside platelet transfusions as needed to prevent bleeding complications. Emma's past medical history and family history necessitate close monitoring of her response to treatment and potential side effects, particularly infections and bleeding, with prophylactic antibiotics administered if necessary. Her overall nutritional status will be supported with high-protein, high-calorie diet plans, tailored to her tolerance, and intravenous nutrition if required due to potential chemotherapy-induced gastrointestinal side effects. Regular assessment of her condition, including blood tests, bone marrow examinations, and kidney and liver function tests, will guide ongoing treatment adjustments. Emma and her family will receive education on the importance of hospitalization during treatment phase, adherence to therapy protocols, and vigilance for signs of complications. Post-treatment evaluations to determine minimal residual disease levels will be conducted to assess long-term remission sustainability. Based on her progress, hematopoietic stem cell transplantation may be considered as a definitive treatment option, emphasizing the importance of follow-up care and lifestyle modifications to support recovery and reduce leukemia recurrence risks."
    },
    {
        "Patient Information": {
            "Name": "James Wu",
            "Age": "47",
            "Gender": "Male",
            "Medical History": "High blood pressure, Chronic sinusitis"
        },
        "Disease Information": {
            "Disease": "Nasopharyngeal carcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Nasal congestion, tinnitus, hearing loss, blood in mucus, headache, neck lumps",
            "Duration": "Symptoms have been present for approximately six weeks, progressively worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "90 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "38% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "55% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.7 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "500 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "EBV",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Nasopharyngoscope Exam": "Lesion with nodular and rough surface on nasopharynx, easily bleeds",
            "MRI Scan": "Mass in nasopharyngeal area with extent into adjacent structures, indicative of Type II non-keratinizing carcinoma",
            "EBV Serology": "Positive for EBV-associated antibodies",
            "Chest CT": "No signs of lung or mediastinal lymph node metastasis detected",
            "Abdominal Ultrasound": "No abdominal metastases detected",
            "PET/CT Scan": "No evidence of distant metastases"
        },
        "Treatment Plan": "James Wu has been diagnosed with nasopharyngeal carcinoma, a malignancy characterized by symptoms including nasal congestion, blood in mucus, and hearing loss, alongside the presence of cervical lymphadenopathy. Given the diagnosis of major severity and the positive indications for radiotherapy, a comprehensive treatment plan involving intensity-modulated radiation therapy (IMRT) is recommended as the primary approach, owing to the tumor's high sensitivity to radiation. In parallel, induction chemotherapy using a platinum-based regimen may be administered to reduce tumor size and maximize treatment efficacy, followed by concurrent chemoradiotherapy. The use of targeted therapy, potentially employing EGFR inhibitors like cetuximab or immunotherapeutic agents such as PD-1 inhibitors, may be considered to further address tumor growth and manage residual disease. Regular monitoring of EBV DNA levels in the bloodstream will guide ongoing treatment effectiveness and modifications. Supportive care to manage side effects from treatment, including nutritional support, management of dry mouth, and nasal irrigation, will be integral. Psychological support for James and his family will be offered to aid in maintaining a positive outlook and adherence to the treatment regimen. Routine follow-up examinations will be scheduled to monitor for any recurrence or metastasis, with adjustments to the treatment plan as needed."
    },
    {
        "Patient Information": {
            "Name": "Li Wei",
            "Age": "45",
            "Gender": "Male",
            "Medical History": "Family history of nasopharyngeal carcinoma, frequent consumption of pickled foods"
        },
        "Disease Information": {
            "Disease": "Nasopharyngeal carcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Tinnitus, hearing loss, nasal congestion, blood in mucus, headaches, neck lumps, cranial nerve paralysis",
            "Duration": "Symptoms have been present and progressively worsening over several months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "29 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "76 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.7 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "160 U/L (22 − 198 for males)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "350 ng/mL (20 − 500 for males)",
                "CRP": "3 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "EBV DNA detected",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Cervical MRI": "Shows tumor presence with mass in nasopharynx, cervical lymphadenopathy",
            "Chest CT Scan": "No evidence of lung metastasis",
            "PET/CT Scan": "No distant metastasis detected",
            "Nasopharyngoscopy": "Nodular elevations in nasopharynx with rough surface and bleeding on touch",
            "Biopsy": "Confirmed squamous cell carcinoma at nasopharyngeal site",
            "EBV Serology": "High levels of EBV DNA present",
            "Abdominal Ultrasound": "No abdominal metastasis identified",
            "Neurological Examination": "Presence of cranial nerve deficits including facial numbness and double vision"
        },
        "Treatment Plan": "Li Wei has been diagnosed with nasopharyngeal carcinoma, with major severity due to symptoms including persistent nasal congestion, blood-stained mucus, and cranial nerve paralysis. Given the tumor's sensitivity to radiation, intensity-modulated radiation therapy (IMRT) will be initiated as the cornerstone of treatment, focusing the radiation dose precisely on the tumor while sparing adjacent healthy tissues. Due to the tumor's advanced stage, a combined approach with concurrent chemotherapy using Cisplatin will be employed to enhance radiotherapy effectiveness and manage systemic spread risks. Regular nasopharyngoscopy assessments and MRI scans are planned to gauge treatment efficacy and adjust protocols as needed. Li Wei will be monitored for treatment side effects such as dry mouth and nausea, with supportive care including hydration and analgesics provided. Psychological support will be offered to alleviate stress and anxiety related to disease management, as emotional wellbeing is crucial for optimal recovery. Nutritional counseling will ensure adequate intake to support recovery and treatment tolerance. Post-treatment, Li Wei will be engaged in routine follow-up evaluations every three months for the first two years to monitor for recurrence, adjusting to semi-annual reviews from year three to five, and annual reviews thereafter. Lifestyle modifications including a balanced diet low in pickled foods and cessation of smoking will be emphasized during and after treatment."
    },
    {
        "Patient Information": {
            "Name": "Wen Zhang",
            "Age": "45",
            "Gender": "Male",
            "Medical History": "High blood pressure, chronic sinusitis"
        },
        "Disease Information": {
            "Disease": "Nasopharyngeal carcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Intermittent blood in nasal mucus, tinnitus, hearing loss, nasal congestion, headaches, neck lumps, facial numbness, double vision",
            "Duration": "Symptoms have been persistent and worsening over the past several months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (62 − 106)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (4.3 − 5.7)",
                "Hematocrit (Hct)": "43% (38 − 52)",
                "Hemoglobin (Hb)": "140 g/L (130 − 175)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (150 − 400)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.0 × 10^9/L (1.0 − 3.0)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.7 × 10^9/L (2.0 − 7.0)",
                "Monocyte Abs. Ct. (MONO#)": "0.3 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.5)",
                "Eosinophil Percentage (EO%)": "2% (0 − 5)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.1)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (125 − 220)",
                "Muscle Enzymes (CK)": "90 U/L (39 − 308)",
                "Myoglobin": "60 ng/mL (< 70 ng/mL)",
                "Troponin I": "10 ng/L (< 20 ng/L)",
                "Ferritin": "300 ng/mL (30 − 400)",
                "CRP": "5 mg/L (< 10 mg/L)",
                "ESR": "25 mm/hr (< 20 mm/hr)",
                "Procalcitonin": "0.3 ng/mL (< 0.5 ng/mL)",
                "D-dimer": "0.4 mg/L FEU (< 0.5 mg/L FEU)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Epstein-Barr Virus (EBV) Antibodies": "Positive"
            },
            "Nasopharyngoscopy": "Nodular elevation observed on the nasopharyngeal wall with rough surface and tendency to bleed",
            "MRI Scan": "Tumor invasion in nasopharyngeal area with enlargement of cervical lymph nodes",
            "Chest CT Scan": "No evidence of lung metastasis",
            "PET/CT Scan": "Indications of bone metastasis",
            "Pathology Biopsy": "Presence of non-keratinizing squamous cell carcinoma",
            "Serological Diagnosis": "Elevated EBV DNA levels",
            "Cervical Lymph Node Examination": "Bilateral enlargement, hard and non-mobile nodes"
        },
        "Treatment Plan": "Wen Zhang has been diagnosed with nasopharyngeal carcinoma, showing major severity due to the persistence of symptoms such as blood-stained nasal discharge, tinnitus, and hearing loss. His background of high blood pressure and chronic sinusitis could complicate treatment. The treatment plan will primarily involve intensity-modulated radiation therapy (IMRT), which targets tumor cells effectively while minimizing damage to surrounding tissues. Due to the advanced stage of the disease and evidence of bone metastasis, concurrent chemotherapy with platinum-based agents like cisplatin will be initiated to enhance the effectiveness of radiotherapy. Continuous monitoring of EBV DNA levels and cervical lymph node response is crucial throughout treatment. Surgical intervention might be considered if there is recurrence or inadequate response to therapies. Wen will undergo regular nasopharyngoscopy and MRI assessments to evaluate tumor response and detect any recurrence. Supportive care with nutritional supplementation and traditional Chinese medicine may be included to manage side effects and improve the patient’s overall quality of life. Emotional and psychological support will be provided to help Wen manage stress and maintain a positive attitude towards recovery. Follow-ups will be scheduled every three months for the first two years post-treatment, every six months for the next three years, and annually thereafter to monitor his progress and adapt the treatment plan as needed."
    },
    {
        "Patient Information": {
            "Name": "John Carter",
            "Age": "68",
            "Gender": "Male",
            "Medical History": "Chronic smoker, occupational exposure to chemical dyes"
        },
        "Disease Information": {
            "Disease": "Bladder Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless gross hematuria, frequent urination, urgency, dysuria, difficulty urinating, lower back pain and discomfort due to ureteral obstruction",
            "Duration": "Intermittent hematuria lasting several months, with increasing frequency of symptoms",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU /L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "11% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "230 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "520 ng/mL (20 − 500 for males)",
                "CRP": "4 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "NMP22 positive",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Urine Tests": {
                "Routine Urinalysis": "Microscopic hematuria",
                "Urine Cytology": "Presence of tumor cells",
                "Bladder Tumor Antigen (BTA)": "Positive"
            },
            "Imaging Examinations": {
                "Ultrasound": "Bladder mass detected",
                "CT Urography": "Bladder wall thickening and mass with potential muscle invasion",
                "MRI": "Muscle invasion and adjacent organ involvement",
                "Whole-body Bone Imaging": "No bone metastasis",
                "PET-CT": "No lymph node or distant metastases detected"
            },
            "Cystoscopy": "Visible bladder tumor, biopsy confirms urothelial carcinoma",
            "Nuclear Matrix Protein 22 (NMP22)": "Positive"
        },
        "Treatment Plan": "John Carter is diagnosed with major severity bladder cancer with muscle invasion. Urgent surgical intervention is recommended, specifically radical cystectomy and pelvic lymph node dissection, due to potential muscle involvement identified via imaging. Pre-operative evaluations indicate surgery as the primary method for managing the cancer, followed by adjuvant systemic chemotherapy with a platinum-based regimen such as gemcitabine and cisplatin to address any microscopic metastatic disease. Concurrently, systemic immunotherapy with PD-L1 inhibitors may be considered if chemotherapy resistance is observed. Radiation therapy could be employed as an adjunct if surgery is deemed unfeasible or if residual cancerous tissues persist post-surgery. Preoperative counseling to discuss potential urinary diversion options post-cystectomy should be conducted, emphasizing the importance of stoma care post-procedure. John is urged to quit smoking and reduce exposure to chemical dyes to mitigate cancer progression and recurrence. Comprehensive follow-ups will be initiated, including cystoscopy, urine cytology, and imaging studies to monitor for recurrence and manage any complications arising from urinary diversion. Nutritional guidance and support to maintain a healthy diet post-treatment should be provided, alongside a plan for gradual physical activity tailored to John’s preferences and health status. Educational resources on bladder cancer management and support groups may be offered as part of holistic care, ensuring John remains informed and supported throughout his treatment journey."
    },
    {
        "Patient Information": {
            "Name": "William Thompson",
            "Age": "62",
            "Gender": "Male",
            "Medical History": "Chronic smoker, history of occupational exposure to chemicals, recurrent urinary tract infections"
        },
        "Disease Information": {
            "Disease": "Bladder cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless gross hematuria, urinary frequency, urgency, dysuria, difficulty urinating, and lower back pain",
            "Duration": "Symptoms have been present intermittently over the past six months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "105 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.1 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "120 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "5 ng/L (< 14 ng/L)",
                "Ferritin": "200 ng/mL (20 − 500 for males)",
                "CRP": "4 mg/L (< 3 mg/L)",
                "ESR": "22 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.2 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "Bladder tumor antigen (BTA)",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Cystoscopy Exam": "Presence of papillary tumor masses in the bladder",
            "Urine Cytology": "Positive for malignant cells",
            "CT Urography": "Irregular bladder wall thickening, suggestive of muscle invasion",
            "MRI": "Evidence of muscle invasive bladder carcinoma",
            "Chest X-ray": "Normal",
            "Bone Scan": "No evidence of bone metastasis",
            "PET-CT": "Localized disease, no evidence of distant metastases"
        },
        "Treatment Plan": "William Thompson has been diagnosed with muscle-invasive bladder carcinoma, necessitating a comprehensive and aggressive treatment plan. Immediate initiation of treatment includes surgical intervention, with a recommendation for radical cystectomy to remove the bladder and affected surrounding tissues, in conjunction with pelvic lymph node dissection to address potential metastatic spread. Given the localized nature of the disease and the absence of distant metastases, the prognosis for curability remains optimistic. Systemic chemotherapy with a regimen including gemcitabine and cisplatin will be administered preoperatively to shrink the tumor and postoperatively to address any residual disease and reduce the risk of recurrence. Systemic immunotherapy with PD-1 inhibitors may also be considered, given its effectiveness in bladder cancer resistant to conventional treatments. Post-surgical rehabilitation will include urinary diversion management and stoma care to ensure adaptation to urinary reconstruction, with close monitoring for complications. William will also be advised to cease smoking and manage occupational exposure to carcinogenic chemicals as preventive measures against recurrence. Regular follow-up with imaging studies, urine cytology, and bladder tumor markers will be crucial in the surveillance for recurrence and the management of long-term health. Nutritional guidance and physical therapy will support his recovery and overall well-being during the treatment process, with a focus on maintaining a healthy lifestyle to improve outcomes."
    },
    {
        "Patient Information": {
            "Name": "John Doe",
            "Age": "58",
            "Gender": "Male",
            "Medical History": "Chronic smoking history, frequent occupational exposure to aromatic amines due to work in a chemical plant"
        },
        "Disease Information": {
            "Disease": "Bladder Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless gross hematuria, increased frequency of urination, urgency, dysuria, and occasional difficulty urinating",
            "Duration": "Symptoms have been persistent for the past 3 months with intermittent hematuria initially appearing once every few weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Ferritin": "400 ng/mL (20 − 500 for males)",
                "CRP": "6 mg/L (< 3 mg/L)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Urinalysis": "Presence of red blood cells and elevated nuclear matrix protein 22 (NMP22)",
            "Cystoscopy": "Visible tumors within the bladder, biopsy confirms urothelial carcinoma",
            "CT Urography": "Mass in the bladder wall, no evidence of lymph node involvement",
            "MRI": "Muscle invasion assessment shows localized tumor without adjacent organ involvement",
            "Bone Imaging": "Negative for metastases",
            "PET-CT": "No distant metastasis, localized tumor in the bladder"
        },
        "Treatment Plan": "John Doe has been diagnosed with muscle-invasive bladder cancer, requiring a comprehensive treatment plan due to the major severity of the disease. Radical cystectomy with pelvic lymph node dissection is recommended to remove the tumor and prevent further tissue invasion. Given his history of smoking and occupational exposure to aromatic amines, cessation and lifestyle changes to mitigate these risk factors are advised. Preoperative chemotherapy may be considered to reduce tumor size and improve surgical outcomes. Post-surgery, systemic chemotherapy with platinum-based regimens such as gemcitabine and cisplatin will be administered, potentially augmented by PD-1 or PD-L1 inhibitors for enhanced immune response. Radiation therapy may be utilized as an adjunct to combat any residual or microscopic disease. Regular follow-up including urine cytology, imaging studies, and cystoscopy will be critical for monitoring potential recurrence and ensuring effective management. John should maintain a healthy diet, rich in fresh vegetables and low in high-fat foods, while abstaining from smoking and alcohol. Active engagement in a suitable exercise program and adherence to post-operative care guidelines will be crucial for recovery and long-term health."
    },
    {
        "Patient Information": {
            "Name": "Leonard Thompson",
            "Age": "62",
            "Gender": "Male",
            "Medical History": "Chronic smoking, previous episodes of bladder irritation, history of exposure to industrial chemicals"
        },
        "Disease Information": {
            "Disease": "Bladder Tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Painless hematuria, bladder irritation, difficulty urinating",
            "Duration": "Symptoms have been present intermittently over the past two months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU /L (13 − 35)",
                "Urea": "6.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "44% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.4 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.88 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Ferritin": "400 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Urine Cytology": "Presence of atypical cells",
            "MRI Examination": "Solid nodules located in the bladder trigone",
            "CT Scan": "No signs of invasion outside the bladder",
            "Ultrasound": "Low-echo mass detected in the bladder wall",
            "Cystography": "Presence of spherical filling defect in bladder",
            "Cystoscopy": "Biopsy confirms transitional cell carcinoma"
        },
        "Treatment Plan": "Leonard Thompson has been diagnosed with a bladder tumor characterized predominantly by painless hematuria, bladder irritation, and difficulty urinating. Given the moderate severity, the treatment plan will primarily focus on surgical intervention alongside potential chemotherapy. Transurethral resection of the bladder tumor (TURBT) is recommended to remove the superficial tumor effectively, minimizing the risk of recurrence. Post-surgery, intravesical chemotherapy using agents like epirubicin will be administered to further reduce recurrence risk. Regular follow-up appointments, including cystoscopic evaluations every three months, will be mandatory to monitor any potential recurrence and to assess the effectiveness of the treatment provided. Leonard will be advised to cease smoking and limit exposure to industrial chemicals that could exacerbate the condition. Nutritional support, moderate exercise, and maintaining a positive outlook will be essential components of his recovery regimen. The multidisciplinary team, including urology and oncology specialists, will continue to oversee Leonard's progress, with adjustments made to the treatment plan based on his response and subsequent imaging results. Active communication and education about symptom monitoring and preventative measures will be provided to Leonard and his family, ensuring optimal adherence to the treatment protocol."
    },
    {
        "Patient Information": {
            "Name": "Jordan Thompson",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Chronic smoking, previous episodes of hematuria"
        },
        "Disease Information": {
            "Disease": "Bladder Tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Painless hematuria, bladder irritation, difficulty urinating",
            "Duration": "Symptoms have been present for the last three weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "25 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.4 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "7 mg/L (< 3 mg/L)",
                "ESR": "22 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Urine Cytology": "Presence of atypical cells",
            "Abdominal CT Scan": "Presence of bladder wall nodular mass with enhancement",
            "Cystoscopy": "Visible tumor in bladder trigone with biopsy taken",
            "Ultrasound Examination": "Low-echo mass connected to bladder wall",
            "MRI Scan": "Lesion with moderate invasion into bladder wall, no lymph node involvement",
            "Tumor Marker Assessment": "Elevated urinary NMP22"
        },
        "Treatment Plan": "Jordan Thompson has been diagnosed with a bladder tumor, specifically transitional cell carcinoma with moderate severity. Due to the presence of hematuria and bladder irritation symptoms, immediate intervention is required. The primary treatment modality will be surgical, with transurethral resection of the bladder tumor (TURBT) planned to remove the superficial lesion. Postoperative intravesical chemotherapy with agents such as pirarubicin or epirubicin will be initiated to minimize recurrence risk, given the tumor's moderate stage. Regular cystoscopy every three months will be necessary to monitor any signs of recurrence or progression, with adjustments to the chemotherapy regimen based on findings. Smoking cessation and reducing exposure to industrial chemicals will be strongly encouraged to lower future risk. Nutritional support alongside lifestyle modifications including quitting smoking, managing any urinary tract infections promptly, and maintaining good hygiene will be incorporated to optimize health outcomes. Regular follow-ups at oncology clinics will be scheduled to assess response to treatment, ensuring a comprehensive and ongoing care strategy is in place. Should new symptoms arise, further imaging and diagnostic tests will be performed to tailor the treatment approach accordingly, with Jordan's adherence to the treatment plan being crucial for his recovery and future quality of life."
    },
    {
        "Patient Information": {
            "Name": "William Thompson",
            "Age": "62",
            "Gender": "Male",
            "Medical History": "Chronic smoker, history of recurrent urinary tract infections, exposure to industrial chemicals"
        },
        "Disease Information": {
            "Disease": "Bladder Tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless hematuria, bladder irritation, difficulty urinating",
            "Duration": "Symptoms have persisted for the past six months with gradual increase in frequency",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "5.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "145 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "200 ng/mL (20 − 500)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "60 μg/L (50 − 150)"
            },
            "Urine Cytology": "Atypical cells present",
            "Ultrasound Examination": "Presence of low-echo mass in the bladder",
            "CT Scan": "Solid-enhanced tumor located at the bladder trigone with invasion to the bladder wall",
            "MRI": "Thickened bladder wall with localized nodular mass, suggests bladder carcinoma",
            "Cystoscopy": "Visible tumor in the bladder trigone area, biopsy performed",
            "Biopsy Results": "Transitional cell carcinoma confirmed",
            "Urine Test": "Microscopic hematuria, slight pyuria",
            "Tumor Marker Assessment": "Elevated levels of bladder tumor markers",
            "Bladder Function Test": "Impaired bladder compliance"
        },
        "Treatment Plan": "William Thompson has been diagnosed with a major severity bladder tumor, identified as transitional cell carcinoma, necessitating a multi-faceted treatment approach due to its invasive nature and his risk factors, including chronic smoking and chemical exposure. The primary treatment will be transurethral resection of the bladder tumor (TURBT) to debulk the mass, followed by intravesical chemotherapy using agents like mitomycin or epirubicin to manage superficial disease and reduce recurrence risk. Given the tumor's invasive characteristics, comprehensive evaluation will determine the need for radical cystectomy. Post-surgery, close monitoring is crucial, with regular cystoscopies every three months in the initial year. For high-grade non-muscle invasive carcinoma, intravesical Bacillus Calmette–Guérin (BCG) therapy may be employed as an adjunct to prevent recurrence. The patient will be advised to cease smoking immediately, reduce exposure to known carcinogens, and adopt a healthier lifestyle to improve the prognosis. Immunotherapy options may be considered if systemic disease develops. William's treatment plan includes education on symptoms of recurrence, adherence to follow-up schedules, and supportive care, including pain management, adequate hydration, and nutritional support. The emphasis will be on reducing further risks, managing his overall health optimally, improving quality of life, and ensuring regular follow-up to evaluate treatment response and adjust as necessary."
    },
    {
        "Patient Information": {
            "Name": "John Doe",
            "Age": "55",
            "Gender": "Male",
            "Medical History": "Ulcerative colitis, rectal polyps"
        },
        "Disease Information": {
            "Disease": "Colon Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Changes in bowel habits, blood in the stool, abdominal pain, weight loss",
            "Duration": "Symptoms have been present for several months, progressively worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7−40)",
                "AST (Aspartate Aminotransferase)": "29 IU/L (13−35)",
                "Urea": "5.6 mmol/L (2.6−8.8)",
                "Creatinine (Cr)": "75 μmol/L (41−81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5−9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5−5.5)",
                "Hematocrit (Hct)": "40% (35−50)",
                "Hemoglobin (Hb)": "130 g/L (115−150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125−350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20−50)",
                "Neutrophil Percentage (NEUT%)": "65% (40−75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8−6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2−1.0)",
                "Monocyte Percentage (MONO%)": "8% (3−10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02−0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 - 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0−0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0−1)",
                "Mean Platelet Volume (MPV)": "10 fL (9−13)",
                "Lactate Dehydrogenase": "190 U/L (135−225)",
                "Muscle Enzymes (CK)": "88 U/L (22−198 for males)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "11 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20−500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0−20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0−0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "CEA elevated",
                "Blood Silver Level": "80 μg/L (50−150)"
            },
            "Colonoscopy Exam": "Presence of adenocarcinoma in the colon with luminal stenosis",
            "CT Scan": "Evidence of extramural invasion and possible lymph node involvement",
            "MRI": "Confirmed local tissue invasion, no distant metastasis observed",
            "Endoscopic Ultrasound": "Depth of infiltration reaches muscularis layer",
            "Fecal Occult Blood Test": "Positive",
            "Histopathological Examination": "Tubular adenocarcinoma",
            "Tumor Marker Test": "Elevated CA19-9 levels",
            "Immunohistochemistry": "Mismatch repair protein status normal",
            "Genetic Monitoring": "Wild-type K-ras and BRAF genes",
            "PET-CT": "No distant metastasis"
        },
        "Treatment Plan": "John Doe has been diagnosed with colon cancer, categorized as major severity due to invasive growth and luminal stenosis observed during colonoscopy. An individualized treatment plan is crafted considering his medical history of ulcerative colitis and rectal polyps, as well as his overall physical condition. Immediate surgical intervention is suggested to remove the tumor, with a preference for laparoscopic minimally invasive surgery due to its reduced recovery time and effective outcomes for early-stage lesions. Following surgical resection, chemotherapy with an FOLFOX regimen, combining oxaliplatin, leucovorin, and 5-fluorouracil, is recommended to eradicate potential micro-metastases and prolong disease-free survival. Nutritional support is crucial during treatment, with a focus on high-fiber, nutrient-rich diets to combat malnutrition and cachexia while managing bowel habits post-surgery. Pain management will be tailored individually, with regular monitoring through tumor marker tests, specifically CEA and CA19-9 levels, to assess treatment efficacy and detect recurrence. Psychological support and lifestyle guidance will be offered to promote a positive mindset and adherence to the treatment protocol. Regular follow-up examinations, including CT and MRI scans, are essential for ongoing assessment and adjustment of treatment strategies. Family education about stoma care will be provided if necessary, ensuring comprehensive management post-discharge. With steadfast adherence to the treatment protocol, John can achieve significant improvements in health and quality of life, while ensuring regular follow-ups to monitor progress and adapt strategies as necessary."
    },
    {
        "Patient Information": {
            "Name": "James Anderson",
            "Age": "55",
            "Gender": "Male",
            "Medical History": "Ulcerative colitis, family history of colorectal cancer"
        },
        "Disease Information": {
            "Disease": "Colon Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Blood in stool, changes in bowel habits, abdominal pain, weight loss, fatigue",
            "Duration": "Symptoms have persisted and escalated over the past four months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "130 U/L (22 − 198 for males)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "250 ng/mL (20 − 500 for males)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "CEA: 15 ng/mL (< 5 ng/mL)",
                "CA19-9": "40 U/mL (< 37 U/mL)"
            },
            "Colonoscopy": "Mass observed in the sigmoid colon with irregular margins",
            "Histopathological Examination": "Adenocarcinoma",
            "CT Scan": "Evidence of localized invasion in the colon, no distant metastasis observed",
            "MRI": "Shows detailed invasion of surrounding colon tissue, preparation for surgical assessment",
            "Tumor Marker Tests": "Elevated carcinoembryonic antigen (CEA) levels",
            "Imaging Examinations": "No abnormalities in lungs or liver"
        },
        "Treatment Plan": "James Anderson is diagnosed with major severity colon cancer, starting in the sigmoid colon, causing notable symptoms such as blood in stool and significant abdominal pain. Given the absence of distant metastasis and localized invasion, a surgical intervention is planned to remove the tumor and affected colon segment. Following surgery, adjuvant chemotherapy will be initiated, aiming to eliminate any microscopic residual disease. The chosen chemotherapy regimen will likely include 5-fluorouracil and oxaliplatin, aligned with the patient's genetic profile. Additionally, James will receive nutritional counseling to support recovery and manage weight loss. Regular follow-ups will be scheduled to monitor carcinoembryonic antigen (CEA) levels and ensure early detection of recurrence. A well-balanced diet focusing on high fiber and low-fat intake will be emphasized, alongside moderate physical activity to maintain overall health. Psychological support will be available to help James cope with the emotional aspects of his diagnosis and treatment path."
    },
    {
        "Patient Information": {
            "Name": "Thomas Carter",
            "Age": "52",
            "Gender": "Male",
            "Medical History": "Chronic ulcerative colitis, family history of colorectal cancer"
        },
        "Disease Information": {
            "Disease": "Colon Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Blood in stool, changes in bowel habits, abdominal pain, weight loss, frequent abdominal bloating",
            "Duration": "Symptoms have been progressively worsening over the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.1 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "41% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "290 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.1 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "95 U/L (22 − 198 for males)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "220 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Carcinoembryonic Antigen (CEA)": "15 ng/mL (< 5)",
                "Carbohydrate Antigen (CA19-9)": "45 U/mL (< 37)"
            },
            "Colonoscopy": "Presence of ulcerative and infiltrative neoplasm in the sigmoid colon",
            "CT Scan": "Thickening of the intestinal wall with potential lymph node involvement",
            "MRI": "Visible mass with signs of local invasion in the sigmoid colon",
            "PET-CT": "Active uptake in sigmoid colon, no distant metastasis detected",
            "Fecal Occult Blood Test": "Positive",
            "Immunohistochemistry": "Positive for MSH2, MLH1 expression"
        },
        "Treatment Plan": "Thomas Carter has been diagnosed with major severity colon cancer, requiring a multidisciplinary approach for optimal management. Given the presence of a significant neoplastic mass in the sigmoid colon and local invasion, immediate surgical intervention is necessary to resect the tumorous growth and any affected lymph nodes, followed by adjuvant chemotherapy to prevent further spread of malignant cells and manage potential micro-metastases. Due to the elevated carcinoembryonic antigen levels, regular monitoring post-surgery is crucial. A chemotherapy regimen, such as FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil), will be implemented to target residual cancerous cells. Nutritional support and pain management will play important roles throughout the treatment process, ensuring Thomas maintains adequate nutrition and comfort. Genetic counseling is recommended due to his significant family history of colorectal cancer. Collaboration with a nutritionist will help establish an appropriate dietary plan geared towards high-fiber, low-fat intake to aid recovery and reduce recurrence risk. Psychological support and continuous engagement with supportive care services are advised to assist Thomas and his family in coping with the emotional and physiological demands of cancer treatment. Regular post-operative imaging and stool tests will be scheduled to monitor recovery and detect potential recurrences early."
    },
    {
        "Patient Information": {
            "Name": "John Smith",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Viral hepatitis, primary sclerosing cholangitis"
        },
        "Disease Information": {
            "Disease": "Bile duct cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Jaundice, right upper abdominal pain, nausea, dark yellow urine, itchy skin, lethargy, weight loss",
            "Duration": "Symptoms have been present for several weeks and are worsening",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "120 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "150 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.4 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Positive",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "115 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "68% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.58 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "320 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "85 U/L (22 − 198)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "No specific antigen detected",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Dilation of intrahepatic bile ducts and a mass seen within the liver",
            "MRI": "Mass lesion in the liver consistent with cholangiocarcinoma, mild ascites",
            "ERCP": "Obstruction in bile duct with stent placement needed",
            "PTC": "Intrahepatic ductal dilation with obstructive mass",
            "Liver Function Tests": "Increased total bilirubin and alkaline phosphatase",
            "Tumor Markers": "Elevated CA19-9, normal CEA",
            "Endoscopic Ultrasound": "Tumor infiltration observed near bile duct",
            "Coagulation Test": "Prolonged prothrombin time",
            "Complete Blood Count": "Anemia and mild leukocytosis",
            "Hepatorenal Syndrome Evaluation": "No evidence of hepatorenal syndrome",
            "Pathological Examination": "Adenocarcinoma of bile duct"
        },
        "Treatment Plan": "John Smith has been diagnosed with cholangiocarcinoma, which has resulted in the obstruction of bile ducts and significant jaundice. The primary goal of treatment is symptom relief and maintaining quality of life. Given the advanced stage of the disease, surgical resection is not feasible. Placement of a biliary stent via ERCP has been performed to relieve jaundice and bile duct obstruction. Nutritional support will be provided to address malnutrition and deficiencies, focusing on easy-to-digest, low-fat foods, supplemented by vitamins and proteins as needed. Chemotherapy regimens including gemcitabine and cisplatin may be initiated to manage disease progression and improve longevity. Vitamin K supplementation is necessary to improve coagulation function. Pain management is crucial, with analgesics prescribed for abdominal pain. Regular monitoring of blood tests, liver function, and imaging studies will be essential to gauge the patient’s response to treatment. Supportive care with psychological counseling will be offered to address mental health and ensure a positive outlook. Bile duct drainage site care will be meticulously maintained to prevent infection. Palliative care options may be explored further to enhance comfort, and home care support is advised to assist with daily living activities and disease management."
    },
    {
        "Patient Information": {
            "Name": "James Thompson",
            "Age": "60",
            "Gender": "Male",
            "Medical History": "Chronic hepatitis B, history of hepatolithiasis"
        },
        "Disease Information": {
            "Disease": "Bile Duct Cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Abdominal pain, jaundice, fatigue, dark urine, pale stools, weight loss",
            "Duration": "Symptoms have gradually worsened over the past few months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "78 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "85 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "82 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Positive",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "150 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "340 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "88 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "500 ng/mL (20 − 500 for males)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "CA19-9",
                "Blood Silver Level": "68 μg/L (50 − 150)"
            },
            "Ultrasound Examination": "Dilation of intrahepatic bile ducts, mass seen at the hepatic hilum",
            "MRI": "Mass-forming lesion in the right liver lobe with biliary obstruction",
            "Endoscopic Ultrasound": "Thickening of bile duct walls and suspected lymph node enlargement",
            "ERCP": "Narrowing of the bile duct with irregular walls",
            "Liver Function Test": "Elevated bilirubin and alkaline phosphatase levels",
            "CA19-9 Level": "Elevated at 120 U/mL (normal < 37 U/mL)",
            "CEA Level": "Normal",
            "Bilirubin Level": "Total bilirubin 25 mg/dL (normal 0.1 - 1.2 mg/dL)",
            "Hepatobiliary Scan": "Decreased uptake in the right liver lobe"
        },
        "Treatment Plan": "Given the diagnosis of advanced bile duct cancer and the presence of comorbid chronic hepatitis B and previous hepatolithiasis, James Thompson will require a comprehensive approach to manage his symptoms and improve his quality of life. Surgical resection is not feasible due to the extent of the disease and potential distant metastasis. An interdisciplinary team will focus on palliative care measures, including biliary stenting through ERCP to alleviate jaundice and improve bile flow. Chemotherapy with gemcitabine and cisplatin is considered to manage tumor progression, although its curative potential is limited. Nutritional support will be critical, emphasizing a diet low in fat with adequate protein intake, utilizing enteral nutrition if necessary, to manage malnutrition and maintain strength. Vitamin K supplementation and monitoring of coagulation parameters will be essential due to impaired liver function and the risk of bleeding. Regular follow-ups will include imaging to assess disease progression and adjust treatment as necessary. James and his family will receive support and education on managing symptoms at home and maintaining a high quality of life, with a focus on psychological support and comfort care."
    },
    {
        "Patient Information": {
            "Name": "Thomas Lee",
            "Age": "64",
            "Gender": "Male",
            "Medical History": "Diabetes, Hepatitis B infection, recurrent pyogenic cholangitis"
        },
        "Disease Information": {
            "Disease": "Bile duct cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Abdominal pain, jaundice, fatigue, weight loss, fever",
            "Duration": "Symptoms have been present for approximately 3 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "55 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "60 IU/L (13 − 35)",
                "Urea": "5.3 mmol/L (2.6−8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Positive",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.1 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "180 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.6 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.3 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "3% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.04 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.6% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "CA19-9": "210 U/mL (< 37)",
                "CEA": "5 ng/mL (< 5)",
                "AFP": "4 ng/mL (< 5)",
                "Serum Total Bilirubin": "35 mg/dL (< 1.2)",
                "Direct Bilirubin": "25 mg/dL (< 0.6)",
                "Alkaline Phosphatase": "150 U/L (30 − 120)",
                "Gamma-glutamyl Transpeptidase": "90 U/L (9 − 50)",
                "Prothrombin Time": "17 seconds (11 − 15)",
                "Albumin": "3.2 g/dL (3.5 − 5.2)"
            },
            "Ultrasound Examination": "Mass in the liver with bile duct dilation",
            "MRI": "Intrahepatic mass with involvement of bile ducts",
            "Endoscopic Ultrasound": "Nodular lesions along the distal bile duct",
            "ERCP": "Bile duct stricture with proximal dilation",
            "PTC": "Obstructive lesions in bile ducts",
            "PET-CT": "Metastatic lesions identified in liver and regional lymph nodes",
            "Biopsy": "Adenocarcinoma of bile duct"
        },
        "Treatment Plan": "Thomas Lee has been diagnosed with major severity bile duct cancer, with a history of diabetes and hepatitis B contributing to his current condition. Given the progression and metastasis of the disease, surgical resection is not feasible, focusing instead on palliative care and symptom management. Radiotherapy and chemotherapy are recommended, aiming to control tumor growth and alleviate symptoms. A regimen of gemcitabine combined with cisplatin will be initiated, supplemented by vitamin K and coagulation factors to address coagulopathy due to bile duct obstruction and impaired liver function. Nutritional support through enteral and parenteral feeding is crucial, with a diet low in fat to accommodate lipid digestion issues, ensuring a balanced intake of proteins and electrolytes. Regular monitoring of blood tests, imaging studies, and CA19-9 levels will be necessary to assess treatment efficacy and adjust plans accordingly. Daily life management including skin care to mitigate jaundice-related itching, maintaining hydration, and a positive mental state are imperative. Palliative surgical interventions, such as biliary stenting, may be considered for drainage and symptom relief, along with possible targeted therapies to inhibit tumor pathways. Thomas and his family will receive education about the importance of follow-up, monitoring changes in his condition, and maintaining a supportive home environment to enhance quality of life during treatment."
    },
    {
        "Patient Information": {
            "Name": "Linda Thompson",
            "Age": "68",
            "Gender": "Female",
            "Medical History": "Chronic cholecystitis, gallstones, diabetes"
        },
        "Disease Information": {
            "Disease": "Gallbladder Cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Persistent abdominal pain, palpable mass in the upper right abdomen, progressive jaundice, anorexia, weight loss",
            "Duration": "Symptoms have been worsening progressively over the past three months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "65 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "80 IU/L (13 − 35)",
                "Urea": "7.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "9.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "125 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "6.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "11 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "85 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 300 for females)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.35 ng/mL (< 0.5)",
                "D-dimer": "1.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Irregular hypoechoic mass at the gallbladder fundus with liver invasion",
            "CT Scan": "Tumor invasion into liver and bile ducts, lymph node metastasis",
            "MRI": "Mass extending beyond gallbladder walls, biliary tract dilation",
            "Tumor Marker Test": {
                "CA-199": "800 U/mL (< 37)",
                "CEA": "100 ng/mL (< 5)"
            },
            "PET-CT": "High uptake indicating metastasis to lymph nodes and liver"
        },
        "Treatment Plan": "Linda Thompson has been diagnosed with advanced gallbladder cancer with metastasis, necessitating an immediate and well-coordinated treatment plan centered around palliation rather than curability. Radical surgery is not feasible due to the late stage of disease progression and extensive metastasis, hence palliative care aimed at symptom management and quality of life improvement is paramount. Linda will be initiated on chemotherapy regimen tailored to control tumor growth and alleviate symptoms, potentially using gemcitabine-based therapy, complemented by radiotherapy to manage local tumor invasion and reduce pain. Analgesic and antispasmodic medications will be administered to manage persistent abdominal pain and discomfort, alongside nutritional support to counteract weight loss and anorexia. Enzyme supplements and hepatoprotective agents will be provided to support liver function. Endoscopic biliary stenting or nasobiliary drainage might be necessitated to relieve jaundice and improve bile drainage. Regular monitoring through imaging and blood tests will be essential to evaluate the effectiveness of treatment and adjust the therapeutic approach accordingly, ensuring adverse effects are minimized and Linda's comfort is prioritized. Linda and her family will be guided through this challenging phase, emphasizing the importance of supportive care, regular follow-up appointments, and psychological support to help cope with the diagnosis and maintain a positive outlook."
    },
    {
        "Patient Information": {
            "Name": "Julia Smith",
            "Age": "68",
            "Gender": "Female",
            "Medical History": "History of gallstones, hypertension, and diabetes"
        },
        "Disease Information": {
            "Disease": "Gallbladder Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent dull upper right abdominal pain, palpable mass in the upper right abdomen, progressive jaundice, anorexia, weight loss",
            "Duration": "Symptoms have developed increasingly over the past few weeks",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "52 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "65 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.7 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.6 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.08 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "270 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (<90 ng/mL)",
                "Troponin I": "15 ng/L (< 14 ng/L)",
                "Ferritin": "550 ng/mL (20 − 500 for females)",
                "CRP": "45 mg/L (< 3 mg/L)",
                "ESR": "38 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "1.2 mg/L FEU (0 − 0.5)",
                "Rh Type": "Negative",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Gallbladder wall thickening with polypoid lesions",
            "CT Scan": "Infiltration of gallbladder wall and involvement of nearby hepatic tissue",
            "MRI": "Enhanced thickening of gallbladder wall with liver invasion, probable lymph node metastasis",
            "Tumor Markers": "Elevated levels of CEA and CA-199",
            "Endoscopic Ultrasound": "Mass involving liver and gallbladder wall",
            "PET-CT": "Increased uptake in gallbladder, suggestive of malignancy"
        },
        "Treatment Plan": "Julia Smith is facing a challenging diagnosis of gallbladder cancer, characterized by major severity due to symptoms such as dull abdominal pain and jaundice. Given the advanced nature of her condition and the poor curability, the treatment plan focuses primarily on managing symptoms and attempting to extend survival. Surgical intervention, specifically radical cholecystectomy, may be considered if the tumor stage allows, aiming for complete resection of the gallbladder and adjacent tissues if feasible. For unresectable or advanced stages, palliative care with supportive therapies including chemotherapy using gemcitabine, possibly combined with radiotherapy to alleviate symptoms and decrease tumor progression, might be recommended. Nutrition management will be crucial, involving easily digestible foods and potential nutritional supplements to counteract cachexia. Symptomatic relief for jaundice, abdominal pain, and digestive issues through liver protection agents and analgesics will be administered as required, alongside monitoring for infections. Careful postoperative observation and tailored follow-up plans, including regular imaging and blood tests, will be pivotal for ongoing assessment of her condition. Julia is encouraged to adhere to medical advice, engage in moderate exercise as tolerated, and maintain a positive outlook to optimize her quality of life during treatment. Regular consultations will ensure adjustments to the treatment strategy based on her response and new developments in medical care."
    },
    {
        "Patient Information": {
            "Name": "Evelyn Thompson",
            "Age": "68",
            "Gender": "Female",
            "Medical History": "Chronic cholecystitis, gallstones, obesity, diabetes"
        },
        "Disease Information": {
            "Disease": "Gallbladder Cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Persistent upper right abdominal pain, palpable mass in upper right abdomen, progressive jaundice, weight loss, anorexia",
            "Duration": "Symptoms have gradually worsened over the past three months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "70 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "85 IU/L (13 − 35)",
                "Urea": "9.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "90 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "6.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.7 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.6% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "500 ng/mL (20 − 500 for females)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Carcinoembryonic Antigen (CEA)",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Imaging Studies": {
                "Abdominal Ultrasound": "Mass detected in the gallbladder, gallstones present",
                "CT Scan": "Tumor invading liver and extrahepatic bile ducts, enlarged lymph nodes",
                "MRI": "Confirms tumor mass in gallbladder with liver invasion, biliary ductal obstruction",
                "Endoscopic Ultrasound": "Mass with irregular borders, involvement of liver tissue",
                "PET-CT": "Increased metabolic activity in gallbladder region indicating malignancy"
            },
            "Tumor Marker Tests": {
                "Carcinoembryonic Antigen (CEA)": "Elevated",
                "CA-19-9": "Significantly elevated"
            }
        },
        "Treatment Plan": "Evelyn Thompson's diagnosis of advanced gallbladder cancer necessitates a carefully managed treatment approach. Due to the widespread malignancy and severe liver and bile duct involvement, surgical intervention is limited to palliative measures. A multidisciplinary team will closely monitor and assess her condition, focusing on alleviating symptoms and maintaining quality of life. Chemotherapy regimens based on gemcitabine may be initiated to attempt slowing tumor progression, complemented by radiotherapy aimed at reducing local tumor burden. Supportive care is crucial to address her symptoms, including liver-protective agents and medications to relieve jaundice. Nutritional support will be emphasized due to her weight loss and anorexia, and analgesics will be administered to manage pain. Given the limited curability of her condition, the focus will also be on providing psychological support and palliative care services to ensure her comfort and dignity. Regular follow-ups will be scheduled to adapt the treatment plan according to her needs, and to monitor for any potential complications arising from treatment or disease progression."
    },
    {
        "Patient Information": {
            "Name": "Richard Thompson",
            "Age": "68",
            "Gender": "Male",
            "Medical History": "History of smoking, Clonorchis sinensis infection, gallstones"
        },
        "Disease Information": {
            "Disease": "Bile Duct Tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless jaundice, dark urine, yellowing of the sclera and skin, clay-colored stools, skin itching, fatigue, anorexia, weight loss, palpable abdominal mass",
            "Duration": "Symptoms have been progressively worsening over the past few weeks",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "70 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "85 IU/L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.6% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "270 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "5 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Imaging Studies": {
                "Abdominal Ultrasound": "Dilation of bile ducts above the tumor",
                "CT Scan": "Mass found in the bile duct with potential liver metastasis",
                "MRI": "Shows bile duct tumor extent, non-resectable",
                "Endoscopic Ultrasound": "Bile duct obstruction confirmed",
                "ERCP": "Bile duct obstruction with non-obstructive mass below it",
                "PTC": "Bile duct condition above obstruction assessed",
                "PET-CT": "Confirms malignant potential with no distant metastasis",
                "Choledochoscopy": "Non-resectable mass confirmed in bile duct"
            }
        },
        "Treatment Plan": "Richard Thompson has been diagnosed with a bile duct tumor, which has been classified as non-resectable due to its location and extent of involvement, as shown by MRI and PET-CT. Given the severity of his condition, immediate palliative care is necessary. The primary treatment goal is to manage symptoms and improve quality of life. Endoscopic retrograde cholangiopancreatography (ERCP) will be performed to insert a stent to alleviate the obstruction and manage jaundice. Percutaneous transhepatic biliary drainage (PTBD) is planned to further relieve biliary obstruction. Neoadjuvant chemotherapy may be considered to potentially downstage the tumor, making it more amenable to future surgical intervention though the likelihood of curative resection remains low. In addition, nutritional support, as well as medication for symptom control, including anti-pruritics for itching and analgesics for pain management, will be provided. Regular follow-up with oncology and hepatobiliary teams will ensure dynamic adaptation of the treatment plan, focusing on maintaining Richard's quality of life and managing any complications that may arise."
    },
    {
        "Patient Information": {
            "Name": "John Stevens",
            "Age": "72",
            "Gender": "Male",
            "Medical History": "History of gallstones, Clonorchis sinensis infection, and cirrhosis"
        },
        "Disease Information": {
            "Disease": "Bile duct tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless jaundice, weight loss, dark urine, pale stools, itchy skin, anorexia, fatigue, anemia",
            "Duration": "Symptoms have persisted and gradually worsened over the past several months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "78 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "90 IU /L (13 − 35)",
                "Urea": "8.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.8 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "118 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.12 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.9% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "110 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "700 ng/mL (20 − 500 for males)",
                "CRP": "30 mg/L (< 3 mg/L)",
                "ESR": "60 mm/hr (0 − 20)",
                "Procalcitonin": "0.8 ng/mL (< 0.5)",
                "D-dimer": "1.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Normal",
            "Abdominal Ultrasound": "Dilation of intrahepatic bile ducts",
            "Abdominal MRI": "Intrahepatic bile duct tumor with possible metastasis",
            "Serological Diagnosis": "Elevated bilirubin levels",
            "Biliary Imaging": "Obstruction in intrahepatic bile ducts",
            "Percutaneous Transhepatic Cholangiography": "Dilation above tumor site",
            "Positron Emission Tomography-Computed Tomography (PET-CT)": "Potential distant metastasis",
            "Endoscopic Retrograde Cholangiopancreatography": "Dilation below obstruction, stenting may be required",
            "Choledochoscopy": "Indication of malignant bile duct stricture",
            "Pathological Examination": "Adenocarcinoma histology confirmed"
        },
        "Treatment Plan": "John Stevens has been diagnosed with a major severity bile duct tumor, which is primarily adenocarcinoma with indications of potential metastasis. Given the nature and stage of the tumor, surgical resection is the most viable option for treatment; however, in cases where the tumor is deemed non-resectable due to metastasis or other complications, neoadjuvant chemotherapy may be considered to downstage the tumor in hopes of later surgical intervention. Prior to surgery, biliary drainage may be necessary due to John's elevated bilirubin levels and potential for cholangitis, ensuring the patient is stable and reducing complications during surgery. During the surgical procedure, efforts will be focused on removing as much of the tumor as possible, and if radical resection is not achievable, palliative measures such as biliary stenting or drainage will be implemented to relieve symptoms. Post-surgery, John will require regular monitoring and follow-up evaluations, including assessment of tumor markers (CEA, CA19-9) and imaging studies to track any recurrence or progression. Enhanced nutritional support and management of coexisting conditions, including any symptoms or complications associated with cirrhosis and gallstones, will be necessary. John will also benefit from lifestyle adjustments, such as smoking cessation, dietary modifications, and overall health improvements to reduce risk factors for disease progression. With a comprehensive and proactive approach, treatment plans will be tailored to John's response, including potential enrollment in clinical trials for targeted therapies or adjunctive treatments that may offer improved outcomes. Close collaboration between John and his healthcare team is essential to effectively manage his condition, with regular appointments and adherence to the treatment protocol being crucial for optimal outcomes."
    },
    {
        "Patient Information": {
            "Name": "Robert Harrison",
            "Age": "68",
            "Gender": "Male",
            "Medical History": "Chronic jaundice, history of smoking, previous liver fluke infection"
        },
        "Disease Information": {
            "Disease": "Malignant Bile Duct Tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless jaundice, dark urine, yellowing of the sclera and skin, pale stools, skin itching, weight loss",
            "Duration": "Symptoms have been persisting and worsening over the past 3 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "52 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "60 IU/L (13 − 35)",
                "Urea": "6.1 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Total Bilirubin": "380 μmol/L (3 − 20)",
                "Direct Bilirubin": "250 μmol/L (0 − 5)",
                "Alkaline Phosphatase (ALP)": "650 IU/L (44 − 147)",
                "Gamma-Glutamyl Transferase (GGT)": "450 U/L (15 − 85)",
                "CA 19-9": "1200 U/mL (< 37)",
                "CA 125": "85 U/mL (< 35)",
                "Carcinoembryonic Antigen (CEA)": "15 ng/mL (< 5)",
                "White Blood Cell Ct. (WBC)": "5.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.1 × 10^12/L (3.5 − 5.5)",
                "Hemoglobin (Hb)": "100 g/L (130 − 170)",
                "Platelet Ct. (PLT)": "180 × 10^9/L (150 − 400)",
                "Lactate Dehydrogenase": "240 U/L (135 − 225)"
            },
            "Abdominal Ultrasound": "Dilation of the bile ducts with a mass in the distal bile duct",
            "CT Scan": "Mass in the distal bile duct causing obstruction, no visible liver metastasis",
            "MRI": "Advanced tumor in the distal bile duct with unclear margins",
            "Endoscopic Ultrasound": "Obstructive features in the distal bile duct, confirming mass presence",
            "PET-CT": "Increased uptake in bile duct area with no distant metastasis",
            "Endoscopic Retrograde Cholangiopancreatography (ERCP)": "Obstruction at the distal bile duct with dilation above the obstruction",
            "Percutaneous Transhepatic Cholangiography (PTC)": "Severe stricture in the distal bile duct",
            "Choledochoscopy": "Presence of malignant features in bile duct stricture"
        },
        "Treatment Plan": "Robert Harrison has been diagnosed with a malignant distal bile duct tumor presenting major severity symptoms, including persistent painless jaundice and weight loss over the past three months. Given the advanced nature of the tumor and the currently unresectable state, surgical resection is not feasible, hence a multidisciplinary approach is necessary. Initial treatment involves palliative measures to relieve symptoms and improve quality of life. ERCP with biliary stenting is recommended to alleviate the obstructive jaundice, and possibly PTBD if ERCP is insufficient. Neoadjuvant chemotherapy may be employed in an attempt to downstage the tumor, potentially rendering it operable in the future. Simultaneously, nutritional support and management of any biliary infections are crucial. Regular monitoring using tumor markers such as CA 19-9 and imaging studies are necessary to assess the progress and effectiveness of the treatment. Follow-up care includes evaluations every three months with a focus on physical condition and laboratory markers. Precautionary measures like quitting smoking and managing risk factors such as gallstones and liver infections are essential for his long-term care."
    },
    {
        "Patient Information": {
            "Name": "John Doe",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Hypertension, Type 2 diabetes"
        },
        "Disease Information": {
            "Disease": "Malignant Lymphoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless progressive lymph node enlargement, night sweats, unexplained fever, weight loss, fatigue",
            "Duration": "Symptoms have been present for approximately 6 months, with gradual worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (70 − 110)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "9.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (4.5 − 5.5)",
                "Hematocrit (Hct)": "38% (40 − 50)",
                "Hemoglobin (Hb)": "120 g/L (135 − 175)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (150 − 400)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 40)",
                "Neutrophil Percentage (NEUT%)": "60% (50 − 70)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.2 × 10^9/L (1.0 − 3.0)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.4 × 10^9/L (2.0 − 7.0)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (2 − 8)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.5)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4 − 5.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0.01 − 0.1)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (7.5 − 11.5)",
                "Lactate Dehydrogenase": "260 U/L (100 − 220)",
                "Muscle Enzymes (CK)": "150 U/L (90 − 180)",
                "Myoglobin": "70 ng/mL (28 − 72)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "500 ng/mL (20 − 320 for males)",
                "CRP": "5 mg/L (< 10 mg/L)",
                "ESR": "50 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mild mediastinal lymphadenopathy",
            "Chest Computerized Tomography": "Enlarged cervical and supra-clavicular lymph nodes",
            "Serological Diagnosis": "Elevated LDH levels",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for relevant viral antibodies",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative for EBV",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Mild tonsillar hypertrophy",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "John Doe has been diagnosed with malignant lymphoma, presenting with major severity due to persistent systemic and localized symptoms such as painless lymph node enlargement, unexplained fever, night sweats, and weight loss. Given the stage and severity of his condition, a combination of therapies is recommended to maximize efficacy and improve quality of life. Chemotherapy will be initiated with the CHOP regimen, known to be effective in treating non-Hodgkin lymphoma, administered in cycles every three weeks alongside Rituximab (R-CHOP regimen) to target CD20-positive B-cell lymphoma, if applicable. Supportive care will include managing side effects with antiemetics for nausea, analgesics for pain management, and growth factors to address potential blood count suppression. In cases of treatment resistance or significant residual disease, local radiotherapy may be considered to target specific lymph node regions. Regular monitoring for treatment response through imaging and laboratory tests will be critical. Additionally, the patient will be offered nutritional support, psychological counseling, and education about the disease and its treatment plan, involving family members to ensure comprehensive care. Future options, including possible participation in clinical trials for novel therapies or stem cell transplantation, may be evaluated based on treatment progress and response."
    },
    {
        "Patient Information": {
            "Name": "Richard Thompson",
            "Age": "62",
            "Gender": "Male",
            "Medical History": "Former smoker, hypertension, previous Epstein-Barr virus infection"
        },
        "Disease Information": {
            "Disease": "Malignant Lymphoma (Non-Hodgkin Lymphoma)",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless progressive lymph node enlargement, unexplained fever, night sweats, weight loss, fatigue, skin itching",
            "Duration": "Symptoms have been noticeable over the past 3 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "6.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.7 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "150 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.12 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "250 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for males)",
                "Myoglobin": "85 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for males)",
                "CRP": "45 mg/L (< 3 mg/L)",
                "ESR": "50 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "No significant findings",
            "Chest Computerized Tomography": "Mediastinal lymph node enlargement",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Positive for EBV antibodies",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Richard Thompson, diagnosed with major severity non-Hodgkin lymphoma, presents with symptomatic lymph node enlargement, unexplained fever, and night sweats, indicating significant disease progression over the past three months. A treatment plan involving combination chemotherapy with the R-CHOP regimen is recommended, encompassing rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone to target lymphoma cells effectively. Chemotherapy cycles will occur every three weeks, accompanied by regular monitoring for treatment response and potential side effects such as bone marrow suppression, requiring supportive care measures like growth factor support for neutropenia. Concurrently, targeted therapy with Ibrutinib may be initiated for its efficacy in inhibiting lymphoma proliferation. Radiotherapy may be considered for localized control of affected lymph nodes, especially if symptoms persist or disease progression is detected. Nutritional support, hydration, and pain management are crucial for maintaining Richard's quality of life, along with psychological support to address the emotional challenges of treatment. Regular follow-up appointments will be scheduled to monitor his progress, adjust therapeutic interventions as needed, and ensure he receives comprehensive care tailored to his needs, including potential enrollment in clinical trials for innovative therapies should standard treatments prove insufficient."
    },
    {
        "Patient Information": {
            "Name": "Richard Thompson",
            "Age": "68",
            "Gender": "Male",
            "Medical History": "Hypertension, previous history of bronchitis"
        },
        "Disease Information": {
            "Disease": "Malignant lymphoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Night sweats, unexplained fever, fatigue, progressive lymph node enlargement in the neck and underarm areas, weight loss",
            "Duration": "Symptoms have been present and worsening over the past three months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "33 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "87 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.7 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "9.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.1 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.85 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.7 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.45 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.12 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "185 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "350 ng/mL (20 − 500 for males)",
                "CRP": "30 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Mediastinal lymph node enlargement",
            "Serological Diagnosis": "Elevated LDH levels",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Positive for Epstein-Barr virus antibodies",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Richard Thompson has been diagnosed with major severity malignant lymphoma, specifically involving progressive lymph node enlargement and systemic symptoms such as unexplained fevers and significant night sweats over the past three months, requiring a targeted and intensive treatment strategy. The treatment will incorporate combination chemotherapy, potentially employing the R-CHOP regimen comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in cycles, adapting to his specific subtype and responsiveness, along with potential involvement of new molecular targeted drugs such as ibrutinib for advanced cases or relapsed conditions. Given Richard's age and prior history of hypertension, careful monitoring for cardiotoxicity and nephrotoxicity will be essential during treatment, with interventions to manage any arising side effects like bone marrow suppression, necessitating supportive measures such as growth factor support and transfusions. Radiation therapy may be considered for specific localized lymph node involvements if chemotherapy alone proves less effective, ensuring doses are optimally configured to minimize collateral damage. Richard will also benefit from supportive therapies, including nutritional support to counteract treatment-related weight loss and fatigue, along with psychological support to address the stress and emotional challenges of ongoing treatment. Regular follow-ups and imaging tests, such as PET/CT scans, will be conducted to assess treatment efficacy and adjust protocols as required. Open communication with Richard and his family regarding treatment expectations and potential outcomes will be maintained to ensure a comprehensive understanding and adherence to the therapeutic regimen, aiming for maximum remission or disease control. Post-treatment recovery plans may incorporate rehabilitative care focusing on physical recovery and immune system bolstering, aligning with Richard's overall health objectives and quality of life improvement."
    },
    {
        "Patient Information": {
            "Name": "Emily Johnson",
            "Age": "4",
            "Gender": "Female",
            "Medical History": "Frequent respiratory infections, persistent fatigue, and pallor over the past few months"
        },
        "Disease Information": {
            "Disease": "Childhood Acute Lymphoblastic Leukemia (ALL)",
            "Severity Level": "Major Severity",
            "Symptoms": "Unexplained low-grade fever, anemia, bleeding, lymphadenopathy, hepatosplenomegaly, and fatigue",
            "Duration": "Symptoms have manifested progressively over the past three months with an acute phase lasting six weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "3.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "32 μmol/L (28 − 60 for children)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.0 for children)",
                "Total Cholesterol (TC)": "3.9 mmol/L (< 4.8 for children)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "15.0 × 10^9/L (5.0 − 12.0 for children)",
                "Red Blood Cell Ct. (RBC)": "3.2 × 10^12/L (4.0 − 5.2 for children)",
                "Hematocrit (Hct)": "28% (35 − 45 for children)",
                "Hemoglobin (Hb)": "90 g/L (110 − 140 for children)",
                "Platelet Ct. (PLT)": "50 × 10^9/L (150 − 450)",
                "Lymphocyte Percentage (LYMPH%)": "60% (25 − 50)",
                "Neutrophil Percentage (NEUT%)": "20% (30 − 60)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "9.0 × 10^9/L (1.5 − 7.0)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.5 − 8.0)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.1 − 0.8)",
                "Monocyte Percentage (MONO%)": "10% (2 − 8)",
                "Eosinophil Abs. Ct. (EO#)": "0.02 × 10^9/L (0.02 − 0.5)",
                "Eosinophil Percentage (EO%)": "0.5% (0.5 − 5)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.1)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "7.8 fL (7.4 − 10.4)",
                "Lactate Dehydrogenase": "600 U/L (100 − 350)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Bone Marrow Biopsy": "Hypercellular marrow with 80% lymphoblasts",
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Normal",
            "Serological Diagnosis": "Positive for specific leukemia markers",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Cerebrospinal Fluid Examination": "No evidence of central nervous system involvement",
            "Serum Antibody Test": "Positive for leukemia marker antibodies",
            "Nucleic Acid Amplification Test": "Negative for viral infections",
            "Eosinophil Count in Sputum": "Normal"
        },
        "Treatment Plan": "Emily Johnson has been diagnosed with childhood acute lymphoblastic leukemia (ALL) with major severity. An immediate induction chemotherapy regimen will be initiated to rapidly reduce the tumor burden and control symptoms such as low-grade fever, anemia, and bleeding. The treatment will follow specific pediatric protocols tailored to her risk stratification, including phases of induction, consolidation, intensification, and maintenance therapy. Intrathecal chemotherapy will be implemented to prevent central nervous system leukemia. Close monitoring of blood counts and liver and kidney function will guide the management of any side effects. Antibiotics and antifungal medications will be administered to prevent opportunistic infections due to the immunocompromised state. Family education on infection prevention and Emily's mental health is essential. Hematopoietic stem cell transplantation will be considered if standard chemotherapy outcomes are suboptimal, with regular follow-ups to monitor treatment response and adjust the plan accordingly. Nutritional support and psychological counseling will be provided to ensure optimal recovery and quality of life."
    },
    {
        "Patient Information": {
            "Name": "Ethan Liu",
            "Age": "4",
            "Gender": "Male",
            "Medical History": "No significant past medical history"
        },
        "Disease Information": {
            "Disease": "Childhood Acute Lymphoblastic Leukemia (ALL)",
            "Severity Level": "Major Severity",
            "Symptoms": "Unexplained fever, anemia, bleeding, lymphadenopathy, hepatosplenomegaly, bone and joint pain",
            "Duration": "Symptoms have progressed rapidly over the past two weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "4.1 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "42 μmol/L (41 − 81)",
                "Triglycerides (TG)": "0.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "15.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "2.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "28% (35 − 50)",
                "Hemoglobin (Hb)": "85 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "90 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "80% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "15% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "12 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.7 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.02 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "11 f l (9 − 13)",
                "Lactate Dehydrogenase": "260 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500)",
                "CRP": "42 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "40 μg/L (50 − 150)"
            },
            "Bone Marrow Biopsy": "Presence of immature lymphoid cells with blasts accounting for 80%",
            "Cerebrospinal Fluid Examination": "No leukemic cells detected",
            "Chest X-ray Exam": "Normal",
            "Abdominal Ultrasound": "Enlargement of liver and spleen",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Bacterial Culture": "Negative",
            "Pulmonary Function Test": "Normal gas exchange",
            "Electrolyte Panel": "Normal",
            "Coagulation Tests": "Prolonged prothrombin time",
            "Genetic Analysis": "No Philadelphia chromosome detected"
        },
        "Treatment Plan": "Ethan Liu has been diagnosed with pediatric acute lymphoblastic leukemia, necessitating an immediate and comprehensive treatment approach due to the rapid progression of symptoms such as fever, anemia, and lymphadenopathy. The primary mode of treatment will involve induction chemotherapy using a protocol such as CCCG-ALL-2015, which combines multiple chemotherapeutic agents to target leukemia cells effectively. Intrathecal chemotherapy will also be administered to prevent central nervous system infiltration, ensuring comprehensive coverage of leukemic cells. Regular monitoring of blood counts and liver and kidney function will be crucial to adjust chemotherapy dosing and prevent potential complications. Concurrent supportive care will be provided, including transfusions for anemia and thrombocytopenia, prophylactic antibiotics to prevent infections, and antipyretics and analgesics to manage fever and pain. Considering Ethan's low platelet count, precautions will be taken to avoid bleeding, such as avoiding impact sports and using a soft-bristled toothbrush. Nutritional support will be tailored to maintain his weight and support his immune system, and psychosocial support will be offered to ensure mental well-being during treatment. Post-recovery, regular follow-ups including physical exams, blood tests, and possibly imaging studies will be important to monitor for relapse and manage long-term health outcomes. Emphasis will be placed on maintaining a healthy lifestyle, encouraging moderate physical activity, and achieving a balanced diet to optimize recovery and minimize future health risks."
    },
    {
        "Patient Information": {
            "Name": "Liam Chen",
            "Age": "4",
            "Gender": "Male",
            "Medical History": "No significant past medical history"
        },
        "Disease Information": {
            "Disease": "Childhood Leukemia (Acute Lymphoblastic Leukemia)",
            "Severity Level": "Major Severity",
            "Symptoms": "Unexplained fever, anemia, bleeding, and infiltration by leukemia cells (hepatosplenomegaly, lymphadenopathy)",
            "Duration": "Symptoms have been present for approximately 3 months, with acute manifestations in the past month",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "25 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "50 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "15.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "28% (35 − 50)",
                "Hemoglobin (Hb)": "90 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "80 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "60% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "30% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "9.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.3 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.2 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "400 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198 for males)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "500 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Bone Marrow Biopsy": "Hypercellular marrow with 75% lymphoblasts",
            "Cytogenetic Analysis": "t(12;21) ETV6-RUNX1 fusion",
            "CSF Analysis": "No leukemic cells detected",
            "Chest X-ray Exam": "Normal",
            "Abdominal Ultrasound": "Hepatomegaly and splenomegaly observed",
            "Lumbar Puncture": "No central nervous system involvement",
            "Coagulation Profile": "Prolonged prothrombin time",
            "Immunophenotyping": "Positive for CD10, CD19, and TdT markers"
        },
        "Treatment Plan": "Liam Chen has been diagnosed with acute lymphoblastic leukemia, presenting with symptoms of fever, anemia, and bleeding due to significant infiltration by leukemia cells into the liver and spleen. The treatment plan involves immediate initiation of induction chemotherapy to reduce leukemia cell burden and alleviate symptoms. A standard chemotherapy protocol following the CCCG-ALL-2015 regimen will be implemented, comprising sequential phases of induction, consolidation, intensification, and maintenance therapy to achieve complete remission and prevent relapse. Intrathecal chemotherapy will be concurrently administered to prevent potential central nervous system involvement. In view of the cytogenetic findings, targeted therapy utilizing tyrosine kinase inhibitors may be considered if resistance emerges or upon relapse to enhance treatment efficacy. Hematopoietic stem cell transplantation will be evaluated if the disease does not respond to initial treatment or exhibits high-risk genetic markers. Throughout the treatment, regular monitoring of blood counts, liver function tests, and bone marrow assessments will be conducted to adapt the treatment and manage any adverse effects. To ensure Liam's holistic care, supportive therapy including anti-emetics, nutritional support, and psychosocial counseling will be offered to maintain his quality of life during his treatment journey. Emphasis on infection prevention is critical due to anticipated myelosuppression, necessitating prophylactic antibiotics and stringent infection control measures."
    },
    {
        "Patient Information": {
            "Name": "John Doe",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Chronic obstructive pulmonary disease, Hypertension, Former smoker with a 40-pack-year history"
        },
        "Disease Information": {
            "Disease": "Non-small cell lung cancer (NSCLC)",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent cough, hemoptysis, chest pain, wheezing, shortness of breath",
            "Duration": "Symptoms have been gradually worsening over the past 3 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "40 IU/L (7−40)",
                "AST (Aspartate Aminotransferase)": "38 IU/L (13−35)",
                "Urea": "5.5 mmol/L (2.6−8.8)",
                "Creatinine (Cr)": "80 μmol/L (41−81)",
                "Triglycerides (TG)": "1.6 mmol/L (<1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (<5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5−9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5−5.5)",
                "Hematocrit (Hct)": "45% (35−50)",
                "Hemoglobin (Hb)": "135 g/L (115−150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125−350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20−50)",
                "Neutrophil Percentage (NEUT%)": "60% (40−75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8−6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2−1.0)",
                "Monocyte Percentage (MONO%)": "7% (3−10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02−0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4−8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0−0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0−1)",
                "Mean Platelet Volume (MPV)": "10 f l (9−13)",
                "Lactate Dehydrogenase": "230 U/L (135−225)",
                "Muscle Enzymes (CK)": "150 U/L (22−198 for males)",
                "Myoglobin": "70 ng/mL (<90 ng/mL)",
                "Troponin I": "10 ng/L (<14 ng/L)",
                "Ferritin": "320 ng/mL (20−500 for males)",
                "CRP": "8 mg/L (<3 mg/L)",
                "ESR": "30 mm/hr (0−20)",
                "Procalcitonin": "0.4 ng/mL (<0.5)",
                "D-dimer": "0.7 mg/L FEU (0−0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Chest X-ray Exam": "Presence of a mass in the right upper lobe with possible atelectasis",
            "Chest Computerized Tomography": "Mass in the right upper lobe, with mediastinal lymph node involvement, no pleural effusion",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bronchoscopy": "Visible tumor in the bronchial area, biopsy taken for histological examination",
            "Sputum Examination": "Positive for malignant cells",
            "Serum Tumor Markers": "Elevated carcinoembryonic antigen (CEA)",
            "Pulmonary Function Test": "Reduced lung function with obstructive pattern",
            "Genetic Testing": "Positive for EGFR mutation"
        },
        "Treatment Plan": "John Doe has been diagnosed with non-small cell lung cancer (NSCLC), showing extensive involvement of the mediastinal lymph nodes. Given his smoking history and chronic obstructive pulmonary disease, a personalized multidisciplinary treatment approach is recommended. Immediate initiation of targeted therapy with gefitinib, an EGFR tyrosine kinase inhibitor, is advised due to the presence of an EGFR mutation. Chemotherapy may be considered to complement targeted therapy, with options such as pemetrexed combined with platinum-based agents, tailored to the specific histological subtype and the patient's overall health status. Surgical intervention in the form of lobectomy may be considered if the tumor's progression is localized and amenable post-targeted therapy response. Continuous low-flow oxygen therapy and dietary modifications should be implemented to address dyspnea and improve nutritional status. Follow-up pulmonary function tests, imaging, and regular monitoring of tumor markers will be conducted to assess therapy effectiveness and adjust treatment as needed. Lifestyle changes, including smoking cessation and pulmonary rehabilitation exercises, are essential to enhance recovery and quality of life, with support systems provided to ensure the patient's adherence to the care plan. Regular follow-up appointments will focus on tracking progress and adapting the treatment approach as necessary to achieve the best possible outcomes."
    },
    {
        "Patient Information": {
            "Name": "John Doe",
            "Age": "68",
            "Gender": "Male",
            "Medical History": "Chronic obstructive pulmonary disease (COPD), History of smoking"
        },
        "Disease Information": {
            "Disease": "Lung Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent cough, blood-streaked sputum, chest pain, wheezing, shortness of breath, hoarseness",
            "Duration": "Symptoms have been ongoing and progressively worsening over the past six months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "90 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.35 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "350 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mass observed in the right upper lobe with potential pleural effusion",
            "Chest Computerized Tomography": "3.5 cm mass in the upper right lobe with mediastinal lymph node involvement",
            "Serological Diagnosis": "Elevated levels of tumor markers",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired pulmonary function",
            "Sputum Examination": "Presence of blood-streaked sputum and atypical cells",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Reduced lung capacity and volume",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "John Doe has been diagnosed with non-small cell lung cancer at an advanced stage, characterized by symptoms such as persistent cough, chest pain, and blood-streaked sputum. Given the major severity and progression of his condition, a comprehensive treatment plan is essential. The recommended approach involves systemic chemotherapy using a platinum-based regimen to target the cancer cells and attempt to slow the disease's progression. If the cancer cells express specific genetic mutations, molecular targeted therapies may be considered to improve survival rates and quality of life. In addition, palliative care will be provided to manage symptoms, such as pain relief and alleviating respiratory distress, and possibly radiotherapy to target local tumors causing significant symptoms or obstruction. Nutritional support, including high-protein diets, can improve recovery and overall health during treatment. Regular imaging and blood tests will be conducted to monitor the effectiveness of therapy and adjust the treatment approach as necessary. Smoking cessation support should be provided, emphasizing the importance of avoiding further exposure to carcinogens to prevent further deterioration of lung function. Psychological support and counseling services will aid in managing the emotional impact of the diagnosis, ensuring patient compliance and engagement in the treatment plan, and frequent follow-ups will be essential to monitor the disease's progression and manage any emerging complications."
    },
    {
        "Patient Information": {
            "Name": "Daniel Thompson",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Chronic Obstructive Pulmonary Disease, Heavy smoker for 40 years, Hypertension"
        },
        "Disease Information": {
            "Disease": "Lung Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent cough, hemoptysis, wheezing, chest pain, dyspnea, hoarseness",
            "Duration": "Symptoms have been present for several months but have worsened significantly in the last few weeks",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7−40)",
                "AST (Aspartate Aminotransferase)": "29 IU /L (13−35)",
                "Urea": "5.5 mmol/L (2.6−8.8)",
                "Creatinine (Cr)": "82 μmol/L (41−81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.4 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5−9.5)",
                "Red Blood Cell Ct. (RBC)": "4.7 × 10^12/L (3.5−5.5)",
                "Hematocrit (Hct)": "43% (35−50)",
                "Hemoglobin (Hb)": "140 g/L (115−150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125−350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20−50)",
                "Neutrophil Percentage (NEUT%)": "70% (40−75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.5 × 10^9/L (1.8−6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2−1.0)",
                "Monocyte Percentage (MONO%)": "6% (3−10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02−0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4−8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0−0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0−1)",
                "Mean Platelet Volume (MPV)": "10 f l (9−13)",
                "Lactate Dehydrogenase": "180 U/L (135−225)",
                "Muscle Enzymes (CK)": "190 U/L (22−198)",
                "Ferritin": "300 ng/mL (20−500)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0−20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0−0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B"
            },
            "Chest X-ray Exam": "Increased opacity in the right lung with cavitation",
            "Chest Computerized Tomography": "Large mass in the right upper lobe with evidence of local invasion and pleural effusion",
            "Serological Diagnosis": "Elevated carcinoembryonic antigen (CEA)",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Severe restriction and obstruction",
            "Sputum Examination": "Presence of atypical cells",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Significant restriction noted",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal",
            "Bronchoscopy": "Mass obstructing the main bronchus, biopsies taken"
        },
        "Treatment Plan": "The diagnosis of lung cancer with major severity for Daniel Thompson necessitates an intensive and multidisciplinary approach, given the local invasion and pleural effusion observed in recent imaging. Palliative chemotherapy is recommended to manage tumor growth and alleviate symptoms, particularly targeting tumor reduction to ease respiratory functions. Agents such as carboplatin combined with pemetrexed are proposed, considering Daniel's medical history and current condition, alongside regular monitoring of blood counts and liver function to adjust dosages as needed. Additionally, radiation therapy may be applied to local areas for pain relief and further tumor control, especially given the severe chest pain experienced by the patient. Supportive care will include oxygen supplementation, pain management using opioids, and nutritional support to maintain strength and well-being. Smoking cessation is crucial, and arrangements for psychological counseling will be made to support this transition. Daniel's family will be guided on maintaining a serene environment, reducing exposure to environmental pollutants, and providing emotional support to encourage adherence to treatment. Regular follow-up will be scheduled to assess the response to therapies and modify the plan based on Daniel's progress, aiming to enhance quality of life and prolong survival, while respecting his autonomy and preferences in care decisions."
    },
    {
        "Patient Information": {
            "Name": "Lily Thompson",
            "Age": "59",
            "Gender": "Female",
            "Medical History": "Chronic bronchitis, former smoker, exposure to kitchen fumes"
        },
        "Disease Information": {
            "Disease": "Lung adenocarcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Chronic cough, hemoptysis, chest pain, fatigue, decreased appetite, shortness of breath",
            "Duration": "Symptoms have been present for several months, with increasing intensity",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "150 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "9 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198 for females)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for females)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Not detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Presence of peripheral lung masses and nodules",
            "Chest Computerized Tomography": "Lung masses with possible invasion of surrounding tissues",
            "Serological Diagnosis": "Elevated tumor markers",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Abnormal cells detected",
            "Nasopharyngeal Examination": "Unremarkable",
            "Serum Antibody Test": "Negative for common respiratory pathogens",
            "Pulmonary Function Test": "Reduced lung capacity",
            "Nucleic Acid Amplification Test": "Negative for respiratory viruses",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Unremarkable",
            "Nasal Endoscopy": "Unremarkable"
        },
        "Treatment Plan": "Lily Thompson's diagnosis of lung adenocarcinoma, characterized by major severity with symptoms indicative of advanced disease, prompts an immediate and meticulous approach to her care, prioritizing an integrative treatment regime. Given Lily's former smoking history and chronic bronchitis, it is essential to individualize her treatment strategy through comprehensive multidisciplinary collaboration incorporating thoracic surgery, oncology, and respiratory medicine inputs. The suggestion of potential surgical intervention, focusing on localized tumor resection, will be evaluated in conjunction with neoadjuvant chemotherapy aimed at reducing tumor size and improving surgical outcomes. Immunotherapy targeting specific oncogenic driver genes may be considered if genetic testing reveals actionable mutations, potentially integrating PD-1/PD-L1 inhibitors as a pivotal treatment element. Post-surgery, adjuvant therapies including radiotherapy and systemic chemotherapy will be implemented to manage and mitigate the risk of local recurrence or metastatic progression, complemented by supportive care measures such as nutritional support, respiratory physiotherapy, and palliative care to enhance quality of life. Attention to Lily’s nutritional status, potentially addressing deficiencies, underscores the holistic aspect of this treatment plan, while maintaining vigilant surveillance through routine imaging and tumor marker assessments to gauge treatment efficacy and adjust the strategy as needed. Long-term follow-up and prevention strategies, including smoking cessation and regulation of environmental exposures, will be integral to her care approach, ensuring proactive management and optimal recovery prospects."
    },
    {
        "Patient Information": {
            "Name": "Emily Chen",
            "Age": "52",
            "Gender": "Female",
            "Medical History": "Chronic bronchitis, history of smoking"
        },
        "Disease Information": {
            "Disease": "Lung adenocarcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent cough, hemoptysis, chest pain, shortness of breath, weight loss, fatigue",
            "Duration": "Symptoms have been present for the past 3 months with increasing severity",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "39 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "42 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "82 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.3 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.1 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "115 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.88 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.9 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for females)",
                "Myoglobin": "72 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for females)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.9 mg/L FEU (0 − 0.5)",
                "Rh Type": "Negative",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mass lesion in the left upper lobe with possible hilar involvement",
            "Chest Computerized Tomography": "Lobulated mass with irregular margins in the left upper lobe, mediastinal lymph node enlargement",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderate obstruction",
            "Sputum Examination": "Blood-streaked sputum",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for atypical antibodies",
            "Pulmonary Function Test": "Reduced lung volume and gas exchange",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Emily Chen has been diagnosed with major severity lung adenocarcinoma, presenting symptoms including persistent cough, hemoptysis, and chest pain. Due to the advanced nature of the disease, characterized by the presence of a mass in the left upper lobe and mediastinal lymph node involvement, a comprehensive and multidisciplinary approach is necessary for treatment. While surgery might be an option for localized resectable tumors, Emily's condition suggests a need for systemic treatment rather than surgical intervention. Given her history of smoking and chronic bronchitis, she poses a higher risk for aggressive progression. Chemotherapy and targeted therapy tailored to the molecular profile of her tumor should be initiated to slow disease progression and manage symptoms, potentially including drugs like Bevacizumab or Erlotinib based on genetic testing results. Additionally, considering her current nutritional status and potential for weight loss and fatigue, nutritional support and supplementation may be advised to maintain her strength during treatment. Immunotherapy could be explored as a frontier treatment option post-chemotherapy, aiming to boost her immune response against the cancer cells. Palliative care measures including analgesics for pain management and bronchodilators for respiratory relief should be employed to improve quality of life. Regular imaging and blood tests will be necessary to monitor treatment efficacy and disease progression, with modifications to the treatment plan made as required. Emily and her family would benefit from counseling on disease management, including understanding the prognosis, potential side effects of treatment, and the importance of adhering to medical advice and follow-up appointments for ongoing assessment and care."
    },
    {
        "Patient Information": {
            "Name": "Jane Doe",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "Chronic bronchitis, history of heavy smoking, exposure to indoor air pollution"
        },
        "Disease Information": {
            "Disease": "Lung Adenocarcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent blood-streaked sputum, cough, chest pain, localized wheezing, shortness of breath, fatigue",
            "Duration": "Symptoms have been present for several months with gradual progression",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "38 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "75 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.3 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.3 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "11% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "72 ng/mL (< 90 ng/mL)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "20 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "CEA Elevated",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mass lesion in the right lung",
            "Chest Computerized Tomography": "Invasive adenocarcinoma in the right upper lobe, with signs of mediastinal lymph node involvement",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Reduced lung capacity",
            "Sputum Examination": "Presence of malignant cells",
            "Pulmonary Function Test": "Impaired gas exchange",
            "Bronchoscopy": "Visible lesion in the bronchus",
            "Sputum Cytology": "Suspicious for adenocarcinoma",
            "Pathological Examination": "Confirms adenocarcinoma",
            "Neck Ultrasonography": "Suspected lymph node metastasis",
            "Brain MRI": "No signs of metastasis",
            "Bone Scan (ECT)": "No signs of bone metastasis"
        },
        "Treatment Plan": "Jane Doe has been diagnosed with lung adenocarcinoma with mediastinal lymph node involvement, indicating a major severity level of disease progression. Given the current stage of her cancer and the examination results, a personalized treatment plan will be initiated. Due to the tumor's invasive nature and lymph node involvement, a combination of neoadjuvant chemotherapy followed by surgical intervention, if applicable, will be considered. Lobectomy or pneumonectomy with systematic mediastinal lymph node dissection may be performed to remove the tumor and affected lymph nodes. Post-surgical systemic chemotherapy and radiotherapy are strongly indicated to prevent metastasis and recurrence. Targeted therapy may be explored based on genetic testing results, focusing on driver genes pertinent to her condition. Immunotherapy may also be integrated into her treatment protocol, aiming at enhancing her immune response against tumor cells. Regular monitoring through imaging and blood tests to evaluate her response to treatment and detect potential complications is crucial. Nutritional support, psychological counseling, and lifestyle modifications such as smoking cessation and air quality improvement are recommended to enhance her quality of life during treatment. Long-term follow-up care will be scheduled, with adjustments to her treatment strategy based on her evolving condition and response to therapies."
    },
    {
        "Patient Information": {
            "Name": "John Smith",
            "Age": "67",
            "Gender": "Male",
            "Medical History": "Chronic lymphadenopathy, rheumatoid arthritis, history of EBV infection"
        },
        "Disease Information": {
            "Disease": "Non-Hodgkin lymphoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless enlargement of superficial and mediastinal lymph nodes, night sweats, fatigue, weight loss, and abdominal pain due to retroperitoneal lymph node involvement",
            "Duration": "Symptoms have progressively worsened over the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "90 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "11 ng/L (< 14 ng/L)",
                "Ferritin": "550 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Enlarged mediastinal lymph nodes",
            "Chest Computerized Tomography": "Multiple enlarged lymph nodes in mediastinal and abdominal regions",
            "Serological Diagnosis": "Elevated LDH levels indicating poor prognosis",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "John Smith has been diagnosed with aggressive non-Hodgkin lymphoma, specifically diffuse large B-cell lymphoma, presenting with pronounced lymphadenopathy and systemic symptoms including fatigue and weight loss. Chemotherapy is the primary treatment strategy, with the R-CHOP regimen comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone being initiated to target the malignant B cells effectively. This treatment will follow a cycle of 2 to 3 weeks, with close monitoring of blood cell counts and potential adverse effects such as neutropenia and infection. Supportive care is crucial during chemotherapy, with nutritional support ensuring high-calorie, high-protein intake, and adequate hydration to bolster the patient’s strength and manage potential side effects. Antipyretics may be administered to address any fever, and pain relief measures will be implemented to improve comfort. John will receive regular imaging assessments and blood tests to evaluate the treatment's efficacy and adjust plans accordingly. Additionally, should the lymphoma prove refractory or relapsing, hematopoietic stem cell transplantation will be considered as a further step to restore normal hematopoietic functions. Family support and maintaining a positive outlook are essential components of John's treatment journey, with periodic consultations and lifestyle adjustments facilitating optimal recovery. Post-treatment, John may be advised on pulmonary rehabilitation and regular medical check-ups to monitor well-being and prevent recurrence of the disease."
    },
    {
        "Patient Information": {
            "Name": "John Smith",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "History of hepatitis C, rheumatoid arthritis, and family history of lymphomas"
        },
        "Disease Information": {
            "Disease": "Non-Hodgkin Lymphoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless enlargement of cervical and supraclavicular lymph nodes, night sweats, weight loss, fever",
            "Duration": "Symptoms have been present for the past 6 weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "38 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "180 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "60% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "35% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "3.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.3 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "500 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "No significant intrathoracic lesions observed",
            "Chest Computerized Tomography": "Enlarged lymph nodes in the neck region",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Negative for viral particles",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for specific antibodies",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative for relevant pathogens",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "John Smith has been diagnosed with Non-Hodgkin lymphoma at a major severity level, characterized by painless lymph node enlargement in the cervical and supraclavicular regions, along with systemic symptoms such as night sweats, fever, and weight loss. Given the presence of diffuse large B-cell lymphoma, an aggressive approach combining chemotherapy and targeted therapy is recommended. The R-CHOP chemotherapy regimen will be initiated, including rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, to tackle the malignancy effectively. Close monitoring for treatment response and side effects will be necessary, adjusting doses based on tolerance and effectiveness. Complementary support through nutritional management to maintain overall health and strength alongside scheduled PET/CT scans will aid in assessing treatment progression and necessary modifications. John will be educated on signs of potential adverse reactions and the necessity for adherence to therapy, with regular consultations scheduled to adapt the treatment strategy as the disease evolves towards remission. Family support and open communication about the emotional and physical impacts of treatment will be encouraged, promoting a positive outlook on recovery."
    },
    {
        "Patient Information": {
            "Name": "John Thompson",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Hypertension, rheumatoid arthritis"
        },
        "Disease Information": {
            "Disease": "Non-Hodgkin Lymphoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless progressive lymphadenopathy primarily in cervical and supraclavicular nodes, fatigue, weight loss, night sweats",
            "Duration": "Symptoms have been present for approximately 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "33 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "180 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "45% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "50% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "3.4 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.05 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.8% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "400 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "350 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "50 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "No significant findings",
            "Chest Computerized Tomography": "Enlarged cervical and supraclavicular lymph nodes",
            "Serological Diagnosis": "Elevated LDH indicating poor prognosis",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for specific lymphoma markers",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "John Thompson is diagnosed with non-Hodgkin lymphoma at an advanced stage with significant lymphadenopathy and systemic symptoms, including weight loss, fatigue, and night sweats. Given the major severity of the condition, immediate initiation of combination chemotherapy using the R-CHOP regimen is recommended, involving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, administered in 2- to 3-week cycles to target the aggressive nature of diffuse large B-cell lymphoma. Due to John's age and existing conditions like hypertension and rheumatoid arthritis, careful monitoring of his cardiovascular status and immune function is essential, with adjustments to therapy in case of adverse reactions. Additional supportive care with nutritional support, analgesics for comfort, antipyretics for fever, and potential targeted therapy with ibrutinib may be considered to enhance treatment efficacy and manage symptoms. Regular imaging, blood tests, and monitoring of lymph node changes are vital to assess treatment response and adjust therapy accordingly. John and his family will be educated on the importance of following the treatment plan, recognizing signs of deterioration, maintaining a balanced diet, participating in mild physical activity, and ensuring adequate rest. Long-term care involves regular follow-up appointments, managing side effects, and ensuring compliance with treatment protocols to improve prognosis and quality of life."
    },
    {
        "Patient Information": {
            "Name": "Jessica Lee",
            "Age": "48",
            "Gender": "Female",
            "Medical History": "Persistent HPV infection, history of smoking, high parity"
        },
        "Disease Information": {
            "Disease": "Cervical Cancer Stage III",
            "Severity Level": "Major Severity",
            "Symptoms": "Contact bleeding, abnormal vaginal bleeding, frequent urination, lower abdominal pain, fatigue, anemia",
            "Duration": "Symptoms have progressively worsened over the past 6 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "90 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.6 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "115 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "180 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "11% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "High-risk HPV 16",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Pelvic Ultrasound": "Large tumor with parametrial invasion",
            "MRI": "Tumor spreading into pelvic wall with hydronephrosis",
            "Serological Diagnosis": "Elevated SCC antigen levels",
            "HPV Testing": "Positive for HPV types 16 and 18",
            "Colposcopy": "Irregular lesions on cervix",
            "Biopsy": "Squamous cell carcinoma",
            "Cancer Marker Examination": "Elevated CA125 and CA199",
            "Urinary Function Test": "Obstructive pattern",
            "Pathological Examination": "Stage III pathology confirmed"
        },
        "Treatment Plan": "Jessica Lee's cervical cancer has been diagnosed at stage III, with significant local invasion affecting the pelvic region, necessitating aggressive treatment. Due to the advanced stage and major severity of her symptoms, including vaginal bleeding, frequent urination, and fatigue, concurrent chemoradiotherapy is recommended as the primary treatment strategy. This will include external beam radiotherapy combined with intracavitary brachytherapy to maximize tumor cell eradication locally, complemented by chemotherapy agents such as cisplatin and paclitaxel to enhance tumor sensitivity and further inhibit cancer progression. As surgical intervention is not feasible given the tumor's extent and her current health status, the treatment will focus on eliminating cancer cells while maintaining quality of life through symptom management, such as pain relief and addressing anemia. HPV vaccination will be discussed for prevention of further HPV infections, and genetic counseling may be offered. Regular follow-up examinations, including imaging and cancer marker tests, will be conducted to assess tumor response and modify the treatment plan accordingly. Nutritional support to combat anemia and improve overall health will be provided, while psychological support and family involvement are encouraged to aid in her recovery and mental well-being. Lifestyle modifications, including smoking cessation and physical activity as tolerated, are recommended to enhance her body's resilience against cancer progression and treatment side effects. Post-treatment, consistent monitoring will continue to ensure optimal management and quality of life, with emphasis on prevention, detection of recurrence, and overall health improvement."
    },
    {
        "Patient Information": {
            "Name": "Hannah Chen",
            "Age": "45",
            "Gender": "Female",
            "Medical History": "Positive for high-risk HPV, smoker, history of recurrent abnormal Pap smears"
        },
        "Disease Information": {
            "Disease": "Cervical Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Abnormal vaginal bleeding, contact bleeding after sexual intercourse, foul-smelling vaginal discharge, lower abdominal pain",
            "Duration": "Symptoms have been present and worsening over the past six months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "25 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.1 mmol/L (< 5.18)",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Ferritin": "80 ng/mL (20 − 200 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "Serum Tumor Marker SCC": "Elevated",
                "CEA": "3.0 ng/mL (< 2.5)",
                "CA125": "50 U/mL (0 − 35)"
            },
            "Cervical Cytology": "Presence of atypical squamous cells",
            "HPV Test": "Positive for HPV type 16",
            "Colposcopy": "Lesion observed, biopsy indicated",
            "Cervical Biopsy": "Confirmed squamous cell carcinoma",
            "Transvaginal Ultrasound": "Enlargement of the cervix with irregular borders",
            "MRI": "Tumor invasion into nearby tissue, but no lymph node involvement",
            "PET-CT": "No distant metastasis detected"
        },
        "Treatment Plan": "Hannah Chen has been diagnosed with cervical cancer at a major severity level, necessitating a well-coordinated treatment approach. Given her symptoms of vaginal bleeding, contact bleeding after intercourse, and foul-smelling discharge, immediate intervention is crucial. Her treatment plan will include a combination of surgical and radiotherapy approaches. A radical hysterectomy is recommended to remove the cervix, uterus, surrounding tissues, and pelvic lymph nodes. This will be followed by adjuvant radiotherapy to target residual tumor cells and prevent recurrence. Chemotherapy may be considered if further imaging reveals lymph node involvement or metastasis. Hannah's smoking history and HPV infection status underline the importance of lifestyle modification and vaccination counseling. Nutritional support and prophylactic measures against infection and anemia will be integrated into her care, along with psychological support from her family and healthcare team to ensure emotional well-being and adherence to the treatment plan. Regular follow-ups and cervical screenings will be scheduled post-treatment to monitor for any signs of recurrence or progression, adjusting the treatment protocol as necessary to optimize her recovery and overall health outcomes."
    },
    {
        "Patient Information": {
            "Name": "Emily Zhang",
            "Age": "45",
            "Gender": "Female",
            "Medical History": "Chronic HPV infection, smoker, multiple childbirths"
        },
        "Disease Information": {
            "Disease": "Cervical cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Contact bleeding, abnormal vaginal bleeding, increased vaginal discharge, lower abdominal pain",
            "Duration": "Symptoms have been noticeable for the past 3 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "25 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "65 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "90 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "5 ng/L (< 14 ng/L)",
                "Ferritin": "150 ng/mL (20 − 300 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "HPV 16 and 18",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Pelvic Exam": "Visible cervical lesion with contact bleeding",
            "Pap Smear": "Abnormal cervical cells detected",
            "HPV Test": "Positive for high-risk HPV types 16 and 18",
            "Colposcopy": "Cervical lesion with vascular irregularities",
            "Cervical Biopsy": "Confirmed squamous cell carcinoma",
            "MRI Scan": "Tumor extends to upper two-thirds of the vagina, no pelvic wall invasion",
            "Ultrasound": "No pelvic organ metastasis detected",
            "Histopathological Examination": "Invasive squamous cell carcinoma, Stage IIA",
            "Serum Tumor Markers": "SCC: 3.5 ng/mL (0 − 2.5), CYFRA21-1: 3.0 ng/mL (0 − 3.3)"
        },
        "Treatment Plan": "Emily Zhang has been diagnosed with cervical cancer, classified as Stage IIA with major severity. Given her age and confirmed HPV infection, the treatment plan involves a multidisciplinary approach. A radical hysterectomy with pelvic lymphadenectomy will be performed to ensure the complete removal of the cancerous tissue. This will be followed by adjuvant chemoradiotherapy aimed at reducing the risk of recurrence and addressing any microscopic residual disease. Considering her smoking history, cessation programs will be introduced to enhance the overall treatment efficacy and recovery. Nutritional support focusing on a protein-rich diet will assist in managing anemia and maintaining overall health during treatment. Regular follow-ups and imaging will be scheduled to monitor Emily’s progress and detect any early signs of recurrence. An emphasis will be placed on family support and psychological counseling to aid in her mental and emotional recovery throughout the treatment process. Post-treatment, pelvic rehabilitation exercises will be advised to restore function and strength."
    },
    {
        "Patient Information": {
            "Name": "Michael Thompson",
            "Age": "55",
            "Gender": "Male",
            "Medical History": "Chronic Hepatitis B, Type 2 Diabetes, Cirrhosis, Heavy Alcohol Consumption"
        },
        "Disease Information": {
            "Disease": "Primary Liver Cancer (Hepatocellular Carcinoma)",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent dull ache in liver area, fatigue, loss of appetite, jaundice, fever, abdominal bloating",
            "Duration": "Symptoms have been progressively worsening over the past 3 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "110 IU/L (7 – 40)",
                "AST (Aspartate Aminotransferase)": "130 IU/L (13 – 35)",
                "Urea": "5.5 mmol/L (2.6 – 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 – 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Positive",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 – 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 – 5.5)",
                "Hematocrit (Hct)": "38% (35 – 50)",
                "Hemoglobin (Hb)": "120 g/L (115 – 150)",
                "Platelet Ct. (PLT)": "90 × 10^9/L (125 – 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 – 50)",
                "Neutrophil Percentage (NEUT%)": "72% (40 – 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.9 × 10^9/L (1.3 – 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.24 × 10^9/L (1.8 – 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 – 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 – 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 – 0.52)",
                "Eosinophil Percentage (EO%)": "0.7% (0.4 – 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 – 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 – 1)",
                "Mean Platelet Volume (MPV)": "10.5 fL (9 – 13)",
                "Lactate Dehydrogenase": "250 U/L (135 – 225)",
                "Muscle Enzymes (CK)": "198 U/L (22 – 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "13 ng/L (< 14 ng/L)",
                "Ferritin": "700 ng/mL (20 – 500 for males)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "50 mm/hr (0 – 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "1.2 mg/L FEU (0 – 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "AFP 500 ng/ml (>400 ng/ml)",
                "Blood Silver Level": "60 μg/L (50 – 150)"
            },
            "Ultrasound": "Enlarged liver with multiple focal lesions",
            "CT Scan": "Large hepatocellular carcinoma in right lobe with intrahepatic metastasis",
            "MRI": "Heterogeneous mass with central necrosis in the liver",
            "Liver Biopsy": "Confirmed poorly differentiated hepatocellular carcinoma",
            "Serum Alpha-fetoprotein (AFP)": "Elevated to 500 ng/ml",
            "Liver Function Test": "Impaired",
            "Hepatitis Panel": "Chronic Hepatitis B infection",
            "Ascites Fluid Analysis": "Mildly elevated protein content",
            "Bilirubin Level": "Elevated indicating jaundice",
            "Abdominal Ultrasound": "Presence of ascites and enlarged spleen",
            "Endoscopy": "No varices observed"
        },
        "Treatment Plan": "Michael Thompson has been diagnosed with advanced primary liver cancer. Given his significant medical history of chronic Hepatitis B, cirrhosis, and type 2 diabetes, a multi-disciplinary treatment approach is necessary. Unfortunately, due to the major severity and stage of the disease, curative surgical options are limited. Palliative care will focus on improving quality of life and managing symptoms. Antiviral therapy will be maintained to manage his Hepatitis B infection, and supportive care for liver function will be emphasized, including the use of liver-protective medications. Targeted therapy with Sorafenib may be considered to slow disease progression, and radiotherapy might be explored as part of a comprehensive treatment plan focusing on palliative benefits. In addition, Michael will receive nutritional support to manage his diabetes and improve his overall nutrition status, helping to combat fatigue and loss of appetite. Pain management and psychological support will also be integral parts of the treatment to enhance his quality of life. Regular follow-ups with imaging and serum AFP tests are necessary to monitor disease progression and adjust treatments as necessary. Family education on recognizing symptoms of deterioration and supporting Michael's mental health is crucial during this challenging time."
    },
    {
        "Patient Information": {
            "Name": "Liam Zhang",
            "Age": "55",
            "Gender": "Male",
            "Medical History": "Chronic Hepatitis B, Cirrhosis"
        },
        "Disease Information": {
            "Disease": "Primary Liver Cancer (Hepatocellular Carcinoma)",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent dull ache in the liver area, bloating, loss of appetite, occasional fever, jaundice, ascites",
            "Duration": "Symptoms have been present and progressively worsening over the past six months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "75 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "90 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Positive",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "37% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "150 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "9% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "3.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "800 ng/mL (20 − 500 for males)",
                "CRP": "20 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "1.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "AFP (Alpha-fetoprotein)": "500 ng/ml (> 400 indicates liver cancer)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Complex mass in liver area, indicating potential malignancy",
            "Serological Diagnosis": "Chronic Hepatitis B infection",
            "Viral Antigen Detection": "Positive for Hepatitis B",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Positive for Hepatitis B antibodies",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Positive for Hepatitis B",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal",
            "Liver Ultrasound": "Large mass detected, suggestive of hepatocellular carcinoma",
            "Enhanced MRI": "Lesion >2 cm, vascular invasion suspected",
            "Liver Biopsy": "Confirmed hepatocellular carcinoma"
        },
        "Treatment Plan": "Liam Zhang has been diagnosed with primary liver cancer with moderate to major severity, compounded by his chronic hepatitis B infection and cirrhosis, necessitating a comprehensive and multi-faceted treatment approach. Given the advanced stage of liver cancer, surgical resection might be considered if feasible based on tumor localization and liver function reserve. Liver transplantation could be evaluated as a treatment option under specific criteria, considering both tumor characteristics and liver condition. Symptomatic supportive treatments like pain management, nutritional support, and ascites management will be prioritized to improve quality of life. Targeted therapy with drugs such as sorafenib or lenvatinib could be initiated for tumor growth inhibition, along with possible immunotherapy trials to assess efficacy. Antiviral therapy for hepatitis B will continue to stabilize liver function and minimize further complications. Regular imaging and serological tests will monitor tumor response and adjust treatment protocols accordingly. Psychological support for Liam and his family will be crucial to manage emotional stress during this challenging phase. A nutritionist-guided dietary plan will ensure optimal nutrition, potentially supplemented by parenteral support if necessary. Ongoing assessment will determine the success of interventions and guide adjustments to the treatment strategy, focusing on tumor control and maintaining liver function. Regular follow-ups will play a key role in detecting any recurrence or metastasis at the earliest possible stage, enhancing the prognosis."
    },
    {
        "Patient Information": {
            "Name": "Li Wei",
            "Age": "55",
            "Gender": "Male",
            "Medical History": "Chronic hepatitis B infection, cirrhosis, type 2 diabetes"
        },
        "Disease Information": {
            "Disease": "Liver Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Liver area pain, fatigue, fever, loss of appetite, abdominal bloating",
            "Duration": "Symptoms have been progressively worsening over the past few months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "78 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "92 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Positive",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.1 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "140 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.4 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.15 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.05 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.8% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "320 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "500 ng/mL (20 − 500 for males)",
                "CRP": "12 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "AFP 600 ng/mL (>400 ng/mL indicates liver cancer)",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Imaging Exams": {
                "Ultrasound": "Large mass in the right hepatic lobe with irregular borders",
                "CT Scan": "Liver mass with size approximately 8 cm with vascular involvement",
                "MRI": "Heterogeneous liver mass with signs of local infiltration",
                "PET-CT": "Increased uptake in the liver consistent with hepatic malignancy"
            },
            "Serological Diagnosis": "Elevated alpha-fetoprotein consistent with liver cancer",
            "Allergen Test": "Normal",
            "Liver Biopsy": "Poorly differentiated hepatocellular carcinoma"
        },
        "Treatment Plan": "Li Wei has been diagnosed with advanced liver cancer, complicated by his chronic hepatitis B infection, cirrhosis, and type 2 diabetes. Given the size of the tumor and its involvement with the surrounding vasculature, surgical resection poses significant risks. A multidisciplinary team approach is essential, integrating targeted therapy with lenvatinib or sorafenib to inhibit tumor growth and slow disease progression. Immunotherapy options, such as PD-1 inhibitors, may be considered based on genetic profiling and Li Wei's overall response to treatment. Close monitoring of his liver function and glycemic control is crucial, and antiviral therapy will continue to prevent further liver damage. Due to the blockage of the portal vein, interventional therapy like transarterial chemoembolization (TACE) may be utilized to decrease the tumor's blood supply and shrink its size. Pain management, liver-protective drugs, and nutritional support should be part of his palliative care to enhance his quality of life. Regular follow-ups and imaging will be conducted to assess treatment efficacy, and Li Wei and his family should be informed of the potential need for adapting the treatment strategy based on his evolving clinical status."
    },
    {
        "Patient Information": {
            "Name": "Alice Johnson",
            "Age": "68",
            "Gender": "Female",
            "Medical History": "Hypertension, history of frequent infections, mild anemia"
        },
        "Disease Information": {
            "Disease": "Myelodysplastic Syndromes",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Fatigue, weakness, frequent infections, mild anemia, occasional bleeding episodes",
            "Duration": "Symptoms have been persisting and gradually worsening over the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "3.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "33% (35 − 50)",
                "Hemoglobin (Hb)": "98 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "95 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.1 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "12% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None identified",
                "Blood Silver Level": "100 μg/L (50 − 150)"
            },
            "Bone Marrow Aspiration": "Dysplasia in erythroid lineage with increased ring sideroblasts",
            "Bone Marrow Biopsy": "Hyperactive proliferation with abnormal cell development",
            "Flow Cytometry": "Abnormal phenotype suggesting monoclonal populations in myeloid lineages",
            "Gene Mutation Detection": "Presence of SF3B1 mutation",
            "Cytogenetic Analysis": "Chromosomal abnormalities typical for MDS",
            "Chest X-ray Exam": "Normal",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Respiratory Function Test": "Normal"
        },
        "Treatment Plan": "Alice Johnson has been diagnosed with myelodysplastic syndromes (MDS) with moderate severity, characterized by anemia, frequent infections, and occasional bleeding episodes. The primary treatment focus will be to improve hematopoiesis and enhance her quality of life. Alice will commence treatment with the demethylating agent azacitidine to help reduce transfusion requirements and delay disease progression. Immunomodulators such as lenalidomide will be considered if further symptom management is required, especially for cytogenetic abnormalities. Supportive care will involve regular blood transfusions to manage anemia and platelet transfusions in case of significant bleeding. Prophylactic antibiotics will be administered to reduce the risk of infections due to neutropenia. Alice will be strongly advised to adhere to environmental hygiene standards to prevent infections and avoid activities that could lead to bleeding. Regular monitoring through complete blood count, bone marrow examinations, and cytogenetic analysis will be essential to assess treatment efficacy and modify plans as necessary. Alice and her family will be educated on identifying symptoms of complications and the importance of regular follow-up visits. If her condition progresses, hematopoietic stem cell transplantation may be considered, depending on her overall health status and availability of a suitable donor. Psychological support will also be provided to maintain a positive outlook, which can significantly impact her overall well-being and response to treatment."
    },
    {
        "Patient Information": {
            "Name": "Walter Thompson",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Hypertension, History of smoking, Occasional respiratory infections"
        },
        "Disease Information": {
            "Disease": "Myelodysplastic Syndromes",
            "Severity Level": "Major Severity",
            "Symptoms": "Anemia, fatigue, weakness, recurrent infections, mild bleeding, splenomegaly",
            "Duration": "Symptoms have been progressively worsening over several months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.45 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "2.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "30% (35 − 50)",
                "Hemoglobin (Hb)": "90 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "70 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "23% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.64 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "1.68 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.08 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "2.9% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.01 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.4% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "245 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "27 U/L (22 − 198 for males)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "620 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "32 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Absence of specific antigen detected",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Bone Marrow Aspiration": "Hypercellular marrow with dysplastic changes in erythroid and myeloid lineages",
            "Cytogenetic Analysis": "Presence of chromosomal abnormalities indicative of MDS",
            "Bone Marrow Biopsy": "Increased blast cells, presence of ring sideroblasts",
            "Flow Cytometry": "Multiple related phenotype abnormalities",
            "Gene Mutation Analysis": "Detected SF3B1 mutation"
        },
        "Treatment Plan": "Walter Thompson is facing a challenging diagnosis of myelodysplastic syndrome, characterized by significant anemia, recurrent infections, and bleeding tendencies. Treatment aims to improve hematopoietic function, manage symptoms, and slow disease progression. Given the absence of a suitable stem cell donor at present, the focus will be on drug therapy. The use of demethylating agents, such as azacitidine, is planned to reduce transfusion dependence and delay disease progression. Supportive care will include regular red blood cell and platelet transfusions to manage anemia and prevent bleeding, alongside prophylactic antibiotics to mitigate infection risk due to neutropenia. Immunomodulators may be considered if cytogenetic analysis suggests a response, and lenalidomide can be trialed given his chromosomal profile. Walter will require thorough monitoring, with routine blood tests, bone marrow evaluations, and infection assessments. An emphasis on lifestyle modifications, such as maintaining oral and perineal hygiene, alongside a balanced diet avoiding raw or hard-to-digest foods, is crucial to prevent infections and minimize bleeding risks. Walter and his family will receive education on recognizing infection or bleeding signs, and the importance of adhering to a strict follow-up regimen to manage this complex condition effectively."
    },
    {
        "Patient Information": {
            "Name": "Eleanor Smith",
            "Age": "67",
            "Gender": "Female",
            "Medical History": "Symptoms of anemia for several months; no significant history of infections or bleeding disorders"
        },
        "Disease Information": {
            "Disease": "Myelodysplastic Syndromes (MDS)",
            "Severity Level": "Major Severity",
            "Symptoms": "Fatigue, pallor, recurrent infections, easy bruising, occasional breathlessness, mild splenomegaly",
            "Duration": "Symptoms have persisted over the past several months with gradual worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "36 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "29 IU/L (13 − 35)",
                "Urea": "5.3 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "2.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "28% (35 − 50)",
                "Hemoglobin (Hb)": "95 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "90 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.5 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "1.75 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.2 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.01 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.4% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "145 U/L (22 − 198 for males)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "315 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Bone Marrow Aspiration Smear": "Shows hypercellularity and dysplastic hematopoiesis",
            "Bone Marrow Biopsy": "Reveals dysplastic changes in various lineage cells with increased blasts",
            "Chromosomal Analysis": "Detects genetic abnormalities indicative of MDS",
            "Flow Cytometry": "Suggests abnormality in myeloid lineage with monoclonal populations",
            "Gene Sequencing": "Detects mutations consistent with MDS",
            "Complete Blood Count": "Reduction in red blood cells, white blood cells, and platelets",
            "Differential Diagnosis": "Ruled out aplastic anemia and paroxysmal nocturnal hemoglobinuria"
        },
        "Treatment Plan": "Eleanor Smith's diagnosis of myelodysplastic syndromes with major severity necessitates a comprehensive and multi-faceted treatment approach. Given the presence of anemia, recurring infections, and a gradual increase in symptoms, Eleanor will primarily undergo supportive care to manage symptoms including blood transfusions for anemia, and treatments to prevent infections due to neutropenia. Drug therapy will include demethylating agents such as azacitidine to reduce transfusion needs and improve quality of life. Immunomodulators like lenalidomide may be considered to support the hematopoietic function. Eleanor's condition will be closely monitored to assess her responsiveness to treatment, and allogeneic hematopoietic stem cell transplantation will be explored given her age being appropriate and severity of symptoms, as it remains the only curative approach. Protective measures to prevent infections and to manage potential bleeding risks will be advised, emphasizing personal hygiene and environmental safety at home. Eleanor will also benefit from maintaining a recommended diet avoiding raw and cold foods, and ensuring regular follow-ups to adapt the treatment plan based on ongoing evaluations of her health and progress."
    },
    {
        "Patient Information": {
            "Name": "Samuel Thompson",
            "Age": "19",
            "Gender": "Male",
            "Medical History": "Previously healthy, no significant medical history"
        },
        "Disease Information": {
            "Disease": "Osteosarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Severe localized pain in the distal femur, noticeable swelling and a palpable mass, impaired joint movement, and tenderness",
            "Duration": "Symptoms have rapidly progressed over the past three weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "29 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.6 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "260 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "200 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "X-ray Exam": "Lytic bone lesions noted with 'sunburst' pattern around the distal femur",
            "MRI Scan": "Mass extending beyond bone into surrounding soft tissue, with periosteal elevation",
            "Bone Scan": "Increased uptake in the distal femur",
            "CT Scan": "Destructive lesion in the distal femur with soft tissue mass",
            "Biopsy Results": "High-grade osteosarcoma confirmed with presence of osteoid matrix",
            "PET-CT": "Increased metabolic activity in the distal femur, no distant metastases detected"
        },
        "Treatment Plan": "Samuel Thompson has been diagnosed with osteosarcoma in the distal femur, requiring a comprehensive treatment plan that includes neoadjuvant chemotherapy, surgical resection, and adjuvant chemotherapy. He will initially undergo neoadjuvant chemotherapy to reduce the tumor size and eradicate microscopic disease. This will be followed by limb-sparing surgery, aiming to resect the tumor with clear margins while preserving limb function. Post-surgical adjuvant chemotherapy will be administered to minimize the risk of recurrence. Multidisciplinary follow-up care will include regular imaging studies to monitor for recurrence and assess his response to treatment. Pain management and physiotherapy will be integral components of his care to maintain joint mobility and overall quality of life. Samuel will be educated about the importance of adherence to treatment and scheduled follow-ups to ensure optimal recovery and monitoring of potential long-term complications."
    },
    {
        "Patient Information": {
            "Name": "Benjamin Thompson",
            "Age": "16",
            "Gender": "Male",
            "Medical History": "No significant medical history; previously healthy, now presenting with increasing limb pain and swelling around the knee"
        },
        "Disease Information": {
            "Disease": "Osteosarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent localized pain, noticeable swelling and tenderness around distal femur, limited joint mobility, potential for pathological fractures",
            "Duration": "Symptoms have been present and progressively worsening over the past 3 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "74 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.7 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "145 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "62% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "12 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "X-ray Exam": "Shows bone lesion with a 'sunburst' appearance in distal femur",
            "MRI": "Confirms extent of osteosarcoma, significant invasion around joint and soft tissue",
            "CT Scan": "Details the depth of tumor invasion and involvement of adjacent tissues",
            "Pathological Examination": "Biopsy indicates presence of osteoid-producing malignant cells",
            "Bone Scintigraphy": "Shows increased uptake at the lesion site, consistent with osteosarcoma",
            "PET-CT": "Provides detailed metabolic activity of the tumor",
            "Arthrography": "Displays joint effusion and restriction due to tumor pressure",
            "Oncology Consultation": "Confirms diagnosis and recommends staging and treatment plan"
        },
        "Treatment Plan": "Benjamin Thompson is diagnosed with osteosarcoma of the distal femur, requiring a multidisciplinary treatment approach to maximize survival and preserve limb function. Surgical intervention is necessary, with consideration for limb-sparing techniques given the tumor's sensitivity to chemotherapy. NEoadjuvant chemotherapy will be initiated to shrink the tumor pre-operatively, followed by limb-sparing surgery to excise the tumor completely while preserving limb function, given the absence of vascular or nerve bundle involvement. Postoperative adjuvant chemotherapy will be employed to mitigate any remaining tumor burden and prevent recurrence. Despite chemotherapy's role in improving survival rates, regular monitoring and possible radiotherapy are planned to ensure comprehensive treatment. Pain management and physical therapy will support Benjamin's recovery, focusing on regaining mobility and strength in the affected limb. Coordination with orthopedic surgeons, medical oncologists, and radiologists will ensure optimal care, underscored by regular follow-up appointments to track progress. Education for Benjamin and his family about the importance of adherence to treatment and recognizing potential complications, particularly pathological fractures, will be vital. With an emphasis on collaborative management, the treatment aims to achieve maximum recovery potential and long-term health improvements."
    },
    {
        "Patient Information": {
            "Name": "Derek Thompson",
            "Age": "19",
            "Gender": "Male",
            "Medical History": "Recent history of unexplained bone pain and local swelling"
        },
        "Disease Information": {
            "Disease": "Osteosarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent bone pain, local masses on the distal femur, functional impairment, and rapid onset of pathological fractures",
            "Duration": "Symptoms have been progressively worsening over the past 3 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "75 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "145 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.4 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.6% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "120 U/L (22 − 198 for males)",
                "Myoglobin": "45 ng/mL (< 90 ng/mL)",
                "Troponin I": "14 ng/L (< 14 ng/L)",
                "Ferritin": "220 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "N/A",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Imaging Tests": {
                "X-ray": "Osteolytic lesions with periosteal reaction at the distal femur, showing a 'Codman triangle'",
                "CT Scan": "Irregular osteolytic tumor extending through soft tissues",
                "MRI": "High signal intensity on T2-weighted images indicating marrow infiltration",
                "Bone Scan": "Increased uptake at the distal femur suggesting aggressive bone turnover",
                "PET-CT": "Localized high metabolic activity consistent with malignant bone tumor"
            },
            "Pathological Examination": "Biopsy confirms high-grade osteosarcoma with osteoblastic differentiation and infiltrative growth",
            "Biochemical Assay": {
                "Alkaline Phosphatase": "150 U/L (40−129)",
                "Calcium": "2.8 mmol/L (2.2−2.7)"
            }
        },
        "Treatment Plan": "Derek Thompson has been diagnosed with high-grade osteosarcoma located at the distal femur. Considering the major severity and aggressive nature of the tumor, a multidisciplinary treatment approach is essential. Initiation of neoadjuvant chemotherapy aims to reduce the tumor size and eradicate micrometastases, followed by a limb-sparing surgical resection to preserve maximum limb function while ensuring complete tumor excision. Postoperative adjuvant chemotherapy will continue to target any residual cancer cells, reducing the risk of recurrence. Close monitoring of treatment response through MRI and PET-CT imaging will be conducted to assess the effectiveness of the chemotherapy and surgery. The patient will be educated on the importance of adherence to the treatment regimen and the necessity of regular follow-up appointments. Physical rehabilitation will be incorporated into the recovery process to restore limb functionality post-surgery. Derek's overall health status and laboratory parameters will be closely monitored to manage any potential treatment-associated complications, ensuring a comprehensive and individualized care plan aimed at achieving the best possible outcome."
    },
    {
        "Patient Information": {
            "Name": "John Doe",
            "Age": "58",
            "Gender": "Male",
            "Medical History": "Chronic osteomyelitis, hypertension, recurrent respiratory infections"
        },
        "Disease Information": {
            "Disease": "Multiple Myeloma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent and progressively worsening bone pain, osteoporosis, pathological fractures, anemia, hypercalcemia, kidney damage, recurrent infections, increased serum globulin levels, radicular syndrome",
            "Duration": "Symptoms have been continuously intensifying over the past several months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7-40)",
                "AST (Aspartate Aminotransferase)": "29 IU/L (13-35)",
                "Urea": "8.5 mmol/L (2.6-8.8)",
                "Creatinine (Cr)": "110 μmol/L (41-81)",
                "Triglycerides (TG)": "1.9 mmol/L (<1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (<5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5-9.5)",
                "Red Blood Cell Ct. (RBC)": "3.3 × 10^12/L (3.5-5.5)",
                "Hematocrit (Hct)": "32% (35-50)",
                "Hemoglobin (Hb)": "95 g/L (115-150)",
                "Platelet Ct. (PLT)": "150 × 10^9/L (125-350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20-50)",
                "Neutrophil Percentage (NEUT%)": "67% (40-75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.0 × 10^9/L (1.3-3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8-6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2-1.0)",
                "Monocyte Percentage (MONO%)": "9% (3-10)",
                "Eosinophil Abs. Ct. (EO#)": "0.07 × 10^9/L (0.02-0.52)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4-8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0-0.06)",
                "Basophil Percentage (BASO%)": "0.8% (0-1)",
                "Mean Platelet Volume (MPV)": "10 fL (9-13)",
                "Lactate Dehydrogenase": "240 U/L (135-225)",
                "Muscle Enzymes (CK)": "150 U/L (22-198 for males)",
                "Myoglobin": "78 ng/mL (<90 ng/mL)",
                "Troponin I": "12 ng/L (<14 ng/L)",
                "Ferritin": "550 ng/mL (20-500 for males)",
                "CRP": "20 mg/L (<3 mg/L)",
                "ESR": "60 mm/hr (0-20)",
                "Procalcitonin": "0.3 ng/mL (<0.5)",
                "D-dimer": "0.9 mg/L FEU (0-0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None Detected",
                "Blood Silver Level": "65 μg/L (50-150)"
            },
            "Bone Marrow Biopsy": "Presence of abnormal plasma cells confirmed, suggesting myeloma infiltration",
            "Serological Diagnosis": "Elevated serum immunoglobulin levels",
            "Imaging Examination (MRI)": "Multiple bone lesions with involvement of the axial skeleton",
            "Urine Protein Electrophoresis": "Presence of Bence-Jones proteins",
            "CT Scan": "Detection of minor bone damage and extramedullary involvement",
            "PET/CT": "Active lesion observed in multiple sites, including the spine and rib cage",
            "Pulmonary Function Test": "Normal",
            "Renal Function Test": "Impaired renal function due to monoclonal immunoglobulin deposition",
            "Nerve Conduction Study": "Peripheral neuropathy consistent with radicular symptoms"
        },
        "Treatment Plan": "John Doe has been diagnosed with multiple myeloma with major severity, characterized by significant bone pain, anemia, kidney damage, and recurrent infections. The primary treatment approach is chemotherapy, potentially combined with autologous stem cell transplantation if deemed suitable, to achieve disease remission. Bortezomib-based chemotherapy regimens will be initiated, possibly with thalidomide and dexamethasone to enhance therapeutic efficacy. Considering potential transplant eligibility, high-dose chemotherapy followed by autologous stem cell transplantation as consolidation therapy may be pursued if the patient's condition permits, in order to achieve a deeper remission. Maintenance therapy post-transplantation will involve lenalidomide or bortezomib monotherapy to sustain remission and prevent relapse, with periodic monitoring of serum M protein levels to assess disease progression. Pain management strategies, including analgesics such as morphine, will be employed to alleviate bone pain and neuralgia, while supportive care for anemia, consisting of erythropoietin administration, may be employed to improve hematologic function. Attention to kidney function is crucial, with dietary modifications implemented to reduce renal stress, alongside close monitoring for hypercalcemia and hyperuricemia, ensuring sufficient hydration to mitigate renal complications. Routine skeletal imaging and bone marrow assessments will aid in evaluating treatment response and adapting therapeutic strategies as needed. John will be encouraged to adopt a gentle exercise routine with careful monitoring to prevent bone fractures, complemented by nutritional support and infection prevention measures to optimize overall health. Regular follow-ups and monitoring every 3–6 months are advised, ensuring timely adjustments to the treatment plan based on his response, and John will be educated on recognizing potential signs of deterioration, adhering to prescribed medications, and the importance of ongoing care."
    },
    {
        "Patient Information": {
            "Name": "Martha Stevens",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "Chronic osteomyelitis, recurrent pyelonephritis"
        },
        "Disease Information": {
            "Disease": "Multiple Myeloma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent, progressively worsening bone pain, osteoporosis, pathological fractures, progressive anemia, hypercalcemia, kidney damage, recurrent infections",
            "Duration": "Symptoms have gradually intensified over the past six months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "38 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU /L (13 − 35)",
                "Urea": "9.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "120 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.1 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "2.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "29% (35 − 50)",
                "Hemoglobin (Hb)": "95 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "18% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "75% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.86 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.32 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "850 ng/mL (20 − 500 for females)",
                "CRP": "30 mg/L (< 3 mg/L)",
                "ESR": "45 mm/hr (0 − 20)",
                "Procalcitonin": "0.6 ng/mL (< 0.5)",
                "D-dimer": "1.2 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Evidence of osteoporosis with no acute fractures",
            "Chest Computerized Tomography": "Multiple lytic bone lesions consistent with myeloma",
            "Serological Diagnosis": "Elevated monoclonal immunoglobulins",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Positive for secondary bacterial infection",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Normal",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal",
            "Bone Marrow Biopsy": "Presence of abnormal plasma cells indicating myeloma",
            "MRI": "Showed spinal involvement with risk of compression fractures",
            "PET/CT Scan": "High uptake in multiple skeletal regions, confirming myeloma activity"
        },
        "Treatment Plan": "Martha Stevens has been diagnosed with major severity multiple myeloma, characterized by persistent bone pain, anemia, kidney impairment, and recurrent infections. Due to the advanced stage of the disease, an aggressive treatment plan is crucial. Initial treatment will involve induction therapy using a combination of bortezomib, thalidomide, and dexamethasone, especially given her eligibility for a stem cell transplant. Post induction, autologous stem cell transplantation will be considered to achieve remission if clinically feasible. Maintenance therapy using lenalidomide or bortezomib will be implemented long-term post-transplant to sustain remission. In case of bone pain and risk of fractures, pain management will be optimized through analgesics and physical therapy. Regular follow-ups every 3 to 6 months will include serum protein measurements, urine tests for Bence-Jones proteinuria, and skeletal assessments to monitor disease progression. Renal function management is vital, focusing on a low-sodium, low-protein diet to reduce kidney strain. Martha and her family will be educated on symptom management and the importance of adherence to the treatment plan, with daily life adjustments to accommodate her condition. Psychological support will be provided to alleviate emotional stress. In the backdrop of symptomatic care, ensuring prevention of infections will be key, with hygienic practices and timely vaccinations being encouraged. Through multidisciplinary collaboration, the treatment plan aims to manage symptoms, delay disease progression, and improve quality of life."
    },
    {
        "Patient Information": {
            "Name": "Eleanor Johnson",
            "Age": "56",
            "Gender": "Female",
            "Medical History": "Chronic back pain, recurrent kidney infections, osteoporosis"
        },
        "Disease Information": {
            "Disease": "Multiple Myeloma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent and progressively worsening bone pain, anemia, hypercalcemia, kidney damage, recurrent infections",
            "Duration": "Symptoms have been persistent for the past six months, with significant escalation in the last month",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "10.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "125 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.4 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "30% (35 − 50)",
                "Hemoglobin (Hb)": "95 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.0 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.15 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "3.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "9 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for females)",
                "CRP": "20 mg/L (< 3 mg/L)",
                "ESR": "60 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Not applicable",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Bone Marrow Biopsy": "Increased plasma cells, presence of monoclonal plasma cell population",
            "Serum Protein Electrophoresis": "Presence of monoclonal gammopathy",
            "24-hour Urine Protein": "Elevated, presence of Bence-Jones protein",
            "Whole-body X-ray Skeletal Exam": "Multiple lytic lesions observed",
            "Chest Computerized Tomography": "Bone lesions in ribs and thoracic vertebrae",
            "Magnetic Resonance Imaging (MRI)": "Lesions noted in the axial skeleton",
            "PET/CT": "Increased metabolic activity in the pelvis and spine",
            "Cytogenetic Testing": "Abnormalities in chromosome 13",
            "Serum Free Light Chains": "Imbalance detected"
        },
        "Treatment Plan": "Eleanor Johnson is diagnosed with multiple myeloma, characterized by major severity due to her persistent and worsening bone pain, anemia, hypercalcemia, and renal impairment. A multidisciplinary approach is required, involving hematology, oncology, and orthopedics for comprehensive care. Initial treatment will involve induction chemotherapy with a regimen including bortezomib and dexamethasone to reduce the myeloma cell burden. Given the renal impairment, care will be taken to adjust dosing as needed, and Eleanor will be closely monitored for renal function. Autologous stem cell transplantation will be considered after achieving remission as part of a consolidation strategy for eligible patients. Maintenance therapy post-transplant might include lenalidomide or bortezomib to prolong remission. Pain management is crucial, involving bisphosphonates like zoledronic acid for bone protection and analgesics for pain control. Regular monitoring of serum calcium levels and renal function will be essential, along with supportive care measures including hydration and nutritional support tailored to her renal and hematologic status. Eleanor will be advised to avoid exposure to infections through preventative measures, with antibiotic prophylaxis if recurrent infections persist. An individualized follow-up plan will be devised, including regular bone assessments and laboratory evaluations to monitor disease status and adjust treatment accordingly. Her family will be educated about the disease course, treatment options, and potential complications, offering support and resources to help them manage Eleanor’s condition effectively at home."
    },
    {
        "Patient Information": {
            "Name": "Samantha White",
            "Age": "29",
            "Gender": "Female",
            "Medical History": "History of HPV infections; smoker; multiple sexual partners"
        },
        "Disease Information": {
            "Disease": "Cervical Intraepithelial Neoplasia",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Increased vaginal discharge, slight vaginal bleeding after intercourse",
            "Duration": "Symptoms have been noticed steadily for the past 4 weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.3 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.95 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "9.5 fl (9 − 13)",
                "Lactate Dehydrogenase": "160 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198 for females)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "80 ng/mL (20 − 500 for females)",
                "CRP": "1 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "High-risk HPV Types 16 and 18",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Colposcopy Exam": "Lesion observed in transformation zone with white epithelium",
            "Cervical Cytology": "High-grade squamous intraepithelial lesion",
            "HPV Testing": "Positive for high-risk HPV types 16 and 18",
            "Histological Examination": "Confirmed cervical intraepithelial neoplasia",
            "Cervical Biopsy": "High-grade lesion with potential for malignancy",
            "Liquid-Based Cytology": "Abnormal cells detected",
            "Cervical Curettage": "Presence of squamous-cell abnormalities",
            "Colposcopy Imaging": "Localized lesion with visible transformation zone"
        },
        "Treatment Plan": "Samantha White has been diagnosed with moderate cervical intraepithelial neoplasia, linked to high-risk HPV infections. The treatment entails an immediate focus on surgical intervention with options such as Loop Electrosurgical Excision Procedure (LEEP) or cold knife conization to remove the lesioned tissue and provide samples for pathological analysis. Samantha will be counseled through the treatment process, focusing on the potential impact on future pregnancies due to this procedure, including risks such as cervical incompetence or preterm birth. While maintaining a stable partnership and proper sexual hygiene will be emphasized to reduce the risk of reinfection, the patient will also be encouraged to quit smoking and adopt a healthier lifestyle to improve her immune response. Regular follow-ups will be necessary to assess the success of the procedure, including repeated cytology and HPV tests every 4-6 months to ensure no residual lesions or recurrence. Furthermore, Samantha will be advised on the importance of HPV vaccination if eligible and educating herself about the disease to alleviate any psychological stress. After recovery, regular gynecological visits, balanced nutrition, and avoiding high-risk sexual behaviors will be key components of her ongoing preventive care strategy."
    },
    {
        "Patient Information": {
            "Name": "Laura Thompson",
            "Age": "29",
            "Gender": "Female",
            "Medical History": "No prior medical history, non-smoker, sexually active with regular cervical screenings"
        },
        "Disease Information": {
            "Disease": "Cervical Intraepithelial Neoplasia",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Increased vaginal discharge, occasional contact bleeding post-intercourse",
            "Duration": "Symptoms have persisted for approximately 3 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU /L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "95 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "120 ng/mL (20 − 500 for females)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative for oncogenic markers",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Cervical Cytology": "Abnormal cells present, suggestive of low-grade squamous intraepithelial lesion (LSIL)",
            "HPV Test": "Positive for high-risk HPV type 16",
            "Colposcopy": "Visualized areas of abnormal epithelium within the transformation zone",
            "Cervical Biopsy": "Confirms presence of CIN2 (moderate dysplasia)",
            "Cervical Curettage": "No additional lesions detected",
            "Pap Smear": "LSIL detected, warrants further investigation",
            "Serological Diagnosis": "Normal",
            "Imaging Tests": "No evidence of metastasis"
        },
        "Treatment Plan": "Laura Thompson's diagnosis of cervical intraepithelial neoplasia (CIN2) necessitates an immediate intervention to prevent progression to cervical cancer. A Loop Electrosurgical Excision Procedure (LEEP) is recommended to excise the dysplastic tissue while preserving cervical integrity, as Laura is within her reproductive years and may wish to conceive in the future. This outpatient procedure involves minimal recovery time and allows for both therapeutic and diagnostic benefits, as the excised tissue will be further evaluated pathologically. Concurrently, counseling on HPV prevention, including vaccination if not previously administered, and education on safe sexual practices will be reinforced to minimize recurrence risks. Follow-up appointments will include colposcopy and cervical cytology every 4-6 months post-procedure to ensure lesion-free status and early identification of any new changes. Should the margins from the LEEP procedure indicate residual disease, additional treatment, such as cold knife conization, may be considered. Emotional support and lifestyle modifications, focusing on stress management, smoking cessation, and a balanced diet, are equally vital components of Laura's holistic care plan. Ensuring adherence to these guidelines will aid in her recovery and long-term health, ultimately reducing the risk of cervical cancer development."
    },
    {
        "Patient Information": {
            "Name": "Emily Johnson",
            "Age": "32",
            "Gender": "Female",
            "Medical History": "Frequent vaginal discharge with occasional mild odor, history of smoking, multiple sexual partners, use of oral contraceptives"
        },
        "Disease Information": {
            "Disease": "Cervical intraepithelial neoplasia",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Increased vaginal discharge, occasional contact bleeding after intercourse",
            "Duration": "Symptoms have been present intermittently for the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "5.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "65 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.1 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198 for females)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "9 ng/L (< 14 ng/L)",
                "Ferritin": "130 ng/mL (15 − 200 for females)",
                "CRP": "4 mg/L (< 3 mg/L)",
                "ESR": "22 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Cervical Cytology": "Presence of squamous intraepithelial lesion",
            "HPV Testing": "Positive for HPV Type 16",
            "Colposcopy": "Local erythema and white epithelium noted",
            "Cervical Biopsy": "Low-grade squamous intraepithelial lesion",
            "Cervical Curettage": "No significant abnormalities",
            "Pap Smear": "ASCUS (Atypical Squamous Cells of Undetermined Significance)",
            "Liquid-Based Cytology": "Low-grade lesion",
            "Cervical Conization": "Not performed, not indicated"
        },
        "Treatment Plan": "Emily Johnson has been diagnosed with cervical intraepithelial neoplasia, which poses a risk of progressing to cervical cancer. Due to the moderate severity and presence of high-risk HPV type, prompt treatment is essential. The treatment plan for Emily includes monitoring through regular cytology and HPV testing every 6 months, aiming to detect any progression or regression of the lesion. Given the current low-grade nature of the lesions observed through biopsy and colposcopy, physical therapies such as cryotherapy or laser ablation may be considered to remove affected surface tissue, especially in prospective cases where fertility preservation is important. Lifestyle modifications, including quitting smoking, ensuring a balanced diet, and adopting safer sexual practices, will be advised to lower the risk of HPV persistence and lesion advancement. Emily will be educated on the importance of HPV vaccination to prevent further infections and potential lesion progression. Follow-up will be crucial, with regular gynecological examinations and screenings to monitor her response to treatment and adjust the approach as necessary. Counseling support will be provided to address any psychological stress related to the diagnosis, ensuring she remains informed and engaged in her care plan."
    },
    {
        "Patient Information": {
            "Name": "Jason Roberts",
            "Age": "17",
            "Gender": "Male",
            "Medical History": "No prior significant medical history, occasional joint pain misattributed to growing pains"
        },
        "Disease Information": {
            "Disease": "Osteosarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent bone pain, swelling at the distal femur, limited joint movement, visible mass with increased local skin temperature",
            "Duration": "Symptoms have been worsening over the past two months, with pain intensifying at night",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.3 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.15 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "9 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "110 U/L (22 − 198 for males)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "480 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Imaging Tests": {
                "X-ray": "Irregular bone destruction and periosteal reaction at the distal femur",
                "CT Scan": "Mineralization within the tumor, localized bone destruction",
                "MRI": "Invasion into surrounding soft tissue, tumor mass at distal femur",
                "Bone Scan": "Increased radionuclide uptake in the distal femur",
                "PET Scan": "High metabolic activity at the site of the mass"
            },
            "Pathological Examination": "High-grade osteosarcoma confirmed via needle biopsy",
            "Chest CT": "No signs of metastasis",
            "Histology": "Presence of osteoid material indicative of osteosarcoma",
            "Blood Markers": {
                "Alkaline Phosphatase": "200 U/L (45 − 115)",
                "Lactate Dehydrogenase": "Elevated"
            },
            "Nutritional Assessment": "Adequate nutritional status with potential need for increased caloric intake during treatment"
        },
        "Treatment Plan": "Jason Roberts has been diagnosed with major severity osteosarcoma located in the distal femur and requires a comprehensive treatment approach. Preoperative chemotherapy will be initiated to assess the tumor's response and reduce its size prior to surgery. A combination of methotrexate, doxorubicin, and cisplatin will be administered to target the high-grade malignancy effectively. Following a thorough assessment, limb-sparing surgery is considered feasible and optimal for preserving function, given the tumor's location and current status. Rotationplasty or prosthesis replacement will be assessed based on intraoperative findings and feasibility. Post-surgery, adjuvant chemotherapy will continue to address any microscopic metastatic lesions and prevent recurrence, with cycles planned according to the tumor's histological response to initial chemotherapy. Regular imaging, blood tests, and clinical evaluations will monitor the response and guide any necessary adjustments to chemotherapy regimens. Psychological support and counseling will be provided to assist Jason and his family with the emotional aspects of treatment and recovery. Nutritional support will focus on optimal calorie and protein intake to support healing and ongoing treatment. Adherence to the treatment protocol, regular follow-up appointments, and cooperation from Jason and his family are crucial for successful treatment outcomes. Physical therapy will be implemented post-surgery to regain limb function, with gradual increases in physical activity as tolerated. If required, additional surgical interventions such as removal of any detected metastatic lesions in the lungs will be considered based on follow-up imaging and clinical assessments."
    },
    {
        "Patient Information": {
            "Name": "Ethan Wilson",
            "Age": "17",
            "Gender": "Male",
            "Medical History": "Previously healthy, no known hereditary conditions, occasionally experienced bone pain attributed to growing pains"
        },
        "Disease Information": {
            "Disease": "Osteosarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent local bone pain, swelling, palpable lump at the site of pain, restricted movement of adjacent joints, increased local skin temperature",
            "Duration": "Symptoms have been increasing in intensity over the past month",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 - 40)",
                "AST (Aspartate Aminotransferase)": "32 IU /L (13 - 35)",
                "Urea": "5.0 mmol/L (2.6 - 8.8)",
                "Creatinine (Cr)": "75 μmol/L (41 - 81)",
                "Triglycerides (TG)": "1.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.5 × 10^9/L (3.5 - 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.8 × 10^12/L (3.5 - 5.5)",
                "Hematocrit (Hct)": "42% (35 - 50)",
                "Hemoglobin (Hb)": "135 g/L (115 - 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 - 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 - 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 - 75)",
                "Lactate Dehydrogenase": "560 U/L (135 - 225)",
                "Alkaline Phosphatase": "600 U/L (40 - 150)",
                "Ferritin": "150 ng/mL (15 - 200)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)"
            },
            "X-ray Exam": "Irregular bone destruction and periosteal reaction at the metaphysis of the distal femur",
            "CT Scan": "Bone destruction with mineralization of the tumor mass",
            "MRI Exam": "Soft tissue invasion around the distal femur",
            "Bone Scan": "Increased radioactive uptake at the site of the lesion",
            "PET/CT": "High metabolic activity in the distal femur region, no distant metastasis detected",
            "Pathological Examination": "High-grade osteosarcoma with spindle-shaped tumor cells and bone-like tissue formation"
        },
        "Treatment Plan": "Ethan Wilson has been diagnosed with high-grade osteosarcoma in the distal femur with major severity. The treatment plan involves an integrated approach starting with preoperative chemotherapy to reduce the tumor size and assess chemotherapeutic sensitivity. Following chemotherapy, surgical intervention will be planned, aiming for limb-sparing surgery if feasible. This approach will include tumor resection with tumor prosthesis replacement or allogeneic bone transplantation, depending on the extent of the lesion and structural involvement. Post-surgical re-evaluation will guide the continuation of chemotherapy, targeting both the primary site and any potential microscopic metastases, relying on regular CT and MRI scans to monitor treatment efficacy. Pain management is critical, utilizing the WHO three-step analgesic ladder to ensure Ethan's comfort, with NSAIDs and central analgesics deployed judiciously according to tolerance. Psychological support and counseling will be provided to address potential stress and body image concerns associated with treatment outcomes. Adaptive physical therapy will be crucial for functional recovery, supported by nutritional management to maintain his overall health and resilience during therapy. The care team will conduct routine follow-ups and adopt a personalized approach to Ethan's care, focused on optimizing outcomes and ensuring comprehensive support throughout the treatment process."
    },
    {
        "Patient Information": {
            "Name": "Michael Thompson",
            "Age": "16",
            "Gender": "Male",
            "Medical History": "Growing pains, occasional night sweats, history of benign bone tumor"
        },
        "Disease Information": {
            "Disease": "Osteosarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent bone and joint pain, swelling, and local heat, restricted joint movement, growing mass at the distal femur",
            "Duration": "Symptoms have gradually intensified over the past 3 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.7 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "11.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.6 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "3.3 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "7.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.9 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.02 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Alkaline Phosphatase": "230 U/L (30 − 120)",
                "CRP": "55 mg/L (< 3 mg/L)",
                "ESR": "50 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Bone Scan": "Increased radioactive uptake at the distal femur",
            "Chest CT": "No signs of metastasis",
            "MRI": "Soft tissue invasion at the distal femur",
            "PET/CT": "High metabolic activity at the tumor site",
            "X-ray": "Destructive bone changes in the distal femur, irregular new bone formation",
            "Pathological Biopsy": "Confirmed high-grade osteosarcoma",
            "Histology": "Malignant spindle-shaped tumor cells producing bone-like tissue"
        },
        "Treatment Plan": "Michael Thompson has been diagnosed with high-grade osteosarcoma located at the distal femur, necessitating an aggressive treatment approach to maximize chances of recovery while preserving limb function. The treatment plan will begin with preoperative chemotherapy to reduce the size of the tumor and assess its response, using agents like methotrexate, doxorubicin, and cisplatin. Following chemotherapy and re-evaluation through imaging and histological assessments, limb-sparing surgery will be performed if deemed feasible, focusing on extensive resection of the tumor while ensuring negative surgical margins. Postoperative chemotherapy will continue using adjusted regimens based on tumor response, aiming to eradicate microscopic metastases and prevent recurrence. To aid in recovery and maintain joint function, an orthopedic prosthesis may be used to replace affected bone segments. Michael will receive pain management with analgesics following the WHO analgesic ladder, supplemented with NSAIDs for inflammation control. Psychological support and counseling will be provided to address any emotional distress during treatment, alongside nutritional guidance to support physical recovery. Regular follow-up appointments and imaging scans will be scheduled to monitor for any signs of metastasis or recurrence, with chemotherapy regimens being adjusted as necessary. Michael's cooperation and adherence to the treatment protocol will be crucial for optimal outcomes and long-term survival, with family support playing a key role in his journey."
    },
    {
        "Patient Information": {
            "Name": "Sarah Johnson",
            "Age": "17",
            "Gender": "Female",
            "Medical History": "No significant medical history"
        },
        "Disease Information": {
            "Disease": "Primary Malignant Bone Tumor (Osteosarcoma)",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent bone pain, noticeable swelling and mass in the affected limb, localized tenderness, reduced limb function, and occasional low-grade fever",
            "Duration": "Symptoms have progressively worsened over the past 3 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.6 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "320 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "80 ng/mL (12 − 150 for females)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "X-ray Exam": "Irregular moth-eaten appearance with unclear boundaries in femur",
            "CT Scan": "Lesions in the femur with sunburst pattern indicative of osteosarcoma",
            "MRI": "Tumor extent with surrounding soft tissue involvement",
            "Bone Scan": "Increased uptake in affected femur with no metastatic spread",
            "Biopsy": "Histopathology confirms osteosarcoma",
            "Serological Diagnosis": "Normal",
            "Bacterial Culture": "Normal",
            "Pulmonary Function Test": "Normal",
            "Urinary Analysis": "Normal",
            "Ultrasound": "Normal surrounding soft tissue structure"
        },
        "Treatment Plan": "Sarah Johnson has been diagnosed with osteosarcoma in the femur, requiring an aggressive treatment approach due to its major severity. The primary treatment will include limb-sparing surgery to resect the tumor while preserving limb function, considering her preference and the tumor's location. Preoperative neoadjuvant chemotherapy will be initiated to shrink the tumor size and enhance surgical outcomes, followed by postoperative adjuvant chemotherapy to reduce the risk of recurrence. Regular imaging assessments will monitor her response to treatment, with adjustments made if necessary. Limb preservation will be prioritized since there is no neurovascular bundle involvement, and a comprehensive rehabilitation plan will be established to support her recovery and improve limb function post-surgery. Sarah and her family will receive counseling to understand the treatment process, potential side effects, and the importance of follow-up care. Proactive measures will be taken to manage complications and optimize her overall wellbeing throughout the treatment journey."
    },
    {
        "Patient Information": {
            "Name": "Laura Johnson",
            "Age": "18",
            "Gender": "Female",
            "Medical History": "History of bone pain and local swelling in upper limb. No previous fractures or significant illnesses."
        },
        "Disease Information": {
            "Disease": "Osteosarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent bone pain in the upper limb, local swelling, functional impairment, rapid growth of local mass, tenderness.",
            "Duration": "Symptoms have been present and worsening over the past 4 weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "5.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "75 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "350 ng/mL (20 − 500 for females)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None Detected",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "X-ray Examination": "Irregular bone lesions in the humerus with a 'sunburst' appearance",
            "Magnetic Resonance Imaging (MRI)": "Revealed the extent of bone involvement and soft tissue mass surrounding the humerus",
            "Computed Tomography (CT)": "Detected localized bone destruction and surrounding mass, suggestive of osteosarcoma",
            "Biopsy Report": "Confirmed presence of osteosarcoma cells, indicative of malignant bone tumor",
            "Bone Scan (ECT)": "Highlighted increased uptake in the humerus, confirming localized disease",
            "PET-CT Scan": "Showed no signs of distant metastasis, localized to upper limb",
            "Serum Alkaline Phosphatase": "Elevated levels indicating osteoblastic activity",
            "Tumor Marker Analysis": "Normal levels, specific markers for osteosarcoma not detected"
        },
        "Treatment Plan": "Laura Johnson has been diagnosed with osteosarcoma in her upper limb, requiring an immediate and comprehensive treatment approach to prevent progression and ensure effective management. The initial treatment will involve limb-sparing surgery to remove the tumor mass while preserving function, assuming no involvement of major nerves or blood vessels is confirmed. This will include the complete excision of the affected area and surrounding tissue, followed by reconstructive techniques if necessary to maintain limb functionality. Preoperative neoadjuvant chemotherapy will be administered to reduce tumor size and facilitate surgical resection, with subsequent postoperative adjuvant chemotherapy aimed at eradicating residual cancer cells and minimizing recurrence risk. Radiotherapy may be considered if the tumor demonstrates sensitivity and to manage any residual lesion post-surgery. Regular monitoring through imaging studies, including MRI and CT scans, will ensure the tracking of therapeutic progress and detect any signs of recurrence or metastasis early on. Laura will undergo supportive care for symptom management, including pain relief and nutritional support, and be educated on physical therapy exercises to regain strength and mobility in the affected limb. Follow-up consultations will be scheduled to align treatment adjustments with her recovery trajectory, and psychological support will be provided to help her cope with the emotional impact of her diagnosis and treatment. Early detection and continued adherence to the treatment plan are vital for her recovery and long-term health, with reinforcement of compliance through patient education, and potential involvement in a clinical trial for innovative therapies to enhance her prognosis."
    },
    {
        "Patient Information": {
            "Name": "Eleanor Thompson",
            "Age": "35",
            "Gender": "Female",
            "Medical History": "History of localized limb pain, intermittent swelling, no significant past medical issues"
        },
        "Disease Information": {
            "Disease": "Malignant Bone Tumor - Osteosarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent limb pain, localized swelling, functional impairment, weight loss, low-grade fever",
            "Duration": "Symptoms have been intensifying over the past month",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "34 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "72 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "41% (35 − 50)",
                "Hemoglobin (Hb)": "138 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.4 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 300 for females)",
                "CRP": "35 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Serum Calcium Level": "Normal (2.15 - 2.55 mmol/L)",
                "Serum Alkaline Phosphatase": "Elevated (200 U/L)",
                "Tumor Marker - Osteosarcoma": "Positive",
                "Chromosomal Analysis": "t(11;22)(q24;q12) mutation present"
            },
            "X-ray Exam": "Irregular bone lesions with moth-eaten appearance and poorly defined edges, suggestive of osteosarcoma",
            "CT Scan": "Invasive tumor with unclear boundaries and Codman's triangle observed",
            "MRI": "Tumor extension into surrounding soft tissue, neurovascular involvement is not evident",
            "Emission Computed Tomography (ECT)": "Increased uptake in tumorous area, confirms active bone lesions",
            "Digital Subtraction Angiography (DSA)": "Rich blood supply to tumorous region",
            "Biopsy Result": "Confirmed osteosarcoma, high-grade malignant"
        },
        "Treatment Plan": "Eleanor Thompson has been diagnosed with a major severity malignant bone tumor, specifically osteosarcoma, requiring urgent and meticulous intervention. Given the diagnosis, limb-sparing surgery is planned to preserve function while effectively removing the tumor, as clinical evaluations indicate non-involvement of major neurovascular structures. Prior to surgery, neoadjuvant chemotherapy will be administered to shrink the tumor and enhance surgical outcomes, followed by postoperative adjuvant chemotherapy to target any residual cancer cells and prevent metastasis. Radiotherapy may be considered if tumor margins are not clear, focusing on pain management and local control of the disease. Continuous monitoring of Eleanor’s response to chemotherapy is essential, alongside regular imaging to assess treatment progress and adjust the protocol as needed. Rehabilitation services will be initiated post-surgery to restore limb function and improve Eleanor’s quality of life. Nutritional support and management of anemia through supplementation are pivotal in maintaining overall health during treatment. Eleanor will be educated on signs of recurrence or deterioration, emphasizing the importance of adhering to follow-up schedules and preventative measures to avoid complications. Prosthesis fitting will be arranged if limb function requires additional support, ensuring Eleanor's mobility and independence post-treatment."
    },
    {
        "Patient Information": {
            "Name": "James Thompson",
            "Age": "55",
            "Gender": "Male",
            "Medical History": "Chronic inflammation around the anus, history of HPV infection"
        },
        "Disease Information": {
            "Disease": "Perianal Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Anal discomfort, itching, rectal bleeding, palpable lumps at the anal margin, mild pain",
            "Duration": "Symptoms have persisted and gradually worsened over the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.4 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "280 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.8 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "175 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "90 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.25 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative for cancer-specific antigens",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "No significant abnormalities",
            "Abdominal and Pelvic Computerized Tomography (CT)": "Localized mass in perianal region, suggestive of perianal cancer, no distant metastasis",
            "Serological Diagnosis": "Negative for viral markers",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Anal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "No abnormal findings",
            "Anoscopy and Rectoscopy": "Visible lesions with ulcerations and characteristic signs of perianal cancer",
            "Serum Antibody Test": "Negative for HIV antibodies",
            "Pelvic MRI": "Enhanced lesion in the perianal area with no evident pelvic lymph node involvement",
            "Nucleic Acid Amplification Test": "Negative for prevalent viral pathogens",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "James Thompson has been diagnosed with perianal cancer with a severity that warrants a comprehensive treatment approach. Given the localized presentation and the absence of distant metastasis, the treatment will primarily involve concurrent chemoradiotherapy to target the tumor and any potential regional lymph node involvement. This will include the administration of mitomycin and fluorouracil concomitant with pelvic radiotherapy, considering James's overall good health status and his non-HIV-positive status, which suggests he may better tolerate the treatment. Surgery may be considered if the tumor shows local progression, with surgical resection or abdominoperineal resection as potential options. James will also be advised on maintaining a diet that is light yet nutritious, ensuring adequate rest, and engaging in light activities to support his physical and mental well-being throughout the treatment. Psychological support and stress-relief practices will be encouraged to alleviate any anxiety related to the diagnosis and treatment process. Regular follow-up appointments will be crucial to monitor the efficacy of the treatment, assess for any adverse effects, and make necessary adjustments to the therapeutic regimen. Family involvement is important to provide emotional support and assist with daily care needs. Post-treatment, James will be encouraged to adopt lifestyle changes such as safe sexual practices and potentially receive the HPV vaccine to reduce the risk of future occurrences."
    },
    {
        "Patient Information": {
            "Name": "Michael Johnson",
            "Age": "58",
            "Gender": "Male",
            "Medical History": "Chronic anal discomfort, history of HPV infection"
        },
        "Disease Information": {
            "Disease": "Perianal Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Chronic anal discomfort, anal itching, rectal bleeding, palpable lump at the anal margin, inguinal lymph node enlargement",
            "Duration": "Symptoms have been present for approximately 6 months, with slow progression",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "34% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "120 U/L (22 − 198)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "5 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500)",
                "CRP": "7 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "HPV 16 positive",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "No abnormalities detected",
            "Serological Diagnosis": "No indications of systemic infection",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Positive for HPV antibodies",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative for SARS-CoV-2",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Michael Johnson is diagnosed with perianal squamous cell carcinoma, presenting with major symptoms including anal discomfort, itching, and rectal bleeding. The treatment strategy involves an initial combined chemoradiotherapy approach, targeting the tumor and any involved lymph nodes. Given the HPV-positive status, the treatment will emphasize addressing this high-risk factor. The chemoradiotherapy regimen will include concurrent administration of mitomycin and fluorouracil, modulated according to Michael's tolerance and side effect profile. Regular imaging and examination will be conducted to monitor the response of the tumor and adjust the treatment plan if necessary. In case of local recurrence or radiotherapy complications, surgical options like local excision or more extensive abdominoperineal resection may be considered. Michael will receive supportive care to manage the common adverse effects of treatment, such as fatigue and gastrointestinal discomfort, alongside counseling to maintain emotional well-being. Dietary advice will focus on a balanced and easily digestible nutrition plan, with recommendations for moderate physical activities to aid recovery. Michael and his family will be provided with education and resources to recognize signs of progression or complication, ensuring prompt medical attention when needed. Post-treatment, regular follow-ups will be essential to monitor for recurrence, with HPV vaccination recommended as a preventive measure."
    },
    {
        "Patient Information": {
            "Name": "James Hughes",
            "Age": "55",
            "Gender": "Male",
            "Medical History": "Chronic anal discomfort, HPV infection"
        },
        "Disease Information": {
            "Disease": "Perianal cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Anal discomfort, itching, palpable lumps at the anal margin, rectal bleeding, enlarged inguinal lymph nodes, mild pain",
            "Duration": "Symptoms have been present for several months with gradual worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "39 IU/L (7 - 40)",
                "AST (Aspartate Aminotransferase)": "38 IU/L (13 - 35)",
                "Urea": "6.5 mmol/L (2.6 - 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 - 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 - 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 - 5.5)",
                "Hematocrit (Hct)": "36% (35 - 50)",
                "Hemoglobin (Hb)": "115 g/L (115 - 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 - 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 - 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 - 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.95 × 10^9/L (1.3 - 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.8 × 10^9/L (1.8 - 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 - 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 - 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.15 × 10^9/L (0.02 - 0.52)",
                "Eosinophil Percentage (EO%)": "3.5% (0.4 - 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 - 0.06)",
                "Basophil Percentage (BASO%)": "0.8% (0 - 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 - 13)",
                "Lactate Dehydrogenase": "190 U/L (135 - 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 - 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 - 500 for males)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 - 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 - 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative for HPV",
                "Blood Silver Level": "70 μg/L (50 - 150)"
            },
            "CT Scan Results": "Inguinal lymph node enlargement and perianal mass detected",
            "MRI": "Shows extensive involvement of perianal tissues with lymph node metastasis",
            "Proctoscopy": "Identified ulceration and nodular formations in the perianal region",
            "Chest X-ray": "Clear lungs, no evidence of metastatic spread",
            "Pelvic X-rays": "Identified lymph node involvement",
            "Biopsy": "Confirmed squamous cell carcinoma of the perianal region",
            "Anoscopy": "Visible ulceration with necrotic tissue",
            "Immunohistochemistry": "Positive for squamous cell carcinoma markers"
        },
        "Treatment Plan": "James Hughes has been diagnosed with major severity perianal cancer, characterized by anal discomfort, rectal bleeding, and enlarged inguinal lymph nodes. Given the disease's severity and symptoms, combined chemoradiotherapy is recommended, with mitomycin and fluorouracil administered concurrently with targeted pelvic radiotherapy to manage both local and metastatic lesions. Prior to initiating treatment, James will undergo meticulous diet planning to ensure adequate nutrition, along with lifestyle recommendations emphasizing rest and light physical activity to enhance treatment tolerance. Emotional support and counseling will be provided to help maintain a positive and cooperative outlook during therapy. Should acute complications arise, surgical intervention including local excision and stoma creation may be considered to alleviate life-threatening conditions. Throughout the treatment, James will be monitored closely with regular imaging and blood tests to evaluate response and adjust therapy accordingly. Post-treatment, James will require follow-up care to watch for potential recurrence, with family support playing a crucial role in quality of life management, ensuring adequate cognitive and emotional support. Additionally, vaccination with the HPV vaccine is advised to prevent future risk, along with the avoidance of high-risk sexual behaviors. James's cooperation and adherence to the treatment protocol will be vital for optimal management and recovery."
    },
    {
        "Patient Information": {
            "Name": "Elizabeth Wang",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "History of hepatitis B infection, cholecystectomy"
        },
        "Disease Information": {
            "Disease": "Liver tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Abdominal discomfort, jaundice, weight loss, decreased appetite",
            "Duration": "Symptoms have developed progressively over the past 6 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "95 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "120 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.7 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Positive",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "180 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "75% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.8 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "12% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "550 ng/mL (15 − 150 for females)",
                "CRP": "35 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "Alpha-fetoprotein (AFP)",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Large liver mass with hyperechoic areas",
            "CT Scan": "Liver mass with heterogeneous enhancement patterns",
            "MRI Exam": "Solid mass in right liver lobe with irregular margins",
            "Serological Diagnosis": "Elevated alpha-fetoprotein (AFP)",
            "Tumor Marker Detection": "Raised carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9)",
            "Biopsy Test": "Positive for hepatocellular carcinoma",
            "PET-CT": "No evidence of distant metastasis",
            "Liver Function Test": "Impaired liver function with elevated bilirubin levels",
            "Coagulation Function Test": "Mild coagulopathy detected",
            "Virology": "Hepatitis B virus DNA positive"
        },
        "Treatment Plan": "Elizabeth Wang has been diagnosed with a malignant liver tumor, specifically hepatocellular carcinoma, characterized by major severity due to progressive symptoms over the last six months. Given the current condition and medical history, including hepatitis B infection, a comprehensive treatment plan is necessary, with surgical resection as the primary treatment modality. The tumor is resectable, and liver function appears adequate for surgery. Hepatoprotective treatment will be administered pre-surgery to optimize liver function. Post-surgery, close monitoring for complications and disease recurrence is paramount, with periodic imaging and tumor marker assessments. Antiviral treatment for hepatitis B will be initiated to manage viral load and reduce liver inflammation. Targeted therapy with sorafenib may be considered alongside other systemic treatments if surgery is insufficient or recurrence occurs. Nutritional support, psychological counseling, and lifestyle modifications are vital components of the management strategy to enhance recovery and quality of life, including a balanced diet, cessation of alcohol, smoking, and regular physical activity. Follow-up care, incorporating regular check-ups and imaging studies, is essential in tracking Elizabeth's progress and making necessary adjustments to the treatment regimen. Additionally, educating Elizabeth and her family about treatment adherence, potential symptoms of deterioration, and the importance of continued medical evaluations will further support her recovery journey and long-term health."
    },
    {
        "Patient Information": {
            "Name": "Emily Zhang",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "Chronic Hepatitis B infection, Cirrhosis in the past 5 years"
        },
        "Disease Information": {
            "Disease": "Primary Liver Cancer (Hepatocellular Carcinoma)",
            "Severity Level": "Major Severity",
            "Symptoms": "Upper abdominal discomfort, liver area pain, fatigue, weight loss, jaundice",
            "Duration": "Symptoms have been progressively worsening over the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "70 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "85 IU/L (13 − 35)",
                "Urea": "6.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "90 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Positive",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.1 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "150 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.6 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.4 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "260 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for females)",
                "Myoglobin": "78 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "650 ng/mL (20 − 500 for females)",
                "CRP": "40 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "AFP",
                "Blood Silver Level": "68 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Liver mass noted in right lobe",
            "CT Scan": "Enhanced nodular lesion with irregular borders in liver, suggesting hepatocellular carcinoma",
            "MRI": "Dynamic contrast enhancement shows arterial phase hyperenhancement",
            "Serological Diagnosis": "Elevated AFP level indicative of hepatocellular carcinoma",
            "Virology": "HBV DNA: Positive",
            "Tumor Marker Test": "AFP significantly elevated at 500 ng/ml",
            "Liver Biopsy": "Presence of malignant hepatocellular carcinoma cells"
        },
        "Treatment Plan": "Emily Zhang has been diagnosed with primary liver cancer, specifically hepatocellular carcinoma, against the background of chronic hepatitis B and cirrhosis which pose significant health challenges. Due to the major severity of her symptoms, a multidisciplinary treatment approach is recommended. Surgical intervention through partial liver resection should be prioritized to remove the malignant tumor, pending a thorough assessment of her liver function and overall health status to ensure adequate post-operative liver reserve. Additionally, consideration of adjunctive therapies such as transarterial chemoembolization (TACE) or localized radiotherapy may be beneficial to manage any residual cancerous tissues and prevent recurrence. Given her cirrhosis, hepatoprotective treatments and antiviral medications are advised, tailored to suppress HBV replication and protect remaining liver tissues. Monitoring of liver function and tumor markers such as AFP will be crucial throughout her treatment process for effective adjustment of therapeutic strategies. Emily will require comprehensive nutritional support, including high-quality protein intake and avoidance of hepatotoxic substances, to enhance recovery. Psychological support is equally crucial to alleviate the stress and anxiety associated with her diagnosis and treatment. Education on follow-up care and lifestyle modifications will be provided to optimize her long-term health outcomes. Regular check-ups will be necessary to monitor her progress and ensure early detection of any complications or recurrent disease."
    },
    {
        "Patient Information": {
            "Name": "Laura Chen",
            "Age": "46",
            "Gender": "Female",
            "Medical History": "Chronic hepatitis B, mild cirrhosis"
        },
        "Disease Information": {
            "Disease": "Primary Liver Cancer - Hepatocellular Carcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Abdominal discomfort, fatigue, weight loss, jaundice",
            "Duration": "Symptoms have been present for approximately 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "56 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "62 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Positive",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "150 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "18% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "78% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.76 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "14% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for females)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Imaging": "Large mass detected in right lobe of liver",
            "CT Scan": "Heterogeneous density with vascular invasion, consistent with hepatocellular carcinoma",
            "MRI": "Hypervascular mass in liver with satellite nodules",
            "Serological Diagnosis": "Elevated Alpha-Fetoprotein (AFP)",
            "Virology": "Hepatitis B DNA positive",
            "Liver Biopsy": "Confirmed hepatocellular carcinoma",
            "PET-CT": "No distant metastasis detected",
            "Pathological Examination": "Moderately differentiated tumor cells"
        },
        "Treatment Plan": "Laura Chen's diagnosis of hepatocellular carcinoma, in the context of her chronic hepatitis B and mild cirrhosis, necessitates a comprehensive treatment approach. Given her significant clinical symptoms and the available diagnostic findings, the main objective is to control tumor growth and maintain liver function. An immediate plan involves liver resection, with careful preoperative evaluation to ensure that liver function status allows surgical intervention. Post-surgery, antiviral therapy will be critical in managing her hepatitis B infection to reduce liver inflammation and support liver recovery. Molecularly targeted therapy with sorafenib should be initiated postoperatively to inhibit cancer proliferation. Nutritional support and close monitoring of liver function are vital to optimize recovery. Furthermore, Laura should engage in regular follow-up including imaging studies and blood tests to track progress and detect any recurrence early. Psychological support and lifestyle changes such as cessation of alcohol and smoking will be encouraged to improve her overall prognosis. This integrated approach, including surgical and pharmaceutical interventions, aims to achieve the best possible outcome for Laura, with a focus on curative intent while managing underlying liver conditions effectively."
    },
    {
        "Patient Information": {
            "Name": "Evelyn Smith",
            "Age": "62",
            "Gender": "Female",
            "Medical History": "History of chronic hepatitis B and gallstones"
        },
        "Disease Information": {
            "Disease": "Hilar cholangiocarcinoma",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Dull pain and discomfort in the right upper abdomen, jaundice, dark yellow urine, grayish-white stools, severe itching of the skin",
            "Duration": "Symptoms have been progressively worsening over the past 3 weeks",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "85 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "90 IU/L (13 − 35)",
                "Urea": "5.3 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Positive",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.7 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "32% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.3 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "4% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "9 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for females)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Carcinoembryonic antigen (CEA)",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Abdominal Ultrasound": "Intrahepatic bile duct dilation with obstructive lesions",
            "CT Scan": "Mass at the hepatic hilum with invasion of nearby blood vessels",
            "MRI": "Tumor in the hepatic hilum with signs of vascular encroachment",
            "PET-CT": "Increased uptake in the hepatic hilum area",
            "ERCP": "Stenosis in the hepatic hilum with confirmed obstruction",
            "Liver Function Test": "Elevated bilirubin levels indicating jaundice",
            "Tumor Markers": {
                "Alpha-Fetoprotein (AFP)": "Normal",
                "Carcinoembryonic Antigen (CEA)": "High",
                "CA19-9": "Elevated"
            },
            "IgG4 Level": "Within normal range",
            "Autoimmune Antibodies Test": "Negative"
        },
        "Treatment Plan": "Evelyn Smith has been diagnosed with hilar cholangiocarcinoma, a condition with a complex and challenging prognosis due to its location and progression. After assessing her medical status and reviewing the imaging results, surgical intervention is not feasible at this advanced stage, with indications of vascular invasion. Treatment will focus on palliative measures to manage symptoms and improve quality of life. Placement of biliary stents through percutaneous transhepatic cholangial drainage (PTCD) will be crucial in relieving jaundice symptoms and maintaining bile duct patency. Chemotherapy using gemcitabine combined with platinum-based agents will be administered to slow tumor progression and reduce systemic symptoms. Additionally, Evelyn will receive external beam radiotherapy for palliative purposes, aiming to reduce tumor size and associated bile duct obstruction. Radiofrequency ablation may be considered if localized tumor control can be achieved, followed by stent placement to ensure bile duct patency. Close monitoring of liver function tests and tumor markers will be required to assess treatment efficacy and modify approaches as needed. A multidisciplinary team will support Evelyn's care, ensuring comprehensive management of her symptoms, including addressing severe skin itching with appropriate topical treatments and antihistamines to improve comfort. Nutritional support and regular follow-ups are vital in maintaining her overall health and engaging in moderate activity to enhance physical resilience. Her adherence to medical advice and regular evaluations will be key to optimizing her management and improving quality of life during treatment."
    },
    {
        "Patient Information": {
            "Name": "Sarah Johnson",
            "Age": "65",
            "Gender": "Female",
            "Medical History": "Chronic biliary inflammation, hepatitis B, history of gallstones"
        },
        "Disease Information": {
            "Disease": "Hilar cholangiocarcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Right upper abdominal discomfort, indigestion, jaundice with severe skin itching at night, dark yellow urine, grayish white stools",
            "Duration": "Symptoms have developed gradually over the past several months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "75 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "85 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "105 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Positive",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "230 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 75 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (15 − 150 for females)",
                "CRP": "18 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Liver Ultrasound": "Dilated intrahepatic bile ducts",
            "Liver Enhanced CT": "Obstructive lesion at hilar bile duct with invasion into surrounding vasculature",
            "MRI": "Mass at hepatic hilum indicating tumor presence",
            "MRCP": "Obstruction at bile duct confluence",
            "PET-CT": "Increased metabolic activity at the bile duct hilum",
            "Tumor Markers": {
                "CA19-9": "500 U/mL (< 37)",
                "CEA": "7 ng/mL (< 5)"
            },
            "Liver Function Test": "Impaired",
            "Kidney Function Test": "Normal",
            "Coagulation Test": "Mildly increased prothrombin time"
        },
        "Treatment Plan": "Sarah Johnson has been diagnosed with major severity hilar cholangiocarcinoma. Given the advanced nature of the disease and its invasion into surrounding vasculature, curative surgery may not be feasible at this stage. Her treatment plan will involve palliative measures to manage symptoms and improve quality of life. A biliary stent insertion will be performed to alleviate jaundice and improve liver function. Following stent placement, chemotherapy with gemcitabine and platinum-based agents will be initiated to target tumor growth. Radiotherapy might be considered to reduce tumor bulk and provide symptomatic relief. Regular monitoring of liver function, tumor markers, and imaging studies such as CT or MRI will be conducted to assess treatment response and adjust the plan accordingly. Given her hepatitis B status, antiviral therapy will be optimized to protect liver function during treatment. Supportive care, including antipruritics for severe itching and dietary modifications to ease digestion, will be provided. Sarah and her family will be guided on signs of potential complications, such as bile leakage or acute infection, and educated on the importance of follow-up visits in managing her condition. Additional therapies such as photodynamic therapy or radiofrequency ablation may be explored as part of an integrative approach to treatment, aiming to preserve quality of life and extend survival."
    },
    {
        "Patient Information": {
            "Name": "Martha Jacobs",
            "Age": "65",
            "Gender": "Female",
            "Medical History": "Chronic hepatitis B, Bile duct stones"
        },
        "Disease Information": {
            "Disease": "Hilar Cholangiocarcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Dull pain in the right upper abdomen, loss of appetite, jaundice, dark yellow urine, grayish white stools, severe skin itching",
            "Duration": "Symptoms have been present for approximately 3 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "80 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "95 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Total Bilirubin": "15 mg/dL (0.1 − 1.2)",
                "Direct Bilirubin": "10 mg/dL (0 − 0.3)",
                "Alkaline Phosphatase": "250 U/L (44 − 147)",
                "Gamma GT": "190 U/L (9 − 48)",
                "CA19-9": "250 U/mL (< 37)",
                "Carcinoembryonic Antigen (CEA)": "12 ng/mL (< 5)",
                "White Blood Cell Ct. (WBC)": "4.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.6 × 10^12/L (3.5 − 5.5)",
                "Hemoglobin (Hb)": "115 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)"
            },
            "Liver Ultrasound": "Indicated intrahepatic and extrahepatic bile duct dilation",
            "Liver Enhanced CT": "Obstructive lesion at the hepatic duct confluence",
            "MRCP": "Confirmed hilar cholangiocarcinoma, with marked bile duct obstruction",
            "Liver Function Test": "Impaired liver function with elevated bilirubin levels",
            "Tumor Marker Test": "Elevated CA19-9 and CEA levels",
            "Coagulation Test": "Prolonged prothrombin time",
            "Biliary Drainage Fluid": "Elevated bilirubin"
        },
        "Treatment Plan": "Martha Jacobs has been diagnosed with hilar cholangiocarcinoma, with symptoms including jaundice, abdominal pain, and liver dysfunction indicating significant bile duct obstruction. Considering the major severity of her condition and the nature of the tumor, surgical intervention is not an option due to involvement of critical structures and overall health status. The treatment plan includes biliary stent placement via ERCP to relieve obstructive jaundice and improve liver function, followed by a combination of palliative chemotherapy and external beam radiotherapy aimed at controlling tumor progression and managing symptoms. Gemcitabine, in combination with cisplatin, will be used based on her tolerability and response to treatment. Nutritional support and management of pruritus with antihistamines and topical treatments are crucial for maintaining her quality of life. Regular monitoring of liver function, tumor markers, and imaging will be conducted to evaluate the effectiveness of the treatment and adjust as needed. Palliative care and psychological support are essential for ensuring comfort and addressing her emotional wellbeing throughout her treatment journey."
    },
    {
        "Patient Information": {
            "Name": "Liam Thompson",
            "Age": "4",
            "Gender": "Male",
            "Medical History": "No significant medical history, diagnosed with hepatoblastoma upon discovery of abdominal mass"
        },
        "Disease Information": {
            "Disease": "Hepatoblastoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Abdominal mass, occasional abdominal pain, mild anemia, loss of appetite",
            "Duration": "Symptoms observed for the past 3 months, with rapid tumor growth noted",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "55 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "60 IU/L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "50 μmol/L (41 − 81)",
                "Triglycerides (TG)": "0.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.7 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.1 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "35% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "275 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.65 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "9% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Alpha-fetoprotein (AFP)": "2000 ng/mL (very high)",
                "CRP": "4 mg/L (< 3 mg/L)",
                "ESR": "22 mm/hr (0 − 20)",
                "Procalcitonin": "0.05 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Abdominal Ultrasound": "Large solid mass in the liver with rich vascular supply and possible vascular invasion",
            "Abdominal CT Scan": "Single large hypervascular liver mass with areas of calcification and cystic necrosis",
            "Chest X-ray": "No evidence of lung metastasis",
            "MRI of Abdomen": "Confirms findings of CT with detailed assessment of surrounding tissue involvement",
            "Pathological Examination": "Biopsy confirms epithelial type hepatoblastoma",
            "Serum Antibody Test": "Negative for hepatitis markers"
        },
        "Treatment Plan": "Liam Thompson has been diagnosed with hepatoblastoma, which is currently staged at PRETEXT stage III with major severity due to the size of the tumor and rapid growth observed. The primary objective in treating Liam is to achieve resection post-chemotherapy. An initial biopsy confirmed the diagnosis, followed by the administration of neoadjuvant chemotherapy to reduce the tumor size, facilitating a later surgical resection. The chemotherapy regimen is based on his risk stratification and will start with the C5VD protocol, including cisplatin, 5-fluorouracil, vincristine, and doxorubicin. Continuous monitoring of serum alpha-fetoprotein (AFP) levels will help assess treatment response. If the tumor size decreases sufficiently, surgical resection will be planned. During this period, Liam's liver function and general health will be closely monitored to adjust the treatment plan as necessary, with supportive care to manage chemotherapy side effects. Nutritional support and regular follow-ups with pediatric oncology and surgery teams will ensure the best care for Liam, aiming for a curative outcome."
    },
    {
        "Patient Information": {
            "Name": "Ethan Ramirez",
            "Age": "3",
            "Gender": "Male",
            "Medical History": "Mild anemia, abdominal distension"
        },
        "Disease Information": {
            "Disease": "Hepatoblastoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Abdominal mass, abdominal pain, loss of appetite, occasional dizziness and vomiting",
            "Duration": "Symptoms have been present and gradually worsening over the past couple of weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "AFP (Alpha-Fetoprotein)": "120,000 ng/mL (< 10 ng/mL)",
                "ALT (Alanine Aminotransferase)": "60 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "70 IU/L (13 − 35)",
                "Urea": "4.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "45 μmol/L (20 − 65 for children)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (5.0 − 15.5 for children)",
                "Red Blood Cell Ct. (RBC)": "4.0 × 10^12/L (3.9 − 5.3 for children)",
                "Hematocrit (Hct)": "35% (31 − 45 for children)",
                "Hemoglobin (Hb)": "115 g/L (105 − 135 for children)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (150 − 400 for children)",
                "Lymphocyte Percentage (LYMPH%)": "30% (48 − 56 for children)",
                "Neutrophil Percentage (NEUT%)": "60% (31 − 45 for children)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (2.0−8.0 for children)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.5 − 8.0 for children)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "9 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (140 − 225)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "10 mm/hr (0 − 20)"
            },
            "Abdominal Ultrasound Exam": "Single solid mass in the liver with clear margins",
            "Abdominal Computerized Tomography": "Single predominantly solid soft tissue mass in the liver with calcification and cystic necrosis",
            "Serological Diagnosis": "Normal",
            "Viral Infection Testing": "Negative for hepatitis B",
            "Chest X-ray Exam": "No evidence of pulmonary metastasis",
            "Abdominal MRI": "Tumor density high with ossification and calcification, limited to liver",
            "Pathological Examination": "Consistent with hepatoblastoma; epithelial type confirmed",
            "Biopsy": "Indicators of liver precursor cell origin",
            "Differential Diagnosis": "Excludes hepatic hemangioendothelioma and other benign liver tumors"
        },
        "Treatment Plan": "Ethan Ramirez has been diagnosed with hepatoblastoma, which is a malignant liver tumor primarily affecting children. Immediate surgical evaluation and potential intervention are recommended due to the presence of a significant abdominal mass and elevated serum alpha-fetoprotein (AFP) levels. The treatment plan will initially focus on surgical resection of the tumor, which, given its solitary nature and absence of metastasis, should significantly decrease tumor burden. Following surgical resection, chemotherapy will be initiated with a regimen tailored to Ethan's intermediate risk level, utilizing cisplatin, 5-fluorouracil, vincristine, and doxorubicin over consecutive cycles. Continuous monitoring of Ethan’s liver function tests and AFP levels will guide ongoing management and adjust the chemotherapy regimen as necessary. Given the absence of distant metastasis, the prognosis remains favorable with a curative approach, and liver transplantation is not indicated at this time. Supportive measures will encompass nutritional optimization, adequate hydration, and monitoring for chemotherapy-induced side effects, including possible anemia and neutropenia, which may require intervention such as blood transfusions or growth factor support. Family education on treatment adherence, symptom recognition, and follow-up care will be integral for optimal outcomes. Long-term follow-up will involve regular imaging and AFP evaluations to detect potential recurrence and ensure comprehensive recovery, while providing emotional support to mitigate the impact of this life-altering diagnosis on Ethan and his family."
    },
    {
        "Patient Information": {
            "Name": "Liam Carter",
            "Age": "3",
            "Gender": "Male",
            "Medical History": "History of mild anemia and hemihypertrophy, no significant medical interventions prior to diagnosis"
        },
        "Disease Information": {
            "Disease": "Hepatoblastoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Abdominal mass, mild anemia, abdominal distension, loss of appetite, occasional dizziness",
            "Duration": "Symptoms have developed over the past 3 months, with a noticeable increase in abdominal size",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "30 μmol/L (41 − 81)",
                "Triglycerides (TG)": "0.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Count (WBC)": "5.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Count (RBC)": "3.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "29% (35 − 50)",
                "Hemoglobin (Hb)": "95 g/L (115 − 150)",
                "Platelet Count (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "40% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "50% (40 − 75)",
                "Lymphocyte Absolute Count (LYMPH#)": "2.2 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Absolute Count (NEUT#)": "2.75 × 10^9/L (1.8 − 6.3)",
                "Monocyte Absolute Count (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Absolute Count (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Absolute Count (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Alpha-Fetoprotein (AFP)": "100,000 ng/mL (normal < 10,000 ng/mL)",
                "Ferritin": "400 ng/mL (7 − 140)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "20 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Imaging Exams": {
                "Abdominal Ultrasound": "Single solid mass in the liver with clear margins and mildly enhanced echoes",
                "Abdominal CT": "Large predominantly solid tumor in the liver with rich blood supply and calcifications",
                "Chest CT": "No pulmonary metastasis detected",
                "Abdominal MRI": "Complex structure, signs of calcification, no major vascular invasion"
            },
            "Pathological Examination": "Biopsy confirms epithelial type hepatoblastoma with fetal components",
            "Serum Antibody Test": "Negative for viral infections"
        },
        "Treatment Plan": "Liam Carter has been diagnosed with major severity epithelial-type hepatoblastoma. The treatment plan involves a combination of surgery and chemotherapy. Given the size of the tumor and minimally invasive nature, an initial surgical excision is planned to remove the tumor, ensuring clear margins from vital blood vessels. Post-surgery, the C5VD chemotherapy regimen (cisplatin + 5-fluorouracil + vincristine + doxorubicin) will be initiated to target any residual microscopic disease, scheduled every 21 days for a total of 6 cycles. Regular monitoring of serum alpha-fetoprotein (AFP) levels and abdominal imaging will be conducted to evaluate the response to treatment. A tailored nutrition plan will be implemented to support Liam's growth and recovery, alongside moderate physical activity as tolerated to enhance his physical and mental well-being. Family education about the importance of adhering to follow-up schedules and recognizing symptoms that require immediate medical attention will be provided to ensure compliance and optimal outcomes. Regular follow-ups will be organized to monitor Liam's progress and development, with adjustments to the treatment regime made depending on his response and any side effects encountered."
    },
    {
        "Patient Information": {
            "Name": "Alan Thompson",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Chronic smoking habit, history of alcohol use, previous episodes of hoarseness and throat pain"
        },
        "Disease Information": {
            "Disease": "Throat cancer (glottic)",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent hoarseness, foreign body sensation in throat, difficulty swallowing, neck pain, occasional blood-tinged sputum",
            "Duration": "Symptoms have been worsening over the past 6 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "33 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "25 IU/L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.8 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "45% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "160 U/L (22 − 198 for males)",
                "Myoglobin": "45 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "350 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Not detected",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "No significant abnormalities",
            "Laryngeal CT Exam": "Mass found in glottis region with possible invasion to adjacent structures",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Laryngoscopy Exam": "Visible mass in the glottic area with irregular borders",
            "Biopsy": "Confirmed squamous cell carcinoma",
            "Pulmonary Function Test": "Normal",
            "Nasal Endoscopy": "Normal",
            "Ultrasound Examination": "Enlarged cervical lymph nodes detected"
        },
        "Treatment Plan": "Alan Thompson has been diagnosed with stage III glottic laryngeal cancer, characterized by persistent hoarseness, difficulty swallowing, and neck pain. Given the major severity of his condition and tumor location, a multidisciplinary approach is required. Initial management will include a total laryngectomy to remove the cancerous growth, considering the likelihood of lymph node metastasis. Preoperative radiotherapy will be employed to shrink the tumor size. Post-surgical care will involve intensive speech therapy and the use of alternative speaking methods due to the loss of natural vocal function. Chemotherapy regimens involving cisplatin and 5-fluorouracil will be administered postoperatively to reduce recurrence risks. Supportive care includes nutritional support, pain management, and psychological counseling to assist in coping with the lifestyle changes and emotional stress of the condition. Regular follow-up appointments are scheduled for monitoring potential recurrence and ensuring the efficacy of the treatment strategy. Alan will also be educated on lifestyle modifications to cease smoking and alcohol use to prevent further health complications."
    },
    {
        "Patient Information": {
            "Name": "Michael Thompson",
            "Age": "67",
            "Gender": "Male",
            "Medical History": "Chronic smoker, excessive alcohol consumption, history of vocal cord leukoplakia"
        },
        "Disease Information": {
            "Disease": "Throat Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Hoarseness, foreign body sensation in throat, neck pain, persistent cough with blood-tinged sputum, difficulty breathing and swallowing",
            "Duration": "Symptoms have been worsening over the past three weeks",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "29 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "75 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.10 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.05 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.9% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "78 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "350 ng/mL (20 − 500 for males)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "28 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Enlarged lymph nodes near the larynx",
            "Chest Computerized Tomography": "Mass in the supraglottic region extending into the neck",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Fiberoptic Laryngoscopy": "Visible tumor in the supraglottic region with biopsy confirming squamous cell carcinoma",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Presence of blood-tinged mucus",
            "Nasopharyngeal Examination": "Presence of tumor mass and inflammation",
            "Pulmonary Function Test": "Reduced lung capacity",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Ulcerations and swelling present",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Michael Thompson has been diagnosed with major severity throat cancer, presenting symptoms that include hoarseness, neck pain, and persistent cough with blood-tinged sputum. Due to his history as a chronic smoker and heavy alcohol consumer, his condition requires a comprehensive treatment plan. Immediate surgical intervention is recommended to remove the supraglottic tumor and any affected tissue, with possible neck lymph node dissection due to suspected metastasis. Postoperative radiotherapy will be considered to target residual cancer cells and enhance treatment efficacy. If surgery and radiotherapy do not adequately suppress the tumor, chemotherapy involving cisplatin and carboplatin may be considered to reduce recurrence risk. Supportive care is essential to manage breathing difficulties, with potential tracheostomy required if air passage becomes significantly blocked during treatment. Rehabilitation therapy should focus on speech recovery and breathing management after surgical intervention. Michael will be closely monitored post-treatment, with regular follow-ups including laryngoscopy, neck CT, and chest X-ray to track remission and detect recurrence early. Lifestyle changes such as cessation of smoking and alcohol consumption are strongly advised to prevent further complications and improve recovery chances. Emotional support and psychological counseling may be beneficial to manage stress and adapt to changes post-treatment. Both Michael and his family will be educated on managing postoperative care at home, such as tracheostomy maintenance and breathing techniques. Coordination with speech therapists will be vital for recovery of communication abilities, reinforcing the importance of adherence to the treatment plan for optimal recovery."
    },
    {
        "Patient Information": {
            "Name": "James Thompson",
            "Age": "62",
            "Gender": "Male",
            "Medical History": "Chronic smoking, occasional alcohol consumption, history of vocal cord leukoplakia"
        },
        "Disease Information": {
            "Disease": "Throat cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Hoarseness, persistent cough, difficulty swallowing, neck pain, difficulty breathing",
            "Duration": "Symptoms have been progressively worsening over the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal air and tissue distribution",
            "Chest Computerized Tomography": "Lesion in the laryngeal region with no metastasis",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Blood-tinged sputum observed",
            "Nasopharyngeal Examination": "Tumor presence confirmed",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Moderate impairment",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Swelling and lesion observed",
            "Nasal Endoscopy": "Inflamed tissue and tumor presence in the laryngeal area"
        },
        "Treatment Plan": "James Thompson has been diagnosed with major severity throat cancer, primarily affecting the vocal cords and surrounding areas. Due to the gradual worsening of symptoms such as hoarseness, difficulty swallowing, and neck pain over the past six months, an aggressive treatment plan is necessary. Immediate surgical intervention is recommended to remove the tumor, with the possibility of partial laryngectomy to preserve vocal functions or total laryngectomy if deemed necessary by the surgical team. Endoscopic surgery may be opted for in initial stages, followed by radiation therapy post-operation to eradicate any remaining cancer cells. Chemotherapy might be proposed in cases showing signs of high malignancy or potential metastasis. Regular monitoring and follow-up examinations, including laryngoscopy, neck CT, and ultrasound, are essential to assess the treatment progress and detect possible recurrences early. Post-surgery care involves managing breathing and swallowing functions, with the possibility of speech therapy to restore communication abilities if a total laryngectomy is performed. Family support and emotional guidance are vital during recovery, with emphasis on adapting to changes in lifestyle and vocal capabilities. Dietary modifications and hydration should be monitored, avoiding irritants such as smoking and alcohol. If James experiences breathing difficulties or severe pain post-treatment, professional medical assistance should be sought promptly. Rehabilitation strategies will be implemented post-recovery, with periodic evaluations to ensure optimal health and minimal recurrence chances."
    },
    {
        "Patient Information": {
            "Name": "James Taylor",
            "Age": "29",
            "Gender": "Male",
            "Medical History": "History of occasional night sweats and fatigue, no prior immune system diseases or noticeable lymph node enlargement."
        },
        "Disease Information": {
            "Disease": "Hodgkin Lymphoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Painless enlargement of cervical lymph nodes, occasional fever and night sweats, mild fatigue",
            "Duration": "Symptoms have been present intermittently over the past 3 weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "ESR": "30 mm/hr (0 − 20)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ABO Group": "A",
                "Rh Type": "Positive"
            },
            "Chest X-ray Exam": "Slight enlargement of mediastinal lymph nodes",
            "Chest Computerized Tomography": "Enlargement of cervical and mediastinal lymph nodes, no significant organ involvement",
            "Serological Diagnosis": "Elevated LDH levels",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bone Marrow Biopsy": "Presence of Reed-Sternberg cells",
            "CT Scan": "Enlarged cervical lymph nodes observed",
            "MRI": "No signs of extranodal organ involvement",
            "PET/CT": "Localized activity in cervical lymph nodes",
            "Liver and Kidney Function Tests": "Normal",
            "Bone Marrow Aspiration": "No significant bone marrow disruption"
        },
        "Treatment Plan": "James Taylor has been diagnosed with Moderate Severity Hodgkin Lymphoma, presenting primarily with cervical lymph node enlargement, occasional fever, and mild systemic symptoms. The treatment plan involves starting with the ABVD chemotherapy regimen for 4 cycles due to his favorable early staging, aiming to achieve remission. Following chemotherapy, involved field radiotherapy will be administered to ensure clearance of residual cancerous tissues. Regular monitoring of blood counts, liver and kidney function will be crucial to manage potential adverse effects of the treatment. James will receive supportive care to mitigate symptoms such as nausea and fatigue, with nutritional support emphasizing high-calorie, high-protein diets. Psychological support will be provided to encourage a positive mindset and adherence to treatment. James should avoid occupational exposure to chemicals and maintain a healthy lifestyle to reduce recurrence risk. Family members will be advised to support him consistently throughout the treatment process, emphasizing regular follow-up visits and timely medical attention if new symptoms emerge. Continuous reevaluation with PET/CT will be conducted to assess response and adjust treatment as necessary, ensuring optimal management of his Hodgkin Lymphoma."
    },
    {
        "Patient Information": {
            "Name": "Alex Johnson",
            "Age": "25",
            "Gender": "Male",
            "Medical History": "No significant past medical history; No previous lymph node issues"
        },
        "Disease Information": {
            "Disease": "Hodgkin Lymphoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Painless enlargement of cervical lymph nodes, night sweats, fatigue, and low-grade fever",
            "Duration": "Symptoms have persisted for approximately 4 weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "75 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "45% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "40% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "55% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "12 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "320 ng/mL (20 − 500 for males)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "Presence of Reed-Sternberg cells",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal lung appearance",
            "Chest Computerized Tomography": "Mild mediastinal lymph node enlargement",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture": "Negative",
            "Respiratory Function Test": "Normal",
            "Bone Marrow Examination": "Normal cellularity, no tumor infiltration",
            "Lymph Node Biopsy": "Presence of Reed-Sternberg cells",
            "Positron Emission Tomography": "Increased uptake in cervical lymph nodes",
            "MRI": "No CNS involvement detected"
        },
        "Treatment Plan": "Alex Johnson is diagnosed with Hodgkin Lymphoma characterized by moderate severity, presenting with symptoms such as painless cervical lymph node enlargement, night sweats, fatigue, and low-grade fever persisting over the past four weeks. Immediate initiation of the ABVD chemotherapy regimen is recommended as a treatment plan, which is considered the gold standard for Hodgkin Lymphoma, consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine. Considering the moderate severity, this treatment will span over 4 to 6 cycles, subsequently followed by remission involved field radiotherapy to target any residual lymphatic tissue and ensure comprehensive management of the condition. Supportive care will be crucial to manage any adverse effects from chemotherapy, including potential bone marrow suppression, nausea, and risk of infection. Monitoring of hematological parameters, liver, and kidney functions will be performed routinely to assess the response to treatment and adjust the regimen accordingly. Nutritional support and hydration will be emphasized to maintain strength, and antiemetic medications may be provided to alleviate nausea. As Alex is young and the disease is considered curable with standardized treatment, a positive prognosis is anticipated with adherence to the treatment plan. Post-treatment follow-up will be advised to ensure resolution of symptoms and detect any possible recurrence, with emphasis on lifestyle modifications to support recovery and reduce risk factors associated with disease recurrence."
    },
    {
        "Patient Information": {
            "Name": "John Smith",
            "Age": "27",
            "Gender": "Male",
            "Medical History": "Enlargement of superficial lymph nodes, occasional fever, night sweats, fatigue"
        },
        "Disease Information": {
            "Disease": "Hodgkin Lymphoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Painless enlargement of cervical lymph nodes, general fatigue, occasional fever, night sweats",
            "Duration": "Symptoms have been present for three months with progressive lymph node enlargement",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "25 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.6 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative for EBV",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mild mediastinal lymph node enlargement",
            "Chest Computerized Tomography": "Enlarged cervical and supraclavicular lymph nodes",
            "Serological Diagnosis": "Elevated ESR, LDH",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "No abnormal findings",
            "Nasopharyngeal Examination": "Unremarkable",
            "Serum Antibody Test": "Negative for EBV antibodies",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative for viral infections",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "John Smith is diagnosed with Hodgkin's lymphoma in its moderate severity phase, with cervical and supraclavicular lymph node enlargement. The treatment protocol involves a combination of chemotherapy and radiotherapy, commencing with the ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) for 2-4 cycles followed by involved field radiotherapy to target affected lymphatic regions. This regimen is chosen due to the relative curability of Hodgkin's lymphoma, especially in early to moderate stages. Supportive care, including nutritional support and hydration, will be provided to manage the side effects of treatment, particularly considering the possible impacts on his hematopoietic system and overall physical wellness. John will undergo regular monitoring of liver and kidney function tests, LDH, and ESR levels to ascertain the treatment's impact and adjust accordingly. Psychological support and lifestyle adjustments, including stress reduction strategies and moderate physical activity, will be encouraged to improve his quality of life during treatment. Family members will be educated on the importance of adherence to follow-up appointments and monitoring for any signs of disease progression or recurrence, with a proactive emphasis on maintaining a positive outlook throughout the treatment journey."
    },
    {
        "Patient Information": {
            "Name": "Ethan Smith",
            "Age": "8",
            "Gender": "Male",
            "Medical History": "No significant past medical history; recent onset of a painless lump in the arm"
        },
        "Disease Information": {
            "Disease": "Rhabdomyosarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless lump on the arm, occasional mild swelling, weakness in the affected limb",
            "Duration": "Symptoms have been present for approximately one month",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "60 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.2 mmol/L (< 5.18)",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "55% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Imaging Exams": {
                "Ultrasound": "Solid mass in the upper arm, no vascular invasion",
                "MRI": "5 cm soft tissue mass in the left arm, non-invasive appearance",
                "CT Scan": "Chest and abdomen clear, no signs of metastasis"
            },
            "Pathological Tissue Examination": "Confirmed embryonal rhabdomyosarcoma",
            "Bone Marrow Cytology": "Normal",
            "Cerebrospinal Fluid Examination": "Normal",
            "Echocardiography": "Normal heart function"
        },
        "Treatment Plan": "Ethan Smith has been diagnosed with embryonal rhabdomyosarcoma located in his arm, characterized by a significant, but non-metastatic tumor that necessitates a combination of surgery, chemotherapy, and possibly radiotherapy. The recommended treatment plan includes an initial surgery to remove the tumor as completely as possible while preserving function of the surrounding muscle and nerve tissue. Postoperative treatment will involve multi-agent chemotherapy, using the VAC regimen (vincristine, actinomycin D, and cyclophosphamide) to target and eradicate any microscopic residual cancer cells. Given the risk of local recurrence, radiotherapy may be considered if residual tumor tissue is confirmed or if surgical margins are unclear. Continuous monitoring through imaging studies is essential to assess the response to therapy and ensure no new lesions develop. Ethan and his family will be educated on the importance of adhering to scheduled treatments, recognizing potential side effects, and maintaining follow-up appointments to enhance the effectiveness of the treatment and improve prognosis. Nutritional support and physical rehabilitation will also be advised to ensure optimal recovery and strengthen his overall health."
    },
    {
        "Patient Information": {
            "Name": "Emily Thompson",
            "Age": "7",
            "Gender": "Female",
            "Medical History": "No known medical history; presents with a painless lump in the upper arm without prior symptoms or health issues."
        },
        "Disease Information": {
            "Disease": "Rhabdomyosarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless lump on the upper arm, possible difficulty in limb movement, local swelling without redness, recent unexplained weight loss",
            "Duration": "Symptoms have developed over the last few weeks, with tumor size increasing noticeably",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7−40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13−35)",
                "Urea": "5.0 mmol/L (2.6−8.8)",
                "Creatinine (Cr)": "55 μmol/L (41−81)",
                "Triglycerides (TG)": "1.1 mmol/L (<1.7)",
                "Total Cholesterol (TC)": "4.7 mmol/L (<5.18)",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5−9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5−5.5)",
                "Hematocrit (Hct)": "38% (35−50)",
                "Hemoglobin (Hb)": "120 g/L (115−150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125−350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20−50)",
                "Neutrophil Percentage (NEUT%)": "68% (40−75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.4 × 10^9/L (1.8−6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2−1.0)",
                "Monocyte Percentage (MONO%)": "8% (3−10)",
                "Eosinophil Abs. Ct. (EO#)": "0.2 × 10^9/L (0.02−0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4−8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.04 × 10^9/L (0−0.06)",
                "Basophil Percentage (BASO%)": "0.6% (0−1)",
                "Mean Platelet Volume (MPV)": "10 fL (9−13)",
                "Lactate Dehydrogenase": "270 U/L (135−225)",
                "Ferritin": "480 ng/mL (20−500 for females)",
                "CRP": "5 mg/L (<3 mg/L)",
                "ESR": "15 mm/hr (0−20)",
                "Procalcitonin": "0.3 ng/mL (<0.5)",
                "D-dimer": "0.6 mg/L FEU (0−0.5)",
                "Rh Type": "Negative",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50−150)"
            },
            "Magnetic Resonance Imaging (MRI)": "Shows a localized tumor in the upper arm with no signs of metastasis",
            "Chest X-ray Exam": "Normal",
            "CT Scan": "Tumor localized in the arm, size approximately 5 cm",
            "Bone Scan": "No evidence of bone metastasis",
            "Positron Emission Tomography-Computed Tomography (PET-CT)": "No distant metastasis detected",
            "Pathological Tissue Examination": "Confirms embryonal rhabdomyosarcoma subtype",
            "Routine Bone Marrow Cytology": "Normal",
            "Cerebrospinal Fluid Examination": "Normal"
        },
        "Treatment Plan": "Emily Thompson has been diagnosed with rhabdomyosarcoma in the upper arm, classified as major severity due to noticeable tumor growth and recent weight loss. The multidisciplinary treatment approach involves surgical intervention aimed at complete tumor excision, which might include surrounding tissues and potentially affected lymph nodes. Given the localized nature of the tumor and the absence of metastasis, the prognosis remains favorable. Post-surgery, chemotherapy will be initiated using the VAC regimen (vincristine, actinomycin D, and cyclophosphamide) catering to her condition. Radiotherapy will be conducted to ensure no microscopic remnants are left, particularly since it aids in reducing recurrence risk. Regular follow-ups for imaging and blood work will be essential for monitoring her progress and adjusting the treatment plan as necessary. Throughout the treatment, supportive care will focus on maintaining her nutritional status and assisting in managing any side effects of chemotherapy, such as neutropenia, with medications like G-CSF. Emily's family will receive counseling on understanding the disease process, and nutritionists will be involved to help plan a balanced diet to support her immune system during treatment. Recovery plans include initiating gentle physical therapy post-treatment to regain arm strength and prevent muscle atrophy, with an emphasis on maintaining her overall wellbeing and allowing her to engage in age-appropriate activities to enhance recovery."
    },
    {
        "Patient Information": {
            "Name": "Oliver Johnson",
            "Age": "6",
            "Gender": "Male",
            "Medical History": "No previous significant medical history"
        },
        "Disease Information": {
            "Disease": "Embryonal Rhabdomyosarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "A painless lump in the head and neck, nasal congestion, occasional nosebleeds",
            "Duration": "Symptoms have been present for the past month",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "22 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "20 IU/L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "40 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.3 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "40% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "50% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "3.0 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.3 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "4% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "9 ng/L (< 14 ng/L)",
                "Ferritin": "80 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Presence of a soft tissue mass in the neck",
            "Magnetic Resonance Imaging (MRI)": "Soft tissue mass detected with no bone invasion",
            "Biopsy": "Confirmed embryonal rhabdomyosarcoma",
            "Bone Scan": "No indications of bone metastasis",
            "Chest X-ray Exam": "No pulmonary metastasis",
            "CT Scan": "Mass localized to the head and neck region without distant spread",
            "PET-CT": "Localized uptake in head and neck, no sign of metastasis",
            "Routine Bone Marrow Cytology": "Normal",
            "Cerebrospinal Fluid Examination": "No cancer cells detected"
        },
        "Treatment Plan": "Oliver Johnson has been diagnosed with embryonal rhabdomyosarcoma localized to the neck region. The treatment plan involves a multidisciplinary approach including surgery, chemotherapy, and radiotherapy. Surgery will be the primary intervention aiming for complete resection of the tumor, followed by chemotherapy using the VAC regimen (vincristine + actinomycin D + cyclophosphamide) to target any remaining cancerous cells and to prevent recurrence. Radiotherapy will be tailored to Oliver’s specific condition, considering fractional doses to minimize the risk of adverse effects. Given Oliver's age and the tumor location, internal seed radiotherapy may be considered to preserve function and minimize damage to surrounding tissues. Regular monitoring through imaging and blood work will be conducted to assess response to treatment and adjust plans as necessary. Oliver's recovery will involve nutritional support, physical therapy to maintain strength, and routine follow-ups every 3 months for the first year post-treatment to monitor for recurrence. His family will be advised on managing potential side effects of treatment and maintaining a supportive environment at home. The prognosis is favorable given the localized nature of the tumor and Oliver’s overall healthy condition, allowing for a positive outlook with adherence to the prescribed treatment regimen."
    },
    {
        "Patient Information": {
            "Name": "Thomas Smith",
            "Age": "26",
            "Gender": "Male",
            "Medical History": "Previously healthy, no significant family history of cancer"
        },
        "Disease Information": {
            "Disease": "Synovial Sarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless mass near the knee, difficulty moving the leg, swelling",
            "Duration": "Symptoms noticed over the past two months, progressively increasing in size",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "25 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "75 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Solid mass with increased vascularity in the lower limb",
            "MRI Exam": "Tumor with clear demarcation from surrounding tissues but close to major vessels",
            "Chest X-ray": "No signs of lung metastasis",
            "CT Scan": "Confirms the size of the mass, no evidence of calcification",
            "Bone Scan": "No bone involvement detected",
            "Biopsy": "Positive for SYT-SSX1 fusion gene",
            "Pathological Examination": "Presence of spindle cells, characteristics of monophasic synovial sarcoma"
        },
        "Treatment Plan": "Thomas Smith has been diagnosed with synovial sarcoma located near the knee, indicating a major severity level. The primary treatment approach will be surgical excision, ensuring a safe margin of 1cm beyond the tumor boundary. The surgical team will aim to preserve limb function while achieving complete tumor removal; however, partial limb function may be sacrificed to ensure complete excision. Preoperative imaging has shown no involvement of major blood vessels, which could facilitate limb-sparing surgery. Post-surgical therapy will include radiotherapy to target any remaining cancer cells and reduce recurrence risk. The patient is eligible for adjuvant chemotherapy with the ADM+IFO regimen to further enhance therapeutic outcomes and minimize chances of metastasis. Regular follow-ups every 3 months for the first year, including MRI scans and physical exams, will be conducted to monitor progress and detect any signs of recurrence. Thomas is advised to maintain a balanced diet high in protein and engage in moderate physical activity to prevent atrophy and enhance recovery. He and his family will be educated on recognizing symptoms of recurrence and the importance of adhering to the treatment protocol for optimal recovery. Regular consultation with the oncology team and a nutritionist will be arranged to ensure comprehensive care and support."
    },
    {
        "Patient Information": {
            "Name": "Ethan Johnson",
            "Age": "25",
            "Gender": "Male",
            "Medical History": "Previously healthy with no known genetic disorders; recent onset of painless swelling near the knee"
        },
        "Disease Information": {
            "Disease": "Synovial Sarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless swelling near the knee, difficulty in moving the leg, occasional limping",
            "Duration": "Symptoms have been present and gradually worsening over the last six months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.6 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "43% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.95 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.25 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.45 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for males)",
                "CRP": "3 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Not Applicable",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Solid mass near the knee with increased blood flow around the area",
            "CT Scan": "Enhanced CT shows clear boundaries of the mass and its relationship with adjacent tissues.",
            "MRI": "High-resolution images show deep involvement of soft tissue with some signal changes suggestive of a neoplastic lesion.",
            "X-ray": "Shows calcification near the tumor site; changes in adjacent bone structure.",
            "PET-CT": "Shows increased metabolic activity at the tumor site, no distant metastasis detected.",
            "Biopsy": "Positive for SYT-SSX2 fusion gene confirming diagnosis of synovial sarcoma."
        },
        "Treatment Plan": "Ethan Johnson's diagnosis of synovial sarcoma near the knee necessitates a comprehensive treatment approach focused on surgical intervention to achieve complete excision of the tumor. Due to the tumor's major severity and proximity to critical structures, an aggressive surgical plan involving wide excision will be implemented to ensure clear margins and prevent recurrence. Preoperative imaging tests like MRI and CT have provided crucial information, allowing precise surgical mapping to preserve as much limb function as possible. Neoadjuvant chemotherapy will be administered to shrink the tumor pre-surgically, enhancing the likelihood of successful removal. The recommended regimen includes doxorubicin and ifosfamide, known to be effective in the presence of SYT-SSX2 fusion gene. Post-surgical adjuvant radiotherapy will be applied to eliminate residual tumor cells, with chemotherapy cycles following radiotherapy to maximize eradication of micro-metastatic lesions. Regular follow-ups are crucial, involving physical exams and imaging every three months for the first year, then every six months for subsequent years to monitor recovery and detect any signs of recurrence early. Ethan will also receive psychological support and be educated on the importance of adhering to the treatment plan, recognizing symptoms of recurrence, and maintaining a healthy lifestyle to aid in recovery. Nutritional guidance will be provided, emphasizing a balanced diet rich in protein and vital nutrients to support overall health and therapy resilience. Considering the potential for surgical complications, immediate post-operative monitoring will focus on limb function, pain control, and mobility support, with physiotherapy sessions integrated to promote recovery and enhance limb strength and endurance."
    },
    {
        "Patient Information": {
            "Name": "Aiden Turner",
            "Age": "24",
            "Gender": "Male",
            "Medical History": "No significant past medical history, occasional joint pain"
        },
        "Disease Information": {
            "Disease": "Synovial Sarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless mass near the knee, difficulty in moving leg, occasional numbness",
            "Duration": "The mass has been gradually increasing over the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "22 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.8 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "260 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "28 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Imaging Tests": {
                "Ultrasound": "Well-defined solid mass in the popliteal fossa with increased vascularity",
                "CT Scan": "3 cm mass around the knee joint, no evidence of bony invasion, no chest metastasis",
                "MRI": "Solid mass with heterogeneous enhancement and clear demarcation from surrounding tissues",
                "X-ray": "No calcification noted, no bone involvement",
                "Biopsy": "Confirmed presence of SYT-SSX fusion gene, characteristic of synovial sarcoma"
            },
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal"
        },
        "Treatment Plan": "Aiden Turner has been diagnosed with synovial sarcoma, located near his knee, necessitating a combination of surgical, radiologic, and possibly chemotherapeutic interventions due to the major severity level. Surgical resection will be prioritized, aiming for a wide local excision to ensure complete removal of the tumor while minimizing functional loss to the affected limb. Given the size and location of the mass, preoperative radiotherapy may be considered to shrink the tumor, facilitating a more conservative surgery. Postoperative radiotherapy will be employed to eradicate any residual disease and reduce the risk of recurrence. Based on histological findings, adjuvant chemotherapy could be advised using the ADM+IFO regimen for cases with challenging complete excision or high recurrence risk. Regular follow-up post-surgery is imperative, with initial checkups every 3 months, gradually extending to annual visits after 5 years, ensuring early detection of potential recurrences. Throughout treatment, Aiden's diet and activity levels should be managed to support recovery, with consultations from a dietitian and physiotherapist, ensuring optimal physical health and quality of life. Multidisciplinary care will be essential in managing potential surgical and chemotherapeutic side effects."
    },
    {
        "Patient Information": {
            "Name": "Jessica Lin",
            "Age": "39",
            "Gender": "Female",
            "Medical History": "Previous neck ultrasound showing enlarged thyroid with nodules, anxiety about thyroid health"
        },
        "Disease Information": {
            "Disease": "Papillary Thyroid Carcinoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Painless neck mass, difficulty swallowing, hoarseness, slight facial flushing",
            "Duration": "Symptoms observed over the past 3 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.2 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "3.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "11 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "120 U/L (22 − 198 for females)",
                "Myoglobin": "55 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "80 ng/mL (20 − 500 for females)",
                "CRP": "3 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Thyroglobulin",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Examination": "Presence of irregular thyroid nodules with microcalcifications",
            "Neck X-ray": "Observation of thyroid enlargement, normal tracheal positioning",
            "Computed Tomography (CT)": "Thyroid nodules with slight extrathyroidal extension; no cervical lymph node involvement",
            "Thyroid Function Test": "Normal thyroxine levels, elevated TSH",
            "Thyroid Autoantibody Test": "Negative for TgAb and TPOAb",
            "Tumor Marker Test": "Elevated thyroglobulin levels, normal calcitonin",
            "Fine-Needle Aspiration Cytology": "Papillary carcinoma cells identified, benign cellular morphology confirmed",
            "Molecular Marker Test": "BRAF mutation detected",
            "Laryngoscopy": "Normal vocal cord function"
        },
        "Treatment Plan": "Jessica Lin has been diagnosed with papillary thyroid carcinoma with moderate severity. Surgical intervention will be the primary treatment modality, consisting of a total thyroidectomy given the presence of extrathyroidal extension, ensuring complete removal of malignant tissues. In preparation for surgery, a preoperative assessment including comprehensive blood work, imaging, and laryngoscopy has been conducted to confirm vocal cord functionality and evaluate any potential surgical complications. Post-surgical management will include the administration of levothyroxine to suppress TSH levels, preventing recurrence and facilitating hormone balance. Regular follow-up care is crucial for monitoring thyroglobulin levels and ensuring no residual malignant activity, with neck ultrasonography and periodic blood tests scheduled. Due to the presence of BRAF mutation, which may affect the tumor's aggressiveness, close observation and potential enrollment in targeted therapy clinical trials may be considered if necessary. Nutritional support and psychological counseling will be provided to assist Jessica in maintaining a positive outlook and managing stress effectively during recovery. Education regarding post-operative care, thyroid hormone replacement therapy, and lifestyle modifications will be imparted, with an emphasis on adherence to medical advice and avoidance of iodine excess. Long-term monitoring will include regular thyroid function tests to fine-tune hormone replacement therapy and ensure optimal recovery and disease management."
    },
    {
        "Patient Information": {
            "Name": "Emily Chen",
            "Age": "45",
            "Gender": "Female",
            "Medical History": "Family history of thyroid conditions, occasional nodular goiter"
        },
        "Disease Information": {
            "Disease": "Thyroid Cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Painless neck mass, difficulty swallowing, hoarseness, facial flushing",
            "Duration": "Symptoms have been present for three months with gradual worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "35 IU/L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.3 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.1 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "68% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.1 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Thyroglobulin",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Irregular thyroid nodules with microcalcifications and absence of halo",
            "CT Scan": "Mass in the thyroid, possible invasion to adjacent neck muscles",
            "Serological Diagnosis": "Elevated thyroglobulin levels",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderate impairment due to airway compression",
            "Fine-Needle Aspiration Biopsy": "Positive for malignant cells",
            "Thyroid Function Test": "Elevated TSH, Low T3",
            "Thyroid Autoantibody Test": "Positive anti-thyroglobulin antibodies",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Neck X-Ray": "Tracheal deviation"
        },
        "Treatment Plan": "Emily Chen has been diagnosed with moderate severity thyroid cancer, characterized by painless neck mass and symptoms indicating local invasion such as difficulty swallowing and hoarseness. The primary treatment approach will be surgical intervention, specifically total thyroidectomy, given the likelihood of multifocal lesions and potential for aggressive behavior suggested by imaging and biopsy results. Preoperative preparation includes thorough consideration of her medical history, including the presence of nodular goiter. Post-surgery, endocrine therapy with levothyroxine will be initiated to suppress TSH levels and prevent recurrence. Radionuclide therapy with 131I may be considered if postoperative pathology indicates incomplete resection or presence of residual tissue with iodine uptake. Her thyroid function and thyroglobulin levels will be closely monitored postoperatively. If distant metastases or aggressive behavior are detected, external radiotherapy or targeted therapy may be explored. Emily will receive guidance on postoperative monitoring, diet modifications, and lifestyle adjustments, including dietary recommendations to limit potential irritants and maintain balanced nutrition. Regular follow-ups will be scheduled to monitor for signs of recurrence or metastasis, with imaging and serum marker tests as necessary. Emphasis will be placed on holistic management, including psychological support and adherence to the treatment regimen for optimal recovery."
    },
    {
        "Patient Information": {
            "Name": "Elaine Roberts",
            "Age": "52",
            "Gender": "Female",
            "Medical History": "Previous episodes of thyroid nodules, family history of thyroid diseases"
        },
        "Disease Information": {
            "Disease": "Thyroid Cancer - Papillary Thyroid Carcinoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Painless neck mass, difficulty swallowing, hoarseness, facial flushing",
            "Duration": "Symptoms have been present for the past 3 months with gradual worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Thyroglobulin (Tg)": "125 ng/mL (< 55 for females)",
                "Calcitonin": "8 pg/mL (< 10)",
                "Carcinoembryonic Antigen (CEA)": "1.5 ng/mL (< 5)",
                "Thyroid Stimulating Hormone (TSH)": "3.0 mIU/L (0.4 − 4.0)",
                "Free T4 (FT4)": "18 pmol/L (12 − 22)",
                "Free T3 (FT3)": "5.3 pmol/L (3.1 − 6.8)",
                "Anti-thyroglobulin Antibody (TgAb)": "Negative",
                "Thyroid Peroxidase Antibody (TPOAb)": "Positive",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Rh Type": "Negative",
                "ABO Group": "A"
            },
            "Ultrasound": "Presence of a solid hypoechoic nodule with microcalcifications in the right thyroid lobe",
            "Neck X-Ray": "No tracheal compression detected",
            "Computed Tomography (CT)": "Nodule size 3.5 cm with minimal extrathyroidal extension",
            "Fine-Needle Aspiration Cytology (FNAC)": "Suspicious for papillary carcinoma",
            "PET/CT": "No distant metastasis, but cervical lymph node involvement suspected",
            "Laryngoscopy": "Normal vocal cord movement"
        },
        "Treatment Plan": "Elaine Roberts has been diagnosed with papillary thyroid carcinoma at a moderate severity level. The treatment plan involves initial surgical intervention with a total thyroidectomy to excise the tumor and any nearby affected tissues, followed by central neck dissection to address potential lymph node involvement, as indicated by PET/CT findings. Post-surgery, Elaine will undergo radioactive iodine (I-131) therapy to target any residual cancerous thyroid tissue or microscopic metastases. Endocrine therapy with levothyroxine will be initiated to maintain normal thyroid hormone levels and suppress TSH, reducing the risk of recurrence. Regular monitoring of thyroid function, Tg levels, and neck ultrasound evaluations will be conducted postoperatively to detect any signs of recurrence. Elaine will be advised on maintaining a balanced diet, managing stress, and adhering to follow-up appointments for surveillance. Her treatment will include education about potential side effects and the need for lifelong follow-up to monitor for recurrence and ensure optimal health outcomes."
    },
    {
        "Patient Information": {
            "Name": "Emily Jenkins",
            "Age": "68",
            "Gender": "Female",
            "Medical History": "Hypertension, Osteoporosis"
        },
        "Disease Information": {
            "Disease": "Acute Myeloid Leukemia",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Anemia, fever, continuous gum bleeding, pallor, fatigue, dizziness, hepatosplenomegaly",
            "Duration": "Symptoms have been worsening over the past 3 weeks",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7-40)",
                "AST (Aspartate Aminotransferase)": "40 IU/L (13-35)",
                "Urea": "8.5 mmol/L (2.6-8.8)",
                "Creatinine (Cr)": "88 μmol/L (41-81)",
                "Triglycerides (TG)": "1.2 mmol/L (<1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (<5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "50 × 10^9/L (3.5-9.5)",
                "Red Blood Cell Ct. (RBC)": "2.5 × 10^12/L (3.5-5.5)",
                "Hematocrit (Hct)": "30% (35-50)",
                "Hemoglobin (Hb)": "90 g/L (115-150)",
                "Platelet Ct. (PLT)": "50 × 10^9/L (125-350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20-50)",
                "Neutrophil Percentage (NEUT%)": "65% (40-75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "12.5 × 10^9/L (1.3-3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "32.5 × 10^9/L (1.8-6.3)",
                "Monocyte Abs. Ct. (MONO#)": "3.0 × 10^9/L (0.2-1.0)",
                "Monocyte Percentage (MONO%)": "6% (3-10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02-0.52)",
                "Eosinophil Percentage (EO%)": "0.2% (0.4-8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0-0.06)",
                "Basophil Percentage (BASO%)": "0.1% (0-1)",
                "Mean Platelet Volume (MPV)": "10 fL (9-13)",
                "Lactate Dehydrogenase": "320 U/L (135-225)",
                "Muscle Enzymes (CK)": "180 U/L (22-198 for females)",
                "Myoglobin": "75 ng/mL (<90 ng/mL)",
                "Troponin I": "10 ng/L (<14 ng/L)",
                "Ferritin": "700 ng/mL (20-500 for females)",
                "CRP": "25 mg/L (<3 mg/L)",
                "ESR": "50 mm/hr (0-20)",
                "Procalcitonin": "0.8 ng/mL (<0.5)",
                "D-dimer": "1.2 mg/L FEU (0-0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50-150)"
            },
            "Chest X-ray Exam": "Mild pleural effusion and cardiomegaly",
            "Chest Computerized Tomography": "Leukemic infiltration observed in the spleen and liver",
            "Serological Diagnosis": "Elevated uric acid levels",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Mildly impaired",
            "Sputum Examination": "No viral particles detected",
            "Nasopharyngeal Examination": "No significant findings",
            "Serum Antibody Test": "No abnormalities detected",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative for common viral infections",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Gingival inflammation and bleeding",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Emily Jenkins has been diagnosed with acute myeloid leukemia, presenting with severe symptoms such as anemia, continuous bleeding, and signs of systemic infiltration, requiring an aggressive treatment approach. The current state of her condition, combined with her age and underlying medical history, necessitates immediate induction therapy aimed at achieving hematological remission. This will involve initiating a chemotherapy regimen tailored to her specific leukemic profile, which may include cytarabine and daunorubicin (7+3 regimen) as the first line of induction therapy. Due to her severe anemia and low platelet counts, transfusions of packed red blood cells and platelet concentrates will be administered to manage hematological deficits and reduce the risk of complications from bleeding. Infection control is paramount; therefore, prophylactic antibiotics and antifungal agents will be prescribed to mitigate the risk of severe infections, considering her neutropenic status. Nutritional support will emphasize maintaining high caloric and protein intake, supplemented by hydration therapy to manage elevated uric acid levels and minimize renal complications. Regular monitoring of blood counts, liver and renal functions, and response to chemotherapy will guide treatment adjustments. As post-remission therapy options, hematopoietic stem cell transplantation will be evaluated based on her overall response to induction therapy and physical condition. Supportive therapies, including Granulocyte Colony-Stimulating Factor (G-CSF), may be considered to enhance neutrophil recovery post-chemotherapy. Emily and her family will be educated on managing potential side effects of chemotherapy, recognizing signs of infection or bleeding, and the importance of routine follow-ups to closely monitor her health status and adjust treatments as necessary. Emotional support and counseling services will be provided to help her cope with the psychological aspects of her diagnosis and treatment."
    },
    {
        "Patient Information": {
            "Name": "Sophia Zhang",
            "Age": "68",
            "Gender": "Female",
            "Medical History": "Burkitt lymphoma, Benzene exposure, Radiation exposure"
        },
        "Disease Information": {
            "Disease": "Acute Myeloid Leukemia (AML)",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Severe anemia, high fever, spontaneous gum bleeding, and hepatosplenomegaly",
            "Duration": "Symptoms have been progressively worsening over the past month",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "80 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "100 IU/L (13 − 35)",
                "Urea": "8.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "130 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.2 mmol/L (< 5.18)",
                "White Blood Cell Ct. (WBC)": "50.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "2.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "22% (35 − 50)",
                "Hemoglobin (Hb)": "70 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "40 × 10^9/L (125 − 350)",
                "Lactate Dehydrogenase": "600 U/L (135 − 225)",
                "Uric Acid": "560 μmol/L (140 − 360)",
                "Ferritin": "1000 ng/mL (20 − 500 for females)",
                "CRP": "120 mg/L (< 3 mg/L)",
                "Procalcitonin": "0.25 ng/mL (< 0.15)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Bone Marrow Examination": "Hypercellular marrow with 70% blast cells",
            "Cytogenetic Analysis": "Abnormalities detected, t(15;17) translocation",
            "Immunophenotyping": "Myeloid lineage markers CD13, CD33 positive",
            "Serum Biochemistry": "Elevated lactate dehydrogenase (LDH) and uric acid",
            "Complete Blood Count": "Pancytopenia with elevated WBC and reduced RBC and platelets",
            "Chest X-ray Exam": "Normal",
            "MRI Brain Scan": "No central nervous system involvement",
            "Echocardiogram": "Normal heart function"
        },
        "Treatment Plan": "Sophia Zhang presents with an aggressive case of Acute Myeloid Leukemia characterized by severe anemia, significant gum bleeding, and hepatosplenomegaly, compounded by her history of Burkitt lymphoma and prior exposures to benzene and radiation. Given the extreme severity and intractability of her condition, an immediate and intensive treatment protocol is essential. Considering her age and compromised health status, an initial course of induction chemotherapy is planned, utilizing a combination of cytarabine and daunorubicin to attempt cytoreduction and achieve remission. Concurrently, leukapheresis will be utilized to address hyperleukocytosis and prevent complications such as leukostasis. Due to her likelihood of severe neutropenia, Sophia will be placed in a sterile isolation environment with prophylactic antibiotics and antifungal agents prescribed to prevent infections. Blood transfusions will be administered to address anemia, coupled with platelet transfusions to manage bleeding risk. Allopurinol will be used to prevent uric acid nephropathy, given the high cell turnover anticipated with treatment. Each therapy cycle will be meticulously monitored, with close observation of her blood counts and organ function using regular lab tests. The treatment strategy will be adjusted according to Sophia’s response and tolerance. Due to the psychosocial impacts of her diagnosis, Sophia and her family will be supported with counseling and education regarding her prognosis, ensuring they make informed decisions about her care trajectory."
    },
    {
        "Patient Information": {
            "Name": "Jessica Turner",
            "Age": "67",
            "Gender": "Female",
            "Medical History": "Hypertension, Myelodysplastic syndrome"
        },
        "Disease Information": {
            "Disease": "Acute Myeloid Leukemia",
            "Severity Level": "Major Severity",
            "Symptoms": "Anemia, fever, bleeding, fatigue, pallor, shortness of breath, dizziness",
            "Duration": "Symptoms have been progressively worsening over the past 2 weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "34 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "72 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "55 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "30% (35 − 50)",
                "Hemoglobin (Hb)": "95 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "50 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "11 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "38.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "3.0 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.02 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "400 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "105 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "900 ng/mL (20 − 500 for females)",
                "CRP": "35 mg/L (< 3 mg/L)",
                "ESR": "45 mm/hr (0 − 20)",
                "Procalcitonin": "0.8 ng/mL (< 0.5)",
                "D-dimer": "1.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Bone Marrow Examination": "Presence of >30% blast cells, confirming acute myeloid leukemia",
            "Lymph Node Biopsy": "Normal",
            "Cytogenetic Analysis": "Chromosomal abnormalities detected, indicative of AML",
            "Chest X-ray Exam": "No significant abnormalities",
            "MRI": "No CNS involvement detected",
            "Liver Function Test": "Slight elevation, indicative of mild hepatic infiltration",
            "Kidney Function Test": "Normal",
            "ECG": "Normal"
        },
        "Treatment Plan": "Jessica Turner has been diagnosed with acute myeloid leukemia, showing signs of anemia, significant leukocytosis, and a high risk of infection, requiring immediate therapeutic intervention. The treatment regimen involves initiating induction chemotherapy with a combination of cytarabine and daunorubicin to achieve remission of leukemic cells, while pre-treatment management includes administering hydroxyurea to reduce hyperleukocytosis and allopurinol to prevent uric acid nephropathy. Strict infection control measures will be maintained, including prophylactic antibiotics and antifungal agents, given the patient's neutropenic state. Due to her age and existing hypertension, Jessica's chemotherapy will be carefully monitored and adjusted to prevent complications, and she will receive supportive care, including transfusions of red blood cells and platelets to manage anemia and thrombocytopenia. Close monitoring of blood counts, renal function, and liver function will guide the intensity of chemotherapy and supportive measures. Nutritional support with high-protein, high-calorie foods will be encouraged to maintain her strength, alongside measures to address potential chemotherapy-induced nausea. Following successful induction therapy, consolidation treatment will be planned, and possible hematopoietic stem cell transplantation may be considered based on her response and overall health status. Regular consultations and follow-ups will ensure the adaptation of her treatment plan in accordance with her progress and emerging clinical needs."
    },
    {
        "Patient Information": {
            "Name": "Emily Davis",
            "Age": "23",
            "Gender": "Female",
            "Medical History": "No significant medical history; routine gynecological examinations"
        },
        "Disease Information": {
            "Disease": "Mature Ovarian Teratoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Abdominal pain, palpable abdominal mass, occasional bloating",
            "Duration": "Symptoms have been present for approximately three weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "34 IU/L (13 − 35)",
                "Urea": "5.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "74 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.4 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "280 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "150 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "130 U/L (22 − 198 for females)",
                "Myoglobin": "45 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "120 ng/mL (20 − 500 for females)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Pelvic Ultrasound": "Hypoechoic area with scattered calcifications within the ovary, suggesting the presence of a dermoid cyst",
            "Abdominal CT Scan": "Well-defined mass in the left ovary with fat and calcification components, consistent with a mature teratoma",
            "Serum Tumor Markers": {
                "AFP": "Normal",
                "hCG": "Normal",
                "CA125": "Elevated at 48 U/mL (0-35 U/mL)"
            },
            "Pathology Report": "Mature cystic teratoma with no signs of malignancy",
            "MRI": "Not required based on current clinical findings",
            "Chest X-ray": "Clear without signs of metastasis",
            "Laparoscopy": "Confirmed mass identification with biopsy indicating benign teratoma"
        },
        "Treatment Plan": "Emily Davis has been diagnosed with a mature ovarian teratoma, a benign condition with a favorable prognosis. The recommended treatment is surgical removal of the teratoma through minimally invasive means, such as laparoscopy, to preserve ovarian function and ensure complete excision of the tumor. The surgery is aimed at removing the affected ovarian tissue while preserving the contralateral ovary to maintain fertility, given Emily's age and desire for future fertility. Postoperative monitoring will involve regular follow-up visits to check for any signs of recurrence, using both physical examinations and imaging studies as necessary. Complete recovery is expected with no requirement for adjuvant chemotherapy due to the benign nature of the teratoma. Emily will be counseled on the importance of maintaining regular gynecological check-ups to monitor her overall reproductive health."
    },
    {
        "Patient Information": {
            "Name": "Emily Johnson",
            "Age": "25",
            "Gender": "Female",
            "Medical History": "No known genetic disorders; recent onset of abdominal pain and bloating"
        },
        "Disease Information": {
            "Disease": "Mature Ovarian Teratoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Abdominal pain, palpable abdominal mass, bloating",
            "Duration": "Symptoms noticed over the past few months with gradual escalation",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "6.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "75 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "240 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "38% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (15 − 200 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None Detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Examination": "Cystic mass in left ovary approximately 7 cm in diameter",
            "MRI Scan": "Presence of a well-defined unilocular cystic lesion containing hair and calcified elements",
            "Serum AFP Levels": "Normal",
            "Serum hCG Levels": "Normal",
            "Pelvic Examination": "Benign palpable mass noticed",
            "Pathological Examination": "Mature teratoma composed of ectoderm, mesoderm, and endoderm tissues",
            "Laparoscopy": "Confirmed teratoma presence with no signs of malignancy"
        },
        "Treatment Plan": "Emily Johnson has been diagnosed with a mature ovarian teratoma, which is a benign type of germ cell tumor typically found in young women. Since her symptoms have been gradually worsening, surgical removal is recommended to prevent further complications and to relieve persistent abdominal pain and bloating. A laparoscopic approach to tumor enucleation will be employed to preserve the normal ovarian tissue due to Emily's age, ensuring that her fertility is not compromised. During surgery, a thorough exploration of the contralateral ovary will be performed to ensure no bilateral occurrence of teratomas. Post-surgery, Emily will be monitored for recurrence with regular follow-ups involving ultrasound and serum marker tests every few months. Emily will be advised on the importance of adhering to follow-up schedules and notifying her healthcare provider should any new symptoms arise. Lifestyle modifications will be recommended, including a balanced diet and regular physical activity, to support overall health and recovery. No chemotherapy is necessary due to the benign nature of the tumor, and Emily's prognosis is favorable, with expectations of complete resolution following surgical treatment."
    },
    {
        "Patient Information": {
            "Name": "Sophia Johnson",
            "Age": "15",
            "Gender": "Female",
            "Medical History": "No significant past medical history; family history of teratomas noted in maternal lineage"
        },
        "Disease Information": {
            "Disease": "Teratoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Abdominal pain, palpable abdominal mass, abdominal distention",
            "Duration": "Symptoms have been persistent over the past three weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "25 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "22 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "65 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "55% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "CA-125": "55 U/mL (< 35)",
                "Alpha-fetoprotein (AFP)": "20 ng/mL (< 10 ng/mL)",
                "Human Chorionic Gonadotropin (hCG)": "5 IU/L (< 5)",
                "Ferritin": "150 ng/mL (20 − 500 for females)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Complex ovarian mass with mixed echogenicity, possible teratomatous elements seen",
            "MRI": "Confirmed presence of a 7 cm cystic and solid mass in the right ovary with benign characteristics",
            "Serological Diagnosis": "Elevated CA-125 and AFP levels suggestive of tumor presence",
            "Cytological Examination": "No malignant cells observed",
            "Pathological Examination": "Indicates mature teratoma, composed of mature tissue elements",
            "Special Examination": "Laparoscopy revealed well-defined ovarian mass; biopsy confirmed benign mature teratoma",
            "CT Scan": "No signs of metastatic spread; pelvic organs otherwise normal",
            "Tumor Marker Tests": "CA-125, AFP, and hCG tested with AFP being mildly elevated"
        },
        "Treatment Plan": "Sophia Johnson is diagnosed with a mature ovarian teratoma that is benign and carries a good prognosis. The recommended treatment plan involves surgical removal of the mass, considering her young age and the potential for future fertility. Laparoscopic surgery is preferred to minimize recovery time and preserve ovarian function, allowing for the enucleation of the tumor while sparing the unaffected ovary. Given the elevation in tumor markers, continued monitoring is indicated post-surgery to ensure no recurrence or malignant transformation. Additionally, regular follow-up with ultrasound and serum marker analysis every 3-6 months over the next two years is advised to monitor her condition closely. Sophia will be educated on signs of recurrence and the importance of attending scheduled follow-ups. Post-surgical recovery will include pain management and lifestyle guidance to aid in a smooth recuperation. If any changes in symptoms or marker levels are noted, further diagnostic work-up may be warranted to adjust the treatment plan accordingly."
    },
    {
        "Patient Information": {
            "Name": "Alex Chen",
            "Age": "58",
            "Gender": "Male",
            "Medical History": "Hypertension, history of ulcerative colitis"
        },
        "Disease Information": {
            "Disease": "Colon Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Weight loss, abdominal pain, frequent changes in bowel habits, bloody stool, iron-deficiency anemia",
            "Duration": "Symptoms have been present for approximately 3 months, progressively worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "105 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.15 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "9% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "150 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "Carcinoembryonic antigen (CEA)",
                "Blood Silver Level": "85 μg/L (50 − 150)"
            },
            "Colonoscopy Exam": "Presence of a large tumor in the descending colon with ulcerations",
            "Abdominal Computerized Tomography": "Tumor invasion into the muscular layer of the colon wall with enlarged regional lymph nodes",
            "Serological Diagnosis": "Elevated CEA levels",
            "Tumor Markers": "Elevated CA19-9",
            "Digestive Ultrasound": "Normal liver, spleen, pancreas, no metastases detected",
            "Magnetic Resonance Imaging": "Normal findings for liver condition, no metastases observed",
            "Positron Emission Tomography-Computed Tomography (PET-CT)": "No distant metastasis identified",
            "Barium Enema X-ray": "Detects significant narrowing in the descending colon"
        },
        "Treatment Plan": "Alex Chen has been diagnosed with major severity colon cancer located in the descending colon, indicated by iron-deficiency anemia, abdominal pain, bloody stools, and weight loss. Immediate surgical intervention is recommended, possibly involving a left hemicolectomy to remove the primary tumor and affected regional lymph nodes, followed by adjuvant chemotherapy such as FOLFOX regimen post-surgery to reduce the risk of recurrence. Nutritional support and pain management will be essential post-treatment, with a diet focusing on easy-to-digest foods gradually transitioning as recovery progresses. Regular follow-ups involving tumor markers CEA and CA19-9, imaging tests, and possibly PET-CT scans to monitor for potential recurrence or metastasis will be conducted. Pre-treatment assessments, including heart and liver function evaluation, are essential to ensure fitness for surgery and chemotherapy. Given Alex's history of ulcerative colitis, monitoring for potential intestinal obstruction post-surgery will be critical. Psychological support and lifestyle adjustments, including quitting smoking, adequate hydration, and moderate exercise, alongside regular screenings for preventative measures, will aid in promoting overall health and recovery."
    },
    {
        "Patient Information": {
            "Name": "Helen Zhang",
            "Age": "62",
            "Gender": "Female",
            "Medical History": "Chronic ulcerative colitis, history of polyps, family history of colon cancer"
        },
        "Disease Information": {
            "Disease": "Colon Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Bloody stool, abdominal pain, weight loss, emaciation, fatigue, changes in bowel habits",
            "Duration": "Symptoms have been present for approximately 3 months, progressively worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "115 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "18% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "75% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.9 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "230 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for females)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Colonoscopy": "Mass in the sigmoid colon with ulcerative features, biopsy confirms adenocarcinoma",
            "CT Scan": "Massive thickening and constriction in the descending colon, with regional lymph node involvement",
            "MRI": "Evidence of extramural invasion into surrounding tissues, no distant metastases",
            "Ultrasound": "Normal liver and kidney profile",
            "PET-CT": "Localized activity in sigmoid region, no indication of distant spread",
            "Tumor Markers": "Elevated Carcinoembryonic Antigen (CEA) at 12 ng/mL; CA 19-9 in normal range",
            "Fecal Occult Blood Test": "Positive",
            "Barium Enema X-ray": "Significant constriction detected in the sigmoid region"
        },
        "Treatment Plan": "Helen Zhang has been diagnosed with major severity colon cancer localized in the sigmoid colon, with no evidence of distant metastasis. Given her medical history of chronic ulcerative colitis and family predisposition to colon cancer, it is crucial to adopt a comprehensive treatment plan aiming at surgical excision, symptomatic control, and post-treatment surveillance. An immediate surgical intervention is recommended, opting for laparoscopic left hemicolectomy to remove the tumor and regional lymph nodes, ensuring complete disease eradication while minimizing recovery time. Pre-surgical preparation will include nutritional optimization and heart and lung function assessment. Post-surgical adjuvant chemotherapy may be administered using FOLFOX or CapeOx regimen to reduce recurrence risk. Helen will commence with enhanced pain management and nutritional support postoperatively, ensuring her diet includes easily digestible low-residue foods to prevent intestinal obstruction. Her recovery will be supported with respiratory exercises to prevent lung infections and early mobilization to mitigate the risks of bowel adhesion and thrombosis. Regular follow-ups with colonoscopy and imaging tests will be scheduled to monitor her recovery, and tumor marker levels will be checked periodically to assess potential recurrence. Helen is advised to maintain an active lifestyle with moderate physical exercise, avoiding smoking, and managing stress effectively. Given her diagnosis, family counseling and psychological support are recommended to foster a supportive environment conducive to healing and recovery."
    },
    {
        "Patient Information": {
            "Name": "Frank Lin",
            "Age": "62",
            "Gender": "Male",
            "Medical History": "Hypertension, Occasional tobacco use, Family history of colorectal cancer"
        },
        "Disease Information": {
            "Disease": "Colon Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Weight loss, abdominal pain, bloody stool, fatigue, changes in bowel habits",
            "Duration": "Symptoms have been progressively worsening over the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.4 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "240 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "20 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "CEA",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Colonoscopy": "Presence of a malignant mass in the sigmoid colon with biopsy confirming adenocarcinoma",
            "PET-CT Scan": "Detection of liver metastasis",
            "Abdominal MRI": "Secondary lesions in the liver",
            "Ultrasound Examination": "No significant gallbladder or pancreatic involvement",
            "Sigmoidoscopy": "Not performed; full colonoscopy conducted",
            "Serological Diagnosis": "Elevated CEA levels",
            "Tumor Marker Test": "Elevated CA19-9 levels",
            "CT Scan": "Infiltration and thickening in sigmoid colon with regional lymph node involvement",
            "Barium Enema X-ray": "Narrowing of the intestinal lumen"
        },
        "Treatment Plan": "Frank Lin has been diagnosed with major severity colon cancer, with confirmed metastasis to the liver. A multidisciplinary approach has been initiated, combining surgical, chemotherapy, and targeted therapy strategies to ensure comprehensive management. Given the presence of liver metastases, the treatment plan includes a two-stage approach, beginning with neoadjuvant chemotherapy to reduce tumor size and improve surgical outcomes, followed by surgical intervention consisting of colectomy and liver resection. Chemotherapy will utilize FOLFOX regimen combined with Bevacizumab for enhanced efficacy against metastatic sites, and Cetuximab will be considered post-operatively given Frank’s wild-type RAS gene profile. Nutritional support will be emphasized to counteract malnutrition and maintain optimal recovery conditions. Continuous monitoring through regular blood tests, imaging, and tumor marker assessments will be crucial to evaluate treatment effectiveness and adjust therapeutic strategies accordingly. Pain management and supportive care measures will be implemented to ensure quality of life, with dietary adjustments focusing on low-residue, nutrient-dense foods to facilitate recovery and prevent complications. Lifestyle modifications, including enhanced physical activity and psychological support, will be encouraged to support Frank’s overall health and recovery journey."
    },
    {
        "Patient Information": {
            "Name": "Emily Johnson",
            "Age": "35",
            "Gender": "Female",
            "Medical History": "Family history of thyroid issues, radiation exposure during childhood"
        },
        "Disease Information": {
            "Disease": "Papillary Thyroid Carcinoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Thyroid nodule detection during physical examination, slight neck lymph node enlargement",
            "Duration": "Symptoms have been present for approximately 6 months, with gradual progression",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "20 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "25 IU/L (13 − 35)",
                "Urea": "5.1 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Thyroid Stimulating Hormone (TSH)": "2.5 mIU/L (0.4 − 4.0)",
                "Thyroglobulin (TG)": "50 ng/mL (1.4 − 78)",
                "Anti-Thyroglobulin Antibodies (TGAb)": "20 IU/mL (< 115)",
                "CRP": "2.0 mg/L (< 3 mg/L)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Thyroid Ultrasound": "Presence of a solid hypoechoic nodule with microcalcifications",
            "Fine Needle Aspiration Biopsy": "Papillary thyroid carcinoma cells identified",
            "CT Scan": "No evidence of extrathyroid extension or distant metastasis",
            "Laryngoscopy": "Normal vocal cord mobility, no nerve invasion detected"
        },
        "Treatment Plan": "Emily Johnson has been diagnosed with papillary thyroid carcinoma presenting as a moderate severity condition due to the presence of a thyroid nodule and minor lymph node involvement. The treatment plan includes surgical intervention, specifically a thyroid lobectomy to remove the affected lobe, given the absence of extrathyroidal extension and lymph node metastasis. Post-surgery, endocrine therapy with levothyroxine will be initiated to suppress TSH and prevent tumor regrowth. Monitoring of serum thyroglobulin levels and periodic neck ultrasounds will be conducted to ensure no recurrence or metastasis. The patient will be educated on managing potential symptoms of hypothyroidism and the importance of regular follow-up appointments. In addition, maintaining a balanced diet, regular check-ups, and a healthy lifestyle will be emphasized to support recovery and overall health. Emotional support and stress management techniques will be recommended to enhance the treatment outcome and quality of life."
    },
    {
        "Patient Information": {
            "Name": "Emily Johnson",
            "Age": "35",
            "Gender": "Female",
            "Medical History": "No significant medical history, routine check-ups previously showed no thyroid abnormalities"
        },
        "Disease Information": {
            "Disease": "Papillary Thyroid Carcinoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Painless thyroid nodule detected, occasional neck lymph node enlargement",
            "Duration": "Incidental detection during routine physical examination, no symptoms reported over the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 - 40)",
                "AST (Aspartate Aminotransferase)": "35 IU/L (13 - 35)",
                "Urea": "5.5 mmol/L (2.6 - 8.8)",
                "Creatinine (Cr)": "60 μmol/L (41 - 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.5 × 10^9/L (3.5 - 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 - 5.5)",
                "Hematocrit (Hct)": "42% (35 - 50)",
                "Hemoglobin (Hb)": "135 g/L (115 - 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 - 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 - 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 - 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.9 × 10^9/L (1.3 - 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.3 × 10^9/L (1.8 - 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.45 × 10^9/L (0.2 - 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 - 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 - 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 - 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 - 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 - 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 - 13)",
                "Thyrotropin (TSH)": "2.1 mIU/L (0.4 - 4.0)",
                "Thyroglobulin": "60 ng/mL (0 - 55 for post-thyroidectomy)",
                "Thyroglobulin Antibody": "Negative",
                "Lactate Dehydrogenase": "180 U/L (135 - 225)",
                "Ferritin": "100 ng/mL (20 - 500 for females)",
                "Calcium": "9.8 mg/dL (8.5 - 10.5)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 - 20)"
            },
            "Thyroid Ultrasound": "Small hypoechoic nodule in the right lobe of thyroid with irregular borders; no significant abnormal neck lymph nodes",
            "Fine Needle Aspiration Biopsy": "Presence of papillary structures and nuclear features consistent with papillary thyroid carcinoma",
            "Neck CT Scan": "Nodule confined to thyroid gland, no evidence of extrathyroidal extension",
            "Thyroid Hormone Levels": {
                "Total T3": "1.2 ng/mL (0.8 - 2.4)",
                "Total T4": "8.5 μg/dL (5.5 - 11)"
            },
            "Laryngoscopy": "Normal vocal cord movement"
        },
        "Treatment Plan": "Emily Johnson has been diagnosed with papillary thyroid carcinoma of moderate severity, identified as a small thyroid nodule during a routine examination. Given the nature and current status of the carcinoma, a thyroid lobectomy with isthmus resection is planned to ensure removal of the affected tissue while preserving some thyroid function. Post-surgery, Emily will undergo endocrine therapy to maintain low thyroid-stimulating hormone (TSH) levels using levothyroxine. Regular monitoring through serum TSH levels will be conducted initially every 4 weeks, then extended as she stabilizes. In addition, neck ultrasound will be scheduled every 6 months to detect any signs of recurrence or novel nodules. Emily will also have serum thyroglobulin checked post-surgery for further surveillance. She will be advised on nutritional guidelines to support recovery, focusing on a balanced diet rich in fruits, vegetables, and lean proteins while avoiding spicy and irritating foods. Emotional support and guidance on regular exercise and stress management will be provided to help maintain a healthy lifestyle. A follow-up plan will ensure consistent observation of thyroid function and overall health, with ongoing evaluations to adjust the treatment approach as necessary. Lastly, Emily will be educated on self-monitoring techniques to promptly identify any new developments, ensuring active participation in her recovery and continued well-being."
    },
    {
        "Patient Information": {
            "Name": "Emily Thompson",
            "Age": "28",
            "Gender": "Female",
            "Medical History": "Family history of thyroid cancer"
        },
        "Disease Information": {
            "Disease": "Papillary Thyroid Carcinoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Neck lymph node enlargement, thyroid nodule detected during routine physical examination, mild compression symptoms",
            "Duration": "Symptoms have been present for several months, with gradual enlargement of the thyroid nodule",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Thyrotropin (TSH)": "3.0 mIU/L (0.4 − 4.0)",
                "Thyroid Hormones (T3, T4)": "Normal",
                "Anti-thyroglobulin Antibodies (TGAb)": "Positive",
                "Thyroglobulin (TG)": "High",
                "CRP": "3 mg/L (< 10 mg/L)",
                "ESR": "20 mm/hr (0 − 30)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Examination": "Thyroid nodule with irregular boundaries, no capsule, and uneven internal echoes",
            "Fine Needle Aspiration Biopsy": "Presence of papillary structures and nuclear changes consistent with papillary thyroid carcinoma",
            "Genetic Testing": "Positive for BRAF mutations",
            "Computed Tomography": "No evidence of metastasis to surrounding organs or distant locations",
            "Thyroid Radionuclide Imaging": "Uniform uptake indicating benign characteristics",
            "Laryngoscopy": "No recurrent laryngeal nerve damage",
            "Thyroid Hormone Tests": "Normal"
        },
        "Treatment Plan": "Emily Thompson has been diagnosed with moderately severe papillary thyroid carcinoma, with a family history increasing her risk factors. Given the slow progression and overall good prognosis associated with this type of cancer, a comprehensive yet individualized treatment plan is necessary. Initially, Emily will undergo a thyroid lobectomy with isthmus resection to remove the affected thyroid tissue, as there is no indication of cervical lymph node metastasis or extrathyroidal invasion, ensuring preservation of parathyroid function and minimizing nerve injury risks. Following surgery, endocrine therapy using levothyroxine will be administered to maintain thyroid hormone levels and suppress TSH, with regular monitoring to adjust dosage and prevent potential hyperthyroidism. Emily will be monitored for adverse effects, including thyroid toxicity and sleep disturbances. Although no lymph node involvement is evident, a careful postoperative evaluation will ensure that any recurrence or metastasis is addressed promptly. Genetic testing has shown BRAF mutations, guiding targeted therapy options. If necessary, multiple kinase inhibitors like lenvatinib, with a focus on close monitoring for side effects like diarrhea and rash, might be considered based on the progression and response to initial treatments. Emily has been counseled to maintain a balanced diet, avoiding stressors, and engage in regular follow-ups to assess thyroid function and neck health, with periodic ultrasounds and serum thyroglobulin testing to monitor for recurrence. Her treatment and recovery are expected to proceed favorably with adherence to the outlined plan, ensuring optimal management and quality of life."
    },
    {
        "Patient Information": {
            "Name": "Emily Thompson",
            "Age": "8",
            "Gender": "Female",
            "Medical History": "Frequent respiratory infections, history of anemia"
        },
        "Disease Information": {
            "Disease": "Acute Lymphoblastic Leukemia",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Pallor, fatigue, frequent infections, petechiae, nosebleeds, hepatosplenomegaly, fever",
            "Duration": "Symptoms have been present for several weeks with increasing intensity",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "35 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "60 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "White Blood Cell Ct. (WBC)": "100 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "28% (35 − 50)",
                "Hemoglobin (Hb)": "90 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "50 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "80% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "10% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "80 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "10 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "11 fL (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "50 mm/hr (0 − 20)",
                "Procalcitonin": "0.6 ng/mL (< 0.5)"
            },
            "Bone Marrow Examination": "Presence of immature lymphocytes ≥ 20%, indicative of ALL",
            "Cytochemical Tests": "PAS staining ++ with coarse granules",
            "Immunophenotyping": "Positive for B-lineage ALL",
            "Cytogenetics": "Clonal chromosome abnormalities detected",
            "Cerebrospinal Fluid Examination": "No evidence of CNS leukemia",
            "Chest X-ray Exam": "Normal",
            "Ultrasound": "Mild hepatosplenomegaly",
            "CT Scan": "No intracranial involvement",
            "MRI": "Normal head vascular condition"
        },
        "Treatment Plan": "Emily Thompson is diagnosed with B-lineage Acute Lymphoblastic Leukemia requiring immediate and aggressive treatment due to the severity of her symptoms and critical blood abnormalities. Systemic chemotherapy will be initiated with the VDCLP regimen, including cyclophosphamide, vincristine, daunorubicin, PEG-asparaginase, and prednisone, to target leukemic cells aggressively. Due to the high white blood cell count, initial treatment may involve the use of a cell separator to address white blood cell stasis syndrome. Hydration therapy will be employed to prevent hyperuricemic nephropathy, along with monitoring for complications such as electrolyte imbalances. Granulocyte colony-stimulating factor (G-CSF) will be used to shorten periods of neutropenia post-chemotherapy. Supportive care will include transfusions for maintaining hemoglobin levels and managing her low platelet count with platelet transfusions to prevent bleeding. Nutritional support and infection prevention are crucial, with placement in a sterile ward to minimize infection risk due to neutropenia. Following initial induction therapy, intensification and consolidation therapies will be tailored according to response, possibly integrating targeted therapies. Emily’s family will be educated on the importance of a balanced diet, infection prevention, and supportive care to assist her recovery. Continuous follow-up and routine blood tests will be necessary to monitor and adapt her treatment plan as needed, aiming for remission and considering stem cell transplantation if indicated for long-term management."
    },
    {
        "Patient Information": {
            "Name": "Laura Johnson",
            "Age": "12",
            "Gender": "Female",
            "Medical History": "Frequent infections, unexplained fatigue, bruising easily"
        },
        "Disease Information": {
            "Disease": "Acute Lymphoblastic Leukemia",
            "Severity Level": "Major Severity",
            "Symptoms": "Pallor, fatigue, dizziness, frequent infections, fever, bruising, unexplained bleeding",
            "Duration": "Symptoms have been progressively worsening over the past month",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "40 IU/L (7-40)",
                "AST (Aspartate Aminotransferase)": "38 IU/L (13-35)",
                "Urea": "5.8 mmol/L (2.6-8.8)",
                "Creatinine (Cr)": "70 μmol/L (41-81)",
                "Triglycerides (TG)": "1.4 mmol/L (<1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (<5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "30.0 × 10^9/L (3.5-9.5)",
                "Red Blood Cell Ct. (RBC)": "3.0 × 10^12/L (3.5-5.5)",
                "Hematocrit (Hct)": "28% (35-50)",
                "Hemoglobin (Hb)": "90 g/L (115-150)",
                "Platelet Ct. (PLT)": "60 × 10^9/L (125-350)",
                "Lymphocyte Percentage (LYMPH%)": "70% (20-50)",
                "Neutrophil Percentage (NEUT%)": "20% (40-75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "21.0 × 10^9/L (1.3-3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "6.0 × 10^9/L (1.8-6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2-1.0)",
                "Monocyte Percentage (MONO%)": "5% (3-10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02-0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4-8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0-0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0-1)",
                "Mean Platelet Volume (MPV)": "9 f l (9-13)",
                "Lactate Dehydrogenase": "300 U/L (135-225)",
                "Muscle Enzymes (CK)": "80 U/L (22-198 for females)",
                "Myoglobin": "30 ng/mL (<70 ng/mL for females)",
                "Ferritin": "350 ng/mL (12-300 for females)",
                "CRP": "10 mg/L (<5 mg/L)",
                "ESR": "30 mm/hr (0-20)",
                "Procalcitonin": "0.3 ng/mL (<0.5)",
                "D-dimer": "0.6 mg/L FEU (0-0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "80 μg/L (50-150)"
            },
            "Bone Marrow Aspiration": "Hypercellular marrow with increased lymphoblasts",
            "Flow Cytometry": "Presence of CD10, CD19 markers suggestive of B-lineage ALL",
            "Cytogenetic Analysis": "Presence of t(12;21) translocation",
            "Chest X-ray Exam": "No abnormalities detected",
            "Peripheral Blood Smear": "Increased lymphoblasts, decreased mature neutrophils and platelets",
            "CSF Analysis": "Normal, no evidence of leukemic infiltration",
            "Ultrasound": "Hepatosplenomegaly detected",
            "MRI of Head": "No central nervous system involvement"
        },
        "Treatment Plan": "Laura Johnson has been diagnosed with acute lymphoblastic leukemia, a significant and serious condition requiring immediate and aggressive treatment. The primary course of action involves initiating combination chemotherapy tailored to her B-cell ALL type, starting with an induction phase that includes drugs such as vincristine, dexamethasone, and L-asparaginase. Close monitoring of her white blood cell count, liver function, and overall health will be critical in adjusting treatment to minimize side effects and address complications promptly. Supportive care measures, including transfusions for anemia and platelet deficiencies, will be implemented to manage symptoms like fatigue and bruising. Additionally, Laura’s treatment regimen may incorporate prophylactic central nervous system therapy to prevent potential leukemia spread, which could include intrathecal chemotherapy. Nutritional support and infection prevention strategies, including potential use of G-CSF, will be vital to support her immune system throughout treatment. Continued collaboration with her healthcare team will ensure adjustments are made as needed, with the goal of achieving and sustaining complete remission. Following the initial treatment phases, consolidation and maintenance therapies will be critical to mitigate recurrence risk and support long-term recovery. Laura and her family will be educated on the importance of adherence to this treatment protocol, recognizing the signs of infection or adverse effects, and the necessity of regular follow-up visits to monitor her response to therapy and overall health."
    },
    {
        "Patient Information": {
            "Name": "Michael Jennings",
            "Age": "9",
            "Gender": "Male",
            "Medical History": "Frequent infections, mild anemia, history of easy bruising"
        },
        "Disease Information": {
            "Disease": "Acute Lymphoblastic Leukemia",
            "Severity Level": "Major Severity",
            "Symptoms": "Pallor, fatigue, frequent infections, bruising, fever, lymphadenopathy, bone and joint pain",
            "Duration": "Symptoms have been present and progressively worsening over the past 4 weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "44 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "15.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "28% (35 − 50)",
                "Hemoglobin (Hb)": "90 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "80 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "50% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "40% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "7.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "6.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "3% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.02 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "90 U/L (22 − 198)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "700 ng/mL (20 − 500 for males)",
                "CRP": "75 mg/L (< 3 mg/L)",
                "ESR": "60 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "1.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Normal",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Bone Marrow Examination": "Presence of immature lymphocytes > 20%",
            "Cytogenetics": "Clonal chromosome abnormalities detected",
            "Immunophenotyping": "Positive for CD19 and CD22",
            "Cerebrospinal Fluid Examination": "Normal",
            "Chest X-ray Exam": "Normal",
            "Abdominal Ultrasound": "Mild hepatosplenomegaly observed",
            "MRI": "Normal central nervous system",
            "CT Scan": "Normal",
            "Pathologic Examination": "Bone marrow aspiration confirms leukemia cells",
            "Testicular Examination": "Normal, no infiltration"
        },
        "Treatment Plan": "Michael Jennings has been diagnosed with major severity Acute Lymphoblastic Leukemia (ALL). The treatment plan will prioritize systemic chemotherapy aimed at achieving remission, leveraging the VDCLP regimen with vincristine, daunorubicin, cyclophosphamide, L-asparaginase, and prednisone. As Michael is in a high-risk category due to presenting symptoms, early intensification therapy with CAML regimen will be administered. Regular monitoring through blood tests and imaging will assist in tracking Michael's response to treatment, with adjustments made as necessary. Supportive care will include prophylactic antibiotics for infection prevention due to expected neutropenia, blood transfusions to manage anemia and thrombocytopenia, and nutritional support to maintain health amidst treatment side effects. If remission is achieved, maintenance therapy involving alternating chemotherapy regimens will ensue to prevent relapse. Family education on treatment protocols and symptom management will be provided to ensure adherence and optimal care during both hospital stays and at home. Hematopoietic stem cell transplantation will be considered if initial chemotherapy responses are suboptimal or if significant chromosomal abnormalities are persistently detected. Psychological support for Michael and his family will be integral to managing the emotional impacts of ongoing treatment. Overall, the approach aims at achieving complete remission and managing the disease with a focus on long-term survival."
    },
    {
        "Patient Information": {
            "Name": "Jessica Liu",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "Family history of breast cancer, postmenopausal, history of benign breast cysts"
        },
        "Disease Information": {
            "Disease": "Invasive Breast Carcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless breast lump, nipple discharge, axillary lymph node enlargement, peau d'orange appearance of the breast skin",
            "Duration": "Symptoms have been present and gradually worsening over the past six months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "22 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.1 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.6 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "198 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "5 ng/L (< 14 ng/L)",
                "Ferritin": "150 ng/mL (20 − 500 for females)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "BRCA1 Mutation",
                "Blood Silver Level": "110 μg/L (50 − 150)"
            },
            "Mammogram": "Irregular dense mass with microcalcifications in the upper outer quadrant of the right breast",
            "Ultrasonography": "Hypoechoic mass with irregular borders and increased vascularity in the right breast",
            "MRI Scan": "Enhancing mass with rim-like enhancement characteristics in the right breast tissue",
            "Biopsy": "Invasive ductal carcinoma with no special type, grade 2 differentiation",
            "Hormone Receptor Test": "ER-positive, PR-negative, HER2/neu-negative",
            "Chest X-ray": "No metastatic lesions observed",
            "Bone Scan": "Normal",
            "CT Scan": "No distant metastasis observed",
            "Complete Physical": "Overall physical health satisfactory except noted breast findings"
        },
        "Treatment Plan": "Jessica Liu has been diagnosed with major severity invasive ductal carcinoma of the right breast. Given the nature of her cancer, a comprehensive treatment plan focused on surgery followed by adjunctive therapies is recommended. The patient will undergo a right-sided modified radical mastectomy to ensure complete removal of the tumor while assessing axillary lymph nodes for potential metastasis. Post-surgery, Jessica will receive chemotherapy aimed at reducing any residual microscopic disease, using a regimen tailored to her specific cancer characteristics and overall health status. Endocrine therapy with Tamoxifen will be commenced due to the ER-positive status of the tumor, to help prevent recurrence by blocking estrogen receptors. Regular follow-ups will include physical exams and imaging to monitor for any signs of recurrence. A diet rich in vegetables, fruits, and lean proteins will be recommended to support her immune system, and moderate exercise will be encouraged to maintain physical health and manage weight. Psychological support and family counseling are advised to aid Jessica emotionally throughout her treatment journey. Her treatment plan will be reviewed and adjusted as necessary based on her response to the therapies, emphasizing a multidisciplinary approach for optimal management and outcome."
    },
    {
        "Patient Information": {
            "Name": "Elaine Thompson",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "Family history of breast cancer, benign breast disease"
        },
        "Disease Information": {
            "Disease": "Invasive Breast Carcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless breast mass, nipple discharge, breast skin dimpling, axillary lymph node enlargement",
            "Duration": "Symptoms have been noticeable over the past six months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 - 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 - 35)",
                "Urea": "5.5 mmol/L (2.6 - 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 - 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 - 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 - 5.5)",
                "Hematocrit (Hct)": "38% (35 - 50)",
                "Hemoglobin (Hb)": "120 g/L (115 - 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 - 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 - 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 - 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3 - 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 - 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 - 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 - 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 - 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 - 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 - 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 - 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 - 13)",
                "Lactate Dehydrogenase": "220 U/L (135 - 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 - 198)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 - 500)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 - 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 - 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "HER2/neu Positive",
                "Blood Silver Level": "70 μg/L (50 - 150)"
            },
            "Mammography": "Irregular dense mass in the upper outer quadrant of the right breast with microcalcifications",
            "Ultrasonography": "Hypoechoic mass with irregular margins, posterior acoustic shadowing",
            "MRI": "Enhancing mass in the right breast with heterogeneous signal",
            "Core Needle Biopsy": "Invasive ductal carcinoma, ER-positive, PR-positive, HER2-positive",
            "Bone Scan": "No evidence of metastatic disease",
            "CT of Chest": "No evidence of distant metastases",
            "Serum Tumor Markers": "Elevated CA 15-3 levels"
        },
        "Treatment Plan": "Elaine Thompson has been diagnosed with invasive ductal carcinoma of major severity, which requires a comprehensive treatment plan combining surgery and adjuvant therapies. The initial step will involve a modified radical mastectomy to surgically remove the tumor along with affected lymph nodes. Post-surgery, Elaine will undergo adjuvant radiotherapy to decrease the risk of local recurrence, followed by chemotherapy using a regimen tailored to her specific tumor profile, considering the HER2-positive status, making her a candidate for targeted therapy with Trastuzumab. Additionally, Elaine will begin endocrine therapy with Tamoxifen to address the estrogen receptor-positive nature of her cancer. Regular follow-ups and imaging studies will be essential to monitor the effectiveness of the treatment and detect any signs of recurrence. Elaine is advised to maintain a balanced diet and engage in regular physical activity to improve her overall health and reduce cancer risk factors. Psychological support and counseling will be made available to help manage the emotional aspects of her diagnosis and treatment journey, empowering Elaine and her family with knowledge about her condition and the treatments being administered."
    },
    {
        "Patient Information": {
            "Name": "Jessica Lee",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "History of benign breast disease, family history of breast cancer"
        },
        "Disease Information": {
            "Disease": "Invasive Breast Carcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless breast lump, nipple discharge, skin dimpling, axillary lymph node enlargement",
            "Duration": "Symptoms have been present for several months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "75 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "68% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.1 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fl (9 − 13)",
                "Lactate Dehydrogenase": "160 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "145 U/L (22 − 198 for females)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "200 ng/mL (20 − 500 for females)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "BRCA Mutation Screening",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Mammography Exam": "Localized asymmetric dense shadows with calcifications",
            "Ultrasound Exam": "Irregular tumor borders with hypoechoic areas in the left breast",
            "MRI": "Early, rapid enhancement with heterogeneous characteristics",
            "Histopathological Analysis": "Invasive ductal carcinoma with necrotic areas",
            "Biopsy": "Core needle biopsy confirms invasive ductal carcinoma",
            "Hormone Receptor Status": "ER-positive, PR-positive",
            "Genetic Testing": "BRCA1 mutation positive",
            "Axillary Node Assessment": "Enlarged, movable lymph nodes",
            "Surgical Consult": "Discussed breast-conserving surgery options"
        },
        "Treatment Plan": "Jessica Lee has been diagnosed with invasive ductal carcinoma, classified as major severity due to the presence of axillary lymph node enlargement and typical symptoms such as painless breast lump and nipple discharge. The immediate plan involves surgical intervention, prioritizing breast-conserving surgery given the tumor's manageable size and the patient's preference. Preoperative neoadjuvant chemotherapy will be considered to reduce tumor dimensions and improve surgical outcomes. Post-surgery, adjuvant chemotherapy will be initiated to minimize the risk of recurrence, alongside targeted therapy with Trastuzumab due to her HER-2 positive status. Hormone therapy utilizing Tamoxifen will be implemented, given her ER and PR positive status, aiming to reduce estrogen-driven tumor cell proliferation. Radiotherapy focusing on the affected breast and regional lymph nodes will be conducted to further decrease recurrence risk. Genetic counseling and testing have confirmed BRCA1 mutation, guiding the oncologist to tailor Jessica's treatment protocol and offer preventive management strategies for family members. A nutritional regimen rich in vegetables, fruits, and lean proteins along with weight management and regular exercise is advocated to support immune function. Emotional support, counseling, and education on treatment adherence are critical, ensuring Jessica and her family are well-informed regarding potential side effects and monitoring required for complications. Rehabilitation exercises for the arms post-surgery are prescribed to prevent lymphedema, and regular follow-up appointments will be scheduled to evaluate treatment efficacy and adjust accordingly."
    },
    {
        "Patient Information": {
            "Name": "Zhang Wei",
            "Age": "36",
            "Gender": "Female",
            "Medical History": "Previous occurrences of unexplained fever and night sweats, history of fatigue"
        },
        "Disease Information": {
            "Disease": "Non-Hodgkin Lymphoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless progressive enlargement of cervical lymph nodes, fever, night sweats, weight loss, fatigue",
            "Duration": "Symptoms have been present for the past 3 months, progressively worsening",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "125 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "55% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "35% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.75 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "1.75 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.9% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Ferritin": "435 ng/mL (13 − 150 for females)",
                "CRP": "42 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Multiple enlarged lymph nodes in the mediastinal region",
            "Serological Diagnosis": "Elevated β2-microglobulin levels indicating potential poor prognosis",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bone Marrow Biopsy": "Presence of lymphoma infiltration",
            "Lymph Node Biopsy": "Confirmed non-Hodgkin lymphoma with lymphocyte proliferation",
            "PET-CT Scan": "Diffuse lymph node involvement with increased metabolic activity",
            "Pulmonary Function Test": "Normal",
            "Abdominal Ultrasound": "Enlarged lymph nodes in the abdominal region",
            "MRI": "Abnormal lymph node structure in splenic region"
        },
        "Treatment Plan": "Zhang Wei is diagnosed with non-Hodgkin lymphoma, characterized by the major severity level, due to the presence of systemic symptoms such as fever, night sweats, and weight loss, as well as significant lymph node involvement. Her treatment plan involves an individualized approach using a combination of chemotherapy and immunotherapy. The chosen regimen includes R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone), with close monitoring of her response to therapy and possible adjustments based on tolerance and effectiveness. Given the potential poor prognosis indicated by elevated β2-microglobulin levels, regular PET-CT scans will be conducted to assess treatment efficacy. Supportive care will focus on maintaining nutritional status, hydration, and managing any side effects from treatments. Zhang and her family will be advised on infection prevention strategies due to the weakened immune system, with oral hygiene and dietary precautions in place to support her overall health. Psychological support will also be provided to help her cope with her condition and treatment course. Regular follow-up visits will be essential to reassess her condition, treatment strategy, and any potential needs for advanced therapies like autologous hematopoietic stem cell transplantation if remission is achieved."
    },
    {
        "Patient Information": {
            "Name": "Liam Chen",
            "Age": "35",
            "Gender": "Male",
            "Medical History": "Frequent infections, unexplained weight loss, night sweats"
        },
        "Disease Information": {
            "Disease": "Non-Hodgkin Lymphoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless lymph node enlargement, fever, night sweats, unexplained weight loss, fatigue",
            "Duration": "Symptoms have been progressing over the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7-40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13-35)",
                "Urea": "5.5 mmol/L (2.6-8.8)",
                "Creatinine (Cr)": "90 μmol/L (41-81)",
                "Triglycerides (TG)": "1.2 mmol/L (<1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (<5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.0 × 10^9/L (3.5-9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5-5.5)",
                "Hematocrit (Hct)": "40% (35-50)",
                "Hemoglobin (Hb)": "135 g/L (115-150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125-350)",
                "Lymphocyte Percentage (LYMPH%)": "55% (20-50)",
                "Neutrophil Percentage (NEUT%)": "35% (40-75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "4.4 × 10^9/L (1.3-3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.8 × 10^9/L (1.8-6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2-1.0)",
                "Monocyte Percentage (MONO%)": "10% (3-10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02-0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4-8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0-0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0-1)",
                "Mean Platelet Volume (MPV)": "10 fL (9-13)",
                "Lactate Dehydrogenase": "280 U/L (135-225)",
                "Muscle Enzymes (CK)": "120 U/L (22-198)",
                "Myoglobin": "60 ng/mL (<90 ng/mL)",
                "Troponin I": "10 ng/L (<14 ng/L)",
                "Ferritin": "500 ng/mL (20-500)",
                "CRP": "20 mg/L (<3 mg/L)",
                "ESR": "30 mm/hr (0-20)",
                "Procalcitonin": "0.3 ng/mL (<0.5)",
                "D-dimer": "0.7 mg/L FEU (0-0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "55 μg/L (50-150)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Enlarged paraaortic lymph nodes",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for Epstein-Barr virus",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Liam Chen has been diagnosed with non-Hodgkin lymphoma, presenting as major severity due to multiple enlarged lymph nodes and systemic symptoms such as fever, night sweats, and significant weight loss over the past 6 months. Considering the degree of progression and the specific sub-type of lymphoma, an individualized treatment protocol will be initiated. Chemotherapy will be the cornerstone of the treatment, likely employing an R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) to target and reduce the tumor burden effectively. In parallel, radiotherapy may be considered to manage localized lymph node involvement and control symptoms. Regular monitoring through imaging studies like PET-CT will be crucial to assess the response to treatment and adjust accordingly. Supportive care including nutritional support, management of chemotherapy side effects, and prevention of infections will be emphasized given the immune compromise associated with both the disease and its treatment. Liam will also receive information and support on lifestyle modifications, including dietary management emphasizing high-calorie, high-protein intake, and small frequent meals to cope with energy demands. Follow-up care with frequent check-ups and blood tests will be scheduled to monitor hematological responses and potential complications, ensuring a comprehensive approach to his treatment and recovery."
    },
    {
        "Patient Information": {
            "Name": "Emily Zhang",
            "Age": "28",
            "Gender": "Female",
            "Medical History": "No significant past medical history, but reports a family history of lymphoma."
        },
        "Disease Information": {
            "Disease": "Hodgkin Lymphoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Painless progressive lymph node enlargement, unexplained fever, night sweats, weight loss, itching",
            "Duration": "Symptoms have been persistent over the past 6 weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "280 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.63 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.23 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.2 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "80 U/L (22 − 198 for males)",
                "Myoglobin": "45 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for males)",
                "CRP": "7 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "85 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "No significant abnormalities",
            "Chest Computerized Tomography": "Enlarged lymph nodes in the mediastinal region",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for Epstein-Barr virus antibodies",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Emily Zhang has been diagnosed with Hodgkin lymphoma, and given the moderate severity of her condition, it is recommended to initiate the standardized ABVD chemotherapy regimen, consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine. Radiotherapy may be subsequently considered, particularly targeting the affected lymph nodes in the mediastinal region, depending on her response to chemotherapy. Continuous monitoring for any signs of disease progression or treatment-related adverse effects is essential, with regular blood tests and imaging studies planned to assess her response to treatment. Psychological and nutritional support will be provided to help manage side effects and maintain her overall well-being. Emily is advised on the importance of adhering to the treatment plan and attending all scheduled follow-up appointments to ensure the best possible outcome."
    },
    {
        "Patient Information": {
            "Name": "Alice Zhang",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "Frequent gastrointestinal discomfort, anemia, family history of breast cancer"
        },
        "Disease Information": {
            "Disease": "Ovarian Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Abdominal bloating, decreased appetite, anemia, abdominal mass, fatigue",
            "Duration": "Symptoms have been gradually worsening over the past 3 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "34 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "6.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "32% (35 − 50)",
                "Hemoglobin (Hb)": "105 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "245 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "18% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "12% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "185 U/L (22 − 198 for females)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "500 ng/mL (20 − 500 for females)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "55 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.9 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Tumor Marker CA125": "235 U/mL (< 35)",
                "HE4": "90 pmol/L (< 140)"
            },
            "Ultrasound Exam": "Complex pelvic mass with mixed solid and cystic components",
            "Pelvic MRI": "Large irregular mass in the left ovary with signs of local metastasis",
            "CA125 Test": "Elevated CA125 levels consistent with epithelial ovarian cancer",
            "CT Scan": "Evidence of ascites and peritoneal spread",
            "Biopsy": "Confirmatory histopathological findings of serous adenocarcinoma",
            "Pathological Findings": "Invasive epithelial carcinoma with high-grade features",
            "Endoscopy": "Presence of subclinical metastasis in the gastrointestinal tract",
            "Chest X-ray": "Minimal pleural effusion detected",
            "PET-CT": "Elevated metabolic activity in pelvic region indicative of malignancy"
        },
        "Treatment Plan": "Alice Zhang faces a challenging diagnosis of major severity ovarian cancer, requiring a well-coordinated and proactive treatment approach to improve her prognosis and manage the disease effectively. Given the advanced nature of her symptoms, characterized by abdominal discomfort and bloating, as well as significant elevation in tumor markers, initiating treatment with aggressive surgical intervention, including debulking and possible hysterectomy, is paramount to reduce tumor load and optimize subsequent therapies. Following surgical intervention, Alice will undergo a regimen of combination chemotherapy, preferably using paclitaxel and carboplatin, aimed at targeting residual malignancies and preventing further metastasis. Continuous monitoring through CA125 levels and imaging scans will be critical in assessing treatment efficacy and adjusting protocols promptly. Her treatment plan will integrate targeted therapies, including trial use of PARP inhibitors such as olaparib, depending on genetic testing outcomes for BRCA mutations, enhancing maintenance therapy post-surgery and chemotherapy. Alice will benefit from supportive care to mitigate chemotherapy side effects and maintain her nutritional and lifestyle status, including management of fatigue and anemia through dietary adjustments and iron supplements. Emotional and psychological support is essential, providing counseling services to handle the anxiety and stress arising from her condition and treatment journey. Regular follow-ups every three months in the first two years post-treatment, shifting to semi-annual in the subsequent years, will be essential for monitoring recurrence, with potential lifestyle modifications and rehabilitation programs to enhance her quality of life and aid in recovery."
    },
    {
        "Patient Information": {
            "Name": "Laura Chen",
            "Age": "56",
            "Gender": "Female",
            "Medical History": "Family history of breast cancer, previous hysterectomy due to uterine fibroids"
        },
        "Disease Information": {
            "Disease": "Ovarian Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Lower abdominal discomfort, bloating, decreased appetite, fatigue, irregular vaginal bleeding",
            "Duration": "Symptoms have been persistent for the past 3 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.4 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.3 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "9.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "CA125": "150 U/mL (< 35)",
                "HE4": "90 pmol/L (0 − 140)",
                "Alpha-fetoprotein (AFP)": "5 ng/mL (0 − 10)",
                "CEA": "3 ng/mL (0 − 5)",
                "CA199": "25 U/mL (< 37)"
            },
            "Ultrasound Examination": "Presence of a solid-cystic mass in the left ovary with ascites",
            "CT Scan": "Irregular solid mass in the pelvic region with suspicious nodules in the peritoneum",
            "MRI": "Indications of bilateral ovarian enlargement with peritoneal involvement",
            "Cytological Examination": "Malignant cells detected in ascitic fluid",
            "Pathological Histological Examination": "High-grade serous adenocarcinoma",
            "Tumor Marker Examination": "Significantly elevated CA125 levels",
            "PET-CT": "Metastatic lesions likely present in the peritoneum"
        },
        "Treatment Plan": "Laura Chen has been diagnosed with major severity ovarian cancer, specifically high-grade serous adenocarcinoma, which requires an aggressive treatment approach due to the advanced stage and metastatic potential. Immediate surgical intervention involving cytoreductive surgery will be planned to reduce tumor burden and achieve debulking. Post-surgery, platinum-based chemotherapy using a regimen of paclitaxel and carboplatin will be initiated to address any remaining tumor cells and reduce recurrence risk. In view of the recurrent nature of ovarian cancer, continuous monitoring and follow-up will be essential. Additionally, the use of PARP inhibitors like olaparib or niraparib as maintenance therapy may be considered to prolong progression-free survival. Due to the identified peritoneal involvement, integrative support with targeted therapy such as bevacizumab may be evaluated to manage tumor angiogenesis and enhance treatment efficacy. Psychological support and nutritional counseling will be provided to manage treatment-related side effects and improve quality of life. Laura will be closely monitored with regular imaging, tumor marker assessments, and clinical evaluations to adjust the treatment plan as necessary. She will also be encouraged to maintain a healthy lifestyle, including balanced nutrition and physical activities, to support overall well-being and recovery."
    },
    {
        "Patient Information": {
            "Name": "Linda Thompson",
            "Age": "65",
            "Gender": "Female",
            "Medical History": "Hypertension, Family history of breast cancer"
        },
        "Disease Information": {
            "Disease": "Ovarian Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Lower abdominal discomfort, bloating, decreased appetite, fatigue, and frequent urination",
            "Duration": "Symptoms have been present for the past six months with gradual worsening",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "6.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "CA125": "500 U/mL (< 35 U/mL)",
                "Ferritin": "400 ng/mL (15 − 150 for females)",
                "CA153": "25 U/mL (< 25 U/mL)",
                "CEA": "4 ng/mL (< 5 ng/mL)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Pelvic Ultrasound": "Complex adnexal mass with solid and cystic components, presence of ascites",
            "Abdominal MRI": "Large pelvic mass with evidence of peritoneal spread",
            "CT Scan": "Enlarged pelvic lymph nodes and omental caking",
            "Serum Tumor Markers": "Elevated CA125, normal CA153",
            "Cytological Examination": "Presence of malignant cells in ascitic fluid",
            "Histological Examination": "Epithelial ovarian cancer, high-grade serous carcinoma"
        },
        "Treatment Plan": "Linda Thompson is diagnosed with major severity ovarian cancer, characterized by high-grade serous carcinoma. Given the advanced stage of the disease and the presence of ascites and peritoneal spread, an aggressive treatment plan is necessary. Initial treatment will involve cytoreductive surgery aimed at removing as much of the tumor mass as possible to minimize tumor burden and enhance the effectiveness of subsequent chemotherapy. The standard chemotherapy regimen of paclitaxel combined with carboplatin will follow surgery, with attention paid to Linda's overall health and potential side effects. Due to the major severity, targeted therapy with PARP inhibitors like olaparib may be considered in case of BRCA mutations or as part of a recurrence prevention plan. Linda and her family will be counseled on the importance of adherence to the treatment regimen and the need for regular follow-ups to monitor her response to therapy. Emotional and psychological support will be provided to help manage stress and anxiety associated with the diagnosis and treatment process. Continued monitoring of the disease progression through blood tests and imaging studies will guide any necessary adjustments to the treatment plan."
    },
    {
        "Patient Information": {
            "Name": "Samuel Johnson",
            "Age": "67",
            "Gender": "Male",
            "Medical History": "Chronic Bronchitis, Previous history of smoking"
        },
        "Disease Information": {
            "Disease": "Lung Squamous Cell Carcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent dry cough, hemoptysis, shortness of breath, chest tightness, chest pain, cachexia",
            "Duration": "Symptoms have been persisting for several months, with recent significant worsening",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7-40)",
                "AST (Aspartate Aminotransferase)": "25 IU/L (13-35)",
                "Urea": "6.2 mmol/L (2.6-8.8)",
                "Creatinine (Cr)": "88 μmol/L (41-81)",
                "Triglycerides (TG)": "1.7 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "9.0 × 10^9/L (3.5-9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5-5.5)",
                "Hematocrit (Hct)": "40% (35-50)",
                "Hemoglobin (Hb)": "130 g/L (115-150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125-350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20-50)",
                "Neutrophil Percentage (NEUT%)": "65% (40-75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.7 × 10^9/L (1.3-3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.85 × 10^9/L (1.8-6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.78 × 10^9/L (0.2-1.0)",
                "Monocyte Percentage (MONO%)": "9% (3-10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02-0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4-8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0-0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0-1)",
                "Mean Platelet Volume (MPV)": "10 fl (9-13)",
                "Lactate Dehydrogenase": "280 U/L (135-225)",
                "Muscle Enzymes (CK)": "190 U/L (22-198 for males)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20-500 for males)",
                "CRP": "20 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0-20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0-0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Squamous Cell Carcinoma Antigen",
                "Blood Silver Level": "70 μg/L (50-150)"
            },
            "Chest X-ray Exam": "Central lung mass with bronchial narrowing and cavitation",
            "Chest Computerized Tomography": "Large central mass with necrotic changes, bronchial obstruction",
            "Serological Diagnosis": "Elevated Squamous Cell Carcinoma Antigen",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Sputum": "Normal",
            "Respiratory Function Test": "Severely impaired",
            "Sputum Examination": "Presence of malignant cells",
            "Bronchoscopy": "Tumor observed obstructing bronchial passage",
            "Pulmonary Function Test": "Impaired gas exchange and reduced lung capacity",
            "Nucleic Acid Amplification Test": "Negative",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Samuel Johnson has been diagnosed with major severity lung squamous cell carcinoma, heavily influenced by his history of smoking and chronic bronchitis, requiring a strategic management plan. Given the advanced stage of the carcinoma with significant bronchial obstruction, and cachexia, Samuel will benefit from a comprehensive approach employing multimodal treatment strategies. Palliative care focusing on symptom management and improving quality of life will be prioritized due to the non-curative nature of the disease at this stage. Bronchial artery infusion chemotherapy will be considered, employing drugs such as cisplatin or carboplatin in combination with paclitaxel to target the tumor. Radiation therapy may be applied to reduce symptoms and manage tumor growth, though surgical options are limited due to advanced stage and systemic involvement. Nutritional support and pain management are critical, ensuring adequate intake despite dysphagia and addressing cachexia. Psychological support to maintain mental well-being during treatment is essential. Regular follow-ups to monitor progression, adjust treatment protocols, and manage emerging symptoms will be conducted. Family education on care strategies and signs of complication is integral to Samuel's treatment plan, ensuring all measures are taken to maintain his comfort and dignity as the disease progresses."
    },
    {
        "Patient Information": {
            "Name": "James Mitchell",
            "Age": "68",
            "Gender": "Male",
            "Medical History": "Chronic bronchitis, history of smoking, hypertension"
        },
        "Disease Information": {
            "Disease": "Lung Squamous Cell Carcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent dry cough, hemoptysis, shortness of breath, chest pain, fever, cachexia",
            "Duration": "Symptoms have been present for several months with gradual worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "33 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "6.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.7 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.1 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "125 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.84 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.94 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.36 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "210 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Squamous Cell Carcinoma Antigen (SCC-Ag)",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mass in the central lung region with probable atelectasis",
            "Chest Computerized Tomography": "Irregular mass located in the bronchial area with signs of local invasion",
            "Serological Diagnosis": "Elevated SCC-Ag levels",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Presence of malignant cells",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Normal",
            "Pulmonary Function Test": "Restricted airflow pattern",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "James Mitchell has been diagnosed with lung squamous cell carcinoma, likely exacerbated by his history of smoking and chronic bronchitis. An individualized, multi-faceted treatment approach is necessary due to the major severity of the carcinoma and his existing medical conditions. Surgical resection may be considered, especially if the cancer has not metastasized, with the aim to remove the tumor entirely. Postoperative adjuvant therapies such as chemotherapy and radiotherapy will be integrated into his treatment plan to reduce the risk of recurrence and manage any residuals. Cisplatin combined with paclitaxel will be part of the chemotherapy regimen, given their efficacy in treating squamous cell carcinoma. Nutritional support and pulmonary rehabilitation will also be included, addressing cachexia and improving lung function. Continuous monitoring of respiratory function, tumor markers, and imaging will be essential to assess the progression and response to treatments. James will be educated on lifestyle modifications, emphasizing smoking cessation and regular follow-ups to ensure adherence to the treatment protocol, with plans for palliation if his condition advances. Psychological support may be provided to maintain his mental well-being during treatment."
    },
    {
        "Patient Information": {
            "Name": "John Doe",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Chronic smoker with history of COPD"
        },
        "Disease Information": {
            "Disease": "Lung Squamous Cell Carcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent dry cough, hemoptysis, shortness of breath, chest pain",
            "Duration": "Symptoms have developed over the past 3 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "84 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500 for males)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "SCC-Ag",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Presence of mass in the right bronchus with possible lung collapse",
            "Chest Computerized Tomography": "Large mass in the right lung hilum causing atelectasis and obstructive pneumonia",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Decreased lung capacity",
            "Sputum Examination": "Detection of cancerous cells",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Obstructive lung disease",
            "Nucleic Acid Amplification Test": "Negative for viral pathogens",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "John Doe has been diagnosed with lung squamous cell carcinoma with major severity, requiring a strategic approach to manage his condition given the presence of symptoms such as persistent cough, hemoptysis, and chest pain. Due to the advanced nature of the carcinoma, curative treatment options are limited; therefore, the focus will be on managing symptoms and improving quality of life through a palliative treatment strategy. Chemotherapy regimens including cisplatin and gemcitabine will be initiated to reduce tumor progression, accompanied by radiation therapy aimed at minimizing tumor size and alleviating breathing difficulties. Supportive care measures such as analgesics for pain management, steroid therapy to reduce inflammation, and oxygen supplementation will be vital to address respiratory discomfort. Nutritional support will be provided to mitigate weight loss and cachexia associated with his condition, while regular monitoring through CT scans and blood tests will help assess the treatment efficacy and make necessary adjustments. Psychological support and counseling will be offered to help cope with the emotional challenges of living with a major illness, with lifestyle modifications recommended to quit smoking and adopt healthier living practices. Regular follow-up appointments will be essential to track progression and manage any emerging complications. Ensuring adherence to the treatment plan, proper management of symptoms, and maintaining open communication with healthcare providers will be crucial for optimal care and quality of life management."
    },
    {
        "Patient Information": {
            "Name": "Eleanor Thompson",
            "Age": "58",
            "Gender": "Female",
            "Medical History": "Hypertension, Familial history of cancer"
        },
        "Disease Information": {
            "Disease": "Lymphoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Painless progressive enlargement of cervical lymph nodes, fever, night sweats, weight loss",
            "Duration": "Symptoms have been present and gradually worsening over the past 3 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "73 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.1 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.6 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "55% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.8 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.4 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "290 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "120 U/L (22 − 198 for females)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "11 ng/L (< 14 ng/L)",
                "Ferritin": "150 ng/mL (20 − 500 for females)",
                "CRP": "6 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Negative",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "CT Scan": "Enlarged lymph nodes identified in cervical and mediastinal regions, suggestive of lymphoma",
            "Chest X-ray": "Mediastinal widening noted",
            "Bone Marrow Biopsy": "Presence of lymphoma cells",
            "PET-CT": "High uptake areas in the cervical and mediastinal lymph nodes",
            "MRI": "No central nervous system involvement",
            "Immunohistochemistry": "Positive for CD20",
            "Cytometry": "Abnormal lymphoid proliferation detected"
        },
        "Treatment Plan": "Eleanor Thompson has been diagnosed with moderate severity lymphoma, primarily affecting her cervical lymph nodes, with systemic symptoms including fever, night sweats, and weight loss over the past three months. The treatment plan will include a combination of chemotherapy and targeted therapy. The CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) will be initiated, alongside rituximab, a monoclonal antibody targeting CD20-positive cells, due to her lymphoma's expression of CD20. Radiotherapy may be considered if significant residual disease is present after initial chemotherapy cycles. Regular monitoring through blood tests, PET-CT scans, and bone marrow evaluations is crucial to assess response to treatment and make necessary adjustments. Eleanor will also receive supportive care to manage side effects, including anti-emetics for nausea, and possibly growth factor support to prevent neutropenia. Nutritional support and lifestyle modifications will be advised to maintain her overall well-being, and Eleanor will be educated on recognizing potential side effects and the importance of adhering to scheduled follow-ups for optimal treatment outcomes. Long-term monitoring will be required to ensure remission and address any recurrence swiftly."
    },
    {
        "Patient Information": {
            "Name": "Rachel Evans",
            "Age": "36",
            "Gender": "Female",
            "Medical History": "Recent history of painless cervical lymph node enlargement, episodes of night sweats, unexplained weight loss"
        },
        "Disease Information": {
            "Disease": "Lymphoma (suspected Hodgkin's lymphoma)",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless progressive enlargement of cervical lymph nodes, fever, night sweats, weight loss, occasional skin itching",
            "Duration": "Symptoms have been present for the past three months and gradually worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "112 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "180 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "50% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "40% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.25 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "1.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.5 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "11% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.7% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198)",
                "Ferritin": "450 ng/mL (20 − 500)",
                "CRP": "20 mg/L (< 3 mg/L)",
                "ESR": "60 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mediastinal widening noted",
            "Chest Computerized Tomography": "Enlarged mediastinal lymph nodes detected",
            "Serological Diagnosis": "Elevated lactate dehydrogenase, indicative of poor prognosis",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bone Marrow Examination": "Presence of Reed-Sternberg cells",
            "Lymph Node Biopsy": "Histopathology suggests Hodgkin's lymphoma",
            "PET-CT Scan": "Presence of hypermetabolic lymph nodes in mediastinum",
            "MRI": "No central nervous system involvement observed"
        },
        "Treatment Plan": "Rachel Evans has been diagnosed with Hodgkin's lymphoma, and a comprehensive treatment approach integrating chemotherapy and radiotherapy is recommended due to the major severity of the disease and positive curability prognosis. It is advisable to initiate with the ABVD chemotherapy regimen (doxorubicin, bleomycin, vinblastine, dacarbazine) to target the malignancy effectively, while concurrently scheduling radiotherapy sessions to enhance treatment efficacy, particularly in mediastinal regions where lymph node enlargement is prominent. Regular monitoring and follow-up appointments will be crucial to assess the response to therapy and adjust the treatment regimen accordingly, ensuring the minimization of potential side effects. Supportive care measures will be put in place to manage symptoms like fever, night sweats, and weight loss, including antipyretics and nutritional interventions focusing on high protein and vitamin-rich diets. Rachel will be encouraged to engage in moderate physical activity, following medical guidance to support her immune health, and her progress will be closely monitored through periodic imaging studies and blood tests to ensure disease regression. Additionally, Rachel and her family will be educated on the treatment plan, potential side effects, and the importance of adherence to therapy, with a focus on maintaining a positive outlook and a supportive environment during her treatment journey. Following successful treatment, Rachel may be advised to join a support group or consider psychological counseling to address any emotional challenges and enhance her recovery process."
    },
    {
        "Patient Information": {
            "Name": "Emily Johnson",
            "Age": "38",
            "Gender": "Female",
            "Medical History": "Occasional respiratory infections, no prior history of cancer"
        },
        "Disease Information": {
            "Disease": "Non-Hodgkin's Lymphoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless progressive enlargement of cervical lymph nodes, fever, excessive sweating, weight loss, occasional skin itching",
            "Duration": "Symptoms have been progressively worsening over the past three months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "65 μmol/L (41 − 81)",
                "Triglycerides (TG)": "0.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "37% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "45% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "50% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.25 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "85 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "500 ng/mL (20 − 500 for females)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Clear lung fields, no abnormal findings",
            "Chest Computerized Tomography": "Enlarged mediastinal lymph nodes",
            "Serological Diagnosis": "Indicators consistent with lymphoma",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "No viral particles detected",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for specific viral markers",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative for viral presence",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal findings",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Emily Johnson has been diagnosed with non-Hodgkin's lymphoma with major severity symptoms including progressive lymph node enlargement, fever, excessive sweating, and weight loss. Her condition warrants immediate attention, and an integrated approach to treatment is essential for optimal management and recovery. Initial chemotherapy will be initiated with a CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) to target the malignant lymphocytes and achieve remission. Radiotherapy may be considered as an adjunct for localized lymph node masses that persist post-chemotherapy or for central nervous system involvement. Regular monitoring of her blood counts and imaging studies will be crucial in evaluating treatment efficacy and modifying the approach as necessary. Emily will be closely monitored for potential side effects, with supportive care measures such as nutritional support, management of treatment-induced anemia, and protection against infections during the immunocompromised phase. Psychological support will be provided to help Emily maintain a positive outlook, and she will be encouraged to engage in gentle physical activities to aid in overall well-being. Emily's involvement in coordinated medical follow-up and adherence to the treatment protocol will be crucial to manage her condition effectively, ensuring that she receives the best care possible for successful remission and improved quality of life."
    },
    {
        "Patient Information": {
            "Name": "Gary Bennett",
            "Age": "56",
            "Gender": "Male",
            "Medical History": "Hypertension, prolonged fatigue, night sweats, weight loss"
        },
        "Disease Information": {
            "Disease": "Chronic Myeloid Leukemia",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Fatigue, low-grade fever, weight loss, splenomegaly, night sweats",
            "Duration": "Symptoms have been present for several months with gradual escalation",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "50 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "350 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "35 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "5 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "10% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "3 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Bcr-Abl fusion gene",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Normal",
            "Serological Diagnosis": "Presence of Bcr-Abl fusion gene",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for common viral infections",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Positive for Bcr-Abl fusion gene",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Gary Bennett has been diagnosed with chronic myeloid leukemia (CML) in the chronic phase, requiring ongoing intervention to maintain disease control and quality of life. Treatment will center around the initiation of a tyrosine kinase inhibitor (TKI), with Imatinib being the first-line choice due to its established efficacy in chronic-phase CML. This oral medication will be administered daily, with close monitoring for potential side effects such as edema, gastrointestinal discomfort, and fatigue. Regular check-ups are essential for evaluating hematologic, cytogenetic, and molecular responses to the therapy, ensuring that the presence of the Bcr-Abl fusion gene decreases over time. Given the possibility of achieving a stable deep molecular response with sustained treatment, Gary may, later on, discuss medication discontinuation options with his oncologist. Additionally, recommended lifestyle adjustments include avoiding potential triggers such as radiation and chemical exposure, alongside maintaining a nutritious diet and regular physical activity to bolster overall health. Supportive care measures, including addressing any psychological stress and fostering social connections, will be encouraged to improve Gary's coping mechanisms and emotional well-being. Although allogeneic hematopoietic stem cell transplantation remains a potential cure, it is reserved for cases where TKIs fail or disease progresses to an accelerated or blast phase. Routine monitoring and collaborative communication with healthcare providers are key to effectively managing Gary’s treatment and ensuring a good quality of life."
    },
    {
        "Patient Information": {
            "Name": "Richard Thompson",
            "Age": "58",
            "Gender": "Male",
            "Medical History": "Mild hypertension and hyperlipidemia"
        },
        "Disease Information": {
            "Disease": "Chronic Myeloid Leukemia",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Fatigue, low-grade fever, weight loss, splenomegaly",
            "Duration": "Symptoms have been mild and ongoing for the past three months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "38 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "25 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.6 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "37% (35 − 50)",
                "Hemoglobin (Hb)": "115 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "400 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "15 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "2% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.3 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.2 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "1% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "330 U/L (135 − 225)",
                "Uric Acid": "450 μmol/L (250 − 450)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "60 μg/L (50 − 150)"
            },
            "Bone Marrow Cell Morphologic Examination": "Significant granulocytic hyperplasia with decreased erythrocytic series",
            "Cytogenetic Examination": "Presence of Ph chromosome confirmed",
            "Molecular Examination": "Bcr-Abl fusion gene detected by PCR",
            "Biochemical Examination": "Elevated lactate dehydrogenase and uric acid levels",
            "Chest X-ray": "Normal",
            "Bone Density Test": "Normal",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal"
        },
        "Treatment Plan": "Richard Thompson has been diagnosed with chronic myeloid leukemia, presently in the chronic phase, which will require a carefully structured treatment plan focusing on maintaining a stable hematological and cytogenetic response. The recommended first-line treatment for Richard is the use of a tyrosine kinase inhibitor (TKI), such as Imatinib, which should be administered orally daily. Considering the moderately elevated severity, second-generation TKIs such as Nilotinib or Dasatinib may be considered if Imatinib is not adequately effective or tolerated. Regular monitoring of cytogenetic response through PCR for the Bcr-Abl fusion gene will be crucial to assess the effectiveness of the treatment. In addition to medication, Richard is advised to maintain a balanced diet, engage in regular but moderate exercise, and avoid any potential exposure to high doses of radiation or chemical substances. Allogeneic hematopoietic stem cell transplantation is not considered at this stage due to the existing effective drug treatment. Continuous adherence to the prescribed treatment regimen is essential for achieving and maintaining a deep molecular response, and follow-up appointments will be scheduled every three months to monitor progress. Family support, psychological counseling, and patient education are also important components of the treatment plan, ensuring Richard maintains a positive outlook and a good quality of life."
    },
    {
        "Patient Information": {
            "Name": "Helen Zhang",
            "Age": "48",
            "Gender": "Female",
            "Medical History": "Recently diagnosed with chronic myeloid leukemia. Previous episodes of fatigue, low-grade fever, and weight loss noticed over the past three months."
        },
        "Disease Information": {
            "Disease": "Chronic Myeloid Leukemia (CML)",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Fatigue, low-grade fever, weight loss, splenomegaly, occasional night sweats",
            "Duration": "Symptoms have gradually developed over the past few months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.1 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "20 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "37% (35 − 50)",
                "Hemoglobin (Hb)": "115 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "450 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "18% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "76% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "15.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "3% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.6 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "350 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "130 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for females)",
                "CRP": "20 mg/L (< 3 mg/L)",
                "ESR": "38 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "BCR-ABL fusion gene",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Bone Marrow Cell Morphologic Examination": "Significant bone marrow proliferation, increased granulocytic hematopoiesis, presence of Ph chromosome and Bcr-Abl fusion gene",
            "Molecular Examination": "Positive for BCR-ABL fusion gene",
            "Cytogenetic Examination": "Presence of Philadelphia chromosome",
            "Biochemical Examination": "Elevated serum lactate dehydrogenase and uric acid levels",
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Normal",
            "Serological Diagnosis": "Suggestive of chronic myeloid leukemia",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative for viral infections"
        },
        "Treatment Plan": "Helen Zhang has been diagnosed with chronic myeloid leukemia, a condition affecting her hematopoietic system. Given her current moderate severity stage, the treatment will primarily focus on the administration and management of tyrosine kinase inhibitors to control disease progression. Imatinib will be initiated, which is effective against the Bcr-Abl fusion gene driving the disease. Helen will need to adhere strictly to her medication regimen and visit regularly for monitoring her hematologic, cytogenetic, and molecular responses, as well as any potential side effects, including fatigue and gastrointestinal discomfort. While imatinib provides a high disease control rate, Helen will be educated about the importance of maintaining consistent medication adherence and will be informed about potential long-term side effects. Regular follow-ups will involve biochemical examinations to detect any drug-induced complications, alongside cardiovascular monitoring given potential risks associated with second or third-generation inhibitors. Should Helen's condition advance beyond the current stage or should she develop intolerance, the treatment may be modified to include second-generation alternatives like dasatinib or nilotinib. In extreme cases of progression, consultation regarding possible allogeneic hematopoietic stem cell transplantation will be considered, depending on her response to ongoing treatments. Helen will be encouraged to maintain a balanced diet, avoid exposure to radiation or harmful chemicals, and engage in moderate exercise to bolster overall health. Psychological support from family and health professionals is recommended to help alleviate any stress associated with living with CML, and she will be advised to avoid any unverified alternative therapies that may interfere with her treatment plan. Regular communication with her healthcare provider is essential to modulate treatment based on her progress and any side effects encountered."
    },
    {
        "Patient Information": {
            "Name": "Henry Thompson",
            "Age": "68",
            "Gender": "Male",
            "Medical History": "Hypertension, benign prostatic hyperplasia, history of family prostate cancer"
        },
        "Disease Information": {
            "Disease": "Prostate Cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Frequent urination, difficulty urinating, pelvic discomfort, erectile dysfunction",
            "Duration": "Symptoms gradually worsened over the past three months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.7 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "45% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.77 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.44 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Prostate-specific antigen (PSA)": "15 ng/mL (0 − 4)",
                "Ferritin": "220 ng/mL (20 − 500 for males)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "18 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Prostate Ultrasound": "Hypoechoic nodules in the prostate gland",
            "MRI Scan": "Localized prostate irregularity with no signs of metastasis",
            "Biopsy": "Presence of adenocarcinoma cells, Gleason score 6",
            "Pelvic X-ray": "No evidence of bone metastasis",
            "Rectal Examination": "Hard nodules detected in prostate"
        },
        "Treatment Plan": "Henry Thompson has been diagnosed with prostate cancer, characterized by moderate severity symptoms such as frequent urination and erectile dysfunction. Given the localized nature of the cancer, radical prostatectomy is recommended as the primary treatment strategy, alongside a comprehensive evaluation to ensure the cancer is contained within the prostate. Considering the patient's age and general health, minimally invasive laparoscopic surgery or robotic-assisted surgery are preferred for efficient recovery and reduced postoperative trauma. Post-surgery, hormone therapy will be administered using anti-androgen drugs to prevent cancer recurrence and manage potential cancer cell activity. Regular postoperative care, including routine PSA monitoring and follow-up examinations every three months, is crucial for tracking the patient's progress and ensuring successful treatment outcomes. Pain management will be addressed with prescribed medications, while lifestyle adjustments, including dietary modifications and exercise, will support overall health and recovery. Psychological support and education regarding lifestyle changes and adherence to follow-up schedules will be provided to Henry and his family, promoting a positive outlook and ensuring optimal long-term management. Nutritional counseling and support for maintaining a healthy weight will be endorsed to enhance recovery and prevent further complications. Henry will be encouraged to participate in non-strenuous activities to maintain physical fitness and reduce stress, with close monitoring for any signs of cancer progression or treatment side effects."
    },
    {
        "Patient Information": {
            "Name": "Robert Johnson",
            "Age": "67",
            "Gender": "Male",
            "Medical History": "Hypertension, Family history of prostate cancer"
        },
        "Disease Information": {
            "Disease": "Prostate Cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Frequent urination, difficulty urinating, pelvic discomfort, erectile dysfunction",
            "Duration": "Symptoms have gradually developed over the past six months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "6.4 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.7 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.3 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "9.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "250 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "Prostate-Specific Antigen (PSA)",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Prostate-Specific Antigen (PSA) Test": "Elevated",
            "Digital Rectal Examination": "Presence of irregular nodules",
            "Prostate Biopsy": "Presence of cancer cells with Gleason score indicating moderate aggressiveness",
            "Rectal Ultrasound": "Detects hypoechoic nodules",
            "Bone Scan": "No signs of bone metastasis",
            "Computed Tomography (CT)": "Localized mass within prostate",
            "Magnetic Resonance Imaging (MRI)": "Localized prostate tumor with no signs of spread"
        },
        "Treatment Plan": "Robert Johnson has been diagnosed with moderately severe prostate cancer. The cancer cells have been confirmed by biopsy with a moderate Gleason score, indicating moderate aggressiveness but no evidence of metastasis. Treatment will begin with radical prostatectomy, aiming to remove the prostate gland along with adjacent seminal vesicles while reconstructing the urinary tract. A laparoscopic approach will be utilized for minimal invasiveness and quicker recovery. Post-surgical care includes attention to incision care to prevent infection and pain management using non-aspirin analgesics. Hormone therapy will be considered as an adjunctive treatment to reduce androgen levels and inhibit tumor growth. The patient will be closely monitored with regular PSA tests to ensure the success of the treatment and detect any signs of recurrence. Radiotherapy may be employed if further local control is needed. Dietary modifications, including a reduction of high-fat foods, combined with moderate exercise are recommended to enhance recovery and overall health. Support from family is crucial during this period to ensure Robert maintains an optimistic outlook and adheres to the treatment regimen. Follow-up examinations will be crucial to track progress and adjust the treatment plan as necessary."
    },
    {
        "Patient Information": {
            "Name": "James Thompson",
            "Age": "68",
            "Gender": "Male",
            "Medical History": "Hypertension, Benign Prostatic Hyperplasia"
        },
        "Disease Information": {
            "Disease": "Prostate Cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Frequent urination, difficulty urinating, pelvic discomfort, erectile dysfunction",
            "Duration": "Symptoms have been gradually worsening over the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "90 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "6 mg/L (< 3 mg/L)",
                "ESR": "10 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Prostate Specific Antigen (PSA)",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Prostate-Specific Antigen (PSA)": "8.0 ng/mL (Normal < 4.0 ng/mL)",
            "Digital Rectal Examination": "Prostate enlargement with nodular hard areas",
            "Transrectal Ultrasound": "Detection of hypoechoic nodules within the prostate",
            "Prostate Biopsy": "Presence of malignant cells, Gleason score 7",
            "Bone Scan": "No evidence of metastasis",
            "CT Scan": "Prostate enlargement with irregular contours",
            "MRI": "Prostate capsule breach without distant metastasis",
            "Chest X-ray Exam": "Normal",
            "Serological Diagnosis": "Normal",
            "Allergen Test": "Normal",
            "Pulmonary Function Test": "Normal gas exchange",
            "Eosinophil Count in Sputum": "Normal"
        },
        "Treatment Plan": "James Thompson has been diagnosed with moderately aggressive prostate cancer. Due to the localized nature of the cancer and current symptoms, a combination of treatment strategies is recommended to manage his condition efficiently. The initial treatment approach will involve a radical prostatectomy whereby the prostate and any potentially affected nearby tissues will be surgically removed. This option is preferred due to its effectiveness in treating localized cancer within the prostate. Pre-surgical evaluation will include a thorough assessment of James's overall health and fitness for surgery. Post-surgery, James will be closely monitored for any signs of recurrence, primarily through regular follow-up examinations and PSA level testing. Hormone therapy may be considered in the case of cancer recurrence, involving medications like bicalutamide to block testosterone effects, as prostate cancer cells rely significantly on androgens for growth. Radiation therapy will be evaluated as a potential adjunctive treatment to target any residual cancer cells while minimizing impacts on healthy tissues. It is crucial for James to adhere to lifestyle modifications, including maintaining a balanced diet, engaging in moderate physical activity, and avoiding smoking and excessive alcohol consumption to support overall health and recovery. Psychological support and regular communication with healthcare providers will empower James in managing his health optimally, ensuring any concerns are addressed timely. Nutritional counseling and interventions will be implemented based on James's needs post-surgery, with the goal of preventing weight loss and promoting recovery while adhering to regular medical consultations to monitor his progress and make necessary adjustments to the treatment plan."
    },
    {
        "Patient Information": {
            "Name": "Lily O'Hara",
            "Age": "46",
            "Gender": "Female",
            "Medical History": "Family history of breast cancer, obesity, excessive alcohol consumption"
        },
        "Disease Information": {
            "Disease": "Breast Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Breast lump, nipple discharge, axillary lymphadenopathy, unexplained weight loss, fatigue, and anemia",
            "Duration": "Symptoms have progressively worsened over the last 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "29 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "110 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "95 U/L (22 − 198 for females)",
                "Myoglobin": "60 ng/mL (< 70 ng/mL)",
                "Troponin I": "9 ng/L (< 14 ng/L)",
                "Ferritin": "150 ng/mL (15 − 150 for females)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Mammography": "Irregular mass with microcalcifications in the upper outer quadrant of the right breast",
            "Ultrasound": "Hypoechoic lesion in the right breast with irregular borders",
            "MRI": "Enhanced uptake in the right breast mass indicating potential malignancy",
            "Biopsy": "Invasive ductal carcinoma confirmed",
            "Immunohistochemistry": "HER-2 positive, ER positive, PR positive",
            "Tumor Marker Tests": "Elevated CA15-3 levels",
            "Chest X-ray": "Clear",
            "Bone Scan": "No evidence of metastatic bone disease",
            "Liver Function Test": "Normal",
            "Brain MRI": "Normal"
        },
        "Treatment Plan": "Lily O'Hara has been diagnosed with invasive ductal carcinoma of the breast, and the treatment plan will involve a multidisciplinary approach. Given the HER-2 positive status, targeted therapy with trastuzumab is recommended to inhibit oncogenic signaling and reduce tumor growth, in conjunction with chemotherapy using anthracycline and taxane-based regimens to address systemic micrometastatic disease. Endocrine therapy with tamoxifen will be administered due to ER and PR positive receptor status to prevent estrogen-driven growth of cancer cells. Surgical management will consist of a modified radical mastectomy to remove the tumor and affected tissues, preserving overall function and appearance, with potential lymph node dissection to assess regional involvement. Post-operative radiation therapy will target any residual cancer cells in the chest area to prevent local recurrence. Lily will receive comprehensive health education to empower her, with psychological support emphasized to manage the emotional impact of the diagnosis. Nutritional guidance to maintain a healthy weight and lifestyle changes, including regular physical activity and cessation of alcohol use, will be integral to the plan to further reduce recurrence risk. Regular follow-ups are crucial to monitor treatment efficacy, with imaging tests and blood marker evaluations planned periodically to detect any signs of disease progression or recurrence. Lily will be educated on breast self-examination techniques to help recognize changes timely, facilitating prompt intervention if needed. This comprehensive regimen aims to maximize her chances of remission and optimize her quality of life."
    },
    {
        "Patient Information": {
            "Name": "Yuan Li",
            "Age": "48",
            "Gender": "Female",
            "Medical History": "Family history of breast cancer, early menarche at age 11"
        },
        "Disease Information": {
            "Disease": "Breast Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Breast lump in the upper outer quadrant, peau d'orange skin changes, axillary lymphadenopathy, nipple discharge",
            "Duration": "Symptoms noticed over the past 3 months, progressively worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.4 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "68% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.6 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.4 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.3 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "90 U/L (22 − 198 for females)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "< 14 ng/L",
                "Ferritin": "100 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "22 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "BRCA mutation test",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Mammography": "Irregular mass with spiculated margins in the upper outer quadrant",
            "Breast Ultrasound": "Hypoechoic lesion with irregular borders measuring 4 cm in the upper outer quadrant, axillary lymph node enlargement",
            "MRI": "Multifocal masses in the right breast, suggestive of invasive ductal carcinoma",
            "Biopsy": "Positive for malignancy, invasive ductal carcinoma",
            "Tumor Marker Tests": "Elevated CA 15-3 and CEA levels",
            "Immunohistochemistry": "ER positive, PR positive, HER-2 negative, Ki-67 moderately elevated",
            "PET Scan": "No distant metastasis detected",
            "Chest X-ray": "Unremarkable",
            "Bone Scan": "No evidence of bone metastasis",
            "Liver Ultrasound": "Normal"
        },
        "Treatment Plan": "Yuan Li has been diagnosed with invasive ductal carcinoma of the breast, presenting with a large tumor mass and axillary lymph node involvement, categorized under major severity due to the current size and symptoms. The treatment plan will involve a comprehensive and multidisciplinary approach, starting with neoadjuvant chemotherapy to reduce the tumor size, utilizing anthracycline-based regimens combined with taxanes to maximize effectiveness. This will be followed by surgical intervention; a breast-conserving surgery if feasible, or otherwise a total mastectomy might be necessary based on the tumor response to chemotherapy and personal preference regarding breast conservation. Post-surgery, adjuvant chemotherapy and radiotherapy will be administered to mitigate recurrence risk, especially since the lymph nodes are involved. Endocrine therapy will be a crucial component due to ER and PR positivity, likely starting with tamoxifen or an aromatase inhibitor post-menopause to target hormone-driven proliferation. Yuans's care will include stringent follow-up and monitoring via mammography and ultrasound at recommended intervals to track response and adjust the therapeutic approach if needed. A robust support system involving counseling and rehabilitation will be provided to address any psychological and physical challenges, aiding in coping and recovery. Lifestyle modifications focusing on nutrition and regular physical activity will be advised to enhance overall health and well-being, with cessation of smoking and reduction in alcohol intake emphasized to minimize further risk."
    },
    {
        "Patient Information": {
            "Name": "Olivia Johnson",
            "Age": "47",
            "Gender": "Female",
            "Medical History": "Family history of breast cancer, obesity, early menarche"
        },
        "Disease Information": {
            "Disease": "Breast Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Breast lump with irregular edges, nipple discharge, swollen axillary lymph nodes, fatigue, weight loss",
            "Duration": "Symptoms have been present and worsening over the past six months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.4 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "68% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.32 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.08 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.44 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.15 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500)",
                "CRP": "12 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Breast Ultrasound": "Presence of irregular hypoechoic mass in the upper outer quadrant of the right breast",
            "Mammography": "Dense breast tissue with visible calcifications in the mass area",
            "Biopsy": "Invasive ductal carcinoma confirmed",
            "Tumor Marker Tests": "Elevated CA15-3 levels",
            "Immunohistochemistry": "HER-2 positive, ER positive, PR positive",
            "Chest Computerized Tomography": "No evidence of distant metastasis",
            "MRI Scan": "Multifocal lesion within the breast tissue"
        },
        "Treatment Plan": "Olivia Johnson has been diagnosed with invasive ductal carcinoma, which warrants a comprehensive treatment approach tailored to her condition and her predisposing factors, including family history and obesity. Given the HER-2 positive status, she will undergo targeted therapy with trastuzumab to specifically interfere with tumor growth. Surgery remains the cornerstone of her treatment, and a modified radical mastectomy is planned to ensure complete removal of affected breast tissue and regional lymph nodes, given the presence of axillary lymphadenopathy. Following surgery, adjuvant chemotherapy with a regimen including taxanes and anthracyclines will be initiated to eradicate microscopic residual disease and reduce recurrence risks. Endocrine therapy will also be integrated, aiming to inhibit estrogen's influence due to ER and PR positivity. Regular blood tests, imaging studies, and tumor marker monitoring will be essential in evaluating the efficacy of the treatment and adjusting protocols as necessary. Psychosocial support and lifestyle modifications are critical, promoting a balanced diet, regular physical activity, and emotional well-being throughout the treatment journey. Olivia will be closely monitored for potential side effects of the various therapies, especially considering the cardiovascular risks associated with trastuzumab, and she will be educated on the importance of adherence to the treatment plan and the significance of follow-up care to ensure optimal recovery and long-term prognosis."
    },
    {
        "Patient Information": {
            "Name": "Emily Johnson",
            "Age": "23",
            "Gender": "Female",
            "Medical History": "No significant medical history"
        },
        "Disease Information": {
            "Disease": "Breast Fibroadenoma",
            "Severity Level": "Minor Severity",
            "Symptoms": "Round, smooth, well-defined, and mobile painless lump in the breast tissue, occasionally a sense of fullness or dull pain related to the menstrual cycle",
            "Duration": "The lump was discovered during a self-exam one month ago and has remained the same size",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "25 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "20 IU /L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "0.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "120 U/L (22 − 198 for females)",
                "Myoglobin": "45 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "40 ng/mL (12 − 150 for females)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "10 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Breast Ultrasound": "A well-circumscribed, encapsulated hypoechoic area consistent with fibroadenoma",
            "Mammogram": "Not applicable",
            "MRI Exam": "Not conducted",
            "Fine-needle Aspiration Cytology": "Non-malignant epithelial and stromal cells observed",
            "Additional Scans": "Not performed",
            "Pathology Report": "Consistent with simple fibroadenoma, negative for cancerous cells"
        },
        "Treatment Plan": "Emily Johnson is diagnosed with a simple breast fibroadenoma, presenting as a minor severity condition. Due to the benign nature of the fibroadenoma and the absence of any alarming features, the recommended approach is conservative management through regular follow-up observation. Emily should have a breast ultrasound every six months to monitor any changes in the size or characteristics of the fibroadenoma. There is no immediate indication for surgical intervention, as the fibroadenoma has not shown signs of rapid growth and remains asymptomatic other than occasional mild discomfort associated with her menstrual cycle. Lifestyle modifications are also advised, including maintaining a balanced diet rich in high-protein and low-fat foods, avoiding caffeine and alcohol, ensuring adequate hydration, managing stress, and engaging in regular exercise to support her overall health. Emily will be educated on how to perform self-examinations to monitor the fibroadenoma and instructed to report any significant changes in size, texture, or associated symptoms. Should there be any rapid enlargement or additional concerning features in the future, a re-evaluation and potential minimally invasive surgical options may be considered. Annual breast checkups are recommended to ensure early detection and management of any new developments."
    },
    {
        "Patient Information": {
            "Name": "Emily Thompson",
            "Age": "23",
            "Gender": "Female",
            "Medical History": "No significant medical history; regular menstrual cycles; occasional breast tenderness during menstruation."
        },
        "Disease Information": {
            "Disease": "Breast Fibroadenoma",
            "Severity Level": "Minor Severity",
            "Symptoms": "Painless, movable lump in the breast, noticed when bathing; occasional fullness during menstrual cycle.",
            "Duration": "Lump has been present for approximately 6 months without significant change in size.",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "29 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "25 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "55% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.75 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.75 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.15 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "3% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198 for females)",
                "Myoglobin": "55 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "150 ng/mL (20 − 500 for females)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Negative",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Breast Ultrasound Exam": "Well-circumscribed, oval, hypoechoic lesion measuring 2 cm in diameter, with no signs of malignancy.",
            "Breast MRI": "Not performed",
            "Mammogram": "Not indicated for current age and breast density",
            "Fine Needle Aspiration Cytology": "Confirmed benign fibroadenoma without atypical cells.",
            "Core Needle Biopsy": "Not performed, due to benign features on ultrasound and cytology."
        },
        "Treatment Plan": "Emily Thompson has been diagnosed with a minor severity breast fibroadenoma, characterized by a painless and movable lump in the breast. Given the benign nature and slow growth of the fibroadenoma, a conservative management approach through regular follow-up observation every six months is recommended. Emily should undergo periodic breast ultrasounds to monitor any changes in the fibroadenoma's size and characteristics. Surgical intervention is not necessary unless there is significant growth or changes indicating potential malignancy. Patients are advised to maintain a balanced diet rich in proteins, vitamins, and low in fats, and to avoid alcohol and caffeine, which may exacerbate symptoms. Regular exercise and a positive mental outlook are crucial in managing fibroadenomas. Emily is encouraged to perform self-examinations post-menstruation for any size alterations or discomfort. Education on fibroadenoma and its management will be provided. Should rapid growth or unusual symptoms occur, timely consultation with a breast specialist is essential to reassess the treatment plan and consider surgical options if necessary."
    },
    {
        "Patient Information": {
            "Name": "Hannah Simmons",
            "Age": "23",
            "Gender": "Female",
            "Medical History": "No significant medical history"
        },
        "Disease Information": {
            "Disease": "Breast Fibroadenoma",
            "Severity Level": "Minor Severity",
            "Symptoms": "Painless, movable breast lump, occasionally full and dull ache around menstrual cycle",
            "Duration": "Lump has been present for several months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.6 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.4 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.65 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.15 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "125 U/L (22 − 198 for females)",
                "Myoglobin": "45 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "80 ng/mL (20 − 300 for females)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Breast Ultrasound": "Oval, well-circumscribed hypoechoic area indicating fibroadenoma",
            "Mammogram": "Not recommended for current patient age",
            "Breast MRI": "Not applicable",
            "Fine-Needle Aspiration": "Benign epithelial and stromal cells consistent with fibroadenoma",
            "Core Needle Biopsy": "Not performed",
            "Excisional Biopsy": "Not indicated",
            "Frozen Section": "Not applicable",
            "Pathology": "Consistent with simple fibroadenoma",
            "Breast X-ray": "Oval, clearly defined high-density shadow"
        },
        "Treatment Plan": "Hannah Simmons has been diagnosed with a simple fibroadenoma, a benign breast condition that is common for her age group. Given the minor severity of her symptoms and the stable nature of the lump over the past several months, the recommended course of action is follow-up observation rather than immediate surgical intervention. Hannah is advised to have a breast ultrasound every six months to monitor any changes in the size or characteristics of the fibroadenoma. No medication is currently necessary, as these lumps rarely become malignant and pose low risk if carefully observed. Hannah is encouraged to maintain a balanced diet rich in vegetables and fruits, and to avoid high-fat foods which may burden the breasts. She is also advised to limit alcohol and caffeine consumption, as these can affect estrogen levels. Regular physical activity and stress management will support her general well-being and potentially prevent further growth of the fibroadenoma. In the event of significant changes in the fibroadenoma's size or symptoms, consultation with her healthcare provider will be essential to reassess and potentially modify her treatment plan."
    },
    {
        "Patient Information": {
            "Name": "Emily Thompson",
            "Age": "47",
            "Gender": "Female",
            "Medical History": "No prior history of breast disease; occasional alcohol consumption; history of late childbirth at age 32"
        },
        "Disease Information": {
            "Disease": "Breast Tumor (Malignant - Breast Cancer)",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless breast lump, local skin dimpling, axillary lymph node enlargement",
            "Duration": "Symptoms have been present for approximately 3 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.1 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.6 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "64% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "9% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "150 ng/mL (20 − 500)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "22 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Examination": "Hypoechoic mass with irregular borders in the upper outer quadrant of the right breast",
            "Mammography": "Dense lump with spiculated margins in the right breast",
            "MRI": "Multifocal high signal intensity masses in the right breast, suggestive of breast cancer",
            "Fine Needle Aspiration": "Positive for malignant cells",
            "Core Needle Biopsy": "Invasive ductal carcinoma",
            "Excisional Biopsy": "Confirmed invasive ductal carcinoma with clear margins",
            "Tumor Marker Test": "Elevated CA 15-3 levels",
            "Sentinel Lymph Node Biopsy": "Positive for cancer cells",
            "Breast Cancer Genetic Test": "Positive for BRCA1 mutation"
        },
        "Treatment Plan": "Emily Thompson has been diagnosed with invasive ductal carcinoma of the right breast with axillary lymph node involvement, necessitating a comprehensive treatment approach. Given the major severity of her condition, a surgical intervention via modified radical mastectomy is recommended to effectively remove the tumor and prevent further spread, followed by axillary lymph node dissection to address lymph node metastasis. Post-surgical chemotherapy with an anthracycline combined with a taxane regimen will be initiated to target residual cancer cells, with cyclophosphamide and doxorubicin being used in conjunction with paclitaxel, coupled with regular monitoring through blood tests to ensure adequate liver and kidney function. Radiation therapy will be considered based on the results of post-surgical histological analysis to reduce the risk of local recurrence, focusing on the chest wall and regional lymph nodes. Due to the presence of the BRCA1 mutation, endocrine therapy with tamoxifen or aromatase inhibitors such as anastrozole will be employed to limit estrogen receptor-positive cancer cell growth. Additionally, targeted therapy using trastuzumab will be administered given the HER2 expression, with cardiac monitoring in place due to potential cardiac toxicity. Nutritional support and psychosocial care will be provided to ensure holistic management of her condition, with regular follow-ups scheduled to monitor treatment response and adjust accordingly. Emily's adherence to the treatment protocol, lifestyle adjustments including increased physical activity and dietary modifications, and vigilance in recognizing signs of deterioration are crucial for optimal management and recovery. Her family will be educated on the importance of emotional support during this journey, ensuring Emily's transition into post-treatment rehabilitation with a focus on recovery and long-term health benefits."
    },
    {
        "Patient Information": {
            "Name": "Natalie Thompson",
            "Age": "47",
            "Gender": "Female",
            "Medical History": "No previous history of breast disease, has experienced occasional hormonal imbalances"
        },
        "Disease Information": {
            "Disease": "Breast Tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless lump in breast, local skin dimpling, axillary lump, occasional nipple discharge",
            "Duration": "Symptoms have been noticeable over the past two months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "72 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.4 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "62% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.54 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.4 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "175 U/L (22 − 198 for females)",
                "Myoglobin": "45 ng/mL (< 90 ng/mL)",
                "Troponin I": "5 ng/L (< 14 ng/L)",
                "Ferritin": "130 ng/mL (15 − 150 for females)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.05 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Tumor Marker CA 15-3": "30 U/mL (< 30)",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Mammography": "Dense mass with irregular borders, suggestive of malignancy",
            "Breast Ultrasound": "Hypoechoic lesion with spiculated margins",
            "Breast MRI": "Enhanced lesion with multifocal appearances",
            "Fine Needle Aspiration": "Atypical ductal hyperplasia with suspicious cells",
            "Core Needle Biopsy": "Invasive ductal carcinoma",
            "Chest X-ray": "No evidence of metastasis",
            "Bone Scan": "Pending results",
            "Liver Function Test": "Normal",
            "Kidney Function Test": "Normal",
            "Hormone Receptor Status": "ER positive, PR positive, HER2 negative"
        },
        "Treatment Plan": "Natalie Thompson has been diagnosed with an invasive ductal carcinoma in the breast, as confirmed by core needle biopsy results. Given the major severity of her condition and the presence of symptoms such as local skin dimpling and axillary lumps, a comprehensive treatment plan is necessary. The treatment will commence with a modified radical mastectomy to surgically remove the tumor and ensure the removal of potentially involved lymph nodes. Following surgical intervention, chemotherapy involving a taxane-based regimen will be initiated to target any residual malignant cells, in consideration of her early-stage hormone receptor-positive status. Concurrently, Natalie will undergo endocrine therapy with tamoxifen to mitigate the estrogen receptor positivity of the carcinoma, thereby inhibiting its growth. Radiation therapy will be considered post-surgery to reduce the risk of local recurrence, contingent on the results of the surgical pathology report. Throughout treatment, regular follow-ups, including blood tests, imaging, and potentially additional biopsies will be crucial to monitor the treatment response and to adjust the therapy plan as needed. Natalie will be advised on lifestyle modifications, including dietary adjustments and regular physical activity, to support her overall health and improve treatment outcomes. Psychological support and counseling will also be offered to help her cope with the diagnosis and treatment process, ensuring a holistic approach to her recovery. Adherence to the treatment plan will be emphasized to achieve the best possible prognosis, with Natalie being educated about the importance of regular check-ups and self-examinations to detect any changes early on. Additionally, genetic counseling may be considered to evaluate potential hereditary risk factors and to guide future preventive strategies for her and her family members."
    },
    {
        "Patient Information": {
            "Name": "Emily Johnson",
            "Age": "45",
            "Gender": "Female",
            "Medical History": "Family history of breast cancer, occasional alcohol consumption"
        },
        "Disease Information": {
            "Disease": "Malignant Breast Tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless breast lump, dimpled skin, peau d'orange changes, axillary lump indicating lymph node involvement",
            "Duration": "Symptoms have been persisting and worsening over the past few weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "90 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.6 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Negative",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Mammogram": "Irregular spiky edges and increased density in the breast lump",
            "Breast Ultrasound": "Presence of a solid mass with irregular borders",
            "MRI Scan": "Indicates multifocal breast cancer",
            "Fine Needle Aspiration": "Confirms malignant cells",
            "Core Biopsy": "Positive histological diagnosis for breast cancer",
            "Hormone Receptor Test": "Positive for estrogen receptor",
            "HER2 Test": "Positive",
            "Lymph Node Examination": "Enlarged axillary lymph nodes",
            "CT Scan": "No evidence of distant metastasis",
            "Bone Scan": "Normal",
            "Liver Function Test": "Normal",
            "Serum Tumor Marker Test": "Elevated carcinoembryonic antigen"
        },
        "Treatment Plan": "Emily Johnson has been diagnosed with a malignant breast tumor with major severity, as evidenced by the presence of a painless lump with dimpled skin and axillary lymph node involvement. Immediate surgical intervention is recommended, with options including breast-conserving surgery or modified radical mastectomy, depending on the tumor's characteristics and Emily's preferences. Given the estrogen receptor positivity and HER2 overexpression, a comprehensive treatment plan will include endocrine therapy with tamoxifen and targeted therapy with trastuzumab to address the hormone receptor status. Preoperative chemotherapy may be considered to shrink the tumor, and post-operative radiotherapy will be employed to minimize recurrence risks. Supporting treatments include analgesics for pain management post-surgery, and regular monitoring of blood counts and liver function tests during chemotherapy cycles. Emily is advised to maintain regular follow-ups post-treatment every six to twelve months, incorporating imaging examinations to monitor potential recurrence. Her cooperation with this planned regimen is crucial in optimizing recovery and preventing further metastasis. In addition, lifestyle modifications such as regular exercise and dietary adjustments to avoid high-fat foods are recommended to aid in recovery and reduce recurrence risk."
    },
    {
        "Patient Information": {
            "Name": "Emily Thompson",
            "Age": "35",
            "Gender": "Female",
            "Medical History": "History of hydatidiform mole pregnancy, recent miscarriage"
        },
        "Disease Information": {
            "Disease": "Choriocarcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Abnormal vaginal bleeding, elevated serum hCG levels, presence of lung metastasis symptoms such as dyspnea and chest pain",
            "Duration": "Symptoms have been persistent for approximately 8 weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "68 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "240 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for females)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Evidence of small nodular opacities in bilateral lung fields",
            "Chest Computerized Tomography": "Multiple small nodular opacities consistent with metastatic disease",
            "Serological Diagnosis": "Elevated serum hCG levels",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Mild impairment due to lung metastasis",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Normal",
            "Pulmonary Function Test": "Mild obstruction",
            "Nucleic Acid Amplification Test": "Negative for common pathogens",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Emily Thompson has been diagnosed with major severity choriocarcinoma, exhibiting persistent abnormal vaginal bleeding and symptoms of lung metastasis. Immediate initiation of chemotherapy is recommended, utilizing a combination regimen tailored to her specific condition, including methotrexate and actinomycin D, to effectively target the malignant cells and manage metastatic spread, particularly to lung tissue. Strict monitoring of blood hCG levels will guide treatment efficacy and intervals of chemotherapy administration, anticipated to extend over several weeks with necessary adjustments. Due to the metastatic involvement of the lungs, adjunctive thoracic radiotherapy may be considered to alleviate respiratory symptoms and reduce tumor burden, complemented by supportive care to manage chemotherapy-induced side effects such as nausea and gastrointestinal discomfort. Follow-up imaging studies, including CT scans of the chest, liver, and brain, will be integral in assessing response to treatment and potential disease progression. Contraceptive measures are crucial during and post-treatment, with strict adherence to follow-up schedules for ongoing evaluation and potential further intervention if resistance or recurrence is noted. Emily and her healthcare team will work closely to manage symptoms, adhere to the chemotherapy protocol, and explore surgical options if necessary to remove resistant lesions. Psychological support and counseling will be provided to Emily to assist in coping with the emotional and physical challenges of her diagnosis and treatment journey."
    },
    {
        "Patient Information": {
            "Name": "Grace Williams",
            "Age": "35",
            "Gender": "Female",
            "Medical History": "Previous history of molar pregnancy"
        },
        "Disease Information": {
            "Disease": "Choriocarcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Abnormal vaginal bleeding, elevated serum hCG, uterine subinvolution, lung metastasis symptoms like cough and chest pain",
            "Duration": "Symptoms have been ongoing for the past two months with increasing intensity",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.8 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for females)",
                "Myoglobin": "60 ng/mL (< 70 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "200 ng/mL (10 − 120 for females)",
                "CRP": "4 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Pelvic Ultrasound": "Enlarged uterus with evidence of retained products",
            "Chest X-ray Exam": "Nodules in lung fields suggestive of metastasis",
            "Chest Computerized Tomography": "Multiple lung nodules indicating metastasis",
            "Serological Diagnosis": "Elevated hCG levels confirmed",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Brain MRI": "No evidence of metastasis",
            "Abdominal Ultrasound": "Normal liver and kidney morphology",
            "Gynecological Examination": "Signs of uterine subinvolution",
            "Blood hCG Level": "Extremely elevated, consistent with choriocarcinoma"
        },
        "Treatment Plan": "Grace Williams has been diagnosed with choriocarcinoma, a highly malignant trophoblastic tumor, with symptoms suggesting lung metastasis and a significantly elevated hCG level. The primary treatment plan involves initiating a chemotherapy regimen tailored to Grace's specific condition, considering her major severity diagnosis. Chemotherapy drugs such as methotrexate and dactinomycin will be administered, with close monitoring for effectiveness and potential side effects. Follow-up blood tests will be conducted to track hCG levels, evaluating the treatment's impact on tumor activity. Given the presence of lung metastases, additional imaging and potential surgical intervention will be considered if chemotherapy alone is insufficient in reducing tumor burden. Throughout the treatment, Grace will receive supportive care to manage any adverse effects of chemotherapy, including anti-nausea medications and hematopoietic growth factors if necessary. Strict monitoring for signs of metastasis progression will be maintained, and Grace will be educated on recognizing symptoms that warrant immediate medical attention. Family planning and contraception advice will be provided to prevent conception during and shortly after the treatment period. Regular follow-ups will be scheduled to adjust treatment protocols as needed to ensure the best possible outcomes and timely identification of recurrence or resistance."
    },
    {
        "Patient Information": {
            "Name": "Emily Johnson",
            "Age": "32",
            "Gender": "Female",
            "Medical History": "Previous miscarriage, history of oral contraceptive use"
        },
        "Disease Information": {
            "Disease": "Choriocarcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Abnormal vaginal bleeding, elevated serum hCG, uterine subinvolution, lung metastasis presenting as chest pain and dyspnea",
            "Duration": "Symptoms have persisted for 6 weeks following a miscarriage",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "9% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.02 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "260 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 70 ng/mL)",
                "Troponin I": "5 ng/L (< 14 ng/L)",
                "Ferritin": "200 ng/mL (15 − 150 for females)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Elevated hCG levels",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Presence of small nodular opacities suggestive of lung metastases",
            "Chest Computerized Tomography": "Confirmation of lung nodules and signs of metastatic lesions",
            "Serological Diagnosis": "Elevated serum hCG",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Ultrasound Examination": "Uterine enlargement and suboptimal involution with ovarian cystic changes",
            "Pelvic MRI": "Demonstrates uterine and pelvic lesions consistent with choriocarcinoma",
            "Brain CT/MRI": "No evidence of metastasis",
            "Liver Function Test": "Slightly elevated enzymes",
            "Renal Function Test": "Normal",
            "Echo Examination": "Normal"
        },
        "Treatment Plan": "Emily Johnson has been diagnosed with choriocarcinoma, which is characterized by abnormal vaginal bleeding and metastatic signs in the lungs. Due to the highly malignant nature of this trophoblastic tumor, prompt initiation of chemotherapy is crucial. The treatment plan will be individualized according to the FIGO staging and prognostic scoring guidelines, targeting specifically her diagnosed stage and risk category. Given the major severity of her condition, combination chemotherapy comprising methotrexate, etoposide, and actinomycin D is recommended to aggressively target the malignancy and prevent further metastasis. Surgical intervention may be considered if chemotherapy alone fails to control the disease, or if there is significant risk of drug-resistant lesions or massive hemorrhage. Monitoring and support through regular blood tests, imaging assessments, and monitoring of hCG levels will be essential to evaluate treatment efficacy and adjust therapeutic strategies as needed. Emily is encouraged to adhere strictly to the chemotherapy regimen and follow-up schedule, while ensuring effective contraception is maintained for at least 12 months post-treatment to prevent pregnancy and allow for thorough recovery monitoring. Preventive management of chemotherapy side effects and education on recognizing signs of recurrence or complications are critical components of her care plan, ensuring optimal outcomes and long-term health preservation."
    },
    {
        "Patient Information": {
            "Name": "Linda Taylor",
            "Age": "47",
            "Gender": "Female",
            "Medical History": "No prior significant breast diseases, maintains routine check-ups"
        },
        "Disease Information": {
            "Disease": "Breast Ductal Carcinoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Bloody nipple discharge, palpable breast lump with firm texture, smooth surface and clear boundaries",
            "Duration": "Symptoms have been noticeable for approximately 3 weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.6 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.7 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "90 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "80 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Breast Ultrasound": "Identified dilated ducts with papillary solid echoes within the retro-areola region",
            "Ductography": "Round intraductal filling defects noted with duct dilation",
            "Breast MRI": "Shows a 1 cm intraductal lesion with smooth edges in the retro-areola area alongside duct dilation",
            "Cytology": "Fine needle aspiration cytology reveals benign ductal epithelial cells",
            "Exfoliative Cytology": "Presence of epithelial cells, no tumor cells identified",
            "Fiberoptic Ductoscopy": "Smooth duct walls observed with minor intraductal lesions"
        },
        "Treatment Plan": "Linda Taylor's condition of moderate severity intraductal papilloma demands a precise approach to ensure complete lesion removal while maintaining breast aesthetics. Surgical excision will be performed, focusing on segmental excision under direct ductoscopic visualization, allowing for accurate localization of the affected ducts and limiting the extent of surgical intervention. This approach also reduces scarring. Prior to surgery, preoperative imaging and fine-needle aspiration cytology will guide precise surgical planning. Post-surgery, regular follow-ups with imaging and physical examinations will be scheduled to monitor recovery and check for recurrence. Considering the potential for hormonal influence on papilloma formation, hormone level assessments will be conducted and managed accordingly. Linda is advised to maintain a nutritious diet rich in vitamins and proteins to support recovery while avoiding smoking and alcohol. She will engage in light physical exercises including yoga to aid in maintaining physical and mental wellness. Awareness and regular self-examinations are encouraged to support early detection and treatment of any new changes."
    },
    {
        "Patient Information": {
            "Name": "Emma Johnson",
            "Age": "38",
            "Gender": "Female",
            "Medical History": "No prior significant medical conditions, regular check-ups"
        },
        "Disease Information": {
            "Disease": "Breast ductal carcinoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Nipple discharge, palpable lump in the areola area, occasional tenderness",
            "Duration": "Symptoms have been present for the past 2 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "72 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "95 U/L (22 − 198 for females)",
                "Myoglobin": "55 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "130 ng/mL (20 − 200 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "18 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Breast Ultrasound": "Presence of clear, smooth papillary solid echoes within the dilated duct lumen",
            "Breast MRI": "Round intraductal filling defects with duct dilation",
            "Breast Ductography": "Oval intraductal filling defects noted",
            "Fine Needle Aspiration Cytology": "No malignancy detected",
            "Fiberoptic Ductoscopy": "Direct visualization shows duct dilation with smooth walls, confirming intraductal papilloma"
        },
        "Treatment Plan": "Emma Johnson has been diagnosed with breast ductal papilloma, for which a minimally invasive surgical approach is recommended due to its moderate severity and benign nature. Surgical excision under fiber ductoscopy will ensure the precise removal of affected ducts with minimal scarring, preserving normal breast tissue. This approach is preferable to traditional methods due to its minimal invasiveness and the aesthetic satisfaction it offers post-surgery. Preoperative imaging and ductoscopic localization will guide the surgery, ensuring accurate removal of the papilloma. Post-surgery, Emma will be monitored for potential complications such as bleeding or hematoma and will undergo regular follow-up exams to ensure successful healing and recovery. Additionally, Emma is advised to maintain a healthy lifestyle with regular breast self-examinations and specialized check-ups to promptly identify any changes. Dietary adjustments towards a high-protein, vitamin-rich intake, along with the avoidance of greasy and spicy foods, will be recommended to support her recovery. Keeping a positive mindset and engaging in light physical activities like yoga will aid physical and mental well-being, helping manage stress and anxiety effectively during the treatment and recovery process. Emma is also encouraged to seek regular medical consultations for early detection and treatment of any future breast conditions."
    },
    {
        "Patient Information": {
            "Name": "Emily Johnson",
            "Age": "38",
            "Gender": "Female",
            "Medical History": "No significant medical history; regular self-examinations and routine mammograms; occasional discomfort in the breast and a past incident of nipple discharge"
        },
        "Disease Information": {
            "Disease": "Breast ductal carcinoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Nipple discharge, palpable breast lump, tenderness in the breast area",
            "Duration": "Symptoms have been present for approximately three months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.6 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "90 U/L (22 − 198 for females)",
                "Troponin I": "5 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (15 − 150 for females)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "58 μg/L (50 − 150)"
            },
            "Breast Ultrasound": "Presence of clear, smooth papillary solid echoes within the dilated duct lumen in the retro-areola region",
            "Breast MRI": "Round intraductal lesion approximately 1 cm in diameter located in the retro-areola region with duct dilation, no evidence of malignancy",
            "Ductography": "Oval intraductal filling defect with duct dilation",
            "Biopsy": "Benign papilloma tissue, no signs of malignancy",
            "Fiberoptic Ductoscopy": "Visualization of duct dilation with smooth walls",
            "Cytology": "No malignant cells detected in nipple discharge",
            "Hormonal Profile": "Estrogen levels within normal range"
        },
        "Treatment Plan": "Emily Johnson has been diagnosed with a moderate severity intraductal papilloma of the breast. Given her symptoms of nipple discharge and a palpable lump, surgical intervention is recommended to remove the papilloma and prevent potential malignant transformation. Minimally invasive surgery under fiber ductoscopy is the preferred approach, offering precise localization and excision with minimal scarring. Emily will undergo a ductoscopic-based excision procedure, ensuring complete removal of the lesion with preservation of healthy breast tissue. Postoperative care will include monitoring for signs of complications such as bleeding or hematoma formation, and regular follow-up appointments for evaluation and breast ultrasounds to ensure proper healing and any recurrence detection. Emily is advised to maintain a balanced diet rich in fruits, vegetables, and proteins, avoid smoking and alcohol, and engage in regular physical activity to support overall health. Breast self-examinations will be emphasized as part of her ongoing health monitoring plan, along with routine mammograms. Psychological support may be provided to alleviate anxiety related to the condition and treatment process. Emily’s adherence to the treatment plan and follow-up care will be crucial for effective management and recovery, with continued monitoring for any changes in breast health."
    },
    {
        "Patient Information": {
            "Name": "John Zhang",
            "Age": "67",
            "Gender": "Male",
            "Medical History": "Chronic gastroesophageal reflux disease, Barrett's esophagus, and a long history of smoking and alcohol consumption."
        },
        "Disease Information": {
            "Disease": "Esophageal cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Progressive dysphagia, persistent pain behind the sternum, significant weight loss, intermittent hematemesis, and back pain",
            "Duration": "Symptoms have been progressively worsening over the past 6 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "29 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "79 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mild esophageal dilation with no visible pulmonary metastasis",
            "Chest Computerized Tomography": "Circumferential thickening of the esophagus with no distant metastasis",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "No viral or bacterial pathogens detected",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "John Zhang has been diagnosed with advanced esophageal cancer characterized by progressive dysphagia, significant weight loss, and persistent sternum pain. Given the major severity of the condition and the involvement of surrounding tissues, a comprehensive treatment plan including chemoradiotherapy is essential. Immediate initiation of neoadjuvant chemotherapy is recommended to shrink the tumor and address potential micrometastases, using a combination of cisplatin and 5-fluorouracil, which are standard for squamous cell carcinoma. Concurrent radiotherapy should be planned to maximize tumor response. Surgical resection may be considered based on the response to initial treatment and re-evaluation of the tumor staging. Nutritional support is critical due to significant weight loss, with a focus on enteral nutrition via gastrostomy feeding to maintain calorie intake and nutritional status. Regular monitoring of blood chemistry and imaging to assess the treatment response is vital, with potential adjustments to the chemotherapy regimen depending on tolerance and efficacy. John and his family should be counseled on the importance of adherence to the treatment regimen and recognizing symptoms of potential complications. Psychological support and palliative care options should be discussed to manage pain and improve quality of life during treatment. Post-treatment follow-ups will be essential to monitor his condition and make timely modifications to his treatment plan as necessary."
    },
    {
        "Patient Information": {
            "Name": "Li Wei",
            "Age": "62",
            "Gender": "Male",
            "Medical History": "Chronic gastroesophageal reflux disease, high alcohol consumption, heavy smoking"
        },
        "Disease Information": {
            "Disease": "Esophageal Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Progressive dysphagia, persistent pain behind the sternum, significant weight loss, back pain",
            "Duration": "Symptoms have been progressing over several months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU/L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.7 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.3 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.1 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "190 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.3 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.79 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "CEA (Carcinoembryonic Antigen)",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mediastinal widening and esophageal dilatation",
            "Chest Computerized Tomography": "Thickening of the esophageal wall with narrowing of the lumen",
            "Endoscopic Examination": "Nodular mass with mucosal congestion and narrowing of the esophageal lumen",
            "Endoscopic Ultrasound": "Invasion into the muscularis propria and presence of involved local lymph nodes",
            "Barium Swallow Test": "Irregular narrowing with filling defect in the mid-esophagus",
            "PET-CT": "Localized uptake in the mid-esophagus with nodal involvement",
            "Serum Tumor Marker Test": "Elevated CYFRA21-1, High SCC levels"
        },
        "Treatment Plan": "Li Wei has been diagnosed with major-severity esophageal cancer, which has progressed significantly and is affecting his ability to swallow and causing substantial weight loss. Given the advancement of the disease and Li's overall health condition, a comprehensive treatment plan involving chemoradiotherapy is proposed. Surgery is not currently an option due to the extent of locoregional spread and lymph node involvement. Initial treatment will focus on concurrent chemoradiotherapy aimed at reducing the tumor size and controlling symptoms, with periodic reassessment to evaluate the response to treatment. Primary chemotherapy agents will include cisplatin and 5-fluorouracil, complemented by targeted radiotherapy focused on the esophageal region. Nutritional support will be critical, utilizing enteral nutrition via gastrostomy feeding to ensure Li maintains adequate nutrition and energy levels to withstand treatment. Pain management will be prioritized with appropriate analgesic therapy to improve quality of life, and medication will be administered to manage symptoms such as dysphagia. Throughout this period, frequent monitoring of his blood parameters and imaging will be conducted to track disease progression and adjust treatment protocols accordingly. Post-treatment, if the cancer becomes operable, surgical resection may be reconsidered after careful evaluation. Li's family will be informed on the importance of adhering to the treatment regimen, recognizing signs of complications, and attending regular follow-up consultations. Palliative care interventions, including support for coping with the psychological burden of cancer, will also be integrated into Li's care plan to optimize his quality of life during treatment."
    },
    {
        "Patient Information": {
            "Name": "Li Wei",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Occasional heartburn, chronic gastroesophageal reflux disease (GERD)"
        },
        "Disease Information": {
            "Disease": "Esophageal Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Progressive dysphagia, persistent pain behind the sternum, significant weight loss, burning sensation under the xiphoid",
            "Duration": "Symptoms have been present and worsening over the past six months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "38 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 7.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.7 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.8 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (130 − 175)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.15 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Cytokeratin Fragment 19 (CYFRA21-1)": "3.5 ng/mL (< 3.3)",
                "CEA": "4.0 ng/mL (< 5)",
                "SCC": "2.0 ng/mL (< 1.5)"
            },
            "Endoscopic Examination": "Nodular masses and ulcerations in the thoracic middle segment esophagus",
            "Endoscopic Ultrasound": "Tumor invasion through the full circumference of the esophagus with regional lymph node involvement",
            "PET-CT": "Increased uptake in the middle thoracic esophagus with a few mediastinal lymph nodes",
            "MRI": "Thickening of the esophageal wall consistent with neoplastic infiltration",
            "Barium Swallow X-ray": "Irregular narrowing of the esophageal lumen in the middle segment",
            "CT Scan": "Localized thickening and narrowing of the esophagus with possible lymph node metastasis",
            "Fiberoptic Bronchoscopy": "No invasion of trachea or bronchi"
        },
        "Treatment Plan": "Li Wei has been diagnosed with major severity esophageal cancer, primarily affecting the middle segment of the esophagus. Given the progressive nature and symptoms including significant dysphagia and weight loss, a comprehensive treatment plan is essential. An initial approach involving concurrent chemoradiotherapy is recommended to reduce tumor size and address regional lymph node involvement, followed by surgical resection if deemed operable post-therapy. Neoadjuvant chemotherapy can help shrink the tumor and prevent micrometastasis, utilizing drugs like 5-fluorouracil and cisplatin. Post-treatment, ongoing surveillance with regular imaging and endoscopic evaluations will be necessary to monitor for recurrence or metastasis. Nutritional support is critical, as Li Wei struggles with dysphagia and weight loss, necessitating enteral feeding through a gastrostomy if required, to ensure adequate caloric and nutrient intake. Post-surgical recovery will include gradual reintroduction of a liquid diet, progressing to soft foods, with careful monitoring of swallowing function. Psychological support and family education about the disease and its management will be provided to maintain a positive outlook and improve quality of life. Follow-up care will include visits every three months to assess recovery and adjust the treatment plan as needed."
    },
    {
        "Patient Information": {
            "Name": "Sophia Thompson",
            "Age": "3",
            "Gender": "Female",
            "Medical History": "Family history of neuroblastoma, recurrent abdominal pain"
        },
        "Disease Information": {
            "Disease": "Neuroblastoma",
            "Severity Level": "High Severity",
            "Symptoms": "Abdominal distension, constipation, unexplained weight loss, fatigue, bone pain",
            "Duration": "Symptoms have been persisting for several months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "60 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "300 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.35 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "350 ng/mL (20 − 500 for males)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Neuroblastoma",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Normal",
            "Serological Diagnosis": "Elevated catecholamine metabolites",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Normal",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative for SARS-CoV-2",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal",
            "Abdominal Ultrasound": "Presence of mass in the abdomen",
            "Bone Marrow Aspiration": "Presence of neuroblastoma cells",
            "MRI": "Abdominal mass with potential spread"
        },
        "Treatment Plan": "Sophia Thompson has been diagnosed with high-risk neuroblastoma, necessitating an aggressive and comprehensive treatment approach due to the persistence and severity of symptoms such as abdominal distension, weight loss, and fatigue over several months. Immediate initiation of treatment involving multi-drug chemotherapy in conjunction with surgical interventions is recommended to address the tumor and potential metastasis. Given the high-risk classification, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation will be considered to enhance treatment efficacy. Continuous monitoring of catecholamine metabolite levels and imaging assessments is essential to evaluate the progression and response to treatment. Radiotherapy targeting the primary abdominal site may be conducted post-chemotherapy to eradicate residual tumor cells. Additional supportive care, including nutritional management and symptom alleviation, such as pain relief, will be provided to ensure optimal comfort and recovery. Family education regarding the importance of treatment adherence, recognizing symptom changes, and the need for regular follow-ups will be crucial. Long-term follow-up and health surveillance are necessary to assess the impact on growth and development and to prevent recurrence. Sophia and her family will be guided through the treatment process, ensuring understanding and cooperation for optimal outcomes."
    },
    {
        "Patient Information": {
            "Name": "Ethan Parker",
            "Age": "2",
            "Gender": "Male",
            "Medical History": "No significant medical history, previous episodes of abdominal discomfort and unexplained irritability"
        },
        "Disease Information": {
            "Disease": "Neuroblastoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Abdominal pain, abdominal distension, vomiting, fatigue and difficulty breathing",
            "Duration": "Symptoms have been present for 4 weeks, steadily worsening",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "6.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "45 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.1 mmol/L (< 5.18)",
                "White Blood Cell Ct. (WBC)": "8.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "125 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.1 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Ferritin": "850 ng/mL (25 − 200 for children)",
                "Neuron Specific Enolase": "100 ng/mL (< 15)",
                "Catecholamine Metabolites in Urine (VMA and HVA)": "Elevated"
            },
            "Abdominal Ultrasound Exam": "Presence of a heterogeneous mass in the abdominal region",
            "Computed Tomography (CT)": "Mass observed in the adrenal gland with potential infiltration into surrounding tissues",
            "Magnetic Resonance Imaging (MRI)": "Tumor extending into nearby organs with ill-defined margins",
            "MIBG Scan": "Multiple uptake areas indicating extensive neuroblastoma spread",
            "Bone Marrow Aspirate": "Presence of neuroblastoma cells",
            "Biopsy": "Confirms neuroblastoma with MYCN amplification",
            "Echocardiography": "Normal"
        },
        "Treatment Plan": "Ethan Parker has been diagnosed with neuroblastoma with major severity, requiring an aggressive treatment plan due to the tumor's extensive spread and malignant nature. Immediate hospitalization is recommended, and the treatment will consist of a multi-phase approach. Initially, Ethan will undergo induction chemotherapy using a combination of drugs such as Cyclophosphamide and Doxorubicin to reduce tumor size. The feasibility of surgical resection will be evaluated post-chemotherapy depending on tumor shrinkage. Due to high MYCN amplification, high-dose myeloablative chemotherapy, followed by autologous hematopoietic stem cell transplantation, will be considered during the consolidation phase. Radiotherapy will be employed to target residual primary and metastatic sites. Maintenance therapy to eliminate residual tumor cells will include retinoic acid, with potential consideration for immunotherapy targeting neuroblastoma antigens. Regular monitoring and follow-ups will be essential to assess treatment efficacy and manage any side effects. Ethan's nutritional intake will be closely monitored, and supportive care will be provided to address potential chemotherapy side effects. Emotional and psychological support for Ethan and his parents will be crucial throughout the treatment process, ensuring adherence to the treatment protocol and facilitating recovery, with education provided on recognizing signs of deterioration and importance of follow-up care."
    },
    {
        "Patient Information": {
            "Name": "Liam Johnson",
            "Age": "2",
            "Gender": "Male",
            "Medical History": "Unremarkable prior to current presentation, no family history of neuroblastoma"
        },
        "Disease Information": {
            "Disease": "Neuroblastoma",
            "Severity Level": "High Severity",
            "Symptoms": "Abdominal distension, loss of appetite, fatigue, palpable mass in abdomen, and intermittent abdominal pain",
            "Duration": "Symptoms have been present for approximately 2 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "40 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "37% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "265 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.6 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.07 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "350 ng/mL (20 − 500)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Catecholamine Metabolites (VMA, HVA)": "Elevated",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Abdominal Ultrasound": "Large mass in the adrenal region, consistent with neuroblastoma",
            "Magnetic Resonance Imaging (MRI)": "Tumor originating from the abdomen, with evidence of local spread to surrounding tissues",
            "MIBG Scan": "Increased uptake in abdominal mass, suggestive of neuroblastoma",
            "Bone Marrow Aspiration": "Positive for neuroblastoma cells below 10% infiltration",
            "Biopsy and Pathology": "Confirms presence of neuroblastoma with unfavorable histology",
            "Urinary Catecholamines": "Elevated vanillylmandelic acid (VMA) and homovanillic acid (HVA)",
            "Chest X-ray": "Normal, no evidence of primary chest symptoms",
            "Electrolytes": "Within normal limits",
            "Cardiac Evaluation": "Normal"
        },
        "Treatment Plan": "Liam Johnson has been diagnosed with high-risk neuroblastoma, necessitating an aggressive and multifaceted treatment approach. Given the severity and advanced stage of his condition, immediate induction therapy is recommended, involving surgery to remove as much of the tumor as possible, followed by intensive multi-agent chemotherapy to target any residual cancer cells. Given the high-risk classification of his neuroblastoma, we will consider initiating high-dose chemotherapy with autologous hematopoietic stem cell transplantation to help eradicate the tumor cells. Concurrently, radiotherapy will be planned to target the primary tumor site and any remaining metastatic disease. In the maintenance phase, Liam will be administered oral retinoic acid to minimize the risk of relapse. Throughout the treatment, continuous monitoring of his blood counts, liver and kidney function, and electrolytes will be necessary to manage potential side effects and ensure optimal supportive care. Nutritional support, alongside family education on home care, will be provided to aid in Liam’s recovery. Regular follow-ups and imaging tests will be conducted to assess treatment response and modify the treatment plan as required, with the ultimate goal of achieving remission and improving Liam's long-term prognosis."
    },
    {
        "Patient Information": {
            "Name": "Laura Thompson",
            "Age": "65",
            "Gender": "Female",
            "Medical History": "Hypertension, Hypokalemia, Diabetes Mellitus"
        },
        "Disease Information": {
            "Disease": "Adrenal tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Hypertension, Electrolyte imbalance, Abdominal pain, Metabolic abnormalities, Muscle weakness",
            "Duration": "Symptoms have been gradually worsening over the last 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.3 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "240 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "90 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "250 ng/mL (15 − 150 for females)",
                "CRP": "4 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Not applicable",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal findings",
            "Chest Computerized Tomography": "Presence of an adrenal mass on the left side",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Within normal limits",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Normal",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Laura Thompson has been diagnosed with a moderate-severity functional adrenal tumor, presenting with symptoms such as hypertension, metabolic abnormalities, and muscle weakness. Given the nature of the tumor, surgical intervention is recommended as the primary treatment to prevent further complications. A transabdominal laparoscopic adrenal tumor resection will be performed, considering the size and characteristics of the tumor. Preoperative management includes controlling blood pressure and correcting electrolyte imbalances. Post-operative care involves monitoring adrenal cortical function and potentially providing hormone replacement therapy to manage any adrenal insufficiency resulting from surgery. Laura will also be advised on lifestyle modifications, including maintaining a balanced diet and regular physical activity, to support postoperative recovery and prevent recurrence. Regular follow-up appointments will be scheduled to monitor her recovery progress, assess adrenal function, and ensure that there are no signs of tumor recurrence. Laura and her family will be educated on recognizing symptoms that require immediate medical attention and the importance of adhering to the follow-up regimen to optimize health outcomes."
    },
    {
        "Patient Information": {
            "Name": "Jessica Thompson",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "Hypertension, Cushing's syndrome, history of abdominal masses"
        },
        "Disease Information": {
            "Disease": "Adrenal Tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Hypertension, electrolyte imbalance, central obesity, abdominal pain, muscle weakness, palpitations",
            "Duration": "The symptoms have been persistent over the past several months with gradual worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "38 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.6 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "134 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.26 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.6% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "6 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Revealed an adrenal mass with uniform density",
            "Serological Diagnosis": "Hypertension along with hormonal imbalance",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for autoimmune disorders",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal",
            "Adrenal Imaging": "CT shows round adrenal adenoma with clear borders, less than 4 cm"
        },
        "Treatment Plan": "Jessica Thompson has been diagnosed with a major adrenal tumor, which appears to be functional, leading to endocrine-related symptoms such as hypertension and muscle weakness. Given the tumor's benign nature and current size, surgical intervention is recommended, specifically transabdominal laparoscopic adrenal tumor resection. This approach is suitable for the tumor's size and location, aiming to minimize postoperative recovery time and preserve surrounding tissue integrity. Preoperative management will involve normalizing blood pressure and correcting any electrolyte imbalances with medication. Post-surgery, close monitoring of adrenal function will be necessary, with hormone replacement therapy considered if adrenal insufficiency occurs. A dedicated follow-up schedule will be established to ensure no recurrence or complications arise, with regular imaging and biochemical assessments planned. Jessica will be advised on lifestyle modifications, such as adhering to a balanced diet and maintaining regular exercise to aid recovery. Continuous psychological support will be available to help manage anxiety related to her condition and surgery. Regular communication with the healthcare team will be encouraged to promptly address any concerns or symptoms that may suggest the need for further intervention."
    },
    {
        "Patient Information": {
            "Name": "Emily Carter",
            "Age": "35",
            "Gender": "Female",
            "Medical History": "Hypertension, occasional palpitations"
        },
        "Disease Information": {
            "Disease": "Adrenal Tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Hypertension, abdominal pain, palpitations, occasional headache, fatigue",
            "Duration": "Symptoms have been fluctuating over the past six months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "White Blood Cell Ct. (WBC)": "6.2 × 10^9/L (3.5 − 9.5)",
                "Hemoglobin (Hb)": "130 g/L (120 − 160)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Cortisol": "20 μg/dL (5 − 25)",
                "ACTH": "12 pg/mL (7.2 − 63.3)",
                "Plasma Aldosterone-to-Renin Activity Ratio": "30 (preferably <20)",
                "Metanephrine": "500 pg/mL (18 − 111)",
                "Normetanephrine": "700 pg/mL (36 − 287)"
            },
            "Abdominal CT Scan": "3 cm mass in the right adrenal gland, smooth outline, round shape",
            "MRI Scan": "High signal intensity on T2-weighted images, consistent with benign appearance",
            "24-hour Urinary Metanephrines": "Normal",
            "123I-MIBG Scan": "No abnormal uptake"
        },
        "Treatment Plan": "Emily Carter has been diagnosed with a moderate severity adrenal tumor, particularly a benign adenoma in her right adrenal gland, evidenced by her fluctuating symptoms of hypertension and abdominal pain over the past six months. The primary treatment plan is surgical intervention, specifically a transabdominal laparoscopic adrenal tumor resection, recommended given the size and benign nature of the tumor. The procedure will aim to remove the tumor effectively while minimizing impact on surrounding structures, with careful attention to the tail of the pancreas during surgery. Pre-operative management will include monitoring her blood pressure and electrolyte levels to ensure stability, and post-operative care will involve regular follow-up to assess for any signs of recurrence or complications. Given her condition, Emily may require temporary hormone replacement therapy post-surgery until her adrenal function normalizes. Furthermore, she will be advised to maintain a balanced diet, engage in regular physical activity, and monitor her blood pressure as part of her postoperative care and recovery plan. Regular hospital check-ups will be essential in assessing her recovery progress and adjusting the treatment plan accordingly. Emily and her family will be educated on recognizing symptoms that warrant immediate medical attention and the importance of adhering to follow-up care protocols. Overall, the prognosis is favorable with surgical intervention, and Emily's cooperation in managing her condition through lifestyle adjustments will play a crucial role in her recovery."
    },
    {
        "Patient Information": {
            "Name": "David Anderson",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Hypertension, Obesity, History of smoking"
        },
        "Disease Information": {
            "Disease": "Kidney cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Hematuria, flank pain, abdominal mass, unexplained weight loss, decreased appetite",
            "Duration": "Symptoms have persisted for over 3 months with worsening hematuria and pain",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "38 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU/L (13 − 35)",
                "Urea": "9.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "120 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "34% (35 − 50)",
                "Hemoglobin (Hb)": "105 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "190 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "6.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.05 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "650 ng/mL (20 − 500 for males)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "50 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "2.0 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "68 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Clear lung fields; no evidence of metastasis",
            "Abdominal Ultrasound": "Presence of a solid mass in the left kidney measuring 8 cm",
            "Abdominal CT Scan": "Large solid mass in left kidney with signs of invasion into perirenal fat",
            "MRI": "Mass compatible with renal cell carcinoma; no distant metastases",
            "PET-CT": "No distant metastases detected, local invasion confined to left kidney area",
            "Bone Imaging": "No signs of bone metastasis",
            "Renal Dynamic Imaging": "Reduced function in left kidney",
            "Urinalysis": "Presence of blood in urine",
            "Coagulation Function Test": "Normal",
            "Renal Biopsy": "Clear cell carcinoma confirmed",
            "Radionuclide Renography": "Normal right kidney function"
        },
        "Treatment Plan": "David Anderson has been diagnosed with advanced kidney cancer, likely exacerbated by his pre-existing conditions of hypertension and obesity, necessitating a rigorous and tailored treatment strategy. Given the extreme severity of his renal cell carcinoma, immediate surgical intervention through radical nephrectomy is considered a priority to remove the cancerous mass and prevent further local invasion. The surgery will also include assessment for possible removal of enlarged lymph nodes if detected. Post-surgery, David's treatment will focus on close monitoring of renal function, regular imaging to assess any residual disease, and medical management for systemic control of his hypertension and obesity to optimize recovery. Additionally, interventional therapy like renal artery embolization may be applied to enhance post-operative outcomes and alleviate symptoms. If necessary, ablation therapy could serve as a secondary method to target residual tumor tissues. David will be advised on dietary adjustments to reduce strain on the remaining kidney, including limiting salt and protein intake while encouraging hydration to support renal health, and daily physical activities to improve cardiovascular health. Psychological support will be provided to mitigate anxiety and enhance patient confidence throughout the treatment journey. Follow-up appointments will be crucial to monitor his progress and adjust treatment plans as required, and David will be educated on recognizing symptoms indicating complications, focusing on a positive outlook, and the necessity of adhering to prescribed medications and lifestyle modifications."
    },
    {
        "Patient Information": {
            "Name": "Laura Bennett",
            "Age": "62",
            "Gender": "Female",
            "Medical History": "Hypertension, Obesity"
        },
        "Disease Information": {
            "Disease": "Kidney Cancer (Clear Cell Renal Cell Carcinoma)",
            "Severity Level": "Major Severity",
            "Symptoms": "Hematuria, flank pain, abdominal mass, unexplained weight loss",
            "Duration": "Symptoms have been present for approximately 6 months, progressively worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "8.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "110 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.8 mmol/L (< 5.18)",
                "White Blood Cell Ct. (WBC)": "8.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "230 U/L (135 − 225)",
                "Ferritin": "350 ng/mL (20 − 500 for females)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "22 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Sugar": "6.3 mmol/L (4.0−6.1)"
            },
            "Radiological Exams": {
                "Abdominal Ultrasound": "Large heterogeneous mass in the left kidney, suspicious for malignancy",
                "Abdominal CT Scan": "7.5 cm enhancing renal mass on the left kidney, confined to the renal capsule, no distant metastasis",
                "Chest X-ray": "Clear pulmonary fields",
                "Bone Scan": "No evidence of bone metastasis",
                "MRI": "Mass is enhancing with characteristics typical of clear cell renal carcinoma, no invasion of surrounding structures"
            },
            "Laboratory Tests": {
                "Urinalysis": "Hematuria detected",
                "Renal Function Test": "Compromised renal function with reduced glomerular filtration rate",
                "Coagulation Profile": "Normal",
                "Urinary Cytology": "Negative for malignancy"
            },
            "Biopsy Results": "Clear cell renal cell carcinoma confirmed"
        },
        "Treatment Plan": "Laura Bennett is diagnosed with clear cell renal cell carcinoma, with a 7.5 cm tumor localized to the left kidney, classifying it under Stage II renal cancer. Given her significant comorbidities of hypertension and obesity, treatment planning will prioritize both efficacy and minimizing risk. The primary treatment will involve a radical nephrectomy of the left kidney, which is the standard and most effective approach for localized renal cancer without clear metastases. The surgery will include the removal of the affected kidney while preserving the surrounding adrenal gland, unless abnormalities are detected intraoperatively. Due to the major severity of her condition, her preoperative care will focus on optimizing her overall medical status, including stringent blood pressure management and nutritional support to reduce surgical risks. Postoperatively, comprehensive patient care will involve regular monitoring of vital signs, renal function, and potential complications such as infections or internal bleeding. Given her history of hypertension, medication regimes will be reviewed and adjusted accordingly, ensuring tight blood pressure control, with attention to possible side effects such as renal insufficiency. Rehabilitation will involve gradual reintroduction of physical activity, tailored to her tolerance, with a focus on lifestyle modifications to address obesity, including dietary guidance and moderate exercise. Follow-up will include regular imaging and laboratory assessments to monitor for potential recurrence. Close communication with Laura and her family will ensure understanding and adherence to the treatment plan, reinforcing the importance of regular follow-up appointments post-surgery, and providing emotional and psychological support throughout her recovery journey."
    },
    {
        "Patient Information": {
            "Name": "Eleanor Parker",
            "Age": "64",
            "Gender": "Female",
            "Medical History": "Hypertension, Obesity, History of smoking"
        },
        "Disease Information": {
            "Disease": "Kidney Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Hematuria, back pain, abdominal mass, weight loss, fatigue",
            "Duration": "Symptoms have been present and worsening for the past 3 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "34 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "9.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "110 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.9 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.9 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "137 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.2 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.1 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.3 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "3% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "170 U/L (22 − 198 for females)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "200 ng/mL (13 − 150 for females)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "CA-125",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Abdominal Ultrasound": "Revealed a mass in the right kidney with mixed echogenicity",
            "CT Scan of Abdomen and Pelvis": "Large enhancing mass in the right kidney with infiltration into adjacent tissues and regional lymph node enlargement",
            "MRI": "Confirmed kidney tumor with involvement of renal vein",
            "Chest X-ray": "No metastasis detected",
            "Bone Scintigraphy": "No evidence of bone metastasis",
            "PET-CT": "Localized to the kidney with no distant metastasis",
            "Renography": "Compromised renal function in the right kidney"
        },
        "Treatment Plan": "Eleanor Parker has been diagnosed with kidney cancer, characterized by a significant tumor in the right kidney with local tissue invasion but no distant metastasis. Given the major severity and the presence of lymph node involvement, a combination of surgical and medical approaches is required. Radical nephrectomy is recommended to remove the affected kidney along with the tumor and potentially involved lymph nodes, as her other kidney exhibits adequate function and is expected to compensate. Targeted therapy with tyrosine kinase inhibitors, such as sunitinib or pazopanib, will be initiated post-surgery to reduce the risk of recurrence and manage any residual microscopic disease. Regular monitoring through imaging studies including MRI and CT scans will be scheduled to evaluate treatment efficacy and detect any potential metastasis early. Symptom management will focus on controlling pain and fatigue through prescribed medications and lifestyle modifications aimed at improving overall health. Nutritional counseling and possible referral to physiotherapy will support recovery and enhance quality of life. Eleanor and her family will be educated on the importance of adhering to follow-up appointments and maintaining a healthy lifestyle. Emotional and psychological support services will be made available to help manage stress and anxiety associated with the diagnosis and treatment process. Comprehensive follow-up will include periodic blood tests to monitor renal function and imaging to ensure early identification of any recurrence."
    },
    {
        "Patient Information": {
            "Name": "Emily Zhang",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "Hypertension, Type 2 Diabetes"
        },
        "Disease Information": {
            "Disease": "Neuroendocrine Tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Abdominal pain, nausea, weight loss, visual field defects, hypercalcemia, hypertension",
            "Duration": "Symptoms have been persisting and worsening over the past six months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "38 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "5.6 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "128 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "190 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "71% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.6% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for females)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Chromogranin A (CgA)": "Elevated",
                "Neuron-Specific Enolase (NSE)": "Elevated",
                "5-Hydroxyindoleacetic Acid (5-HIAA)": "Elevated",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "CT Scan": "Presence of a large pancreatic mass with liver metastasis",
            "MRI": "Pancreatic mass invading surrounding structures",
            "Somatostatin Receptor Scintigraphy": "Positive uptake in pancreatic region",
            "Octreotide Scan": "Multiple positive areas indicating metastatic spread",
            "Endoscopy": "Large gastric ulcer and multiple polyps",
            "Pathology Examination": "Poorly differentiated neuroendocrine carcinoma",
            "Bone Scan": "Signs of metastatic bone lesions",
            "Thyroid Function Test": "Normal",
            "Liver Function Test": "Mild dysfunction"
        },
        "Treatment Plan": "Emily Zhang's diagnosis of a major neuroendocrine tumor necessitates a multidisciplinary approach for management, considering the complexity and severity of her condition. Surgical intervention to excise the primary tumor is imperative to alleviate compression symptoms and potentially reduce metastatic spread, given the tumor's current impact on surrounding structures. Preoperative preparation with octreotide may be critical to prevent carcinoid crisis, with postoperative monitoring of hormone levels essential to manage metabolic complications. Adjunctive targeted therapy using somatostatin analogs like octreotide or lanreotide can help control tumor growth and hormonal imbalances, with close monitoring for potential side effects such as gallstones and gastrointestinal disturbances. Radiotherapy may be employed for symptom control and to manage residual tumor mass post-surgery. Due to the metastatic nature of her tumor, chemotherapy using platinum-based regimens could be advised, bearing in mind the potential for bone marrow suppression and other common side effects. Nutritional and lifestyle modifications, including a balanced diet, regular exercise tailored to her capacity, and psychological support, will be vital for her recovery and overall well-being, along with regular follow-up to monitor for recurrence and manage any new symptoms. Family involvement in her care plan is crucial for emotional support, adherence to lifestyle changes, and recognizing signs of deterioration. As her condition is severe, ongoing multidisciplinary evaluations will be necessary to adapt her treatment plan based on disease progression and therapeutic response, with consideration for potential future research and trials as appropriate."
    },
    {
        "Patient Information": {
            "Name": "Katherine Wang",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "Hypertension, previous surgery for benign thyroid nodules"
        },
        "Disease Information": {
            "Disease": "Neuroendocrine Tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Abdominal pain, nausea, weight loss, intermittent hypoglycemia, persistent cough",
            "Duration": "Symptoms have been present and progressively worsening for the past three months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "34 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Chromogranin A (CgA)": "150 ng/mL (< 93)",
                "Neuron-Specific Enolase (NSE)": "25 ng/mL (< 16.3)",
                "Insulin": "12 μU/mL (2.6 - 24.9)",
                "Glucose": "3.0 mmol/L (3.9 − 5.6)",
                "Prolactin": "450 mIU/L (102 − 496)",
                "5-Hydroxyindoleacetic Acid (5-HIAA) in Urine": "8 mg/24h (1-10)"
            },
            "CT/MRI Scan": "Presence of masses in the pancreatic region with mild lymph node engagement",
            "Somatostatin Receptor Scintigraphy": "Elevated uptake indicating multiple lesions",
            "Endoscopy": "Multiple gastric mucosal nodules with biopsies showing neuroendocrine features",
            "18F-FDG PET-CT": "Moderate uptake indicating active gastrointestinal tumors",
            "Pathology Examination": "High differentiation neuroendocrine tumor (G2)",
            "Pulmonary Function Test": "Normal",
            "Thyroid Function Test": "Normal"
        },
        "Treatment Plan": "Katherine Wang has been diagnosed with a major severity neuroendocrine tumor primarily located in the pancreas, with symptoms including abdominal pain, nausea, weight loss, and intermittent hypoglycemia. Surgical intervention is recommended to remove the primary tumor mass due to the well-differentiated nature and the presence of lesions in the pancreatic region. Preoperatively, octreotide treatment will be administered to prevent carcinoid crisis during surgery. Postoperative care includes monitoring for electrolyte imbalances and metabolic symptoms due to hormonal secretion from the tumor, with somatostatin analogs like octreotide or lanreotide prescribed to manage them. Radiotherapy may be considered for lymph node engagement, with regular follow-ups every three months to ensure no recurrence or new metastasis. Dietary adjustments, including frequent small meals and electrolyte-rich foods, will support metabolic stability. Psychological support to manage stress will be crucial, as stress can exacerbate hormonal symptoms. Katherine will be educated on recognizing signs of carcinoid crisis and maintaining regular exercise without excessive exertion, alongside abstinence from alcohol and smoking. Her cooperation with the treatment plan will be essential for effective management and recovery."
    },
    {
        "Patient Information": {
            "Name": "Jessica Thompson",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "Previously diagnosed with gastritis, underwent appendectomy at age 30, familial history of multiple endocrine neoplasia."
        },
        "Disease Information": {
            "Disease": "Neuroendocrine Tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Abdominal pain, nausea, chronic diarrhea, and symptoms of Cushing's syndrome including moon face and hypertension",
            "Duration": "Symptoms have been present and gradually worsening over the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU/L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.95 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.12 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for females)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Chromogranin A (CgA)": "Elevated",
                "Chromogranin B (CgB)": "Normal",
                "Neuron-Specific Enolase (NSE)": "Elevated",
                "5-Hydroxyindoleacetic Acid (5-HIAA)": "Elevated"
            },
            "CT Scan": "Presence of mass in the pancreas with evidence of local metastasis",
            "MRI": "Confirms pancreatic mass with regional lymph node involvement",
            "Somatostatin Receptor Scintigraphy": "Increased uptake in pancreatic and nearby lymph nodes",
            "Endoscopy": "Visible tumors in gastrointestinal tract; biopsy showed neuroendocrine features",
            "Biopsy Pathology": "Well-differentiated neuroendocrine tumor (G2), Ki-67 at 10%"
        },
        "Treatment Plan": "Jessica Thompson is diagnosed with a well-differentiated neuroendocrine tumor of major severity primarily in the pancreas, exhibiting symptoms indicative of Cushing's syndrome due to excess hormone secretion. Initial management will involve somatostatin analogs like octreotide to control hormone symptoms and stabilize metabolic disruptions, alongside symptomatic treatment for Cushing's syndrome. Given the tumor localization and lack of distant metastases, surgical resection of the primary tumor and involved lymph nodes is planned, contingent on further evaluation by a multidisciplinary team. After surgery, postoperative monitoring of hormonal levels and regular imaging every six months for the first two years is essential for detecting potential recurrence or metastasis. Postoperative care will also include managing potential complications such as electrolyte imbalance and ensuring adequate nutrition and hydration. Jessica will receive ongoing psychological support and education on symptom monitoring and lifestyle modifications to assist recovery and prevent excessive fatigue, which could exacerbate a carcinoid crisis. Given her family history, genetic counseling may be advisable to assess risk factors for relatives. Follow-up care will be critical in optimizing outcomes and ensuring quality of life, with adjustments to treatment as needed based on her progress and clinical response."
    },
    {
        "Patient Information": {
            "Name": "Emily Thompson",
            "Age": "45",
            "Gender": "Female",
            "Medical History": "Smoker, history of chronic sinus infections"
        },
        "Disease Information": {
            "Disease": "Parotid Gland Tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Newly developed mass in the parotid region, slow growth, smooth and nodular mass, moderately firm, with clear boundaries",
            "Duration": "Symptoms have been present for approximately 6 months with gradual growth",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.95 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.02 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198 for males)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "5 ng/L (< 14 ng/L)",
                "Ferritin": "130 ng/mL (20 − 500 for females)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.05 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound": "Presence of a well-defined mass in the superficial lobe of the right parotid gland",
            "CT Scan": "3 cm solitary mass located in the superficial lobe, no evidence of local tissue invasion",
            "MRI": "The mass is hyperintense on T2-weighted images, consistent with a benign parotid tumor",
            "Fine Needle Aspiration Cytology": "Consistent with pleomorphic adenoma",
            "Facial Nerve Function Test": "Normal function with no signs of facial paralysis",
            "Chest X-ray": "No metastasis observed, lungs clear",
            "PET-CT": "No distant metastasis detected, localized tumor activity"
        },
        "Treatment Plan": "Emily Thompson has been diagnosed with a pleomorphic adenoma, a benign tumor of the parotid gland, which requires surgical intervention to prevent potential malignant transformation or complications. A superficial parotidectomy is recommended to remove the tumor entirely, ensuring clear margins to minimize the risk of recurrence. Preoperatively, the surgical area will be prepared to ensure optimal access, with facial nerve monitoring during the procedure to ensure nerve preservation and reduce the risk of facial paralysis. Postoperative care will involve regular monitoring for complications such as salivary fistula or facial nerve dysfunction. Emily will be advised to abstain from smoking, as it may affect recovery and increase the risk of recurrence. Nutritional support and adequate hydration will be emphasized to promote healing. Regular follow-up appointments will be scheduled to monitor for signs of recurrence or new lesion development, with imaging studies and clinical examinations as part of the postoperative care plan. Education on recognizing signs of infection or complications will be provided to Emily and her family to ensure prompt medical attention if necessary. A lifestyle modification plan, including cessation of smoking and moderate exercise, will be recommended to reduce future risk factors."
    },
    {
        "Patient Information": {
            "Name": "Sarah Johnson",
            "Age": "45",
            "Gender": "Female",
            "Medical History": "Smoker for 20 years, occasional headaches"
        },
        "Disease Information": {
            "Disease": "Parotid gland tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Palpable mass in the parotid region, facial pain, and occasional numbness",
            "Duration": "Symptoms have been present for the last 2 months with gradual increase",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "29 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.1 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.6 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.7 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.55 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.13 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 fL (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "250 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Examination": "Presence of a solid mass in the superficial lobe of the parotid gland",
            "CT Scan": "Well-defined heterogeneous mass in the parotid gland, no signs of invasion",
            "MRI": "Mass located in the superficial lobe of the left parotid gland; no facial nerve involvement",
            "Fine Needle Aspiration Cytology": "Results consistent with a benign pleomorphic adenoma",
            "PET-CT": "Localized uptake with no distant metastasis",
            "Serological Diagnosis": "Normal",
            "Respiratory Function Test": "Normal",
            "Facial Nerve Function Test": "No abnormalities detected"
        },
        "Treatment Plan": "Sarah Johnson has been diagnosed with a parotid gland tumor, specifically a benign pleomorphic adenoma located in the superficial lobe. Given the major severity of the mass and its gradual increase over the last two months, surgical intervention is planned to entirely remove the tumor and surrounding tissue, ensuring complete excision and minimizing the risk of recurrence. As preparation for surgery, the surgical field will be properly exposed by shaving to ensure a clear operative area, with coordination for postoperative care arrangements discussed with Sarah and her family. The surgical approach will involve superficial parotidectomy under general anesthesia, with the preservation of facial nerve function being emphasized where possible. Post-surgical care will include monitoring for complications such as salivary fistula or gustatory sweating syndrome, with attention to any signs of facial nerve paralysis. Nutritional support, enhanced immune function management, and routine follow-up appointments will be made to assess recovery progress. Lifestyle modifications, including smoking cessation, will be strongly encouraged to promote healing and reduce future health risks, with educational resources provided to assist in these changes. Proactive and regular follow-up appointments will be scheduled to monitor for any changes in health status and ensure swift intervention should any issues arise while Sarah adheres to guidelines for daily management and recovery."
    },
    {
        "Patient Information": {
            "Name": "Linda Thompson",
            "Age": "47",
            "Gender": "Female",
            "Medical History": "Smoker for 20 years, previous benign parotid tumor removal"
        },
        "Disease Information": {
            "Disease": "Parotid Gland Tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "A newly developed mass in the parotid region, slow growth without pain, smooth and nodular surface, clear boundaries, movable mass",
            "Duration": "The mass has been present for about 6 months, with a slow increase in size",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.6 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.1 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "55% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.4 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6.5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "70 U/L (22 − 198)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "100 ng/mL (20 − 500)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Ultrasound Examination": "Well-defined, hypoechoic mass in the superficial lobe of the parotid gland",
            "MRI Scan": "Contrast-enhanced MRI shows a well-circumscribed, non-invasive lesion in the superficial lobe of the parotid gland",
            "Fine Needle Aspiration Cytology": "Benign lymphoepithelial lesion",
            "Chest X-ray Exam": "Normal",
            "Serological Diagnosis": "Normal",
            "Nasal Endoscopy": "Normal",
            "Oral Pharyngeal Examination": "Normal"
        },
        "Treatment Plan": "Linda Thompson has been diagnosed with a parotid gland tumor, presenting as a slow-growing, well-defined mass with benign characteristics. Given the moderate severity and benign nature of the tumor, surgical intervention is recommended. A superficial parotidectomy will be performed to completely remove the tumor and surrounding gland tissue, ensuring thorough excision to prevent recurrence. Preoperative preparations will include shaving the surgical area and performing necessary imaging studies to confirm the tumor's exact location and extent. Postoperatively, Linda will be closely monitored for complications such as facial nerve damage or salivary fistula. Pain management and care for the surgical site will be part of the immediate postoperative plan, with instructions provided for home care to avoid infection and ensure proper healing. Regular follow-ups will be scheduled to assess recovery and monitor for any signs of recurrence. Linda will be advised to cease smoking to reduce the risk of future parotid gland issues and improve overall health. Nutritional support and lifestyle modifications, including moderate exercise, will enhance her recovery and reduce the likelihood of complications. The collaborative effort between medical professionals and Linda's adherence to the postoperative care plan will be crucial for successful treatment and rehabilitation."
    },
    {
        "Patient Information": {
            "Name": "Ethan Lee",
            "Age": "3",
            "Gender": "Male",
            "Medical History": "No significant past medical history; normal development until presenting with abdominal mass"
        },
        "Disease Information": {
            "Disease": "Wilms tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Asymptomatic abdominal mass, occasional abdominal pain, mild abdominal distention, no hematuria, no hypertension",
            "Duration": "Symptoms noted by parents for approximately 1 week, with mass identified during routine pediatric examination",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "25 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "3.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "40 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lactate Dehydrogenase": "160 U/L (135 − 225)",
                "Alpha-Fetoprotein (AFP)": "Normal",
                "Neuron-Specific Enolase (NSE)": "Normal"
            },
            "Abdominal Ultrasound": "Solid mass detected in right kidney; no invasion of surrounding tissues",
            "Abdominal CT Scan": "Confirms 5 cm unilateral Wilms tumor in right kidney; no evidence of metastatic spread",
            "Chest CT": "No lung metastasis detected",
            "Urine Analysis": "No hematuria observed",
            "Kidney Function Test": "Normal function maintained"
        },
        "Treatment Plan": "Ethan Lee has been diagnosed with a moderate severity unilateral Wilms tumor located in the right kidney. Given the early stage and localized nature of the tumor, a treatment plan involving initial surgical intervention is recommended. This will include a radical nephrectomy of the affected kidney to ensure complete removal of the tumor, followed by a tailored chemotherapy regimen post-surgery to reduce the risk of recurrence. The chemotherapy plan will likely follow the AV regimen, involving Vincristine and Dactinomycin, to be administered over several weeks as required by postoperative pathology results. Regular monitoring of Ethan's kidney function is crucial due to the removal of one kidney, alongside supportive care including adequate nutrition and hydration to support recovery. Postoperative follow-up will be essential at regular intervals to monitor his recovery and assess any late effects or signs of tumor recurrence. Long-term, Ethan will require lifestyle adjustments to maintain optimal health with a single kidney, and his family will receive guidance on dietary and activity considerations to support his growth and development. The prognosis is favorable with anticipated curability due to early detection and comprehensive treatment."
    },
    {
        "Patient Information": {
            "Name": "Ethan Johnson",
            "Age": "4",
            "Gender": "Male",
            "Medical History": "Ethan was diagnosed with isolated hemihypertrophy, a condition known to be associated with an increased risk of Wilms' tumor. No other significant medical history or hereditary conditions known."
        },
        "Disease Information": {
            "Disease": "Wilms' Tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Asymptomatic abdominal mass, abdominal pain, occasional hematuria, and mild hypertension",
            "Duration": "Symptoms have been noticeable over the past few weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "25 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "3.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "40 μmol/L (41 − 81)",
                "Triglycerides (TG)": "0.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "125 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.65 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "50 U/L (22 − 198 for males)",
                "Myoglobin": "40 ng/mL (< 90 ng/mL)",
                "Troponin I": "5 ng/L (< 14 ng/L)",
                "Ferritin": "70 ng/mL (20 − 500 for males)",
                "CRP": "3 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Abdominal Ultrasound": "Presence of a unilateral mass in the left kidney without involvement of the renal pelvis",
            "Abdominal CT": "Solid mass in the left kidney, no evidence of renal vein or inferior vena cava thrombus",
            "Chest CT": "No pulmonary metastasis observed",
            "Renal Function Test": "Normal",
            "Urinalysis": "Microscopic hematuria noted",
            "Renal Biopsy": "Not performed as per standard protocol for unilateral Wilms' tumor",
            "Tumor Markers": "No specific markers indicative of teratoid Wilms' tumor present"
        },
        "Treatment Plan": "Ethan Johnson, a 4-year-old male diagnosed with a unilateral Wilms' tumor of moderate severity, will undergo treatment following the COG protocol. The initial step involves a radical resection of the tumor through a unilateral nephrectomy to effectively remove the mass. Post-surgery, chemotherapy will be administered, likely utilizing the AV regimen consisting of Vincristine and Dactinomycin, tailored to prevent recurrence and eliminate any residual malignant cells. No preoperative chemotherapy is planned as the tumor appears operable and localized. Postoperative monitoring will focus on preventing hypertension and maintaining renal function, with regular follow-ups and imaging to track his recovery and detect any signs of recurrence early. Nutrition support will form a critical aspect of his post-treatment care, enhancing recovery and boosting immunity. Daily exercises will be integrated to maintain physical strength, complemented by a balanced diet rich in proteins and essential nutrients. Parents will be advised to maintain all medical records and monitor Ethan's condition diligently, alerting medical professionals to any changes in symptoms or new developments. Follow-ups are scheduled every three months initially, transitioning to longer intervals as advised, with the aim of ensuring Ethan's complete recovery and monitoring his renal health post-nephrectomy."
    },
    {
        "Patient Information": {
            "Name": "Liam Johnson",
            "Age": "4",
            "Gender": "Male",
            "Medical History": "No known medical history; presenting with abdominal mass and abdominal pain."
        },
        "Disease Information": {
            "Disease": "Wilms tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Asymptomatic abdominal mass, occasional abdominal pain, some degree of hematuria",
            "Duration": "Symptoms have been present for approximately 1 month",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "40 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.6 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.7 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "55% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.1 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.3 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "150 U/L (135 − 225)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "75 ng/mL (20 − 500)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Abdominal Ultrasound": "Presence of unilateral kidney tumor without renal vein thrombus",
            "Enhanced Abdominal CT": "Unilateral lesion localized to left kidney, no signs of metastasis or thrombus",
            "Chest CT": "No lung metastasis detected",
            "MRI": "Confirms unilateral kidney tumor, no inferior vena cava involvement",
            "Urinalysis": "Presence of microscopic hematuria",
            "Bone Scan": "Normal",
            "Biopsy": "Histologically classified as mixed type Wilms' tumor"
        },
        "Treatment Plan": "Liam Johnson has been diagnosed with Wilms tumor localized in the left kidney, with a moderate severity level. Given the promising prognosis associated with Wilms tumor, a structured treatment plan has been devised. Initial treatment will involve a surgical approach as per the Children's Oncology Group (COG) protocol, with radical resection of the affected kidney being planned due to the tumor's unilateral nature. Post-surgery, chemotherapy will be administered based on histopathology and staging results, aiming to eliminate any residual tumor cells and prevent recurrence. The AV regimen, consisting of vincristine and dactinomycin, is recommended for Liam, reflecting a balance between efficacy and tolerability. Follow-up radiotherapy may also be applied as a precautionary step to ensure complete eradication of the tumor cells. Continuous monitoring through imaging studies and laboratory tests will be vital to track progress and adjust treatments as necessary. During the treatment period, supportive care will be provided to address potential side effects and nutritional needs, ensuring Liam maintains strength and well-being. Liam's family will be educated on the importance of follow-up care, recognizing signs of potential complications, and ensuring adherence to the treatment plan for optimal recovery. With a favorable prognosis, it is anticipated that Liam will make a full recovery, supported by regular follow-ups to monitor kidney function and overall health in the years following treatment."
    },
    {
        "Patient Information": {
            "Name": "James Lee",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Chronic atrophic gastritis, Helicobacter pylori infection"
        },
        "Disease Information": {
            "Disease": "Stomach cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Upper abdominal pain, weight loss, anorexia, anemia",
            "Duration": "Symptoms have been persistent and worsening over several months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "34% (35 − 50)",
                "Hemoglobin (Hb)": "100 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.14 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.4 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "160 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "9 ng/L (< 14 ng/L)",
                "Ferritin": "700 ng/mL (20 − 500 for males)",
                "CRP": "7 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "CEA - 5.0 ng/mL (0 − 3)",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Gastroscopy": "Irregular, ulcerated masses in the antrum of the stomach",
            "Biopsy": "Adenocarcinoma cells identified",
            "CT Scan": "Thickening of the gastric wall with local lymph node involvement",
            "Abdominal Ultrasound": "No evidence of distant metastasis",
            "Endoscopic Ultrasound": "Tumor invasion into the muscularis propria",
            "X-ray Barium Meal": "Ulcer-like lesions with filling defects",
            "MRI": "No liver metastasis detected",
            "PET-CT": "Increased metabolic activity indicative of malignancy"
        },
        "Treatment Plan": "James Lee's diagnosis of major severity stomach cancer, characterized by progressive symptoms such as upper abdominal pain and significant weight loss, necessitates an integrated treatment approach. Given the tumor's location and depth of invasion, surgical intervention in the form of a gastrectomy is proposed, followed by adjuvant chemotherapy to address regional lymph node involvement and enhance overall survival prospects. Perioperative nutritional support will be crucial, ensuring maintenance of his nutritional status, which can enhance both recovery and quality of life post-surgery. Additionally, symptomatic pharmacotherapy will be employed, including proton pump inhibitors to reduce gastric acid secretion and manage gastritis-related discomfort, along with analgesics for pain control. Regular imaging and endoscopic assessments will be scheduled post-operatively to monitor for recurrence or metastasis. His current Helicobacter pylori infection, noted in his medical history, may be addressed concurrently with antibiotics to diminish potential tumor progression risks. A multidisciplinary team approach involving gastroenterology, oncology, and nutritional specialists will support James through this treatment journey. Maintaining open communication with him and his family will be vital to ensure adherence to the plan and to provide psychological support throughout the treatment process."
    },
    {
        "Patient Information": {
            "Name": "John Doe",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Chronic gastritis, Helicobacter pylori infection, history of gastric polyps"
        },
        "Disease Information": {
            "Disease": "Stomach Cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Upper abdominal pain, weight loss, anorexia, cachexia",
            "Duration": "Symptoms have been progressively worsening over the past 6 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "8.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "115 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "74% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.4 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "150 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "12 mg/L (< 3 mg/L)",
                "ESR": "22 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "CEA elevated",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Gastroscopy Exam": "Large ulcerated mass in the stomach",
            "Biopsy": "Confirmed adenocarcinoma",
            "Abdominal CT Scan": "Tumor infiltration in gastric wall and local lymph node metastasis",
            "Endoscopic Ultrasound": "Deep infiltration into gastric muscularis propria",
            "PET-CT": "Suspicion of liver metastasis",
            "Serum Tumor Markers": "Elevated CEA, CA19-9, and CA125",
            "Ultrasound": "Liver shows signs of metastasis",
            "MRI": "Confirmed hepatic metastasis"
        },
        "Treatment Plan": "John Doe's stomach cancer diagnosis indicates advanced disease with local and hepatic metastasis, requiring a comprehensive treatment strategy focused on symptom management and extending survival. Due to the extreme severity and lack of curability, aggressive surgical intervention is not feasible; instead, a combination of palliative chemotherapy primarily involving platinum and fluorouracil will be initiated, complemented by targeted therapy using trastuzumab, given HER-2 overexpression, contingent upon cardiac assessment. Nutritional support through enteral nutrition will address cachexia and anorexia, alongside medications like megestrol to stimulate appetite, omeprazole to protect gastric mucosa, and analgesics for pain management. Antiemetic drugs like dexamethasone will counteract chemotherapy-induced nausea. Regular follow-up with imaging and serum tumor marker tests will monitor disease progression closely, adapting the therapeutic plan as needed. Additionally, psychological support is crucial, encouraging John and his family to prioritize a balanced diet, maintain a positive outlook, manage symptoms effectively, and address psychological distress associated with the challenges of advanced cancer."
    },
    {
        "Patient Information": {
            "Name": "James Anderson",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Chronic gastritis, Helicobacter pylori infection, smoking"
        },
        "Disease Information": {
            "Disease": "Stomach cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Upper abdominal pain, weight loss, anemia, loss of appetite, black stools",
            "Duration": "Symptoms have been worsening over the past 6 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "35 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.6 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.4 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "30% (35 − 50)",
                "Hemoglobin (Hb)": "90 g/L (135 − 175)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "4% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "230 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (30 − 400 for males)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "60 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "CEA: 7 ng/mL (0 − 5)",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Gastroscopy": "Large irregular mass with ulceration in the gastric body",
            "Endoscopic Ultrasound": "Tumor infiltrating into the muscularis propria",
            "CT Scan": "Localized thickening of the gastric wall with regional lymphadenopathy and no distant metastasis",
            "MRI": "No liver metastasis detected",
            "PET-CT": "Increased metabolic activity in the gastric lesion, no distant metastatic sites",
            "Biopsy": "Moderately differentiated adenocarcinoma",
            "CEA (Carcinoembryonic Antigen)": "Elevated",
            "CA19-9 (Cancer Antigen 19-9)": "Normal",
            "CA724 (Cancer Antigen 72-4)": "Elevated",
            "CA125 (Cancer Antigen 125)": "Normal"
        },
        "Treatment Plan": "Given the advanced nature of James Anderson's stomach cancer, characterized by a large irregular mass with ulceration and infiltration into the muscularis propria, the primary focus of treatment will be palliative, aimed at alleviating symptoms and enhancing quality of life. Surgical intervention is not recommended due to the extensive local involvement and associated risks. A multidisciplinary approach will be employed, including systemic chemotherapy with a combination of platinum-based compounds and fluorouracil, to slow the progression of the disease. Supportive care will be provided, including nutritional support to address cachexia and symptomatic treatments for pain and gastric acid management with proton pump inhibitors. Additionally, palliative radiation therapy may be considered to control local symptoms like pain or bleeding. James will receive psychological support to help cope with the diagnosis, and his family will be involved in care discussions to ensure holistic support. Regular monitoring through imaging and tumor markers will guide treatment adjustments. Emphasis will be placed on maintaining James's comfort and dignity throughout the treatment process, with a focus on pain management and quality of life improvement."
    },
    {
        "Patient Information": {
            "Name": "Sophia Anderson",
            "Age": "60",
            "Gender": "Female",
            "Medical History": "Previous episodes of abdominal pain and bloating; family history of Carney-Stratakis syndrome"
        },
        "Disease Information": {
            "Disease": "Gastrointestinal Stromal Tumor",
            "Severity Level": "Intermediate Severity",
            "Symptoms": "Abdominal bloating, early satiety, occasional melena",
            "Duration": "Symptoms have been present intermittently over the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "32% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.44 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.7 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "11% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.3 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "120 U/L (22 − 198 for females)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "200 ng/mL (20 − 300 for females)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Negative",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Abdominal Ultrasound": "Presence of a mass in the stomach with unclear margins",
            "CT Scan": "GIST identified in the stomach, measuring approximately 4cm",
            "MRI": "Soft tissue mass in the gastric region with potential liver metastasis",
            "Endoscopic Ultrasound": "Hypo-echoic lesion detected with potential bleeding sites",
            "Stool Test": "Positive for occult blood",
            "Genetic Testing": "Positive mutation in c-kit gene",
            "Respiratory Function Test": "Normal",
            "Urinalysis": "No abnormal findings",
            "Electrolyte Test": "Normal",
            "Serum Antibody Test": "Negative for PDGFRA mutation"
        },
        "Treatment Plan": "Sophia Anderson is diagnosed with an intermediate severity gastrointestinal stromal tumor located in the stomach, necessitating a personalized and comprehensive treatment approach. The primary recommendation is surgical resection to remove the tumor, given its localized nature, followed by targeted therapy to reduce recurrence risk. Preoperative treatment with Imatinib may be initiated to minimize surgical complications and ensure complete removal, especially considering the positive c-kit mutation. Postoperative adjuvant therapy with Imatinib is advised for 3 years to prevent recurrence, given the intermediate risk assessment. Regular follow-ups will include CT scans and MRI evaluations every 3 months for the first 3 years to monitor for potential metastasis or recurrence. Symptomatic management for occasional melena includes iron supplementation for anemia and pain relief as necessary. Nutritional support with a diet of easily digestible foods will be provided to address early satiety and abdominal bloating. Lifestyle modifications will be encouraged, incorporating moderate exercise and stress-relieving practices to improve quality of life. Sophia and her family will receive counseling on adherence to the treatment plan and recognizing signs of worsening symptoms, with additional support to mitigate psychological impacts and boost her recovery chances."
    },
    {
        "Patient Information": {
            "Name": "James Thompson",
            "Age": "58",
            "Gender": "Male",
            "Medical History": "No significant medical history but a family history of gastrointestinal issues."
        },
        "Disease Information": {
            "Disease": "Gastrointestinal stromal tumor",
            "Severity Level": "Intermediate Severity",
            "Symptoms": "Abdominal bloating, early satiety, occasional nausea and fatigue due to anemia",
            "Duration": "Symptoms have been present for several months, gradually becoming more noticeable",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "25 IU /L (13 − 35)",
                "Urea": "6.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.4 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "9% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "50 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "9 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500 for males)",
                "CRP": "4 mg/L (< 3 mg/L)",
                "ESR": "22 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "85 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Normal",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for specific pathogens",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal",
            "Abdominal Ultrasound": "Presence of a mass in the stomach region",
            "Endoscopic Ultrasound": "Identified submucosal tumor in the gastric wall",
            "Biopsy": "Confirmed gastrointestinal stromal tumor, spindle cell type",
            "Genetic Testing": "Positive for c-kit gene mutation"
        },
        "Treatment Plan": "James Thompson has been diagnosed with an intermediate-severity gastrointestinal stromal tumor located in the stomach. Given the tumor's size and confirmed genetic mutation, surgical intervention is recommended as the primary treatment to ensure maximal eradication of the tumor tissue while preserving surrounding organ function. Preoperative administration of imatinib may be considered to potentially reduce tumor size and improve surgical resection outcomes. Postoperative adjuvant therapy with imatinib will be administered for 3 years to minimize recurrence risk, specifically tailored to the genetic profile of the tumor. Regular follow-up appointments will be scheduled every 3 months for comprehensive imaging assessments, including CT or MRI scans, to monitor for any signs of recurrence or metastasis. In conjunction with the medical regimen, supportive care will be provided to manage symptoms such as fatigue and abdominal discomfort. Nutritional guidance will be integral to maintaining a balanced diet, encouraging light, easily digestible meals. Psychological support and counseling are also essential components to address the emotional impact of the diagnosis and treatment. The overall treatment strategy aims for a positive prognosis with ongoing assessment to refine and adjust the therapeutic approach based on James's response to treatment."
    },
    {
        "Patient Information": {
            "Name": "Evelyn Thompson",
            "Age": "58",
            "Gender": "Female",
            "Medical History": "Hypertension, Carney-Stratakis syndrome"
        },
        "Disease Information": {
            "Disease": "Gastrointestinal stromal tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Abdominal bloating, abdominal pain, early satiety, occasional nausea",
            "Duration": "Symptoms began approximately 3 months ago and have been progressively worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "72 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.9 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.4 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.6 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.4 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "4% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "CT Scan": "Confirmed presence of a 4 cm mass in the stomach, suggestive of gastrointestinal stromal tumor",
            "MRI": "Showed infiltration into surrounding tissues, no signs of distant metastasis",
            "PET-CT": "No distant metastasis detected, localized tumor",
            "Endoscopic Ultrasound": "Identified submucosal tumor in the gastric wall",
            "Biopsy Pathology": "Positive for gastrointestinal stromal tumor with spindle cell type",
            "Immunohistochemistry": "CD117 positive, c-KIT mutation detected",
            "Liver Function Test": "Normal",
            "Kidney Function Test": "Normal",
            "Electrolyte Balance Test": "Normal",
            "Stool Test": "Positive for occult blood"
        },
        "Treatment Plan": "Evelyn Thompson's moderate severity gastrointestinal stromal tumor requires a combination of surgical and medical management. Given the potential for surgical resection, it is recommended to initiate pre-surgical treatment with imatinib to potentially reduce the tumor size and increase the chances of a successful complete resection. The treatment plan involves administering imatinib for a duration of 3-6 months, with close monitoring of tumor response through regular imaging assessments. Following a successful response to pre-surgical therapy, Evelyn will undergo a surgical procedure to excise the tumor from the gastric wall. Postoperatively, adjuvant therapy with imatinib may be considered for a period of 1 to 3 years based on her risk assessment and response to initial treatment. Regular follow-ups and imaging will be imperative to monitor for any signs of recurrence. Evelyn should maintain a balanced diet with easy-to-digest foods and ensure regular physical activity to support recovery. It is essential for Evelyn and her family to be informed about the importance of adherence to the treatment regimen and the need for regular medical reviews to ensure the best possible outcomes."
    },
    {
        "Patient Information": {
            "Name": "Eleanor Smith",
            "Age": "77",
            "Gender": "Female",
            "Medical History": "Postmenopausal, history of HPV infection, lichen sclerosus"
        },
        "Disease Information": {
            "Disease": "Vulvar Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent vulvar itching, pain, cauliflower-like mass on the vulva, groin mass due to lymph node metastasis, abnormal pigmentation on the vulva, urinary frequency, dysuria",
            "Duration": "Symptoms have persisted for several months with gradual worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "36 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.4 mmol/L (< 5.18)",
                "White Blood Cell Ct. (WBC)": "8.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.6 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "240 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.7 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "9% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "6 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 300 for females)",
                "CRP": "7 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Human Papillomavirus (HPV)",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "No lung metastasis",
            "Vulvar Examination": "Cauliflower-like mass with ulceration",
            "Pelvic Magnetic Resonance Imaging (MRI)": "Enlarged lymph nodes in the groin, mass connection to surrounding structures",
            "Colposcopic Biopsy": "Presence of squamous cell carcinoma",
            "PET-CT Scan": "No distant metastasis detected",
            "Fine Needle Aspiration of Groin Lymph node": "Positive for malignancy",
            "Urinary Function Test": "Impaired due to urethral involvement",
            "Rectal Examination": "No rectal involvement"
        },
        "Treatment Plan": "Eleanor Smith has been diagnosed with vulvar cancer, exhibiting major severity due to persistent symptoms and lymph node involvement. The approach to treatment will focus primarily on comprehensive surgery, including wide vulvar excision and groin lymph node dissection, tailored to her condition. Preoperative planning involves radiation therapy to reduce tumor volume, facilitating surgical efficacy, and minimizing invasion of surrounding organs. Post-surgical adjuvant radiation will be considered if the margins are not clean or if lymph node metastasis is observed, aiming to prevent recurrence. Chemotherapy may be applied in combination with radiation for advanced tumor control, particularly considering her sensitivity. Additional supportive measures include quitting smoking, maintaining a balanced diet, and enhancing overall immunity. Regular monitoring and imaging will ensure the detection of any recurrence or metastasis. Post-recovery, encouraging a healthy lifestyle with HPV vaccination will be crucial in preventing future occurrences. Follow-up assessments every 3 months will be vital in ensuring recovery progress and adjusting the treatment plan as needed."
    },
    {
        "Patient Information": {
            "Name": "Margaret Johnson",
            "Age": "78",
            "Gender": "Female",
            "Medical History": "Postmenopausal, history of HPV infection, previous vulvar lichen sclerosus"
        },
        "Disease Information": {
            "Disease": "Vulvar Cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Persistent vulvar itching, a cauliflower-like mass on the vulva, groin mass indicating lymph node metastasis, abnormal vulvar pigmentation, urinary frequency and dysuria",
            "Duration": "Symptoms have persisted for over 1 year",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.25 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "50 U/L (22 − 198 for females)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "7 ng/L (< 14 ng/L)",
                "Ferritin": "150 ng/mL (20 − 500 for females)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "HPV related vulvar lesions",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "No lung metastasis detected",
            "Chest Computerized Tomography": "Normal pulmonary findings",
            "Serological Diagnosis": "Positive for squamous cell carcinoma antigen",
            "Viral Antigen Detection": "HPV positive",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Normal",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative for SARS-CoV-2",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal",
            "Biopsy of Vulvar Lesion": "Invasive squamous cell carcinoma detected",
            "Groin Lymph Node Examination": "Positive lymph node metastasis in the groin",
            "MRI": "Enlarged groin lymph nodes and vulvar tumor invasion to surrounding tissues",
            "Cystoscopy": "No urethral involvement",
            "Rectoscopy": "Normal rectal findings"
        },
        "Treatment Plan": "Margaret Johnson has been diagnosed with advanced vulvar cancer with lymph node metastasis, necessitating an aggressive treatment approach. Given the severity of her condition and lymph node involvement, immediate surgery to excise the vulvar tumor and affected groin lymph nodes is imperative. Prior to surgery, radiation therapy may be utilized to shrink the tumor size, with a focus on maintaining organ function. Postoperative radiation therapy will be essential to target residual tumor cells and groin lymph nodes with potential metastasis, incorporating pelvic lymph node radiotherapy if necessary. Chemotherapy may be considered as an adjuvant treatment to improve patient survival and reduce recurrence, utilizing regimens suited for squamous cell carcinoma with potential biological therapy such as interferon and interleukin-2. Due to Mrs. Johnson's advanced age and possible comorbid conditions, personalized treatment focusing on minimizing surgical trauma and enhancing recovery is crucial. Her treatment plan will also focus on lifestyle improvements like smoking cessation, balanced nutrition, regular hygiene, and HPV vaccination to prevent recurrence, with regular follow-up care every 1-3 months for the first year and adjustments based on her progress. Her family will play a vital role in symptom monitoring and adherence to medical advice, encouraging a positive approach to recovery. Healthcare professionals will educate Mrs. Johnson on recognizing signs of metastasis and the importance of adherence to the treatment regimen."
    },
    {
        "Patient Information": {
            "Name": "Eleanor Fisher",
            "Age": "78",
            "Gender": "Female",
            "Medical History": "Postmenopausal, hypertension, history of HPV infection"
        },
        "Disease Information": {
            "Disease": "Vulvar Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent vulvar itching, nodular mass on the labia majora, inguinal lymph node enlargement, occasional vulvar pain",
            "Duration": "Symptoms have been present and worsening over the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.4 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "160 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "90 U/L (22 − 198 for females)",
                "Myoglobin": "55 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "200 ng/mL (15 − 200 for females)",
                "CRP": "6 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Normal",
            "Serological Diagnosis": "Positive for squamous cell carcinoma antigen",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal",
            "Biopsy of Vulvar Lesion": "Invasive squamous cell carcinoma",
            "Groin Ultrasound": "Enlarged lymph nodes with suspicious features",
            "Pelvic MRI": "Confirms vulvar mass with involvement of surrounding tissues"
        },
        "Treatment Plan": "Eleanor Fisher has been diagnosed with vulvar squamous cell carcinoma, a major severity condition, particularly considering her advanced age and existing hypertension. An individualized treatment plan will be developed, focusing on surgical intervention as the primary course of action. A modified wide local excision of the vulvar tissue will be performed to ensure complete removal of the cancerous lesion, and a sentinel lymph node biopsy in the groin will be conducted to assess potential lymphatic spread. Preoperative evaluations confirmed the absence of distant metastasis, making surgical resection feasible. The surgical plan may also include the excision of suspicious groin lymph nodes, accompanied by targeted postoperative radiotherapy if any lymph nodes are found to be involved. Due to the patient's advanced age and medical comorbidities, perioperative management will involve meticulous cardiovascular monitoring and blood pressure control. Adjuvant radiation therapy is considered to help decrease the likelihood of recurrence, focusing on the vulvar region and potentially the groin if lymphatic involvement is confirmed. Chemotherapy is not a primary treatment for this patient but may be considered alongside radiation if any high-risk features are identified post-surgery. Eleanor will also be provided with supportive care, including pain management, nutritional support, and psychological counseling to ensure comprehensive care throughout her treatment journey. Regular follow-up appointments will be scheduled to monitor recovery, address any complications, and initiate any further interventions if needed. Preventive strategies, including counseling on HPV vaccination for her family members, will be emphasized to reduce future risks. Eleanor is encouraged to maintain a healthy lifestyle, with cessation of smoking and careful monitoring of her cardiovascular health being key aspects of her ongoing care plan."
    },
    {
        "Patient Information": {
            "Name": "Jessica Thompson",
            "Age": "65",
            "Gender": "Female",
            "Medical History": "Chronic cough, occasional hemoptysis, history of smoking (40 pack-years)"
        },
        "Disease Information": {
            "Disease": "Small Cell Lung Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent cough, hemoptysis, dyspnea, wheezing, chest pain, weight loss",
            "Duration": "Symptoms have been persistent for several months, with increased severity over the past month",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "75 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "240 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "15 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for females)",
                "CRP": "35 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative for SARS-CoV-2",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mass in the right upper lung field with possible pleural effusion",
            "Chest Computerized Tomography": "Large mass in right upper lobe with mediastinal lymph node enlargement",
            "Serological Diagnosis": "Positive for small cell lung carcinoma markers",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Presence of malignant cells",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for recent infections",
            "Pulmonary Function Test": "Reduced lung capacity",
            "Nucleic Acid Amplification Test": "Negative for respiratory pathogens",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Unremarkable",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Jessica Thompson has been diagnosed with small cell lung cancer, which has progressed to an advanced stage, necessitating immediate intervention centered on combined radiotherapy and chemotherapy. Due to the rapid progression and moderate symptom severity, a regimen including etoposide and platinum-based chemotherapy will be initiated, tailored to her specific situation and disease stage. Concurrently, chest radiotherapy during the early cycles of chemotherapy will be crucial to manage tumor growth and prevent metastasis. Consideration for immunotherapy with atezolizumab or durvalumab may be taken, given the extensive stage of the disease. Supportive care including nutritional support, pain management, and psychological counseling will be provided to enhance her quality of life, with close monitoring of treatment response and potential side effects such as fatigue, dyspnea, and gastrointestinal disturbances. Regular imaging and blood tests will be conducted to assess progress and adapt the treatment plan accordingly. Jessica and her caregivers will be educated on recognizing signs of adverse reactions, adhering to the treatment protocol, and preparing for potential palliative measures to improve comfort and prolong survival. Follow-up care with a multidisciplinary team will be pivotal to address any complications and adjust therapies to ensure optimal management, with particular attention to mitigating risks of recurrence and managing psychological and social wellbeing."
    },
    {
        "Patient Information": {
            "Name": "Daniel Hughes",
            "Age": "63",
            "Gender": "Male",
            "Medical History": "Heavy smoker for 40 years, history of COPD, recurrent respiratory infections"
        },
        "Disease Information": {
            "Disease": "Small cell lung cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Persistent cough, hemoptysis, dyspnea, chest pain, weight loss, superior vena cava obstruction syndrome",
            "Duration": "Symptoms have been worsening over the past month",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "50 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "60 IU/L (13 − 35)",
                "Urea": "6.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "90 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.6 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "115 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "180 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "16% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "75% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.72 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.37 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.48 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "12% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "210 U/L (22 − 198 for males)",
                "Myoglobin": "90 ng/mL (< 90 ng/mL)",
                "Troponin I": "30 ng/L (< 14 ng/L)",
                "Ferritin": "700 ng/mL (20 − 500 for males)",
                "CRP": "80 mg/L (< 3 mg/L)",
                "ESR": "50 mm/hr (0 − 20)",
                "Procalcitonin": "0.8 ng/mL (< 0.5)",
                "D-dimer": "1.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "CEA elevated",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Large mass in right upper lung with mediastinal widening",
            "Chest Computerized Tomography": "Extensive mediastinal lymphadenopathy, possible right lung tumor with pleural involvement",
            "Serological Diagnosis": "Elevated CEA levels indicative of malignancy",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Presence of malignant cells",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for specific viral infections",
            "Pulmonary Function Test": "Reduced lung capacity and airflow",
            "Nucleic Acid Amplification Test": "Negative for viral pathogens",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Daniel Hughes has been diagnosed with extensive-stage small cell lung cancer, characterized by an aggressive progression and poor prognosis. Due to the severity of his condition and extensive metastasis, an immediate initiation of combined chemotherapy and radiotherapy is recommended as the primary treatment approach. Chemotherapeutic regimens including etoposide and platinum compounds will be administered, tailored to his specific response and tolerance levels. Additionally, immunotherapy with atezolizumab or durvalumab may be considered to potentially enhance treatment efficacy, alongside the possibility of prophylactic cranial irradiation to prevent brain metastases. Supportive care is essential, focusing on nutritional support, pain management, and maintenance of water and electrolyte balance. Continuous monitoring of his respiratory function and adaptation to his chemotherapy regimen is crucial, with regular imaging assessments to evaluate treatment efficacy and any progression of the disease. A multidisciplinary team will support Daniel, addressing his physical symptoms and psychological wellbeing throughout his treatment journey. Smoking cessation will be a critical aspect of his care, aiming to improve his quality of life and reduce further complications. Due to the poor prognosis and risk of metastasis, palliative care may be integrated early to enhance comfort and quality of life, with regular follow-ups and adjustments to the treatment plan based on his response and tolerance. Community support and education on recognizing symptoms of metastasis and deterioration will be provided to Daniel and his family."
    },
    {
        "Patient Information": {
            "Name": "Evelyn Thompson",
            "Age": "65",
            "Gender": "Female",
            "Medical History": "Chronic obstructive pulmonary disease, history of smoking for 40 years, hypertension"
        },
        "Disease Information": {
            "Disease": "Small Cell Lung Cancer (Extensive Stage)",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Persistent cough with bloodstained sputum, severe dyspnea, chest pain, weight loss, fatigue, dysphagia",
            "Duration": "Symptoms have been progressively worsening over the past 3 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "39 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.7 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "180 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "350 ng/mL (20 − 500 for females)",
                "CRP": "35 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mediastinal widening and multiple masses in the lung fields",
            "Chest Computerized Tomography": "Extensive metastases in both lungs with lymph node involvement",
            "Serological Diagnosis": "Elevated tumor markers",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Severely impaired",
            "Sputum Examination": "Presence of malignant cells",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Normal",
            "Pulmonary Function Test": "Consistent with restrictive lung disease",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Evelyn Thompson has been diagnosed with extensive stage small cell lung cancer, presenting with symptoms such as persistent cough with bloodstained sputum, severe dyspnea, and significant weight loss. An aggressive treatment regime combining chemotherapy and radiotherapy is vital due to the advanced and invasive nature of her cancer. A first-line chemotherapy regimen that includes a combination of etoposide and platinum-based drugs will be initiated to target rapidly proliferating cancer cells. Given the extensive metastasis, atezolizumab, an immune checkpoint inhibitor, will be combined with chemotherapy to enhance the body's immune response against cancer. Early intervention with radiotherapy is recommended to manage local tumor progression and improve survival prospects. Pain management and nutritional support are critical, with regular monitoring of side effects from chemotherapy and radiotherapy. Palliative care teams will provide comprehensive support to address physical symptoms, such as fatigue and pain, along with psychological issues like anxiety and depression. Regular follow-ups are necessary to evaluate the treatment's effectiveness and adjust protocols as needed, ensuring Evelyn's quality of life is prioritized alongside her cancer management. Efforts to quit smoking and maintain a balanced lifestyle are encouraged to aid in her overall recovery and mitigate further health risks."
    },
    {
        "Patient Information": {
            "Name": "Jonathan Park",
            "Age": "67",
            "Gender": "Male",
            "Medical History": "Chronic smoker, hypertension, family history of prostate cancer"
        },
        "Disease Information": {
            "Disease": "Adenocarcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent dry cough, hemoptysis, shortness of breath, chest pain",
            "Duration": "Symptoms have been present for over six months, with gradual worsening",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "27 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "89 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.7 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.7 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "145 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "240 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.6 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "230 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "SARS-CoV-2 Nucleocapsid",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mass in the right upper lobe with spiculation",
            "Chest Computerized Tomography": "Irregular nodule with pleural involvement in the right lung",
            "Serological Diagnosis": "Elevated CEA",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Presence of malignant cells",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Reduced volume and capacity",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Jonathan Park has been diagnosed with an advanced case of lung adenocarcinoma, characterized by persistent dry cough, hemoptysis, and chest pain over the past months. Given the major severity of his condition, a multi-disciplinary approach is crucial. Surgical intervention is not feasible due to the advanced stage and pleural involvement. The treatment plan focuses on palliative care aimed at symptom management and prolongation of life. Chemotherapy regimens including cisplatin and paclitaxel are proposed to control tumor growth, potentially combined with targeted therapy, contingent upon molecular profiling results. Radiotherapy will be considered to alleviate symptoms and manage local tumor control. Regular monitoring of tumor markers and imaging is essential to assess the response to treatment. Supportive care involving analgesics for pain management, bronchodilators for respiratory ease, and nutritional support will be provided. Psychological support and smoking cessation programs are recommended to improve quality of life and reduce further risk factors. Jonathan and his family will receive counseling on the prognosis and be encouraged to make informed decisions about his care preferences and goals."
    },
    {
        "Patient Information": {
            "Name": "Eleanor Thompson",
            "Age": "65",
            "Gender": "Female",
            "Medical History": "Hypertension, Previous breast lump biopsy, Family history of breast cancer"
        },
        "Disease Information": {
            "Disease": "Breast Adenocarcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Breast lump, skin adhesions, edema, peau d'orange appearance, fatigue",
            "Duration": "Symptoms have been progressing over the last 3 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "125 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "235 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "56 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "9 ng/L (< 14 ng/L)",
                "Ferritin": "180 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "ER/PR positive, HER2 negative",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Mammography": "Presence of irregular mass with microcalcifications suggestive of malignancy",
            "Breast Ultrasound": "Hypoechoic mass with irregular borders",
            "Biopsy Report": "Invasive ductal carcinoma, grade 2, ER/PR positive, HER2 negative",
            "Genetic Testing": "BRCA1/2 mutations absent",
            "MRI of the Breast": "Confirms presence of mass with spiculated margins",
            "CT Scan": "No evidence of metastasis",
            "Bone Scan": "No osseous metastases observed",
            "Liver Ultrasound": "Normal",
            "Pelvic Ultrasound": "Normal"
        },
        "Treatment Plan": "Eleanor Thompson has been diagnosed with breast adenocarcinoma, characterized by an invasive ductal carcinoma that is estrogen receptor-positive and HER2-negative. Due to the tumor's major severity, a multidisciplinary approach will be adopted, focusing on a combination of surgical and adjuvant treatments. A modified radical mastectomy is recommended to excise the malignant tissues effectively, followed by hormone therapy using tamoxifen or an aromatase inhibitor to target the hormone receptor-positive nature of the tumor, potentially reducing the risk of recurrence. Post-surgery, adjuvant radiotherapy may be considered to address any remaining cancerous cells, with chemotherapy regimens like cyclophosphamide, methotrexate, and fluorouracil (CMF) reserved for higher-risk patients if necessary. Regular monitoring of cancer marker levels (CA153, CEA) and imaging studies will ensure timely detection of any recurrence or metastasis. Nutritional support and physical rehabilitation will enhance recovery, and psychological counseling will be made available to support Eleanor through her treatment journey. Follow-up appointments will be crucial in adjusting the treatment plan as needed, empowering Eleanor with information about her treatment progression, lifestyle modifications to reduce cancer risk, and ensuring her overall well-being in the long term."
    },
    {
        "Patient Information": {
            "Name": "Anne Johnson",
            "Age": "62",
            "Gender": "Female",
            "Medical History": "History of benign breast disease, family history of breast cancer, chronic pancreatitis"
        },
        "Disease Information": {
            "Disease": "Adenocarcinoma of the lung",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent dry cough, hemoptysis, shortness of breath, chest tightness, weight loss",
            "Duration": "Symptoms have been progressively worsening over the past 2 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "38 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "41 IU/L (13 − 35)",
                "Urea": "6.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.1 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.6 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "68% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.6 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "9.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "230 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "350 ng/mL (20 − 500 for females)",
                "CRP": "20 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "CA 19-9",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Peripheral lung nodules with spiculation and pleural indentation",
            "Chest Computerized Tomography": "Mass with deep lobulation in the right lower lobe, suspected lymph node involvement",
            "Serological Diagnosis": "Elevated CA 19-9 and CEA levels",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Presence of atypical cells",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Reduced vital capacity and gas exchange",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Anne Johnson has been diagnosed with adenocarcinoma of the lung, characterized by major severity and rapid progression of symptoms over the past two months. Due to the advanced stage and suspected lymph node involvement, surgical intervention may not be feasible. A comprehensive treatment plan will be implemented, beginning with a combination of chemotherapy drugs such as carboplatin and paclitaxel to target the tumor and manage symptoms. Adjuvant radiotherapy will be considered to improve local control of the disease. Molecular targeted therapy using tyrosine kinase inhibitors may be explored to address driver gene mutations. Symptomatic management including bronchodilators, cough suppressants, and nutritional support will be provided to alleviate respiratory distress and overall discomfort. Psychological support and counseling are crucial to help Anne cope with the emotional impact of her diagnosis and treatment. Regular follow-up appointments will be scheduled to monitor her response to treatment and adjust the therapeutic approach as necessary. Anne and her family will be informed about the importance of adherence to the treatment regimen and educated on recognizing signs of deterioration or complications. Comprehensive care with the involvement of a multidisciplinary team will aim to improve her quality of life during the treatment process."
    },
    {
        "Patient Information": {
            "Name": "James Thompson",
            "Age": "63",
            "Gender": "Male",
            "Medical History": "Type 2 diabetes diagnosed 12 years ago, chronic pancreatitis, smoker with a history of heavy smoking for 30 years"
        },
        "Disease Information": {
            "Disease": "Pancreatic cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Persistent upper abdominal pain, significant weight loss, jaundice, newly developed diabetes, fatigue, mental and emotional disorders",
            "Duration": "Symptoms have been present and worsening over the past 6 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "75 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "90 IU/L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "215 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.9 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.14 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.04 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "250 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (30 − 400)",
                "CRP": "20 mg/L (< 3 mg/L)",
                "ESR": "55 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Imaging Exams": {
                "Abdominal CT scan": "Mass in the pancreatic head with bile duct obstruction",
                "MRI": "Liver metastasis, enlarged pancreatic duct",
                "PET-CT": "High metabolic activity in the pancreatic and hepatic regions",
                "Endoscopic Ultrasound": "Large pancreatic mass with malignant features"
            },
            "Pathology Exam": "Biopsy confirmed ductal adenocarcinoma with tissue necrosis",
            "Tumor Marker Analysis": "Elevated CA199 at 500 U/ml, CEA at 15 ng/ml, CA125 at 60 U/ml"
        },
        "Treatment Plan": "The treatment plan for James Thompson encompasses palliative and supportive care aimed at alleviating pain and improving quality of life, given the advanced stage of pancreatic cancer with metastasis. As surgical intervention is not an option due to the extensive spread of the disease, the focus is on managing symptoms through a multidisciplinary approach. A combination of chemotherapy with gemcitabine and pain management using opioid analgesics will be initiated to provide relief from severe abdominal pain, following the WHO's pain relief guidelines. Nutritional support through a high-protein, easily digestible diet, along with pancreatic enzyme supplements, will aid in maintaining nutritional status, while antiemetic drugs are prescribed to address chemotherapy-induced nausea. The oncologist will evaluate potential inclusion in a clinical trial for immunotherapy, with genetic testing for MSI or MMR prior. Regular follow-up every month will include assessments of liver and kidney function, complete blood count, tumor markers, and imaging studies to monitor progression and adjust therapy as needed. Emotional support through counseling will be provided to mitigate mental and emotional disorders; communication with James and his family will be crucial throughout, emphasizing the importance of adherence to the treatment plan and lifestyle adjustments, including cessation of smoking and alcohol consumption to improve prognosis and welfare. For refractory pain not controlled by medication, interventional pain management such as neurolysis may be considered. Community support resources will be explored to assist in managing home care effectively."
    },
    {
        "Patient Information": {
            "Name": "James Thompson",
            "Age": "58",
            "Gender": "Male",
            "Medical History": "Chronic pancreatitis, Type 2 diabetes mellitus, long-term smoking history"
        },
        "Disease Information": {
            "Disease": "Pancreatic Cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Upper abdominal pain, persistent back pain, significant weight loss, jaundice, fatigue, loss of appetite",
            "Duration": "Symptoms have been progressively worsening over the past 6 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "75 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "85 IU /L (13 − 35)",
                "Urea": "9.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "120 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "36% (35 − 50)",
                "Hemoglobin (Hb)": "115 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "9% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "90 ng/mL (< 90 ng/mL)",
                "Troponin I": "13 ng/L (< 14 ng/L)",
                "Ferritin": "550 ng/mL (20 − 500 for males)",
                "CRP": "35 mg/L (< 3 mg/L)",
                "ESR": "45 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "CA19-9",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Dilated bile duct, pancreatic duct dilation",
            "Enhanced CT Scan": "Mass in pancreatic head with bile duct obstruction, no distant metastasis",
            "MRI": "Obstruction at bile duct, pancreatic duct dilation",
            "PET-CT": "Increased metabolic activity in pancreatic head region",
            "Endoscopic Ultrasound": "Identified lesion in pancreatic head, needle biopsy performed",
            "Pathology Test": "Ductal adenocarcinoma confirmed via biopsy",
            "Tumor Marker Test": "Elevated CA19-9, CA125, and CEA levels",
            "Liver Function Test": "Elevated total bilirubin and direct bilirubin",
            "Physical Exam": "Signs of jaundice, palpable gallbladder"
        },
        "Treatment Plan": "James Thompson is diagnosed with pancreatic cancer located in the pancreatic head, exhibiting extreme severity due to significant symptom presentation including jaundice, weight loss, pain, and fatigue. Given the advanced stage and insidious nature of the disease, curative options are limited, necessitating an approach focusing on palliation and quality of life enhancement. Immediate surgical intervention such as the Whipple procedure may be considered for palliative relief, primarily aimed at alleviating biliary obstruction and associated symptoms; however, current findings on tumor spread might limit surgical candidacy. Chemotherapy using a gemcitabine regimen may be initiated to prolong survival and manage symptoms, with potential integration of targeted therapies following genetic assessment for drug responsiveness. Pain management through the WHO's three-step ladder of analgesia will be critical, employing opioids and considering interventional pain therapies if required. Monitoring blood sugar levels through appropriate diabetic management and ensuring nutritional support will be essential, particularly in maintaining caloric intake and countering cachexia. Supportive care addressing James's psychological well-being and providing emotional support will complement clinical treatment, ensuring that he and his family are informed about forthcoming evaluations and the necessity of routine follow-up. Given the familial history and genetic predisposition, discussions regarding advanced care planning should be prioritized. The comprehensive treatment plan will be tailored based on James's response to initial therapies, with regular reviews to adjust medical interventions accordingly."
    },
    {
        "Patient Information": {
            "Name": "Michael Johnson",
            "Age": "58",
            "Gender": "Male",
            "Medical History": "Diabetes for over 10 years, Chronic pancreatitis, Heavy smoking history"
        },
        "Disease Information": {
            "Disease": "Pancreatic Cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Upper abdominal discomfort, significant weight loss, jaundice, severe back pain, fatigue, loss of appetite",
            "Duration": "Symptoms have been present for several months, with rapid deterioration in recent weeks",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "55 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "60 IU /L (13 − 35)",
                "Urea": "6.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "90 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.6 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "115 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "190 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "18 ng/L (< 14 ng/L)",
                "Ferritin": "550 ng/mL (20 − 500 for males)",
                "CRP": "45 mg/L (< 3 mg/L)",
                "ESR": "38 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.9 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "No significant findings, focus remains on abdominal region",
            "Serological Diagnosis": "Elevated CEA, CA199 levels",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Normal",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal",
            "Abdominal Ultrasound": "Dilation of bile duct and pancreatic duct",
            "Enhanced CT of Abdomen": "Masses in pancreatic region indicating advanced tumor",
            "MRI/MRCP": "Obstruction and dilation of bile and pancreatic ducts visualized",
            "PET-CT": "High metabolic activity in pancreatic region with signs of extrapancreatic metastasis",
            "Endoscopic Ultrasound (EUS)": "Small lesions observed, biopsy indicates malignancy",
            "Pathology Testing": "Positive for ductal adenocarcinoma"
        },
        "Treatment Plan": "Michael Johnson's pancreatic cancer diagnosis reflects an advanced stage with a poor prognosis, underscoring the need for a palliative treatment approach. Given his existing conditions of long-standing diabetes and chronic pancreatitis, alongside a history of heavy smoking, a multidisciplinary management strategy tailored to his symptoms and disease progression is essential. Surgery is not a viable option due to the extent of cancer spread. Chemotherapy regimens such as gemcitabine monotherapy, potentially supplemented by immunotherapy agents like PD-1 inhibitors, might offer some therapeutic benefit and help manage disease progression. Pain management will be critical, adhering to WHO's pain relief ladder, with opioids necessary to address severe pain. Nutritional support, considering his cachexia, will involve pancreatic enzyme supplements to aid digestion. Endoscopic stenting may alleviate jaundice and obstruction, enhancing quality of life. Emotional and psychological support is equally important, addressing any mental health challenges arising from his diagnosis. Follow-up care will focus on symptom management and palliative measures, with regular blood work, imaging studies, and tumor marker assessment ensuring optimal monitoring and adjustment of the treatment regimen. Family education and support regarding symptom vigilance, treatment adherence, and lifestyle adjustments, including dietary recommendations, will play a significant role in improving Michael's quality of life despite the advanced nature of his illness. Traditional Chinese Medicine may be considered to alleviate symptoms and improve his overall wellbeing, cooperating with conventional measures for comprehensive care."
    },
    {
        "Patient Information": {
            "Name": "Hannah Smith",
            "Age": "52",
            "Gender": "Female",
            "Medical History": "Recent discomfort swallowing, history of cervicitis, occasional esophageal discomfort"
        },
        "Disease Information": {
            "Disease": "Carcinoma in situ",
            "Severity Level": "Minor Severity",
            "Symptoms": "Discomfort swallowing food, dryness in the throat, local erosion in the esophageal lining",
            "Duration": "Symptoms noticed and gradually worsening over the past three months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "4.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "60 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "36% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "90 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Ferritin": "100 ng/mL (20 − 200 for females)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Endoscopic Examination": "Localized mucosal congestion with superficial erosion in the esophagus",
            "Esophagogastroduodenoscopy": "Histology confirmed carcinoma in situ in esophageal lining",
            "Ultrasound Examination": "No detectable mass in the breast",
            "Breast Cytology": "Normal",
            "Cervical Cytology Smear": "Normal",
            "Nuclear Imaging": "No invasive cancer signs detected",
            "Histological Biopsy": "Confirms carcinoma in situ with cells not breaching basal membrane",
            "Tumor Marker Tests": "Negative for carcinoma markers"
        },
        "Treatment Plan": "Hannah Smith's diagnosis of carcinoma in situ of the esophagus has been established through endoscopic examination and histological biopsy. Due to the non-invasive nature of the condition, an endoscopic mucosal resection is recommended as a primary treatment method to effectively remove the affected site. This minimally invasive procedure will ensure complete removal of localized cancerous cells while causing minimal discomfort and recovery time. Further evaluation through regular endoscopic surveillance will be necessary to monitor for potential progression or recurrence, and patient education regarding esophageal health and dietary modifications will be provided. Hannah is advised to follow up with her gastroenterologist for monitoring and possible treatment of any precancerous lesions detected in future screenings. Since her condition is highly curable in this early stage, a proactive approach will focus on maintaining regular health checks and adopting lifestyle changes, including dietary adjustments to minimize potential risk factors for esophageal cancer development. Additionally, psychological support and routine examinations will be emphasized to ensure her physical and mental well-being throughout recovery."
    },
    {
        "Patient Information": {
            "Name": "Alice Zhang",
            "Age": "52",
            "Gender": "Female",
            "Medical History": "Previous history of cervicitis and irregular Pap smears"
        },
        "Disease Information": {
            "Disease": "Cervical Carcinoma in situ",
            "Severity Level": "Moderate Severity",
            "Symptoms": "No noticeable lumps, occasional abnormal discharge, detected during routine health screening",
            "Duration": "No obvious symptoms for the past year, detected during routine examination",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.9 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.3 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "37% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "240 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "55% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.86 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.41 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "C-Reactive Protein (CRP)": "2 mg/L (< 3 mg/L)",
                "Ferritin": "120 ng/mL (20 − 500 for females)",
                "ESR": "10 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Negative",
                "ABO Group": "A",
                "Specific Antigen": "HPV detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Pap Smear": "Atypical squamous cells of undetermined significance",
            "Colposcopy": "Identified abnormal cervical epithelium",
            "Cervical Biopsy": "Pathology confirmed carcinoma in situ",
            "HPV Testing": "Positive for high-risk HPV types",
            "Pelvic Ultrasound": "Normal uterine and ovarian structure",
            "Vaginal Examination": "No visible lesions"
        },
        "Treatment Plan": "Alice Zhang has been diagnosed with cervical carcinoma in situ, detected during routine health screening, thus presenting an excellent opportunity for early intervention with a high likelihood of cure. A simple hysterectomy is recommended as a definitive treatment for cervical carcinoma in situ due to its effectiveness in completely removing the pre-cancerous cells, preventing progression to invasive cancer. The patient will undergo preoperative counseling to discuss the benefits and risks associated with the procedure, along with potential alternatives such as cone biopsy if fertility preservation is a consideration. Post-surgical follow-up will include regular Pap smear tests and HPV screenings to monitor for any signs of recurrence, essential due to her history of cervicitis and irregular Pap smears. Adequate supportive care, including pain management and psychological support, will be provided to ensure a smooth recovery. Alice will be educated on maintaining a healthy lifestyle, emphasizing the importance of not smoking, consuming a balanced diet, and engaging in regular exercise to reduce cancer recurrence risks. Regular consultations with her healthcare team will be scheduled to ensure successful treatment outcomes and long-term health management."
    },
    {
        "Patient Information": {
            "Name": "Laura Smith",
            "Age": "52",
            "Gender": "Female",
            "Medical History": "Frequent cervicitis, family history of cervical cancer"
        },
        "Disease Information": {
            "Disease": "Carcinoma in situ (Cervical)",
            "Severity Level": "Minor Severity",
            "Symptoms": "Local erosion, roughness, minor elevations, occasional discomfort similar to cervicitis",
            "Duration": "Detected during routine screening, estimated to have been present for a few months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "65 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.9 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "9% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.04 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.7% (0 − 1)",
                "Mean Platelet Volume (MPV)": "9.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198 for females)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "120 ng/mL (20 − 500 for females)",
                "CRP": "3 mg/L (< 10 mg/L)",
                "ESR": "18 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "No specific antigen detected",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Pap Smear": "Atypical squamous cells of undetermined significance",
            "Colposcopy Examination": "Irregular lesions on the cervix, biopsy needed",
            "Biopsy Examination": "Confirmed carcinoma in situ",
            "HPV Test": "Positive for high-risk HPV types",
            "Ultrasound Examination": "No abnormal masses detected in pelvis",
            "Breast Examination": "Normal",
            "Endoscopic Examination": "Normal esophagus, no signs of carcinoma in situ",
            "Skin Examination": "No signs of Bowen's disease"
        },
        "Treatment Plan": "Laura Smith has been diagnosed with minor severity carcinoma in situ of the cervix, detected during routine health screening. Given the high curability of the condition, a treatment plan that includes a simple hysterectomy is recommended to effectively remove the affected area and prevent progression. Post-operative care will involve monitoring for any signs of recurrence, regular follow-up consultations, and possible HPV vaccination to reduce the risk of future occurrences. Psychological counseling and support will be provided to help Laura manage the emotional impact of the diagnosis and treatment. Laura will be educated on lifestyle modifications to prevent recurrence, including quitting smoking, practicing safe sexual behaviors, maintaining a balanced diet, and engaging in regular physical activity. Regular screenings and gynecological check-ups will be crucial to ensure her continued health and recovery. The healthcare team will work closely with Laura to ensure adherence to the treatment plan, involving her in the decision-making process and addressing her concerns and preferences. By taking proactive measures, Laura can anticipate a favorable prognosis with minimal disruption to her daily life."
    },
    {
        "Patient Information": {
            "Name": "John Doe",
            "Age": "53",
            "Gender": "Male",
            "Medical History": "Phimosis, Smoking, Infrequent Personal Hygiene"
        },
        "Disease Information": {
            "Disease": "Penile Cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Presence of papules and ulcerations on the glans, purulent discharge, occasional bleeding during intercourse, and mild pain",
            "Duration": "Symptoms have been present and gradually worsening for the past 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "27 IU /L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.4 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "160 U/L (22 − 198 for males)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500 for males)",
                "CRP": "4 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "SCC Antigen",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Lesion identified at the glans with no evident invasion of the tunica albuginea",
            "MRI": "Localized mass in the glans area with slight invasion noted",
            "Pathological Examination": "Confirms squamous cell carcinoma",
            "Inguinal Lymph Node Biopsy": "Negative for metastasis",
            "Serological Diagnosis": "Normal",
            "Urinalysis": "Normal",
            "Physical Examination": "Presence of indurated mass on the glans with ulceration"
        },
        "Treatment Plan": "John Doe has been diagnosed with penile cancer with moderate severity, as indicated by the localized mass in the glans and absence of lymph node metastasis. The treatment will primarily focus on surgical intervention to excise the tumor while attempting to preserve penile structure and function. A partial penectomy is recommended, given that the cancer is confined to the glans area, which should aid in maintaining both urination and some sexual function. Post-surgery, John will undergo localized radiation therapy to ensure all cancer cells are eradicated and to prevent recurrence. In the presence of any signs of infection such as purulent discharge, appropriate antibiotics will be administered after obtaining culture results to ensure effective treatment. Follow-up appointments will be arranged to closely monitor healing, with regular physical examinations to identify any potential recurrence. John will be advised on personal hygiene improvement and smoking cessation to aid in his recovery and reduce future cancer risk. Nutritional support and possible psychological counseling will be offered to support his mental and physical well-being during and after treatment."
    },
    {
        "Patient Information": {
            "Name": "Jonathan Carter",
            "Age": "55",
            "Gender": "Male",
            "Medical History": "Phimosis, Excessive foreskin, History of HPV infection"
        },
        "Disease Information": {
            "Disease": "Penile Cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Papules, ulcers, or cauliflower-like masses on the glans with a tingling or burning sensation, bleeding signs under the foreskin, difficulty urinating",
            "Duration": "Symptoms have been present for several weeks with gradual progression",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.7 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.7 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "46% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.7 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "195 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "151 U/L (22 − 198 for males)",
                "Myoglobin": "67 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "245 ng/mL (20 − 500 for males)",
                "CRP": "4 mg/L (< 3 mg/L)",
                "ESR": "18 mm/hr (0 − 20)",
                "Procalcitonin": "0.12 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Squamous Cell Carcinoma Antigen",
                "Blood Silver Level": "56 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Shows tumor invasion in the glans, but no invasion into the tunica albuginea",
            "MRI": "Clear indication of lesion on glans without lymph node involvement",
            "Biopsy": "Confirmed squamous cell carcinoma",
            "Pathological Examination": "Tumor cells limited to mucosa without stromal invasion",
            "Inguinal Lymph Node Palpation": "No palpable lymph nodes",
            "Serological Diagnosis": "Normal",
            "HPV Test": "Positive for high-risk HPV types"
        },
        "Treatment Plan": "Jonathan Carter has been diagnosed with moderate severity penile cancer, with symptoms including papules and ulcers on the glans and difficulty urinating. Given the diagnosis, a combination of surgical and radiation therapy is recommended to effectively manage the condition. Initial management will include a partial penectomy, as the tumor is confined to the glans, with the goal of preserving some sexual function and upright urination ability. As there is no lymph node involvement, conservative management of the lymph nodes will be taken initially, with regular monitoring. Radiation therapy will be utilized post-surgery to ensure local control and reduce the risk of recurrence. Antibiotics will be prescribed to manage any potential infections due to ulcerations and purulent discharges in the affected area. Regular follow-up and imaging will be essential for monitoring Jonathan's progress, with the potential for penile reconstruction if there is no recurrence within two years. In addition, engagement in pelvic floor exercises will be encouraged to maintain urinary function, and comprehensive support including psychological counseling will be offered to help manage any emotional stress related to the diagnosis and treatment. A multidisciplinary approach involving oncologists, urologists, and a supportive care team will be employed to provide holistic care for Jonathan's health and recovery."
    },
    {
        "Patient Information": {
            "Name": "John Thompson",
            "Age": "53",
            "Gender": "Male",
            "Medical History": "Phimosis, excessive foreskin, chronic inflammation of the glans"
        },
        "Disease Information": {
            "Disease": "Penile Cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Papules and ulcers on the glans with bleeding under foreskin, purulent discharge, difficulty urinating, pain during intercourse",
            "Duration": "Symptoms have been present for approximately 3 months with gradual worsening",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "170 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "11 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Ultrasound": "Presence of cauliflower-like mass on the glans with no visible invasion of tunica albuginea",
            "MRI": "Lesion localized to the glans, no evidence of lymph node metastasis",
            "Pathology": "Squamous cell carcinoma confirmed by biopsy of the penile mass",
            "SCC Antigen": "Elevated, indicating tumor burden",
            "Physical Examination": "Palpation reveals tenderness and nodules on foreskin and glans"
        },
        "Treatment Plan": "John Thompson is diagnosed with penile cancer, presenting with moderate symptoms including papules, ulcers, bleeding, and difficulty urinating. Given the moderate severity of his condition, surgical intervention is recommended to remove the tumor mass while preserving penile functionality as much as possible. Partial penectomy will be performed, focusing on removing cancerous tissue while maintaining urination and sexual function. Preoperative assessment has not indicated lymph node metastasis, suggesting a positive prognosis. Post-surgery, radiation therapy may be utilized to prevent recurrence and ensure local tumor control. Antibiotics will be administered to manage any infection resulting from the tumor area's purulent discharge, with regular cleaning and dressing changes essential for preventing further complications. Nutritional support, moderate exercise, and family care will be advocated to aid recovery and bolster mental health. Follow-ups every two months for the first year will be scheduled to monitor for signs of recurrence, with potential penile reconstruction considered if the recovery progresses well. John will be guided on maintaining hygiene and safe sexual practices to reduce the risk of HPV infection, alongside psychological support to manage any embarrassment or stress from the condition and treatment."
    },
    {
        "Personal Information": {
            "Name": "Margaret Johnson",
            "Age": "65",
            "Gender": "Female",
            "Medical History": "Chronic pancreatitis, hypertension"
        },
        "Disease Information": {
            "Disease": "Pancreatic Tumor",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Abdominal pain, jaundice, weight loss, cachexia",
            "Duration": "Symptoms have been progressively worsening over the past three months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "75 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "90 IU /L (13 − 35)",
                "Urea": "9.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "110 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "400 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "210 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "1000 ng/mL (20 − 500 for females)",
                "CRP": "80 mg/L (< 3 mg/L)",
                "ESR": "55 mm/hr (0 − 20)",
                "Procalcitonin": "0.8 ng/mL (< 0.5)",
                "D-dimer": "1.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Pancreatic cancer marker CA 19-9",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "CT Scan": "Large mass in the head of the pancreas with involvement of surrounding tissues and distant metastasis",
            "MRI": "Advanced stage pancreatic tumor with vascular encasement",
            "Endoscopic Ultrasound": "Significant mass with mixed solid and cystic components in the pancreas",
            "PET-CT": "High uptake indicating malignancy and metastasis to liver and lungs",
            "ERCP": "Ductal compression and obstruction",
            "Liver Function Test": "Impaired liver function with elevated bilirubin",
            "Tumor Marker Test": "Elevated CA 19-9 levels",
            "Biopsy": "Adenocarcinoma of the pancreas"
        },
        "Treatment Plan": "Margaret Johnson has been diagnosed with an advanced pancreatic tumor characterized by extreme severity, with metastasis to the liver and lungs. Her medical history of chronic pancreatitis and current hypertension complicates the treatment plan. Surgery is not viable due to the widespread metastasis and vessel encasement, and the treatment will focus on palliative care to manage symptoms and improve quality of life. Chemotherapy with agents such as Gemcitabine or Nab-Paclitaxel will be initiated to attempt tumor reduction and alleviate symptoms, alongside targeted radiotherapy where feasible, to control local tumor growth and reduce pain. Supportive care will include analgesics for pain management, antiemetics for nausea, and nutritional support to address cachexia and weight loss, along with regular blood glucose monitoring due to potential glucagonoma effects. Follow-ups for liver function and other organ involvement will be essential, with collaborative care from oncology, gastroenterology, and palliative specialists to ensure comprehensive management. Margaret and her family will be counseled on the prognosis and given psychological support, with hospice care options discussed as necessary, ensuring respect for her comfort and dignity throughout the progression of her illness."
    },
    {
        "Patient Information": {
            "Name": "Margaret Baxter",
            "Age": "65",
            "Gender": "Female",
            "Medical History": "Chronic pancreatitis, Type 2 diabetes, Hypertension"
        },
        "Disease Information": {
            "Disease": "Pancreatic Tumor - Pancreatic Ductal Adenocarcinoma",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Abdominal pain, jaundice, weight loss, new-onset diabetes, back pain, pale stools",
            "Duration": "Symptoms have progressed over the past 6 months with increased intensity",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "70 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "80 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.7 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "180 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for females)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Carbohydrate Antigen 19-9 elevated",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Abdominal CT Scan": "Shows a mass in the pancreatic head with bile duct obstruction and liver metastases",
            "MRI": "Further characterizes the mass with pancreatic ductal dilation",
            "Endoscopic Ultrasound": "Identifies a hypoechoic mass in the pancreatic head with involvement of surrounding vessels",
            "Biopsy": "Confirms pancreatic ductal adenocarcinoma",
            "PET-CT": "Shows increased uptake in the pancreatic mass and liver metastases",
            "Tumor Marker Test": "CA 19-9 significantly elevated",
            "Liver Function Test": "Elevated bilirubin levels, indicating jaundice",
            "Blood Sugar Level": "18 mmol/L (high, correlating with new-onset diabetes)"
        },
        "Treatment Plan": "Margaret Baxter has been diagnosed with advanced pancreatic ductal adenocarcinoma, characterized by a mass in the pancreatic head with liver metastases and bile duct obstruction causing jaundice. Due to the extreme severity and advanced stage of the disease, the primary goal is palliative care to enhance her quality of life and manage symptoms. Chemotherapy with Gemcitabine and Nab-Paclitaxel may be used to slow tumor progression and relieve symptoms, although the prognosis remains poor. Endoscopic stenting of the bile duct can be performed to alleviate jaundice and improve liver function, while pain management will be key, utilizing opioids or other analgesics as necessary. Focus will be placed on nutritional support and managing her new-onset diabetes, with insulin therapy required to control blood glucose levels. A multidisciplinary approach involving oncologists, gastroenterologists, and palliative care specialists will tailor ongoing management to Margaret’s symptoms and preferences, providing psychological support and counseling to both her and her family. Regular assessments will determine her response and make necessary adjustments to her treatment plan, with hospice care being considered as her condition progresses. It is crucial to maintain open communication with Margaret to ensure her goals and wishes are prioritized throughout her treatment journey."
    },
    {
        "Patient Information": {
            "Name": "Sandra Thompson",
            "Age": "58",
            "Gender": "Female",
            "Medical History": "Hypertension, Diabetes, Previous episodes of chronic pancreatitis"
        },
        "Disease Information": {
            "Disease": "Pancreatic Tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Upper abdominal pain, weight loss, jaundice, fatigue",
            "Duration": "Symptoms have been progressively worsening over the past 3 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "60 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "72 IU/L (13 − 35)",
                "Urea": "5.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "82 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.7 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "480 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "130 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "9 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for females)",
                "CRP": "12 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Abdominal CT Scan": "Enlarged pancreatic duct with irregular mass in the head of the pancreas, suggestive of malignancy",
            "MRI": "Heterogeneous mass in the pancreas with possible invasion of surrounding tissues",
            "Endoscopic Ultrasound (EUS)": "Complex mass with mixed echogenicity, biopsy indicated",
            "PET-CT": "Increased uptake indicating high metabolic activity in the pancreas",
            "ERCP": "Dilated biliary tree due to obstructive mass in the pancreas",
            "CA 19-9 Tumor Marker": "Elevated",
            "Biopsy": "Adenocarcinoma of the pancreas"
        },
        "Treatment Plan": "Sandra Thompson has been diagnosed with a pancreatic tumor, specifically an adenocarcinoma in the head of the pancreas, indicated by symptoms of abdominal pain, jaundice, and significant weight loss over the last three months. As the tumor is diagnosed at a major severity level, a comprehensive treatment plan incorporating surgical intervention, chemotherapy, and supportive care is essential. Immediate surgical options such as a pancreatoduodenectomy, commonly known as the Whipple procedure, will be considered to remove the tumor. Post-surgical adjuvant chemotherapy with a regimen including Gemcitabine and Nab-Paclitaxel will be initiated to manage any residual cancer cells and improve overall survival rates. Given the patient's complexity due to existing diabetes and hypertension, preoperative optimization of blood glucose levels and blood pressure will be managed diligently. Nutritional support and management of symptoms like pain and jaundice through ERCP will be part of preoperative care. Postoperatively, monitoring will involve regular imaging studies and CA 19-9 levels to assess treatment effectiveness and detect any recurrence early. Sandra will be educated about the importance of maintaining a balanced diet, engaging in regular physical activity, and attending follow-up appointments for ongoing monitoring. Psychological support and counseling will be offered to Sandra and her family to aid coping with the diagnosis and treatment process."
    },
    {
        "Patient Information": {
            "Name": "Emma Thompson",
            "Age": "35",
            "Gender": "Female",
            "Medical History": "No significant family history of tumors, sporadic insulinoma diagnosis"
        },
        "Disease Information": {
            "Disease": "Insulinoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Spontaneous hypoglycemic episodes, blood glucose levels below 2.8 mmol/L, hunger, sweating, palpitations, confusion, abnormal behavior",
            "Duration": "Symptoms have been present for several weeks, occurring mainly during fasting periods",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Abdominal CT Exam": "Small pancreatic lesion in the tail, suggestive of insulinoma",
            "MRI": "Enhanced signal in pancreatic tail, correlating with CT findings",
            "Endoscopic Ultrasound": "Clear image of small insulinoma in pancreatic tail",
            "Chromogranin A Test": "Elevated",
            "Pancreatic Polypeptide Test": "Normal",
            "Insulin Suppression Test": "Positive",
            "Serum Biomarkers": "Elevated insulin levels consistent with hypoglycemia",
            "CT Angiography": "Not necessary at this stage",
            "68Ga PET Imaging": "Inconclusive",
            "Pathology": "Biopsy pending"
        },
        "Treatment Plan": "Emma Thompson has been diagnosed with a moderate severity insulinoma, located in the pancreatic tail. Initial treatment will focus on controlling symptoms through medical management, including frequent small meals and intravenous glucose infusion to manage hypoglycemic episodes effectively. Diazoxide may be employed to suppress insulin secretion and alleviate hypoglycemia. Ongoing evaluation of her condition will be crucial, with a close watch on her response to medical management. Should Emma's health allow, a surgical approach may be considered to remove the insulinoma after preoperative localization is confirmed through imaging techniques like CT and endoscopic ultrasound. The surgical option being explored is laparoscopic tumor enucleation, emphasizing preservation of pancreatic tissue. Post-operative monitoring will involve regular checks on blood glucose levels and periodic imaging studies to assess any recurrence. Emma and her family will receive guidance on managing hypoglycemia symptoms and lifestyle adjustments necessary for recovery. The treatment strategy will adapt based on Emma's progress, with potential involvement in clinical trials if conventional approaches are not viable, ensuring her comfort and wellbeing are prioritized throughout the treatment phase."
    },
    {
        "Patient Information": {
            "Name": "Emily Johnson",
            "Age": "45",
            "Gender": "Female",
            "Medical History": "Chronic pancreatitis, smoking history"
        },
        "Disease Information": {
            "Disease": "Insulinoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Spontaneous hypoglycemic symptoms, sweating, palpitations, confusion, brain dysfunction during fasting",
            "Duration": "Symptoms have been present for two weeks, worsening during fasting periods",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.4 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.8% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "350 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Abdominal Ultrasound": "Small mass in the body of the pancreas",
            "CT Scan": "Hyperdense lesion with homogeneous enhancement in the pancreas",
            "MRI": "T1-weighted images show a well-defined lesion in the pancreas",
            "Endoscopic Ultrasound": "Localization of insulinoma in the pancreatic body",
            "Serological Diagnosis": "Elevated Chromogranin A",
            "Hormone Levels": "Elevated insulin levels during hypoglycemic episodes",
            "Pancreatic Function Test": "Mild impairment",
            "Tumor Marker Test": "Normal",
            "Somatostatin Receptor Imaging": "Positive somatostatin receptor expression",
            "Invasive Pancreatic Angiography": "Enhanced uptake in pancreatic body lesion",
            "Pathology": "Grade G1 neuroendocrine tumor, Ki-67 index ≤2%"
        },
        "Treatment Plan": "Emily Johnson has been diagnosed with an insulinoma, which is a functional pancreatic neuroendocrine tumor producing excess insulin and causing significant hypoglycemic symptoms. Due to the moderate severity of her condition and the localization of the tumor in the pancreatic body, surgical intervention is the most appropriate approach to remove the tumor and restore normal insulin secretion levels. Pre-operative imaging, including CT, MRI, and endoscopic ultrasound, has confirmed the precise location of the tumor, guiding the surgical team towards a minimally invasive laparoscopic pancreatectomy, preserving pancreatic function and minimizing recovery time. Diazoxide may be administered pre-operatively to suppress excessive insulin secretion, reducing hypoglycemic symptoms, alongside a regimen of frequent small meals and intravenous glucose to maintain adequate blood sugar levels. Post-operative management will include monitoring for potential complications and regular follow-up imaging and blood tests to ensure complete recovery and detect any possibility of recurrence. Given the benign nature and low-grade pathology of the tumor, the prognosis is highly favorable, and Emily is expected to make a full recovery. Nutritional support and family care will be essential in managing her post-surgical recovery. Additionally, Emily will receive guidance on maintaining a stable lifestyle, with attention to dietary modifications and psychological support to alleviate any stress related to her condition and recovery."
    },
    {
        "Patient Information": {
            "Name": "Alice Johnson",
            "Age": "54",
            "Gender": "Female",
            "Medical History": "Frequent episodes of hypoglycemia, memory decline, family history of Multiple Endocrine Neoplasia type 1 (MEN1)"
        },
        "Disease Information": {
            "Disease": "Insulinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Spontaneous hypoglycemic symptoms, confusion, trembling, palpitations, brain dysfunction, memory decline, episodes of fasting hypoglycemia",
            "Duration": "Symptoms have been present for several months with increasing frequency during fasting periods",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "20 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Chromogranin A (CgA)",
                "Blood Sugar Level": "2.5 mmol/L (3.9−5.6)"
            },
            "Abdominal CT Scan": "Localized small tumor in the tail of the pancreas, enhanced in dynamic scanning",
            "MRI": "Tumor visible in tail of pancreas with uniform density",
            "Endoscopic Ultrasound": "High-resolution image confirming tumor in the tail of pancreas",
            "Serum Chromogranin A Test": "Elevated at 5 times normal level",
            "Pancreatic Polypeptide Test": "Normal",
            "Insulin Test": "Elevated",
            "Glucose Suppression Test": "Positive, indicating insulinoma",
            "Somatostatin Receptor Imaging": "Positive for receptor expression",
            "Pathological Examination": "Grade G1, low-grade neuroendocrine tumor"
        },
        "Treatment Plan": "Alice Johnson has been diagnosed with a functional insulinoma in the tail of the pancreas, which has led to persistent hypoglycemic episodes. Considering the severity of her symptoms and the presence of elevated serum chromogranin A levels, surgical intervention is the preferred treatment approach. Tumor enucleation via laparoscopic surgery is recommended to remove the insulinoma while preserving pancreatic function. Preoperative localization using CT, MRI, and endoscopic ultrasound has pinpointed the tumor's exact location, aiding surgical precision. Post-surgery, Alice's blood sugar levels will be closely monitored to assess recovery, and intravenous glucose may be administered temporarily to manage any residual hypoglycemia. Additionally, she will receive dietary counseling to adhere to a regimen of frequent small meals to stabilize blood glucose levels and avoid fasting-induced hypoglycemia. Follow-up consultations will focus on evaluating her progress and ensuring no recurrence or new tumor development, given her family history of MEN1. Regular serum chromogranin A and glucose tests will be performed during follow-ups to detect any changes early. Alice will be supported through family care and psychological counseling to manage the emotional stress associated with her diagnosis and treatment journey."
    },
    {
        "Patient Information": {
            "Name": "Margaret Thompson",
            "Age": "53",
            "Gender": "Female",
            "Medical History": "Postmenopausal, history of breast lumps, hypertension"
        },
        "Disease Information": {
            "Disease": "Inflammatory Breast Cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Diffuse erythema, edema, peau d'orange over one-third of the breast, rapid progression, breast enlargement, skin redness and hardening, tenderness",
            "Duration": "Symptoms have progressed over the past two weeks",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "65 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "122 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "180 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.9 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.25 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.1% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "170 U/L (22 − 198 for females)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "210 ng/mL (20 − 500 for females)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "55 mm/hr (0 − 20)",
                "Procalcitonin": "0.25 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "HER2 overexpression",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Breast Ultrasound": "Diffuse thickening of the skin with underlying edematous changes and indistinct mass margins",
            "Mammography": "Large area of asymmetric density with skin thickening",
            "Breast MRI": "Extensive skin thickening and edema, large, ill-defined mass in the breast",
            "PET-CT": "Multiple lymph node involvement, no distant metastasis detected",
            "Biopsy": "Inflammatory breast cancer with HER2 overexpression and negative ER/PR receptors",
            "Liver Function Test": "Normal",
            "Kidney Function Test": "Normal"
        },
        "Treatment Plan": "Margaret Thompson's diagnosis of inflammatory breast cancer presents with extreme severity, necessitating immediate and aggressive multidisciplinary treatment. Initial neoadjuvant chemotherapy is imperative to reduce the primary tumor size and lymph node involvement, enabling her to meet surgical criteria for a modified radical mastectomy. Given the HER2-positive status, targeted therapy with trastuzumab and pertuzumab will be administered concurrently with chemotherapy to maximize treatment efficacy. Post-surgery, adjuvant chemotherapy will continue, using a regimen consistent with the pre-operative treatment, followed by radiation therapy to the chest wall and regional lymph nodes to prevent recurrence. Endocrine therapy is not applicable due to the absence of ER/PR receptor expression. Throughout this treatment process, it is crucial for Margaret to maintain her overall health through a balanced diet, regular light exercise, and psychological support to cope with the stress associated with her diagnosis and treatment. Regular follow-ups and imaging studies will be necessary to monitor her response to therapy and make any needed adjustments to her treatment plan. Her family should be actively involved in her care, helping her adhere to medical advice and supporting her emotional well-being."
    },
    {
        "Patient Information": {
            "Name": "Elizabeth Thompson",
            "Age": "52",
            "Gender": "Female",
            "Medical History": "Postmenopausal; history of breast cancer screening; no prior diagnosis of breast cancer"
        },
        "Disease Information": {
            "Disease": "Inflammatory Breast Cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Diffuse erythema, edema, and peau d'orange involving at least one-third of the breast, breast enlargement, skin redness, hardening, tenderness, increased temperature, patchy pigmentation",
            "Duration": "Symptoms have been escalating rapidly over the past week",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.01 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "230 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 300 for females)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "HER2 Overexpression",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Mammography": "Diffuse skin thickening and increased density in affected breast area",
            "Ultrasound": "Increased echogenicity consistent with inflammatory changes",
            "MRI": "Diffuse enhancement and skin thickening in the involved breast, lack of clear mass lesion",
            "PET-CT": "Evidence of early metastasis to regional lymph nodes, suspicious liver lesions",
            "Biopsy": "Positive for invasive ductal carcinoma, HER2 overexpression, estrogen receptor negative",
            "Serum Antibody Test": "Negative",
            "Skin Biopsy": "Cancer emboli in dermal lymphatics",
            "Bone Scintigraphy": "Evidence of bone metastases",
            "Liver Function Test": "Normal"
        },
        "Treatment Plan": "Elizabeth Thompson has been diagnosed with inflammatory breast cancer, demanding a prompt and aggressive treatment strategy due to its rapid progression and poor prognosis. A multidisciplinary approach is essential, beginning with neoadjuvant chemotherapy to reduce the tumor size and inflammatory changes, potentially involving anthracyclines combined with taxanes, given her HER2-positive status, targeted therapy with trastuzumab and pertuzumab will be administered. Following chemotherapy response, modified radical mastectomy is advisable, while immediate breast reconstruction is not recommended. Postoperative therapy will include radiation of the chest wall and regional lymph nodes to minimize recurrence risk, especially considering potential internal mammary involvement. Endocrine therapy is not applicable due to estrogen receptor negativity. Coordination with oncology specialists for regular monitoring through imaging and blood tests is critical to evaluate therapy efficacy and adapt treatment plans accordingly. Elizabeth and her family will be educated on recognizing symptoms of disease progression and the importance of adhering to the treatment regimen. Nutritional support and psychological counseling will be provided to maintain her overall well-being, alongside recommended lifestyle adjustments and regular breast cancer screenings."
    },
    {
        "Patient Information": {
            "Name": "Judy Thompson",
            "Age": "53",
            "Gender": "Female",
            "Medical History": "Postmenopausal, history of chronic mastitis"
        },
        "Disease Information": {
            "Disease": "Inflammatory Breast Cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Diffuse enlargement of the entire breast, edema, peau d'orange, erythema, tenderness, skin ulcerations, rapid progression, early metastasis",
            "Duration": "Symptoms have been present and rapidly worsening over the past two weeks",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "37% (35 − 50)",
                "Hemoglobin (Hb)": "125 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.3 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.01 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "150 ng/mL (20 − 500 for females)",
                "CRP": "35 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "HER2 overexpression",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Mammography": "Diffuse skin thickening and increased breast size with indistinct tumor boundaries",
            "Ultrasound": "Extensive skin edema and increased echogenicity in the breast tissue",
            "MRI": "Diffuse enhancement of the skin and breast parenchyma with skin nodularity",
            "PET-CT": "Increased uptake in the breast and evidence of distant lymph node involvement",
            "Biopsy Results": "Invasive ductal carcinoma with HER2 overexpression, negative for ER and PR",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Respiratory Function Test": "Normal",
            "Bone Scintigraphy": "No evidence of bone metastasis"
        },
        "Treatment Plan": "Judy Thompson is diagnosed with highly aggressive inflammatory breast cancer, necessitating an integrated treatment approach. The plan involves initiating neoadjuvant chemotherapy to reduce tumor size and inflammation, employing an anthracycline and taxane regimen. As HER2 overexpression is confirmed, targeted therapy with trastuzumab and pertuzumab will be introduced, with close monitoring of cardiac function. Following chemotherapy, modified radical mastectomy will be performed, with postoperative radiation therapy to address the chest wall and regional lymph nodes, especially given the presence of distant lymph node involvement. Judy will be followed up with adjuvant chemotherapy based on her response to neoadjuvant treatment, ensuring no cross-resistance to previous drugs if initial regimens are ineffective. Due to negative ER and PR statuses, endocrine therapy is not indicated. Nutritional support and psychological counseling will be provided to manage the side effects of treatment. Regular imaging and blood tests will track her progress, and continued family support is essential. Judy is advised to lead a healthy lifestyle, with balanced nutrition and regular exercise, to aid recovery and maintain strength during treatment. Long-term follow-up is crucial to monitor for any signs of recurrence or metastasis, with adjustments to her care plan as needed."
    },
    {
        "Patient Information": {
            "Name": "Ella Thompson",
            "Age": "15",
            "Gender": "Female",
            "Medical History": "Previous pneumonia, recent respiratory infection, history of cough and chest pains"
        },
        "Disease Information": {
            "Disease": "Inflammatory Myofibroblastic Tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Cough, chest pain, difficulty breathing, mild fever, weight loss",
            "Duration": "Symptoms have persisted for approximately 2 weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "25 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "20 IU /L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "60 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "41% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "300 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "140 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "250 ng/mL (20 − 500 for males)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Localized soft tissue mass in the lung causing compression",
            "Chest Computerized Tomography": "Soft tissue mass identified in the lung region, causing mild compression",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Mildly impaired",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for specific antibodies",
            "Pulmonary Function Test": "Moderate impairment observed",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Ella Thompson has been diagnosed with an inflammatory myofibroblastic tumor located in the lung region, leading to moderate compression and associated respiratory symptoms. The preferred treatment approach is surgical removal of the tumor to alleviate compression and associated symptoms. The identified tumor appears suitable for surgical excision, and preparations for thoracic surgery are underway to ensure complete removal, prioritizing Ella's lung function preservation. Given the tumor's moderate severity, postoperative chemotherapy or ALK inhibitor therapy may be considered based on Ella's response and any molecular characteristics identified during the pathology. Regular follow-up and imaging studies, including CT scans, will be conducted every three to six months to monitor for potential recurrence, given the higher likelihood associated with inflammatory myofibroblastic tumors. Ella's parents will be advised on recognizing signs of recurrence, maintaining scheduled follow-ups, and Ella will receive postoperative care instructions to ensure optimal recovery. Nutritional support, pain management, and respiratory exercises will be integrated into her recovery plan to enhance lung function and overall health outcomes."
    },
    {
        "Patient Information": {
            "Name": "Olivia Johnson",
            "Age": "16",
            "Gender": "Female",
            "Medical History": "No significant previous medical history, some respiratory infections during childhood"
        },
        "Disease Information": {
            "Disease": "Inflammatory Myofibroblastic Tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Cough, chest pain, difficulty breathing, weight loss, mild fever",
            "Duration": "Symptoms have been present and progressively worsening over the last two weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "65 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.9 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.25 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Ferritin": "350 ng/mL (20 − 500 for females)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Presence of a mass in the left lower lung zone",
            "Chest Computerized Tomography": "5 cm soft tissue mass in left lung with mild compression of surrounding structures",
            "Serological Diagnosis": "Elevated levels of inflammatory markers",
            "Viral Antigen Detection": "Negative for common respiratory viruses",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Negative",
            "Respiratory Function Test": "Mild restriction due to mass effect",
            "Sputum Examination": "No pathogens detected",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for known infections",
            "Pulmonary Function Test": "Moderately impaired due to mass effect",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Olivia Johnson has been diagnosed with an inflammatory myofibroblastic tumor located in her left lung, presenting with symptoms such as persistent cough, chest pain, and difficulty breathing. Given the moderate severity and the tumor’s location, surgical excision is recommended as a primary treatment approach. The surgery will aim to remove the tumor completely to minimize the risk of recurrence. Pre-operative imaging tests will guide the surgical strategy, ensuring the tumor is excised with adequate margins. Post-surgery, monitoring through periodic chest imaging, including CT scans, will be crucial to detect any signs of recurrence early. Although the tumor's ALK status is not contributory, regular follow-up with imaging every 3-6 months is advised, extending to yearly checks after the initial recovery period. Due to potential post-operative respiratory compromise, pulmonary rehabilitation might be helpful to improve lung function and quality of life. Olivia will be educated about the signs of recurrence and advised to maintain regular follow-ups, with special attention to any new respiratory symptoms or changes in her health. Given her age, a multidisciplinary approach, including a pediatric specialist, may assist in optimizing her treatment and recovery process, ensuring comprehensive care. Supportive care, including pain management, nutritional support, and psychological counseling, will be provided as needed to assist her and her family in coping with the diagnosis and treatment process."
    },
    {
        "Patient Information": {
            "Name": "Emily Carter",
            "Age": "17",
            "Gender": "Female",
            "Medical History": "History of pneumonia and previous steroid hormone use"
        },
        "Disease Information": {
            "Disease": "Inflammatory Myofibroblastic Tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Abdominal pain, gastrointestinal discomfort, fever, weight loss",
            "Duration": "Symptoms have been present for the past two months with progressive discomfort",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "41% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "320 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.6 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.1 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "90 U/L (22 − 198)",
                "Myoglobin": "40 ng/mL (< 90 ng/mL)",
                "Troponin I": "5 ng/L (< 14 ng/L)",
                "Ferritin": "150 ng/mL (20 − 500)",
                "CRP": "7 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Negative",
                "ABO Group": "A",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Presence of a 6 cm soft tissue mass in the abdomen",
            "Chest Computerized Tomography (CT)": "No abnormalities detected in the lungs",
            "Magnetic Resonance Imaging (MRI)": "Tumor located in the abdomen, with heterogeneous enhancement indicating a possible inflammatory myofibroblastic tumor",
            "Tissue Biopsy": "Confirmed presence of inflammatory myofibroblasts with lymphocytic infiltration",
            "Molecular Diagnosis": "Positive for ALK gene mutation",
            "Abdominal Examination": "Localized pain and tenderness in the lower abdomen"
        },
        "Treatment Plan": "Given Emily Carter's diagnosis of an inflammatory myofibroblastic tumor in the abdomen, surgical intervention is recommended due to the moderate severity and presence of ALK gene mutation. A wide surgical excision will aim to remove the tumor completely to reduce the possibility of recurrence. Post-surgery, close monitoring through imaging tests such as ultrasound and CT will be essential every 3 months for up to 2 years to ensure no recurrence occurs, and then yearly thereafter. Additionally, targeted therapy with ALK inhibitors such as Crizotinib may be considered if any progression or recurrence is noted post-surgery. Supportive treatment will involve managing symptoms like abdominal pain, fever, and weight loss with appropriate medications and nutritional support. It is crucial for Emily and her family to adhere to follow-up appointments and monitor for any new symptoms, ensuring prompt intervention if needed. Long-term follow-up will be crucial in managing her recovery and ensuring optimal health outcomes."
    },
    {
        "Patient Information": {
            "Name": "Margaret Poe",
            "Age": "61",
            "Gender": "Female",
            "Medical History": "Hypertension, Diabetes, Obesity, Post-menopausal bleeding"
        },
        "Disease Information": {
            "Disease": "Endometrial cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Irregular vaginal bleeding, abdominal discomfort, abnormal vaginal discharge",
            "Duration": "Symptoms have been present for two months with increasing frequency",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "150 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for females)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "20 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Pelvic Ultrasound": "Increased endometrial thickness",
            "Pelvic MRI": "Endometrial and myometrial structures suggestive of tumor invasion",
            "Endometrial Biopsy": "Positive for carcinoma cells",
            "CT Scan": "No evidence of distant metastasis",
            "Serum Tumor Marker": "CA125 slightly elevated",
            "Cervical Cytology Test": "Negative for cervical cancer",
            "PET-CT": "No recurrence or metastasis detected",
            "Pathological Examination": "Confirms diagnosis of endometrial cancer"
        },
        "Treatment Plan": "Margaret Poe has been diagnosed with moderate severity endometrial cancer. Considering her age, post-menopausal status, and underlying conditions of hypertension, diabetes, and obesity, a personalized treatment plan is necessary. The primary approach includes total hysterectomy with bilateral salpingo-oophorectomy, ensuring complete removal of the uterus and ovaries to minimize the spread of cancer. Pelvic MRI and ultrasound have shown localized endometrial thickening without distant metastasis, allowing for potential conservation of lymph nodes initially, with monitoring post-surgery for any changes. Following surgery, adjuvant therapy will be considered, including both hormone and chemotherapy, tailored to her histological profile and receptor status. Margaret's progress will be closely monitored through regular follow-up appointments every 3 to 6 months post-surgery, including imaging studies and serum CA125 evaluation. Nutritional support and lifestyle modifications are advised, with emphasis on weight management and controlling her hypertension and diabetes. Margaret will be educated on the importance of adhering to her treatment plan, recognizing signs of potential recurrence, and maintaining a positive lifestyle. The medical team will support Margaret throughout her treatment, ensuring comprehensive care and monitoring to optimize recovery and quality of life."
    },
    {
        "Patient Information": {
            "Name": "Evelyn Thompson",
            "Age": "58",
            "Gender": "Female",
            "Medical History": "Post-menopausal, hypertension, obesity, diabetes"
        },
        "Disease Information": {
            "Disease": "Endometrial cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Abnormal vaginal bleeding, postmenopausal bleeding, dull lower abdominal pain, moderate vaginal discharge",
            "Duration": "Symptoms have been present for several weeks with gradual progression",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "125 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "90 U/L (22 − 198 for females)",
                "Ferritin": "180 ng/mL (15 − 150 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "CA125": "38 U/mL (< 35 U/mL)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Ultrasound": "Increased endometrial thickness with irregular echogenicity, suggestive of possible malignancy",
            "Endometrial Biopsy": "Confirmed diagnosis of endometrial adenocarcinoma with high differentiation",
            "MRI": "Shows invasion confined to the endometrium with no myometrial involvement",
            "CT Scan": "No signs of distant metastasis",
            "PET-CT": "No evidence of metastatic spread",
            "Serum Tumor Markers": "CA125 slightly elevated"
        },
        "Treatment Plan": "Evelyn Thompson has been diagnosed with a moderately severe case of endometrial cancer, and given her age and post-menopausal status, a total hysterectomy with bilateral salpingo-oophorectomy is recommended. Given the moderate extent of the disease and the absence of myometrial invasion on MRI, this surgical approach is expected to provide a favorable prognosis. Post-surgical pathology will determine the necessity of adjuvant therapy. Due to the patient's medical history of hypertension, obesity, and diabetes, a comprehensive preoperative assessment will be prioritized to mitigate surgical risks. Postoperative care will include lifestyle modifications to assist with weight management and control of blood glucose levels. Regular follow-ups every 3 to 6 months post-surgery will be essential, with a focus on monitoring serum CA125, as well as periodic imaging to ensure no recurrence. Evelyn is encouraged to maintain a healthy lifestyle, including a balanced diet and regular physical activity, alongside adherence to her prescribed antihypertensive and antidiabetic medications. Emotional support and counseling will also be offered to address any psychological impact related to her diagnosis and treatment."
    },
    {
        "Patient Information": {
            "Name": "Martha Anderson",
            "Age": "57",
            "Gender": "Female",
            "Medical History": "Hypertension, Diabetes, Obesity, Post-menopausal, Family history of endometrial cancer"
        },
        "Disease Information": {
            "Disease": "Endometrial Cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Irregular vaginal bleeding, abnormal vaginal discharge, dull lower abdominal pain, postmenopausal vaginal bleeding",
            "Duration": "Symptoms have persisted for 6 months with gradual escalation",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "34 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "240 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.68 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500 for females)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None Detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Pelvic Ultrasound": "Enlarged uterus with thickened endometrium",
            "Pelvic MRI": "Endometrial thickening with signs of myometrial infiltration",
            "Endometrial Biopsy": "Presence of adenocarcinoma cells",
            "CT Scan": "Showing no signs of metastasis to pelvic organs",
            "PET-CT": "No evidence of metastasis",
            "Serum Tumor Markers": "Elevated CA125 levels",
            "Histopathological Examination": "Endometrioid adenocarcinoma, G2 differentiation",
            "Pulmonary Function Test": "Normal",
            "Liver Function Test": "Normal",
            "Renal Function Test": "Normal"
        },
        "Treatment Plan": "Martha Anderson has been diagnosed with moderately severe endometrial cancer, with a primary focus on surgical treatment due to the confined nature of the tumor within the endometrium and lack of metastasis. The recommended approach is a total hysterectomy alongside bilateral salpingo-oophorectomy and pelvic lymphadenectomy to ensure all affected tissues are addressed comprehensively. Given her history of hypertension, diabetes, and obesity, pre-operative stabilization of her medical conditions is crucial, involving optimized control of her blood pressure and glucose levels through tailored medications. Post-surgery, adjuvant radiotherapy may be considered to minimize any residual risk of recurrence. Hormonal therapy could be initiated depending on receptor testing outcomes; Martha's tumor has shown positive progesterone receptor expression which makes her a candidate for progestin therapy, aimed at managing residual cancer cells. Chemotherapy is reserved for potential advanced interventions only if pathology indicates aggressive cancer behavior post-surgery. Martha is advised to maintain a well-balanced diet, engage in regular physical activity, and quit any habits that may compromise recovery, such as smoking and excessive alcohol consumption. Regular follow-ups including pelvic exams, serum CA125 assessment, and imaging are essential for early detection of any recurrence. Martha should be educated on potential symptoms of recurrence such as abnormal vaginal bleeding and adhere strictly to the follow-up schedule to ensure optimal recovery and management of her condition."
    },
    {
        "Patient Information": {
            "Name": "John Anderson",
            "Age": "62",
            "Gender": "Male",
            "Medical History": "History of adenomatous polyps, family history of colorectal cancer"
        },
        "Disease Information": {
            "Disease": "Rectal cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Change in bowel habits, blood and mucus in stool, abdominal pain, weight loss, tenesmus",
            "Duration": "Symptoms have been present for the past six months and have progressively worsened",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "29 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.3 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "175 U/L (135 − 225)",
                "Ferritin": "110 ng/mL (30 − 400 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Carcinoembryonic Antigen (CEA)": "12 ng/mL (0 − 5)",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Colonoscopy": "Presence of ulcerative tumor in the lower rectum",
            "CT Scan": "Thickening of the rectal wall, possible local lymph node involvement",
            "MRI": "Confirms rectal wall invasion, no distant metastasis",
            "Endoscopic Ultrasound": "Tumor infiltration into the muscularis propria",
            "Fecal Occult Blood Test": "Positive",
            "Serum Tumor Marker Test": "Increased CEA level",
            "Liver Function Test": "Normal",
            "Kidney Function Test": "Normal",
            "Chest X-ray": "Clear, no metastasis observed"
        },
        "Treatment Plan": "John Anderson has been diagnosed with rectal cancer with a major severity, characterized by bowel habit changes, blood in stool, and significant weight loss over the past six months. An individualized comprehensive treatment plan focusing on surgical intervention is advised, given the tumor's location and characteristics seen in imaging and endoscopic evaluations. Considering the potential lymph node involvement, neoadjuvant chemoradiotherapy will be administered to shrink the tumor and enhance operability. This will be followed by surgical resection, utilizing a sphincter-sparing surgery approach if feasible, given the tumor's proximity to the anal verge. Postoperative adjuvant chemotherapy will be considered to mitigate the risk of recurrence. Nutritional support is vital due to John's weight loss and potential malnutrition, with a high-protein, low-residue diet recommended to sustain strength and support recovery. Pain management and regular monitoring of CEA levels and imaging tests will guide ongoing care, and John will be educated on recognizing symptoms of recurrence. Family involvement in care strategies and creating a supportive environment is crucial for his recovery and quality of life. Given the favorable curability prognosis, adherence to follow-up visits, lifestyle modifications, and regular physical activity, John's prognosis is optimistic with the potential for long-term survival."
    },
    {
        "Patient Information": {
            "Name": "James Anderson",
            "Age": "64",
            "Gender": "Male",
            "Medical History": "Family history of Lynch Syndrome, history of rectal polyps, obesity"
        },
        "Disease Information": {
            "Disease": "Rectal Cancer",
            "Severity Level": "Stage III",
            "Symptoms": "Frequent urgency to defecate, changes in bowel habits, blood and mucus on the stool surface, weight loss, lower abdominal pain",
            "Duration": "Symptoms have progressively worsened over the past 8 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "75 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.75 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.55 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for males)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "CEA elevated",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Colonoscopy": "Tumor identified in the lower rectum, biopsy confirms adenocarcinoma",
            "CT Scan": "Presence of regional lymph node metastasis, no distant metastasis",
            "MRI": "Infiltration to muscular layer observed, no mesorectal involvement",
            "Endoscopic Ultrasound": "Tumor infiltration depth accurately assessed",
            "PET-CT": "No evidence of distant metastasis",
            "Fecal Occult Blood Test": "Positive",
            "Digital Rectal Exam": "Mass detected close to anal margin"
        },
        "Treatment Plan": "James Anderson has been diagnosed with Stage III rectal cancer, highlighting the need for an aggressive and comprehensive treatment approach. The treatment plan includes an immediate combination of preoperative chemoradiotherapy to shrink the tumor and shrink lymph node metastases, facilitating surgical resectability. Once the chemoradiotherapy course is completed over 6 to 8 weeks, radical surgical excision of the tumor and affected lymph nodes will be performed, likely involving total mesorectal excision to maximize the chance of cure. Post-surgery, adjuvant chemotherapy will be recommended to eliminate any remaining microscopic disease and prevent recurrence. Nutritional support is crucial throughout the treatment period to address weight loss and malnutrition, encouraging a high-calorie, high-protein liquid diet to ensure adequate nutritional intake. Pain management will be addressed with appropriate analgesics, considering the need for post-operative recovery. Regular monitoring through blood tests and imaging will track response to treatment, and follow-up colonoscopy will be essential within a year post-surgery to ensure no recurrence or presence of additional polyps. James and his family will receive counseling and education on lifestyle modifications, including dietary changes and exercise, to support his recovery and optimize overall health. In addition, psychological support will be provided to address the emotional and mental aspects of living with cancer, ensuring James is well-supported throughout his treatment journey."
    },
    {
        "Patient Information": {
            "Name": "Jonathan Liu",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Previous episodes of ulcerative colitis, family history of colorectal cancer"
        },
        "Disease Information": {
            "Disease": "Rectal Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Frequent urgency to defecate, changes in bowel habits, bloody stools, weight loss, lower abdominal pain",
            "Duration": "Symptoms have been gradually worsening over the past three months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 – 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 – 35)",
                "Urea": "5.5 mmol/L (2.6 – 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 – 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 – 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.7 × 10^12/L (3.5 – 5.5)",
                "Hematocrit (Hct)": "40% (35 – 50)",
                "Hemoglobin (Hb)": "130 g/L (115 – 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 – 350)",
                "Lymphocyte Percentage (LYMPH%)": "24% (20 – 50)",
                "Neutrophil Percentage (NEUT%)": "68% (40 – 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.08 × 10^9/L (1.3 – 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.06 × 10^9/L (1.8 – 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.42 × 10^9/L (0.2 – 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 – 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.12 × 10^9/L (0.02 – 0.52)",
                "Eosinophil Percentage (EO%)": "2.3% (0.4 – 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 – 0.06)",
                "Basophil Percentage (BASO%)": "0.7% (0 – 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 – 13)",
                "Lactate Dehydrogenase": "190 U/L (135 – 225)",
                "Carcinoembryonic Antigen (CEA)": "7.5 ng/mL (< 5 ng/mL)",
                "Ferritin": "350 ng/mL (20 – 500 for males)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 – 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 – 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50 – 150)"
            },
            "Colonoscopy": "Tumor mass in the lower rectum with partial obstruction",
            "CT Scan": "Evidence of rectal wall thickening and regional lymph node enlargement",
            "MRI": "Confirms tumor invasion into the muscularis propria with no distant metastasis",
            "PET-CT": "Increased metabolic activity at the rectal site and regional lymph nodes",
            "Endoscopic Ultrasound": "Tumor penetration into the muscular layer with regional lymph node involvement",
            "Biopsy": "Moderately differentiated adenocarcinoma",
            "Fecal Occult Blood Test": "Positive",
            "Tumor Marker CA19-9": "Elevated"
        },
        "Treatment Plan": "Jonathan Liu has been diagnosed with major severity rectal cancer, which has presented with symptoms of frequent urgency to defecate, changes in bowel habits, and significant weight loss over the past three months. Given the absence of distant metastasis and the confirmed invasion into the muscularis propria with regional lymph node involvement, a multidisciplinary treatment approach is recommended. Neoadjuvant chemoradiotherapy will be initiated to shrink the tumor and improve surgical outcomes, consisting of a combination of 5-fluorouracil and leucovorin, alongside localized radiation therapy. Following completion of neoadjuvant treatment, a surgical evaluation will determine the feasibility of a sphincter-sparing resection, taking into account the tumor's proximity to the anal verge and Jonathan's overall health condition. If complete resection is achievable, a low anterior resection will be performed to preserve defecatory function, followed by adjuvant chemotherapy to address any potential micrometastatic disease and reduce the risk of recurrence. Throughout treatment, Jonathan will receive nutritional and psychological support to manage weight loss and treatment-associated side effects. Pain management will be tailored to his needs, and regular follow-up with imaging and CEA monitoring will be conducted to assess treatment response and detect any signs of recurrence. Long-term management will include a structured surveillance program, further nutritional guidance to support recovery, and possibly a rehabilitation program to enhance postoperative quality of life and functionality."
    },
    {
        "Patient Information": {
            "Name": "James Peterson",
            "Age": "55",
            "Gender": "Male",
            "Medical History": "Occasional abdominal discomfort, history of a slow-growing, painless soft tissue mass"
        },
        "Disease Information": {
            "Disease": "Liposarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Slowly enlarging, painless soft tissue mass, abdominal discomfort, bloating, loss of appetite",
            "Duration": "Symptoms have been present and progressively noticeable over the past few months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.6 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.9 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.08 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)"
            },
            "Chest X-ray Exam": "Normal findings",
            "Abdominal Ultrasound": "Dense echogenic mass with uneven echoes in the retroperitoneum",
            "Computerized Tomography (CT)": "Large mass with fat density and clear boundaries, slightly lobulated shape in the retroperitoneum",
            "Magnetic Resonance Imaging (MRI)": "Shows mixed echoes with clear boundaries and minimal fatty infiltration",
            "Biopsy": "Well-differentiated liposarcoma with primitive mesenchymal cells and lipoblasts",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture": "Normal",
            "Respiratory Function Test": "Normal",
            "Gastrointestinal Function Test": "Gastrointestinal compression symptoms present",
            "PET-CT": "Some metabolic activity present, suggesting a mixed tissue composition"
        },
        "Treatment Plan": "James Peterson has been diagnosed with well-differentiated liposarcoma, requiring meticulous surgical intervention due to the tumor's retroperitoneal location and accompanying symptoms like abdominal discomfort and loss of appetite. The primary treatment strategy focuses on wide excision surgery, aimed at removing the tumor while minimizing the risk of local recurrence. Preoperative imaging, including CT and MRI, has been conducted to precisely assess the tumor's boundaries and plan the surgical approach. Post-surgery adjuvant radiotherapy may be considered to enhance local control and reduce the recurrence risk, although chemotherapy is unlikely to be effective due to the tumor's insensitivity. James will be advised to maintain a nutritious and easily digestible diet post-surgery to support recovery, engage in moderate exercise as per medical advice, and manage stress to foster a positive emotional state. Regular follow-up checks will be scheduled to monitor for any signs of recurrence, adhering to a protocol of every 3 months for the first 3 years post-surgery, and subsequently every 6 months. Should he experience symptoms indicative of recurrence, further imaging and potential surgical intervention will be evaluated based on tumor size and location. Family support remains crucial, emphasizing adherence to medical guidance and lifestyle modifications to optimize his recovery and long-term health outcomes."
    },
    {
        "Patient Information": {
            "Name": "James Thompson",
            "Age": "52",
            "Gender": "Male",
            "Medical History": "Previously diagnosed with a benign lipoma, history of minor gastrointestinal discomfort"
        },
        "Disease Information": {
            "Disease": "Liposarcoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Slowly enlarging, painless abdominal mass with occasional bloating and abdominal discomfort",
            "Duration": "Symptoms have been present for approximately 6 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "160 U/L (22 − 198 for males)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Clear",
            "MRI Examination": "Presence of well-differentiated mass in the retroperitoneum",
            "Ultrasound Examination": "Large, dense echogenic mass with uneven echoes and clear boundaries",
            "Biopsy": "Well-differentiated liposarcoma",
            "CT Scan": "Mass primarily of fat density with lobulated shape and clear boundaries",
            "PET-CT": "Metabolically active lesion in the retroperitoneum",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture": "Normal",
            "Respiratory Function Test": "Normal",
            "Pathological Examination": "Well-differentiated liposarcoma with mature adipocytes"
        },
        "Treatment Plan": "James Thompson has been diagnosed with well-differentiated liposarcoma, evidenced by a slowly enlarging, painless abdominal mass and abdominal discomfort. The primary treatment approach is surgical excision, and it is recommended that James undergo a wide excision surgery to completely remove the tumor, minimizing the risk of local recurrence. Prior to surgery, comprehensive imaging assessments including MRI and CT will be performed to accurately map the extent of the tumor. Post-surgery, regular follow-ups are crucial to monitor for recurrence or complications, with initial assessments scheduled one month following surgery, and subsequent visits every three months for the first three years, adjusting to every six months thereafter. Nutritional support is vital during the recovery phase, with a focus on easily digestible, high-nutrition foods; moderate exercise as per medical advice will also aid in recovery. Emotional and psychological support should be provided to facilitate a positive outlook through the treatment process. James and his family will be educated on recognizing potential signs of recurrence and the importance of adherence to follow-up schedules. If any signs of recurrence or new symptoms occur, prompt consultation with the oncology department is advised to assess further interventions, potentially including additional surgical procedures based on the specific circumstances. The aim is to ensure successful treatment and promote a high quality of life post-recovery."
    },
    {
        "Patient Information": {
            "Name": "James Anderson",
            "Age": "52",
            "Gender": "Male",
            "Medical History": "Previous surgery for benign lipoma, occasional gastrointestinal discomfort"
        },
        "Disease Information": {
            "Disease": "Liposarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Slowly enlarging, painless soft tissue mass in the abdomen with associated discomfort and occasional bloating",
            "Duration": "Symptoms have been developing slowly over the past several months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "6.1 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "5.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "45% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Imaging Studies": {
                "Ultrasound": "Dense echogenic mass in the abdomen with uneven echoes",
                "CT Scan": "Large mass primarily of fat density in the abdomen with clear boundaries and a slightly lobulated shape",
                "MRI": "Well-defined mass in the abdomen showing differentiation between fat and solid components",
                "PET-CT": "Increased metabolic activity in the abdominal mass, suggesting possible dedifferentiation",
                "Biopsy": "Pathological confirmation of dedifferentiated liposarcoma with varying differentiation stages of adipocytes"
            },
            "Chest X-ray Exam": "Normal",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Respiratory Function Test": "Normal",
            "Liver Function Test": "Normal"
        },
        "Treatment Plan": "James Anderson has been diagnosed with a dedifferentiated liposarcoma located in the abdomen, exhibiting major severity due to the size and metabolic activity of the tumor. Surgical resection is the primary treatment approach, aiming to remove the entire mass with safe margins to prevent recurrence. Preoperative imaging and assessments will be conducted to evaluate surgical risk and plan the procedure meticulously. Given the tumor's dedifferentiated nature, postoperative radiation therapy may be considered to enhance local control, despite the limited sensitivity of liposarcomas to radiotherapy. Nutritional support and management of gastrointestinal symptoms will be provided to ensure adequate recovery post-surgery, and a follow-up schedule will be established for regular monitoring. Family members are encouraged to assist James in maintaining a nutritious diet and a positive lifestyle to support his overall health. Psychosocial support may also be beneficial, helping James cope with the emotional stress of his diagnosis and treatment. Discussions with the oncology team will be ongoing, focusing on the latest advancements in targeted therapy that might offer additional benefits for his condition. Adherence to appointments for imaging and re-evaluation will be critical in the early detection of any recurrence, with potential consideration for further interventions based on clinical progress."
    },
    {
        "Patient Information": {
            "Name": "Henry Thompson",
            "Age": "70",
            "Gender": "Male",
            "Medical History": "Chronic bronchitis, history of smoking (40 pack-years)"
        },
        "Disease Information": {
            "Disease": "Peripheral Lung Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Irritating cough, hemoptysis, dyspnea, chest pain, unintentional weight loss",
            "Duration": "Symptoms have been progressively worsening over the past 3 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "36 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "44 IU/L (13 − 35)",
                "Urea": "8.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "89 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "10.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "145 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "340 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "18% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "77% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.89 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "8.1 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.45 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "4.3% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.15 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.4% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for males)",
                "Myoglobin": "82 ng/mL (< 90 ng/mL)",
                "Troponin I": "9 ng/L (< 14 ng/L)",
                "Ferritin": "420 ng/mL (20 − 500 for males)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "58 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Irregular mass in the peripheral right lung field",
            "Chest Computerized Tomography": "Solitary round mass with spiculated margins in the right lower lobe",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Presence of malignant cells",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Reduced lung volumes and capacities",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Henry Thompson has been diagnosed with advanced-stage peripheral lung cancer, characterized by a significant solitary mass in the right lower lobe of the lung and associated symptoms of persistent cough, hemoptysis, and unintended weight loss. Considering the patient's age, medical history of chronic bronchitis, and extensive smoking history, an aggressive treatment approach with a focus on palliative care is recommended. Due to the major severity and the advancement of the disease stage, surgical intervention is not viable. The primary treatment modalities will include a combination of chemotherapy and targeted therapy to manage tumor growth and alleviate symptoms. Chemotherapy with platinum-based agents such as carboplatin in combination with pemetrexed will be initiated, with cycles planned every three weeks, and the response and side effects closely monitored. Concurrently, targeted therapy with an EGFR inhibitor, such as erlotinib, will be considered if genetic markers suggest sensitivity, aiming to delay disease progression and improve quality of life. Supportive care measures, including pain management, nutritional support, and respiratory therapy, will be provided to improve overall well-being and maintain functionality. Regular follow-ups will assess treatment efficacy and side effects, with adjustments made as necessary. Psychological support and counseling will be offered to help Henry and his family cope with the emotional and psychological impacts of the diagnosis. Smoking cessation support will be provided to prevent further lung damage and reduce the progression of the disease. Hospice care options will be discussed as part of an advance care planning strategy, ensuring alignment with Henry's preferences and promoting quality of life throughout the treatment journey."
    },
    {
        "Patient Information": {
            "Name": "James Thompson",
            "Age": "68",
            "Gender": "Male",
            "Medical History": "Chronic obstructive pulmonary disease, History of smoking"
        },
        "Disease Information": {
            "Disease": "Peripheral Lung Cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Irritating cough, bloody sputum, dyspnea, chest pain, hoarseness, weight loss, pleural effusion",
            "Duration": "Symptoms have been persistent and worsening over the past eight weeks",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "38 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU /L (13 − 35)",
                "Urea": "6.9 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "118 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "18% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "75% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.81 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.4 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "9% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fl (9 − 13)",
                "Lactate Dehydrogenase": "240 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "170 U/L (22 − 198 for males)",
                "Myoglobin": "85 ng/mL (< 90 ng/mL)",
                "Troponin I": "18 ng/L (< 14 ng/L)",
                "Ferritin": "550 ng/mL (20 − 500 for males)",
                "CRP": "45 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Peripheral lung mass with pleural effusion",
            "Chest Computerized Tomography": "Large peripheral adenocarcinoma with lymph node involvement and pleural effusion",
            "Serological Diagnosis": "Elevated Tumor Markers",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Presence of atypical cells",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Impaired lung capacity",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "James Thompson has been diagnosed with peripheral lung cancer at an advanced stage, characterized by significant symptoms including persistent cough, bloody sputum, dyspnea, and weight loss. Given the severity and progression of the disease, a multidisciplinary approach focusing on symptom management and quality of life improvement is essential. The treatment plan will include palliative care measures such as pain management, respiratory function support, and nutritional therapy to address weight loss and maintain energy levels. Chemotherapy may be offered to slow disease progression and manage symptoms, tailored to James's health status and personal wishes, employing agents such as carboplatin and paclitaxel. Targeted therapy may be considered if genetic profiling indicates suitable targets, with immune checkpoint inhibitors also evaluated based on PD-L1 expression levels. Regular monitoring through imaging and blood tests will assess treatment efficacy and adjust strategies as needed. Psychosocial support, including counseling, will be provided to help James cope with the emotional impact of his diagnosis and treatment. Advanced care planning will be discussed to ensure that patient preferences are honored. Follow-up care will be scheduled to optimize symptom management and address any complications that arise."
    },
    {
        "Patient Information": {
            "Name": "Barry Smith",
            "Age": "68",
            "Gender": "Male",
            "Medical History": "Chronic bronchitis, History of smoking, Hypertension"
        },
        "Disease Information": {
            "Disease": "Peripheral lung cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Chronic cough, bloody sputum, chest pain, weight loss, dyspnea, hoarseness",
            "Duration": "Symptoms have progressively worsened over the past 3 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "38 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "8.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.6 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "18% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "75% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.86 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "260 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "198 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "13 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for males)",
                "CRP": "35 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Presence of irregular mass in peripheral lung field",
            "Chest Computerized Tomography": "Irregular mass with lobulated edges and possible pleural invasion",
            "Serological Diagnosis": "Elevated tumor markers",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Presence of malignant cells",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for specific lung cancer markers",
            "Pulmonary Function Test": "Reduced lung capacity",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Barry Smith's diagnosis of extreme severity peripheral lung cancer requires immediate and aggressive treatment. Despite the challenges presented by the advanced stage of the disease, our focus will be on controlling symptoms and extending his life through a well-coordinated oncology team approach. Chemotherapy, using platinum-based agents like cisplatin combined with etoposide, will be initiated to reduce tumor burden, with repeated cycles to be closely monitored for response and side effects. Radiotherapy will be considered to address localized pain and to control the potential for further metastasis, with concurrent chemoradiotherapy being explored as a regimen to maximize efficacy. Given the advanced stage and Barry's overall health, palliative care measures will play a crucial role in managing symptoms such as chest pain and breathing difficulties, including pain relief, respiratory support, and nutritional interventions. Additionally, Barry may benefit from supportive care through traditional Chinese medicine to alleviate treatment-related side effects and foster resilience. Regular follow-ups with CT scans and tumor marker evaluations will be essential in assessing the progression, guiding adjustments in treatment, and ensuring Barry's comfort and quality of life are prioritized throughout his care journey. Barry and his family will be counseled on home care strategies, emotional support, and lifestyle adjustments to maintain his well-being. Social, psychological, and spiritual support will be integrated into his care plan to enhance the overall quality of life during this challenging period."
    },
    {
        "Patient Information": {
            "Name": "Elaine Zhang",
            "Age": "65",
            "Gender": "Female",
            "Medical History": "Gastroesophageal reflux disease, hiatal hernia, obesity, smoking history"
        },
        "Disease Information": {
            "Disease": "Cardia Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Difficulty swallowing, weight loss, upper abdominal pain, hematemesis, fatigue, palpable lumps in the upper abdomen",
            "Duration": "Symptoms have progressively worsened over the past 3 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "38 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "42 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "6.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "100 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "68% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.05 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.26 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.35 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "11 fL (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "500 ng/mL (30 − 400 for females)",
                "CRP": "30 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.9 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Endoscopic Examination": "Nodular and cauliflower-like growths at the esophagogastric junction, ulcerative lesions with mucosal congestion",
            "Ultrasound Endoscopy": "Infiltration into the gastric wall with suspected local lymph node metastases",
            "Barium Meal X-ray": "Visible lesions at the esophagogastric junction with irregular mucosal patterns",
            "CT Scan": "Invasive tumor at the esophagogastric junction with potential involvement of surrounding tissues",
            "PET-CT Scan": "Suspected metastases in mediastinal and abdominal lymph nodes",
            "Tumor Marker Examination": "Elevated CEA, CA19-9, suggesting advanced disease",
            "Biopsy Results": "Poorly differentiated adenocarcinoma consistent with advanced cardia cancer"
        },
        "Treatment Plan": "Elaine Zhang’s advanced cardia cancer diagnosis necessitates an integrated treatment approach focused on symptom management and potential life extension. Given the significant severity of her condition, comprehensive systemic therapy involving chemotherapy paired with targeted therapy like trastuzumab is recommended due to HER-2 positive indications. Initial efforts will focus on maintaining nutritional support through parenteral nutrition, addressing malnutrition and dehydration resulting from her condition. Radical radiotherapy may be considered to manage non-metastatic local lesions and support chemotherapy efforts. Palliative care measures including analgesics for pain management, antiemetics for reducing nausea, and medications to manage gastroesophageal reflux symptoms will aid in improving comfort and quality of life. As surgery is not viable given the metastatic spread, ongoing assessments using imaging studies will guide adjustments in treatment, with regular evaluations every few months to monitor progression and response to therapy. Detailed family and psychosocial support are critical to managing emotional stress. Elaine’s adherence to nutritional support and hydration protocols will be pivotal in ensuring tolerance to systemic therapies. Regular monitoring for changes in symptoms and maintaining a supportive environment will contribute substantially to her care, complemented by post-discharge daily management practices encouraging moderate physical activity and dietary adjustments tailored to her preferences while avoiding potential irritants."
    },
    {
        "Patient Information": {
            "Name": "Lin Zhang",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Gastroesophageal reflux disease, Helicobacter pylori infection"
        },
        "Disease Information": {
            "Disease": "Cardia Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Difficulty swallowing, vomiting after eating, weight loss, upper abdominal pain, low fever, anemia, fatigue",
            "Duration": "Symptoms have progressed over the last three months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (65 − 106)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "105 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "195 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "240 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "120 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "500 ng/mL (20 − 500 for males)",
                "CRP": "30 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "CEA",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Thickening at the esophagogastric junction, possible tumor infiltration",
            "Serological Diagnosis": "Elevated CEA and CA19-9 levels",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Within normal limits",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Lin Zhang has been diagnosed with major severity cardia cancer, underscored by difficulties in swallowing, significant weight loss, upper abdominal pain, and a progression over the past three months. Given the condition's severity, a multidisciplinary treatment strategy is essential to manage the symptoms and improve quality of life, as curability remains unfavorable. The treatment plan will incorporate neoadjuvant chemotherapy to shrink the tumor and possibly make it operable, using regimens that may include fluorouracil and platinum-based compounds. Nutritional support is paramount due to malnutrition and weight loss, with enteral nutrition preferred to parenteral nutrition unless digestive tract function remains impaired. Surgical evaluation will determine the feasibility of tumor resection; if inoperable, chemoradiotherapy may be continued to manage tumor progression and alleviate symptoms. Close monitoring of nutritional intake, managing anemia possibly through transfusions, and supporting electrolyte balance is critical. Pain management, antiemetic medications, and possibly endoscopic interventions to aid food passage may be employed. Psychosocial support and family involvement are crucial in maintaining a positive outlook and adherence to the treatment plan. Continuous imaging and blood marker assessments will track the disease response to therapy, dictating further treatment adjustments. Follow-up care will involve routine check-ups and lifestyle modifications, including dietary adjustments and smoking cessation, aimed at stabilizing the patient's condition and optimizing overall health."
    },
    {
        "Patient Information": {
            "Name": "Liam Chen",
            "Age": "66",
            "Gender": "Male",
            "Medical History": "Gastroesophageal reflux disease, Helicobacter pylori infection, Hiatal hernia"
        },
        "Disease Information": {
            "Disease": "Cardia Cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Difficulty swallowing, weight loss, upper abdominal pain, vomiting after eating, fatigue",
            "Duration": "Symptoms have progressively worsened over the last 6 months",
            "Curability": "No"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "22 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "27 IU/L (13 − 35)",
                "Urea": "6.4 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.9 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "240 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.35 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "9% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "140 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for males)",
                "CRP": "6 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Not Applicable",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Endoscopic Examination": "Advanced stage cardia cancer with ulcerative lesions and mucosal congestion",
            "Ultrasound Endoscopy": "Infiltration of the gastric wall layers with local lymph node involvement",
            "Barium Meal X-ray": "Nodular and ulcerative growths at the gastroesophageal junction",
            "CT Scan": "Evidence of extramural spread with lymph node metastasis",
            "PET-CT Scan": "Positive for metastatic lesions in mediastinal and abdominal lymph nodes",
            "Tumor Marker Examination": {
                "CEA": "12 ng/mL (< 5)",
                "CA19-9": "57 U/mL (< 37)",
                "CA724": "18.4 U/mL (< 6)"
            },
            "Nutritional Status": "Malnourished with notable weight loss"
        },
        "Treatment Plan": "Liam Chen is undergoing treatment for advanced cardia cancer, which has significantly progressed with lymph node involvement and metastasis. Considering the major severity of his condition, a comprehensive and multidisciplinary treatment approach is necessary. The initial phase of treatment includes concurrent chemoradiotherapy to reduce the tumor burden and control disease progression, optimizing conditions for potential surgical intervention. Chemotherapy regimens, such as oxaliplatin and paclitaxel, are being administered to manage metastasis and alleviate cancer-related symptoms, with regular monitoring of hepatic and renal functions to adjust doses accordingly. Nutritional support is crucial to combat malnutrition and improve overall treatment tolerance; hence, enteral nutrition through a nasal feeding tube is being implemented to ensure adequate caloric intake. Symptomatic treatments for pain management, antiemetics for vomiting, and proton pump inhibitors for gastroesophageal reflux are being used to enhance comfort and quality of life. Post chemoradiotherapy, a reassessment through imaging studies will determine the feasibility of surgical resection, aiming for a curative approach if conditions allow. Throughout the treatment, psychological support is provided to mitigate emotional distress and improve Liam’s resilience and adherence to the treatment plan. Ongoing surveillance with routine imaging and blood tests will be crucial to monitor treatment efficacy and adjust therapeutic strategies as needed. The focus remains on achieving the best possible outcome in terms of survival and quality of life for Liam."
    },
    {
        "Patient Information": {
            "Name": "Ryan Thompson",
            "Age": "27",
            "Gender": "Male",
            "Medical History": "Cryptorchidism history, no previous major illnesses"
        },
        "Disease Information": {
            "Disease": "Testicular Cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Single painless mass in the affected testicle, slight swelling and heaviness, mild dull pain",
            "Duration": "Symptoms have been present for about 3 weeks",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "44% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase (LDH)": "185 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "55 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "250 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Presence of a large mass in the left testicle, heterogeneous texture, no retroperitoneal metastasis",
            "CT Scan": "No signs of lymph node metastasis",
            "Tumor Marker Analysis": {
                "AFP": "40 ng/mL (0 − 10)",
                "β-HCG": "15 IU/L (0 − 5)",
                "LDH": "200 U/L (135 − 225)"
            },
            "Chest X-ray Exam": "No lung metastasis detected",
            "Abdominal Examination": "No signs of visceral metastasis",
            "Physical Examination": "Enlarged left testicle with hard mass, negative transillumination"
        },
        "Treatment Plan": "Ryan Thompson has been diagnosed with testicular cancer, with a moderate severity level indicated by the presence of a single painless mass in the affected testicle and elevated AFP and β-HCG levels. The recommended treatment approach involves a radical orchiectomy through an inguinal approach, followed by surveillance and consideration of retroperitoneal lymph node dissection and chemotherapy if metastatic risk is assessed or histological findings indicate non-seminomatous tumors. Chemotherapy options may include cisplatin, vinblastine, and bleomycin, tailored according to the tumor's specific histological type and patient's response. Post-surgery radiotherapy may be considered if seminomas are detected, given their sensitivity to radiation therapy. Ryan is advised to undergo preoperative cryopreservation of semen due to potential impacts on fertility from treatment, alongside professional psychological support to manage the stress and potential sexual dysfunction following treatment. Follow-up care is crucial, involving regular physical exams, tumor marker detection, and imaging studies for at least five years to monitor recurrence. Ryan and his family will receive education on self-examination and signs of deterioration, with the importance of adhering to the treatment plan emphasized. Additionally, supporting psychological wellbeing and social support can enhance recovery outcomes, ensuring Ryan adapts to changes post-treatment and maintains a quality life."
    },
    {
        "Patient Information": {
            "Name": "James Thompson",
            "Age": "30",
            "Gender": "Male",
            "Medical History": "Cryptorchidism, previous orchidopexy surgery"
        },
        "Disease Information": {
            "Disease": "Testicular cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Single painless mass in the affected testicle, slight discomfort, dull pain",
            "Duration": "Symptoms have developed gradually over the past 3 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.8 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "145 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198 for males)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "5 ng/L (< 14 ng/L)",
                "Ferritin": "200 ng/mL (20 − 500 for males)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "18 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "β-HCG positive",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "No lung metastasis",
            "Ultrasound Findings": "Enlarged testis with a solid mass, no abnormalities in epididymis or vas deferens",
            "CT Scan": "No retroperitoneal lymph node metastasis detected",
            "Tumor Marker Levels": {
                "AFP": "Normal",
                "β-HCG": "Elevated",
                "LDH": "Slightly elevated"
            },
            "MRI Findings": "Confirmed presence of testicular tumor, no distant metastasis",
            "Testicular Biopsy": "Presence of germ cell tumor, seminoma type",
            "Abdominal Ultrasound": "No visceral metastasis"
        },
        "Treatment Plan": "James Thompson has been diagnosed with a seminoma type testicular cancer, which has been categorized as moderate severity based on the presence of a single painless mass and elevated β-HCG levels. Given the absence of metastasis and James's medical history of cryptorchidism, a radical inguinal orchiectomy is recommended as the primary treatment, accompanied by postoperative radiotherapy to target any residual cancer cells. The surgery will be followed by serial measurements of tumor markers such as β-HCG and AFP to monitor the response to treatment and detect any potential recurrence. Given the patient's fertility concerns, preoperative cryopreservation of sperm should be discussed and considered. Regular follow-ups will be scheduled post-treatment, including physical examinations and imaging studies like CT scans, to ensure there is no evidence of recurrence or metastasis. Psychological support will be provided to address any anxiety or stress related to the diagnosis and treatment. James will be advised to conduct regular self-examinations of the remaining testis and seek prompt medical attention if any abnormalities are detected."
    },
    {
        "Patient Information": {
            "Name": "James Thompson",
            "Age": "28",
            "Gender": "Male",
            "Medical History": "Cryptorchidism treated in childhood, occasional testicular discomfort"
        },
        "Disease Information": {
            "Disease": "Testicular Cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Single painless mass in the affected testicle, slight discomfort, occasional dull pain",
            "Duration": "Symptoms have been present for approximately 3 months",
            "Curability": "Yes"
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "25 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "5.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "45% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase (LDH)": "300 U/L (135 − 225)",
                "Alpha-fetoprotein (AFP)": "12 ng/mL (< 10 ng/mL)",
                "Beta-Human Chorionic Gonadotropin (β-HCG)": "10 IU/L (< 5 IU/L)",
                "Prostate-Specific Antigen (PSA)": "1.0 ng/mL (0 − 4)",
                "Ferritin": "120 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.2 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B"
            },
            "Ultrasound Examination": "Presence of a solid mass in the left testicle",
            "Chest X-ray Exam": "Normal",
            "Abdominal Computerized Tomography": "No evidence of metastasis",
            "Serological Diagnosis": "Elevated β-HCG and AFP indicative of testicular cancer",
            "Tumor Marker Test": "Elevated levels of LDH, β-HCG, and AFP",
            "Scrotal Examination": "Palpable mass in the left testicle, negative transillumination test",
            "Prostate Examination": "Normal",
            "Retroperitoneal Ultrasound": "No metastasis detected",
            "Physical Examination": "Negative for gynecomastia, palpable mass in testicle"
        },
        "Treatment Plan": "James Thompson has been diagnosed with moderate testicular cancer, requiring a decisive and multifaceted treatment approach. Given the confirmed presence of a testicular mass and elevated tumor markers, the initial step involves a radical inguinal orchiectomy to remove the affected testis, followed by histological examination to determine the tumor type and stage. Based on the results, further treatment options including chemotherapy and possibly radiotherapy will be explored to address microscopic disease and prevent recurrence. Chemotherapy regimens may involve agents such as cisplatin, etoposide, and bleomycin, specifically chosen based on the cancer's specific typology and James's overall health profile. Post-orchiectomy, James will require regular monitoring, including tumor marker tests and imaging studies, to assess treatment efficacy and ensure early detection of potential metastasis or recurrence. Supportive care emphasizing psychological counseling will be essential in managing emotional stress and potential impacts on fertility or sexual function. Fertility preservation measures such as sperm banking should be considered preoperatively. James and his family will receive education and support for adherence to follow-up schedules, ensuring diligent observation and rapid intervention if necessary. Long-term follow-ups will be conducted for at least five years to monitor for any signs of recurrence and to safeguard James's health, with adjustments to the treatment plan made in accordance with his response and condition."
    }
]